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SUMMARY #
The overall focus of this dissertation was to develop, test, and apply 
computational methods integrated with experimental data for peptide and protein 
structure determination.  
Chapter I outlines the need for novel structural biological methods that can lead to 
the characterization of peptides and membrane proteins. The prolactin releasing peptide, 
or PrRP, and the PrRP receptor, as well as ghrelin and the ghrelin receptor, are briefly 
introduced as examples of biomedically relevant systems for which no experimental 
structures are available. The first chapter also provides an overview of computational 
structural biology, including comparative modeling, de novo folding, and overcoming the 
obstacles of effective model scoring and conformational sampling. Portions of the chapter 
concerning comparative modeling and energy evaluation were taken from a Nature 
Protocols publication entitled, "Small-molecule ligand docking into comparative models 
with Rosetta," which was written by Steven Combs*, Samuel DeLuca*, Stephanie 
DeLuca*, Gordon Lemmon*, David Nannemann*, Elizabeth Nguyen*, Jordan Willis*, 
Jonathan Sheehan, and Jens Meiler. Authors with an (*) after the last name contributed 
equally to the publication and are considered equally contributing authors. The author of 
this dissertation contributed significantly to the development, documentation, revision, 
and dissemination of the reported protocol. 
Chapter II is based on the publication, "The activity of the prolactin releasing 
peptide correlates with its helicity," by Stephanie DeLuca, David Rathmann, Annette 
Beck-Sickinger, and Jens Meiler. The author of this dissertation and Daniel Rathmann 
contributed equally to the work reported therein. The author of this dissertation 
#xv#
conducted all modeling and analysis needed to interpret the experimental information. 
The text was written in a collaborative effort, such that the first two authors listed shared 
first authorship. 
Chapter III concerns the characterization of ghrelin structure and dynamics in a 
lipid vesicle environment. Ghrelin, like PrRP, is a peptide hormone that is involved in 
obesity and metabolic disease. Therefore, its three-dimensional structure is of special 
interest in the field of drug discovery. The manuscript entitled, "Integrating solid-state 
NMR and computational modeling to investigate the structure and dynamics of 
membrane-associated ghrelin" by Gerrit Vortmeier, Stephanie DeLuca, Constance 
Chollet, Holger A. Scheidt, Annette Beck-Sickinger, Jens Meiler, and Daniel Huster, 
describes the joint-effort work of both the Meiler and Huster laboratories, at Vanderbilt 
University and Leipzig University, respectively. The author of this dissertation performed 
all modeling of ghrelin using chemical shifts from solid-state NMR spectroscopy, which 
was conducted by the Huster laboratory. In addition, she contributed significantly to data 
interpretation, writing, and editing of the manuscript text and is therefore considered to 
be co-first author with Gerrit Vortmeier. 
RosettaEPR is introduced and described in detail in Chapter IV. It is a 
computational tool for protein structure determination that employs the Rosetta de novo 
folding algorithm with an EPR distance knowledge-based potential. The content of 
Chapter IV is based on the publication, "RosettaEPR:  An integrated tool for protein 
structure determination from sparse EPR data" by Stephanie Hirst, Nathan Alexander, 
Hassane Mchaourab, and Jens Meiler. The author of this dissertation was solely 
#xvi#
responsible for the implementation, testing, reporting, and submission of the manuscript 
for publication. 
In Chapter V, RosettaTMH, a novel membrane protein de novo folding algorithm 
in the Rosetta software suite is introduced. RosettaTMH assembles membrane protein 
topologies via the translation or rotation of entire transmembrane helices at a time. In 
later stages of folding, peptide fragments are inserted into the de novo folded protein 
backbone, much in the same way that soluble proteins are generated with the traditional 
Rosetta method. The author of this dissertation was solely responsible for the 
implementation, benchmarking, and description of RosettaTMH and the work associated 
therewith. The content of Chapter V is based on a manuscript submitted to PLoS ONE 
entitled, "RosettaTMH:  Membrane protein structure elucidation by combining EPR 
distance restraints with assembly of transmembrane helices" by Stephanie DeLuca, 
Samuel DeLuca, and Jens Meiler. 
Chapter VI concludes the main text of this dissertation. The author of this 
dissertation, including the concluding chapter, summarizes the work described in detail in 
Chapters II through V, as well as the implications of the results of that work. The author 
proposes future experiments and outlines the overall goals, motivation, and contributions 
of the herein reported research. 
Appendix A is based on the publication entitled, "Ligand-mimicking receptor 
variant discloses binding and activation mode of prolactin releasing peptide" by Daniel 
Rathmann, Diane Lindner, Stephanie DeLuca, Kristian Kaufmann, Jens Meiler and 
Annette Beck-Sickinger. The structural basis of activation of the prolactin releasing 
peptide receptor by the binding of its endogenous peptide hormone, PrRP, was presented. 
#xvii#
The binding model was generated by taking an iterative approach to computational 
modeling, hypothesis generation, and experimental validation. The author of this 
dissertation performed the majority of the modeling using the experimental data provided 
by collaborators in the Beck-Sickinger laboratory at Leipzig University. She also 
contributed significantly to the manuscript text, thus earning her a co-first authorship on 
the publication, along with Daniel Rathmann and Diane Lindner. 
Appendices B, C, D, E, and F comprise the protocol captures for the scientific 
work reported in Chapters II, III, IV, V, and Appendix A, respectively. The author of this 
dissertation developed, used, and documented all protocols in this dissertation's appendix.
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CHAPTER I 
 
INTRODUCTION 
 
Parts of this chapter were published in (Combs*, DeLuca, S.L.*, DeLuca, S.H.*, 
Lemmon*, Nannemann*, Nguyen*, Willis*, Sheehan, and Meiler, 2013). *These authors 
contributed equally.  
 
Structural biology as a valuable approach to biomedical research 
With the completion of the Human Genome Project in 2001, the field of structural 
biology has played an increasingly prevalent role in advancing our understanding of the 
molecular basis of disease. In 2004, there were fewer than 30,000 depositions in the 
Protein Data Bank (PDB) (1). In contrast, today, there are more than 100,000 publicly 
available three-dimensional (3D) structures, and these numbers continue to grow at 
exponential rates. There were over 5,600 structures deposited in the PDB within the first 
seven months of 2014 alone (www.pdb.org). 
Why is the scientific community so interested in knowing what proteins look like? 
One of the main driving forces is the role that protein structure determination has played 
in drug discovery (2, 3). The structure-function relationship of proteins lies at the core of 
our understanding of biological processes and the basis of disease. If we can "see" a 
protein's 3D structure, we might be able to develop better drugs and therapeutics that 
target it. Indeed, numerous experimentally determined structures, such as that for HIV-1 
protease (4-6), neuroamidase (for influenza) (7, 8), and epidermal growth factor receptor 
(9), have been used for drug lead design and optimization. Furthermore, by structurally 
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characterizing proteins and their interactions with other molecules (e.g., small molecules, 
peptides, other proteins, etc.), we can enhance our exploration of larger scale 
mechanisms, such as intra-cell signaling and cell-to-cell communication.  
 
Membrane proteins play a major role in human disease  
Proteins can be divided into two main groups. Soluble proteins exist in their 
native state in solution, such as in the cytosol of a cell. On the other hand, integral 
membrane proteins, hereafter referred to as membrane proteins (MPs), reside in lipid 
bilayers found in the permeable membranes of cells and organelles. MPs are involved in 
a plethora of physiological functions, including maintaining the proper electrochemical 
balance across cell membranes (10), transporting molecules into and out of the cell (11), 
and facilitating extra- and intra-cellar communication (12, 13). Their malfunction has 
been implicated in a myriad of diseases, including schizophrenia (14), depression (15-
17), diabetes (18-20), cystic fibrosis (21), and cancer (22). It is therefore not surprising 
that MPs make up about one-third of all proteins encoded in the human genome and are 
the biological targets of over half of drugs and therapeutics. 
 
G-protein coupled receptors are a major class of membrane proteins 
G-protein coupled receptors, or GPCRs, comprise one of the biggest MP families. 
There are over 800 GPCRs in the human proteome, which are found all over the body, 
including the brain, heart, and ovaries. Approximately 30% of drugs are designed to 
interact with this important group of proteins (23-26). All GPCRs have seven 
transmembrane helices (TMHs) connected by alternating extra- and intra-cellular loops 
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(ECLs and ICLs, respectively). Upon interaction with a ligand, the receptors are said to 
be "activated," at which point they are bound by G-proteins at the C-terminal helical 
"tail." This then leads to a signal transduction cascade inside the cell. Activation is 
associated with a conformational change in the receptor, which allows for the 
transmission of extracellular signals to the intracellular space (27). 
GPCRs can be divided into five classes based on their sequence homology. These 
classes include class A (rhodopsin-like), B (secretin-like), C (metabotropic glutamate-
like), D (fungal mating pheromone), E (cAMP), and F (frizzled/smoothened) (23, 27). 
Class A GPCRs constitute the largest class and bind small-molecule ligands, peptides, 
and even photons. The two example GPCRs discussed in this chapter, the prolactin 
releasing peptide receptor and the growth hormone secretagogue receptor, belong to class 
A.  
 
The prolactin releasing peptide receptor plays an important role in biological processes 
The prolactin releasing peptide receptor (PrRPR), also known as GPR10 or Hgr3, 
was first discovered to be the receptor of the prolactin releasing peptide (PrRP) via 
reverse pharmacology techniques. This involved screening several tissue extracts against 
the then "orphan" GPCR and testing for cell signaling. While PrRPR mRNA was found 
in the spinal cord, adrenal gland, and femur, it was most abundant in the anterior lobe of 
the brain’s pituitary, which is located below the hypothalamus (28). Even though PrRPR 
appears to be related to prolactin release, it has other biological functions as well. For 
example, PrRPR-knockout mice exhibited increased body weight and fat mass compared 
to wildtype (wt) mice after 11 and 15 weeks (29). Along with the increased body weight 
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and obesity, the knockout mice had decreased glucose tolerance and increased leptin, 
cholesterol, LDL, and HDL. Interestingly, food intake was actually decreased in female 
knockout mice. In addition, the Otsuka-Long-Evans-Tokushima Fatty (OLETF) rat strain, 
which serves as a rodent model of type II diabetes, encodes a mutant form of GPR10, in 
which the amino terminus is truncated. Binding of isotopically labeled PrRP was not 
detected in the reticular thalamus of OLETF rats compared to controls, indicating that the 
receptor mutation may play a role in the diabetes-like phenotype (20). 
 
Prolactin releasing peptide--the endogenous agonist of the PrRPR 
PrRP was originally isolated from bovine hypothalamus (28), but its mRNA has 
since been found in other tissues. In rats, PrRP mRNA was detected in the pituitary, the 
medulla oblongata, and the hypothalamus (30, 31). In humans, it was found in the 
medulla oblongata and the pancreas (31). Interestingly, PrRP is also able to activate RF- 
and FF-amide receptors, such as the human NPFF2 receptor (32). As the endogenous 
agonist of the PrRPR, it is not unexpected that circulating PrRP levels are also associated 
with energy and body weight homeostasis and metabolic diseases, such as obesity and 
diabetes. For example, reduced PrRP mRNA levels are found in fasted male rats and 
obese Zucker rats (33). Further, injection of PrRP into the central nervous system of 
PrRPR-knockout mice resulted in decreased food intake, and repeated administration of 
the peptide appeared to cause increased energy expenditure, as measured by core body 
temperature and oxygen consumption (29). 
PrRP is a member of the RF-amide peptide family, the members of which are so-
named for their arginine-phenylalanine C-terminal residues. There are two isoforms of 
#5#
PrRP, PrRP20 and PrRP31, which have 20 and 31 residues, respectively. Both isoforms 
bind to the PrRPR with a potency of less than 10 nM. The seven C-terminal residues of 
PrRP, PrRP14-20 (PrRP25-31), were also able to stimulate the receptor but exhibited 
reduced binding (30). Later, structure-activity relationship (SAR) studies indicated that 
the 13 C-terminal residues are able to agonize the PrRPR. The authors found that 
amidation of the C-terminus is required for activity and that mutation of R19 / R30 and F20 
/ F31 was not well-tolerated (34). 
Nuclear magnetic resonance (NMR) structural studies of PrRP revealed a stable 
helical conformation with a flexible N-terminus (35), but the Cartesian coordinates of the 
resulting structural ensemble was not made publicly available. Another study also 
published an image of the peptide structure but no experimental details or coordinates 
(36). Therefore, in order to study the structure of PrRP and its interaction with the 
PrRPR, the published chemical shifts (CSs) and nuclear Overhauser effect distances 
(NOEs) were used to generate an ensemble of models that agreed with the experimental 
data (Figure 1). Taken together with circular dichroism (CD) spectroscopic studies and 
receptor activity data collected using several PrRP mutants, it was found that the ability 
of PrRP to activate the PrRPR depends on its helical propensity (37) (Chapter II). The 
models were computationally docked into a comparative model of the PrRPR to provide, 
in addition to a large set of pharmacological data, a structural biological perspective of 
the binding mode of PrRP to PrRPR. Substitution of D6.59 (Ballesteros-Weinstein 
numbering (38)) on the PrRPR to arginine resulted in a constitutively active receptor. 
While the mutant receptor exhibited little to no activity when wt PrRP20 was added to 
expressing cells, activity was recovered with D19PrRP20, indicating that residue 19 on 
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PrRP20 and residue 6.59 on the PrRPR form an electrostatic interaction. Further, double-
cycle mutagenesis experiments pointed to a second interaction partner on the receptor, 
E5.26 (19) (Figure 1, Appendix B). 
 
Figure 1:  Dual binding mode of PrRP to the PrRP receptor 
The 13 C-terminal residues (8-20) of PrRP (green), de novo folded using RosettaNMR (37) 
(Chapter II) docked into the PrRP receptor binding site (lavender) (39) (Appendix B). D6.59 and 
E5.26 on the PrRP receptor and R19 on PrRP are shown as sticks and labeled accordingly. Receptor 
helices are rendered as ribbons. 
 
The ghrelin receptor is implicated in variety of diseases and physiological functions 
 The growth hormone secretagogue receptor 1a (GHSR1a), also known as the 
ghrelin receptor, is another GPCR. It is primarily located in the hypothalamus (40, 41), 
but lower expression levels have also been observed in the thyroid and adrenal glands, 
the myocardium, and the spleen (42, 43). This receptor was first found to be activated by 
the synthetic growth hormone releasing peptide, which stimulates growth hormone 
secretion from the pituitary gland (44). Since then, it has been found to be involved in 
appetite regulation, energy expenditure, and reward-driven behaviors (45, 46), such as 
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alcohol intake in mice (47). Synthetic agonists of the receptor may be useful in improving 
learning and exploratory behavior (48), and ghrelin receptor antagonists reversed ghrelin-
induced increase in food intake (49). GHSR1a exhibits an inherently high basal level of 
activity (50, 51). Interestingly, upon ligand binding, the ghrelin receptor can induce cell 
signaling via multiple pathways, which indicates that it may be capable of functionally 
biased signaling (52). Given the broad range of functions in which this receptor is 
implicated, it is important for the biomedical research community to understand its 
mechanism(s) of activation in the context of its structure and dynamics. 
 
Ghrelin is a unique peptide hormone that activates the ghrelin receptor 
In 1999, the peptide hormone, ghrelin, was discovered to be an endogenous ligand 
of GHSR1a. Several studies have demonstrated ghrelin's importance in regulating 
appetite. For example, increased levels of ghrelin in blood plasma were measured in 
human subjects shortly before mealtime, which then decreased afterwards (53). However, 
in general (i.e., not before meals), obese individuals exhibited decreased amounts of 
ghrelin in their plasma relative to lean individuals (54). In addition to its orexigenic 
effects, administration of ghrelin has been shown to lead to improved memory retention 
(55, 56). 
Ghrelin, like PrRP, is a short peptide, having a primary sequence of 28 amino 
acids. It is the only known peptide hormone that has a lipid modification. Even though 
desacylated ghrelin is more prominent in the bloodstream, Ser3 of the peptide must be 
acylated in order to activate GHSR1a (41, 57). While the original discovery of ghrelin 
pointed to an octanoyl group on Ser3 (41), fatty acids of different lengths can also be 
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added via ghrelin O-acyltransferase (58-60). In addition to the acylation at Ser3, a peptide 
core consisting of residues 1 to 4 is able to activate GHSR1a in vitro (57). 
The structure of ghrelin remains under debate. NMR and CD spectroscopy of both 
ghrelin and desacyl ghrelin indicate that both peptides are highly unstructured in aqueous 
solution (61). More recent studies unsurprisingly indicate that the peptide becomes 
increasingly helical with the addition of trifluorethanol (TFE) (62). This helical model is 
supported by molecular dynamics (MD) simulations performed in a membrane/water 
environment (63), and low-resolution 1H NMR studies in cells support a helical 
secondary structure (64). New structural and dynamical information from solid-state 
NMR (ssNMR) also point to a highly mobile structure, in which a semi-helical peptide is 
bound to the membrane of lipid vesicles (Chapter III). 
 
Membrane protein and peptide structure elucidation by computational methods  
Membrane proteins pose a special challenge for traditional structural biological methods  
Despite their clear biological significance, including the two specific examples 
given above, MPs make up less than 2% of all proteins of known structure. This statistic 
points to a number of technical and methodological difficulties encountered in protein 
over-expression, purification, and structural elucidation. For example, complications 
often include low expression levels, protein aggregation, instability, and insolubility. 
Unlike soluble proteins, MPs must be reconstituted into membrane mimetics that do not 
perturb their native conformations. This often involves extensive screening of appropriate 
conditions (65). Further, once enough protein can be obtained for structural 
characterization, optimal conditions for obtaining diffracting crystals (for X-ray 
#9#
crystallography) or assignable spectra (for NMR) must be established. Additional protein 
engineering, such as site-directed mutagenesis (66), T4-lysozyme (67, 68) fusion, or 
antibody binding (66), may be required in order for a MP to crystallize, which may or 
may not significantly disturb the protein's native conformation. 
A number of technological advances have been made in recent years to address 
the numerous challenges associated with MP structural biology. Among these are 
automated liquid handling and high throughput crystallization for X-ray crystallography 
(69) and methyl-TROSY methods, site-specific labeling, and the use of paramagnetic 
relaxation enhancements for solution NMR (70-72). Other structural biological 
techniques, such as electron paramagnetic resonance (EPR) (73-77), and ssNMR 
spectroscopy (78-81) have also been shown to be useful, but unlike X-ray crystallography 
and solution NMR, these methods do not currently allow for 3D structure elucidation. As 
a result, despite the improvements in technology, much of which has stemmed from 
structural genomics initiatives, MP structures are sorely underrepresented (82) (Figure 2). 
Computational methods for MP structure prediction have also been progressing at a slow 
but steady pace. The two main MP structure prediction approaches are comparative 
modeling and de novo, or ab initio, folding. However, even with an increasing number of 
template structures for comparative modeling and more sophisticated approaches to de 
novo folding, the use of experimental data in order to limit the conformational search 
space is often required (see below). 
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Figure 2:  Human integral membrane proteins 
Pfam (83) families and PDB structures. a) Mapping human MPs to Pfam families. Three 
thousand, three hundred and five (3,305) polytopic α-MPs were extracted from the 20,247 
sequences part of the SwissProt Homo sapiens proteome (UniProt release February 22, 2012) 
using PolyPhobius (84). Assignment of proteins to Pfam families was done as described in (82) 
using the transmembrane assignment of PolyPhobius. Three thousand and sixty-three (3,063) 
MPs can be mapped to a Pfam family (orange); 242 MPs fall outside of the current Pfam 
collection of families (red). b) Human MP Pfam families covered by structure. Human MP Pfam 
families with no structural representative (green) and with at least one structural representative 
(blue: representative is a human protein; light blue: representative is not a human protein) (82). 
 
Small peptides are highly flexible, making structure determination difficult 
 Similarly to MPs, the structure elucidation of small (< 50 amino acids) peptides 
also appears to be challenging. An advanced search of the PDB for molecules in the 
"peptide" class according to the Structural Classification of Proteins (SCOP) (85) having 
sequence homology of less than 90% and fewer than 50 residues returned fewer than 700 
hits, which is less than 1% of all depositions. 
Small peptides are often highly flexible and unstructured, which makes them 
difficult to crystallize. Furthermore, due to their lack of stable secondary structure, NMR 
peak assignment can become cumbersome, if not impossible. Even when chemical shifts 
(CSs) can be assigned, the population of peptide conformations can be highly 
heterogeneous. As a result, structural characterization of peptides is often limited to low-
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resolution techniques, such as CD, fluorescence, and fourier transform infrared (FTIR) 
spectroscopy (86). These methods allow for the study of peptide secondary structure and 
conformations. MD simulations of peptides have also been performed in order to observe 
them on an atomic level, but these simulations are often not long enough to capture 
secondary structure transitions or larger-scale conformational changes (87-90). 
 
Computational modeling can serve as an alternative approach to protein structure 
determination 
There are two main means of computational protein structure prediction: 
comparative modeling, which is often referred to as homology modeling, and de novo, or 
ab initio (i.e., from the primary sequence) folding. These two approaches are 
methodologically distinct from one another, but they can both be used for generating 3D-
models of proteins relatively quickly. Further, they can both be paired with experimental 
information to produce models that are consistent with empirical data. 
 
Comparative modeling relies on the availability of structures of related proteins  
Comparative modeling refers to the elucidation of the tertiary fold of a protein, 
guided by the known structure of another, often homologous, protein. The unknown 
structure is commonly called the “target,” while the protein of known structure, upon 
which the primary sequence of the target is threaded, is termed the “template.” The 
known template structure reduces the conformational search space by providing a protein 
backbone scaffold; areas where the template and target sequences diverge significantly 
are typically remodeled and refined via the loop building application. Although the 
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application is known as “loop building,” a “loop” is defined here as any area where the 
backbone is to be rebuilt de novo, which most often occurs in flexible regions but can 
also include secondary structural elements (SSEs). Comparative models have played a 
major role in aiding experimental design and the interpretation of experimental results. 
They can be employed to help predict structure-function relationships (91), predict 
binding pockets for ligands during structure-based drug design (92), and aid in the 
determination of target residues for site-directed mutagenesis (93, 94). 
Modeller (95) is one of the most popular comparative modeling tools. 
Comparative modeling with Modeller is highly automated and, as with Rosetta, works 
best for cases in which the sequence identity between the target sequence and the 
template structure is 30% or greater. It works by optimizing the comparative model’s 
satisfaction of spatial restraints derived from one or multiple templates. Comparative 
modeling in Rosetta (96, 97) is a multiple-step process that requires more input from the 
user; specifically, user-defined alignment and loop definitions are taken into account 
throughout the process. These definitions can be provided to Modeller but are not 
necessary for the program to generate a model. 
Sometimes, homologous, experimentally determined structures cannot be 
identified for use as templates, in which case homology modeling is not applicable. 
However, as structure is better conserved evolutionarily than sequence, proteins with low 
sequence identity can have similar folds. In this case, 3D-fold recognition meta-servers, 
such as Phyre (98) can be used. Phyre constructs a “fold library” via three steps: 1) 
combining a library of proteins of known structure from the SCOP database (85) with 
new entries from the PDB, 2) scanning the sequences against a non-redundant sequence 
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database, and 3) constructing a sequence profile from the previous step. When a query 
sequence is submitted to the server, Phyre produces a sequence profile of the query with 
potential homologs by running PSI-BLAST, generates a consensus secondary structure 
prediction of the query after running a plethora of secondary structure prediction 
methods, and performs a profile-profile alignment of the results from PSI-BLAST and 
secondary structure prediction by scanning these inputs against the fold library. The 
resulting alignments are scored and ranked (99). Once a suitable template has been 
identified, a sequence alignment should be performed between the target and template 
sequences. 
 
De novo folding with Rosetta 
When only the primary sequence of a protein is known, de novo folding can 
sometimes be used to predict the protein’s tertiary structure. This method of protein 
structure determination is usually only considered when a suitable template structure for 
comparative modeling cannot be found or if the protein has a potentially novel fold. The 
Rosetta software suite is one of the most commonly used programs for de novo folding 
(100-103). However, to date, Rosetta has been shown to successfully fold only small, 
soluble proteins (fewer than 150 amino acids) and performs best if the proteins are 
mainly composed of SSEs (α-helices and β-strands) (104). Helical MPs between 51-145 
residues were predicted within 4Å of the native structure (105). Accurate prediction of 
larger and/or more complex proteins can be achieved with the addition of experimental 
data, such as NMR CSs and distance data (106-108). Further, only sequences of very 
small proteins (up to 80 residues) have been predicted to atomic-detail accuracy in the 
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absence of experimental restraints (109-111). Therefore, whenever an experimental 
structure of a related protein is available, comparative modeling is the method of choice. 
 
Other de novo folding methods are also available 
While Rosetta was one of the earliest tools for de novo protein structure 
prediction, there are numerous other promising software tools as well, but most are 
primarily applicable to soluble proteins. The Zhang lab's QUARK (112), for example, 
was one of the top performers in the template-free modeling category in the most recent 
Critical Assessment of protein Structure Prediction (CASP), which is held biannually 
(113). QUARK, like Rosetta, combines fragment-based assembly with knowledge-based 
potentials. QUARK samples conformational space of protein folds via replica exchange 
Monte Carlo simulations, where the initial structure for each simulation is constructed by 
randomly connecting the peptide fragments, which can range from 1-20 residues. EVFold 
leverages the co-evolution of pairs of residues to generate initial 3D geometries of 
proteins before refining the models using simulated annealing molecular dynamics 
(SAMD) (114). The BioChemical Library de novo folding protocol, called BCL::Fold, 
was able to accurately predict topologies for 61 of 66 test proteins ranging in size from 83 
to 293 amino acids via the movement of idealized SSEs in the presence of knowledge-
based potentials (115, 116). 
 
There are relatively few de novo folding methods for membrane proteins 
Compared to the numerous soluble protein de novo folding tools available, there 
are relatively few MP-specific methods. RosettaMembrane, which was introduced in 
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2006, was initially tested on 12 helical MPs and was able to predict between 51 and 145 
residues with an root mean square deviation (RMSD) of less than 4Å relative to the 
crystal structure (105). In 2009, an alternative version of RosettaMembrane was shown to 
be able to fold 9 of 12 MPs that were 190 to 300 residues in length with approximately 
the same level of accuracy (117). A MP-specific version of EVFold has been reported to 
fold MPs of up to 14 helices with impressive accuracy by employing the same concepts 
as the original EVFold (118). FILM3 employs fragment-based assembly, in which 
secondary structure prediction is used to select fragments, in combination with a scoring 
function that takes only correlated mutational information of the protein into account. 
This method achieved an RMSD of 5.7Å over an MP of 514 residues in length (119). 
 
De novo folding tools for peptides are also limited  
There are a number of tools for folding peptides de novo (120-124). Two of the 
best-performing methods are PEP-FOLD (120) and Rosetta FlexPepDock (121). 
However, PEP-FOLD can only fold peptides that are between 9 and 23 amino acids, and 
FlexPepDock is designed to fold peptides in the presence of the peptide binding site of a 
soluble protein receptor. MD simulations can be used to predict the 3D structures of 
peptides as well, but these tend to be computationally expensive and require non-
equilibrium sampling strategies, such as Monte Carlo, replica exchange, or parallel 
replica dynamics (90, 125, 126). 
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The protein structure prediction sampling and scoring problems 
The two main types of energy functions:  physics-based and knowledge-based 
In order to predict the structures of proteins computationally, computational 
structural biologists must address two main challenges when developing or improving 
prediction methods. These are often referred to as the scoring and sampling problems. 
During modeling, protein conformations are often evaluated via one or more energy, or 
scoring, terms. The set of scoring terms used during model assessment is called the 
scoring function, energy function, or force field. Broadly speaking, energy functions 
come in two primary categories: physics-based and knowledge-based. As implied by the 
name, physics-based scoring functions, or potentials, employ physical principles in their 
treatment of protein conformations. These are most often based on Newtonian's laws of 
motion, in which, for example, chemical bonds are treated as springs. The use of 
Newtonian mechanics-based force fields is commonly, but not always, used in MD 
simulations. 
Knowledge-based potentials (KBPs) make the assumption that, in terms of protein 
structure, naturally occurring phenomena, such as torsion angles, hydrogen bonding 
propensities, etc., are common because they are energetically and biologically favorable. 
These potentials are generally derived by collecting statistics on proteins of known 
structure (e.g., from the PDB) and correlating statistical propensities with energies via the 
Boltzmann relationship. One advantage of KBPs is that they require relatively little 
computational power to generate. However, they are inherently limited in their accuracy 
because they are developed from available protein structures, which can be problematic 
for the evaluation of conformations of MPs and peptides. 
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The RosettaMembrane energy function 
The energy function in Rosetta is derived empirically through analysis of 
observed geometries of a subset of proteins in the PDB. The measurements include, but 
are not limited to: radius of gyration, packing density, distance/angle between hydrogen 
bonds, and distance between two polar atoms. The measurements are converted into an 
energy function through Bayesian statistics (102, 127). The scoring function in Rosetta 
can be separated into two main categories: centroid-based scoring and all-atom scoring. 
The former is used for de novo structure prediction and initial rounds of loop building 
(102, 128, 129). The side-chains are represented as “super-atoms,” or “centroids,” which 
limit the degrees of freedom to be sampled while preserving some of the chemical and 
physical properties of the side-chain. When de novo folding MPs in Rosetta, MP-specific 
scoring terms are used (105). These scoring terms are similar in nature to those used for 
soluble protein folding, but they were derived while taking the RosettaMembrane implicit 
membrane environment account. This membrane environment is divided into 5 main 
sections: 1) inner hydrophobic, 2) outer hydrophobic, 3) interface, 4) polar, and 5) water. 
During folding of MPs, each amino acid's position in the membrane is determined and its 
contribution to the overall energy of the model computed accordingly. 
The RosettaMembrane all-atom scoring function represents side-chains in atomic 
detail (130). Like the centroid-based scoring function, the all-atom scoring function is 
comprised of weighted individual terms that are summed to create a total energy for a 
protein. Most of the scoring terms are derived from statistics generated over proteins of 
known structure. The MP full-atom energy function assesses van der Waals attractive / 
repulsive forces based on the Lennard-Jones 6-12 potential. It also includes scoring terms 
#18#
that evaluate backbone torsion angles, inter-residue pairing propensities, and solvation 
based on the Laaridis-Karplus model (131). There is also an orientation-dependent 
hydrogen bonding term (132). The solvation and hydrogen bonding terms were modified 
in order to account for the implicit membrane environment. While the atomic-level 
RosettaMembrane energy function is important for applications, such as small-molecule 
ligand docking, peptide docking, and comparative modeling, it is not employed during de 
novo folding and will therefore not be discussed in further detail. The development and 
implementation of the scoring function is reported in (130). 
 
Means of limiting protein conformational sampling during de novo folding 
Overcoming the sampling problem is an ever-present goal in the development of 
protein structure prediction methods. While approximations of conformational energies 
using Newtonian physics or KBPs can speed up simulations, sampling complex 
topologies, such as those seen in transporters and GPCRs, often requires the 
implementation of more clever folding algorithms. For example, Rosetta estimates local 
interactions via the use of 3- and 9-amino acid fragments generated from a database of 
proteins of known structure (100, 102). While this allows for efficient sampling for small 
proteins, such as ubiquitin, it is insufficient for folding large proteins with complex folds. 
To address this weakness, BCL::Fold can fold proteins with higher contact order by 
moving entire SSEs (115). EVFold (114, 118, 133) and FILM3 (119) confine the 
conformational search space by generating distance restraints based on co-evolutionary 
information. In the case of RosettaMembrane (105, 117), the implicit membrane 
environment itself imposes an additional constraint due to the fact that it favors the 
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placement of hydrophobic residues in the membrane core and requires helices, which 
alternate N- to C-terminus, to lie relatively orthogonal to the membrane plane.  
 
Combining computational methods with experimental data can further reduce 
conformational search space 
Incorporation of experimental data into structure prediction and analysis has also 
been shown to improve the quality of the final model or ensemble of models (106-108, 
134-137). This is because, in addition to other sampling enhancements, such as fragment 
insertion, experimental restraints can further narrow down the conformational search 
space (Figure 3). Numerous types of experimental data have been incorporated into such 
protocols, including electron density from X-ray crystallography (138) and electron 
microscopy, NMR distance and orientation data (137, 139), EPR distance data (134, 
135), crosslinking restraints (140), small angle X-ray scattering data (141), and deuterium 
exchange mass spectrometry data (142). While these types of information are more often 
applied to de novo protein structure elucidation, they can also be of some utility in the 
building of loops (19), reorientation of domains during comparative modeling, or 
identification of residues involved in ligand binding. 
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Figure 3:  Rosetta approach to limiting conformational sampling 
If all of a protein's conformational space is represented by the gray background, Rosetta enhances 
its sampling of that space by incorporating local sequence bias (blue), evaluating non-local 
interactions based on KBPs (green), and taking experimental data into account (purple). Ideally, 
the native structure or ensemble of structures (star) will be found at the intersection of all three 
approximations. 
 
Protein structure determination by combining NMR and computational methods 
 Protein structure determination using NMR spectroscopy requires that 
computational methods be used to generate an ensemble of models that represents protein 
conformations consistent with restraints derived from the NMR data. The quality of an 
ensemble of models determined by NMR is often reported as RMSD, which is, in this 
case, a measure of precision. That is, the "tightness" of a structural ensemble will have a 
lower RMSD than a "looser" one. Traditionally, the restraints employed during the 
structure calculations are derived from inter-proton distance information arising from 
NOEs, as well as dihedral angle restrictions based on secondary structure definitions 
predicted from the CS values of the individual residues (143). It should be noted that 
other NMR experimental information, such as that resulting from residual dipolar 
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couplings (RDCs) and paramagnetic relaxation enhancements (PREs) can be used as 
well. Typically, the quality of the conformational ensemble is directly related to the 
richness of the NMR dataset. It is often difficult to fully assign NMR CSs, which makes 
the acquisition of such datasets difficult. This is especially the case for intrinsically 
disordered, or unordered, proteins (IDPs and IUPs, respectively), which the protein or 
peptide undergoes conformational changes and dynamics on timescales for which NMR 
is ill-suited. In these cases, additional information, such as from homologs of the protein 
for which 3D structures are available, can be used to generate an ensemble using sparse 
NMR data. Further, "bootstrapping" methods, in which ambiguous NMR structural 
restraints are used for modeling in an iterative fashion, can also be helpful (107, 108, 136, 
144).  
 
Protein structure determination by combining EPR and computational methods 
The applicability of site-directed spin labeling (SDSL) EPR spectroscopy 
combined with X-ray crystallographic information has been demonstrated in the 
characterization of potassium ion channels (145, 146) and ABC transporters (74, 147). 
The secondary structural environment (148), burial state (149, 150), and position in the 
membrane of the spin label can be probed by measuring collision frequencies with 
NiEDDA (Ni(II) ethylenediaminediacetic acid) and molecular oxygen (O2) (151). Global 
geometric restraints can be derived from distances between two spin labels 5-80Å apart. 
EPR distance measurements have been used extensively in studies of protein dynamics 
(152, 153). This structural biological technique requires relatively low amounts of protein 
#22#
due to its sensitivity and is not restricted by protein size or native environment (154), 
making it an appealing tool for studying MP structure and conformational changes. 
The combination of SDSL-EPR and computational modeling is steadily becoming 
a popular method of protein structure elucidation. In 1995, an automated method for 
modeling the 7 TMHs of GPCRs was presented. In addition to other experimental and 
sequence information, SDSL-EPR data provided information concerning labeled 
residues’ orientation relative to the inside or outside of the 7-helix bundle (155). The 
structure of α-synuclein was built and refined using SAMD restrained by EPR-
determined immersion depths and distances. It was found that α-synuclein forms an 
extended, curved α-helical structure that is over 90 amino acids in length (156). In 
another study, EPR-computational modeling hybrid methods were used to propose a 
novel closed conformation of MscS that includes the previously unresolved NH2-
terminus. The authors proposed that the MscS closed state is in a different and more 
compact conformation than the one trapped in the crystal structure (157).  
EPR distances have a rather large uncertainty when translated into distances 
between Cαs or Cβs unless the conformation of the spin label is known at every site. To 
solve this problem, Alexander, et al. presented a low-resolution spin-label model in 
which spin label distances are converted into distance ranges between Cβs by using a 
“motion-on-a-cone” model. This approach was tested on T4-lysozyme and αA-crystallin 
with Rosetta, the results for which yielded 1.0Å and 2.6Å full-atom models, respectively 
(134). In a related approach, the restraint-driven Cartesian transformations (ReDCaT) 
method for calculating conformational changes in MPs employs a distance deviation 
factor, ∂, to define a range between the restraints’ upper and lower limits. After using this 
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method for modeling, analysis of the structural basis of activation gating in the K+ 
channel, KcsA, revealed a mechanism consistent with a scissoring-type motion of the 
TM2 segments (158). The aforementioned structural study of MscS also modeled spin 
labels using ReDCaT (157). More recently, RosettaEPR was introduced, in which an 
EPR distance KBP was derived based on the cone model and used to fold T4-lysozyme to 
atomic detail (135). EPR data from double electron-electron resonance (DEER) 
experiments were also used to guide the modeling of conformational changes seen upon 
GPCR activation (159, 160). Although a spin label rotamer library based on the crystal 
structure of T4-lysozyme labeled with methanethiosulfonate (MTS) has been developed 
(161), methods for modeling EPR spin labels in atomic detail are also desired. Sale, et al. 
described a method for enhancing the utility of dipolar EPR distances as constraints in 
modeling protein structures by explicit incorporation of the spin labels and showed that 
accounting for the probe conformation and tether length increased accuracy of distance 
measures 2-fold (162). Simulated scaling, which couples the random walk of a potential 
scaling parameter and MD in the framework of a Monte Carlo, proved to be an efficient 
means of mapping the MTS spin label to atomic detail in spin-labeled T4-lysozyme 
(163). Additionally, spin label rotamer libraries have been developed (164). 
 
Membrane protein and peptide structure determination made possible by computational-
experimental hybrid technologies 
Computational modeling and experimental data from NMR and EPR 
spectroscopy has the potential to provide much insight into MP structure and function. 
While computational methods alone cannot currently sample conformational space 
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sufficiently enough to reliably predict MP structures, and flexible peptides and complex 
MPs continue to evade structure determination by more traditional methods, when taken 
together, these diverse methods have shown to be synergistic. The work presented in the 
following chapters describe a few examples of how the coupling of computational 
biology with experimental data can enable scientists to learn about the structural basis of 
protein function and presents a new method for MP structure prediction that can be used 
in conjunction with experimental data. 
 #  
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CHAPTER II 
 
THE ACTIVITY OF PROLACTIN RELEASING PEPTIDE CORRELATES 
WITH ITS HELICITY 
 
 
This work is based on publication (DeLuca*, Rathmann*, Beck-Sickinger, and 
Meiler, 2013). *These authors contributed equally. 
 
Summary 
The prolactin releasing peptide (PrRP) is involved in regulating food intake and 
body weight homeostasis, but molecular details on the activation of the PrRP receptor 
remain unclear. C-terminal segments of PrRP with 20 (PrRP20) and 13 (PrRP8-20) 
amino acids, respectively, have been suggested to be fully active. The data presented 
herein indicate this is true for the wildtype receptor only; a 5-10-fold loss of activity was 
found for PrRP8-20 compared to PrRP20 at two extracellular loop mutants of the 
receptor. To gain insight into the secondary structure of PrRP, we used CD spectroscopy 
performed in TFE and SDS. Additionally, previously reported NMR data, combined with 
RosettaNMR, were employed to determine the structure of amidated PrRP20. The 
structural ensemble agrees with the spectroscopic data for the full-length peptide, which 
exists in an equilibrium between α- and 310-helix. We demonstrate that PrRP8-20’s 
reduced propensity to form an α-helix correlates with its reduced biological activity on 
mutant receptors. Further, distinct amino acid replacements in PrRP significantly 
decrease affinity and activity but have no influence on the secondary structure of the 
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peptide. We conclude that formation of a primarily α-helical C-terminal region of PrRP is 
critical for receptor activation. 
 
Introduction 
The prolactin releasing peptide, or PrRP, is a member of the RF-amide peptide 
family and is mainly expressed in the medulla oblongata, brainstem, and hypothalamus 
(30, 31, 165). It is the endogenous agonist of the PrRP receptor (also known as GPR10 or 
hGR3) and interacts with nanomolar binding affinities (28). Furthermore, it has some 
affinity for other RF-amide and FF-amide receptors, such as the hNPFF2 receptor (32). 
These receptors are integral membrane proteins that belong to the large family of G-
protein coupled receptors, or GPCRs, which constitute about one-third of all major drug 
targets (25). While the original function of PrRP was proposed to be the stimulation of 
prolactin secretion (28, 166), it is now generally accepted that this is not the primary 
function of the peptide. Increasing evidence indicates that PrRP plays a significant role in 
food intake and body weight homeostasis (167). Indeed, intracerebroventricular 
administration of PrRP with leptin in rats resulted in body weight gain (33). In addition, 
both PrRP- and PrRP receptor-deficient mice were shown to develop late-onset obesity 
(29). 
PrRP exists in two isoforms: PrRP20 and PrRP31, which consist of 20 and 31 
residues, respectively. The C-terminal residues of both isoforms are identical, and both 
isoforms are biologically equipotent in the activation of the PrRP receptor. It has been 
demonstrated that PrRP can be shortened to PrRP8-20 without any loss of activity at the 
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wildtype (wt) receptor and that these thirteen C-terminal residues are the minimum 
number of amino acids essential for full activation of the PrRP receptor (34).  
Little is known about the mode of binding and activation of the PrRP receptor by 
PrRP, especially on a structural level. This is likely due to the lack of functional 
antagonists of the PrRP receptor and difficulties in structure determination of GPCRs. 
Here, we investigate the importance of the peptide’s secondary structure for receptor 
activation. Nuclear magnetic resonance (NMR) spectroscopy had previously been used to 
determine the structure of PrRP20 in micelles (35). A second study reported an image of 
a PrRP20 structural model without revealing experimental details, such as solvent 
conditions or a list of NMR restraints (36). Neither study made the models publicly 
available. However, D’Ursi et al. provided a list of sparse chemical shifts and nuclear 
Overhauser effect distance restraints (NOEs) (35). We employed RosettaNMR (104, 106, 
168) to generate an ensemble of peptide conformations that is consistent with newly 
obtained circular dichroism (CD) spectroscopy data and this set of NMR restraints. 
Further, we identified receptor mutants for which PrRP8-20 displays a significant loss in 
activation compared to PrRP20. By comparing the activation ability of four PrRP analogs 
on two receptor mutants, we can distinguish direct effects on ligand-receptor interaction 
and indirect effects that result from alteration of peptide helicity. This combined 
computational-experimental approach allows us to understand the interaction of PrRP and 
its receptor on a molecular level. 
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Materials and methods 
Structure determination using RosettaNMR 
Details of the RosettaNMR protocol have been described elsewhere (104, 106, 
137, 168). Briefly, torsion angle restraints were derived from 13 Hα chemical shift values 
using TALOS (169) (Table 1). Further, 28 distance restraints obtained from NOEs 
between backbone hydrogen atoms were used and were classified as either “strong” 
(proton-proton distance ≤ 3Å) or “weak” (proton-proton distance ≤ 5Å) (Table 2). A 
library of overlapping 3- and 9-amino acid peptides spanning residues 8-20 of PrRP20 
were generated from coordinates found in the PDB. During folding, an additional 10 
NOEs resulting from resonances between side-chain protons--again, classified as 
“strong” (≤ 3Å) or “weak” (≤ 5Å)–were included as distance restraints (Table 2).  
Ten thousand backbone-only structural models were generated using 
RosettaNMR’s de novo folding algorithm(100, 102). From these original models, the 
10% most energetically favorable models (according to the RosettaNMR scoring 
function) were refined to atomic detail, including the addition of the functionally 
obligatory C-terminal amide functional group. The RosettaNMR energy function includes 
solvation, electrostatic interactions, van der Waals attraction/repulsion, and hydrogen 
bonding, all of which were included in the assessment of overall structural quality(100, 
170). The 20 conformations that fulfill the distance restraints with deviations smaller than 
1Å and have the lowest RosettaNMR energies constitute a conformational ensemble that 
is consistent with the published NMR data and is physically plausible according to the 
RosettaNMR energy function.  
 
 
 
#29#
Table 1:  Chemical shifts (35) used to generate 3- and 9-amino acid fragments 
Residue)
Δ)in)Hα)
Chemical)
Shifta)W8# 4.34#Y9# 4.03#A10# 4.14#S11# 4.31#R12# 4.18#G13# 3.86#I14# 4.12#R15# 4.65#P16# 4.46#V17# 4.14#G18# 3.94#R19# 4.05#F20# 4.60#
a For G13 and G18, took the first value reported for the Hα chemical shift 
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Table 2:  NOEs (35) used to generate 3- and 9-amino acid fragments and to de novo fold and 
refine PrRP models 
Residue)Pair) NOE)Type) NOE)Strengtha)W8_Y9# HN_HN# weak#b#Y9_A10# HN_HN# weak#A10_S11# HN_HN# weak#S11_R12# HN_HN# weak#G13_I14# HN_HN# weak#I14_R15# HN_HN# weak#V17_G18# HN_HN# strong#G18_R19# HN_HN# strong#W8_Y9# Hα_HN# weak#Y9_A10# Hα_HN# weak#A10_S11# Hα_HN# weak#S11_R12# Hα_HN# weak#R12_G13# Hα_HN# weak#G13_I14# Hα_HN# weak#I14_R15# Hα_HN# weak#P16_V17# Hα_HN# weak#V17_G18# Hα_HN# strong#G18_R19# Hα_HN# weak#R19_F20# Hα_HN# strong#
W8DY9) HβDHN)c) weak)
Y9DA10) HβDHN) weak)
S11DR12) HβDHN) weak)
R12DG13) HβDHN) weak)
I14DR15) HβDHN) strong)
P16DV17) HβDHN) weak)
V17DG18) HβDHN) weak)
R19DF20) HβDHN) strong)Y9_S11# HN_HN# weak#A10_R12# HN_HN# weak#S11_G13# HN_HN# weak#Y9_S11# Hα_HN# weak#A10_R12# Hα_HN# weak#S11_G13# Hα_HN# weak#P16_G18# Hα_HN# weak#I14_V17# Hα_HN# weak#P16_R19# Hα_HN# weak#
R12DR15) HαD)Hβ) weak)
I14DV17) HαD)Hβ) weak)
a NOEs were classified as either “weak” (proton-proton distance ≤ 5Å) or “strong” (proton-proton 
distance ≤ 3Å); b Color key:  white=d(i,i+1); light gray=d(i,i+2); dark gray=d(i,i+3); c Bolded text 
indicates that the NOE occurred between side-chain protons and was only used during folding 
(not fragment generation). 
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Peptide synthesis 
PrRP20, PrRP14-20, PrRP8-20, PrRP4-20, A15PrRP20, A19PrRP20, and 
A20PrRP20 were synthesized by automated multiple solid-phase peptide synthesis on the 
multiple peptide synthesizer Syro II (MultiSynTech GmbH, Witten, Germany) using the 
orthogonal Fmoc/tBu strategy.59 Rink amide resin (30 mg, resin loading 0.6 mmol·g-1), 
obtained from Iris Biotech GmbH (Marktredwitz, Germany), was used to produce the C-
terminally amidated peptides. Nα-Fmoc (N-(9-fluorenyl)methoxycarbonyl)-protected 
amino acids were purchased from Iris Biotech GmbH (Marktredwitz, Germany). The 
protected amino acids (10eq) were dissolved in 0.5 M tert-butyl alcohol in 
dimethylformamide and activated in situ by diisopropylcarbodiimide (DIC) (10eq). 
Removal of protection groups and final cleavage of the peptide from the resin was 
accomplished simultaneously using a cleavage cocktail consisting of either trifluoroacetic 
acid (TFA)/thioanisole/1,2-ethanedithiol (90:7:3 v/v/v) for tryptophan-containing 
peptides or TFA/thioanisole/p-thiocresol (90:5:5 v/v/v) within 3 hours.  
Peptide purification was achieved by preparative reversed-phase HPLC (Vydac 
RP18-column, 22 × 250 mm, 10 µm/300Å, Grace, Deerfield, IL, USA or Phenomenex 
Jupiter 10 U Proteo column, 250 × 21.20 mm, 90Å, Aschaffenburg, Germany) using 
0.08% TFA in either acetonitrile or methanol (MeOH) and 0.1% TFA in water as the 
eluting system to yield homogenous peptides of > 90% purity. The peptides were 
characterized by mass spectrometry using matrix-assisted laser desorption ionization 
time-of-flight (MALDI-TOF) mass spectrometry on an Ultraflex III MALDI-TOF/TOF 
mass spectrometer (Bruker Daltonics, Bremen, Germany). Analytical reversed-phase 
HPLC was performed on a Vydac RP18-column (4.6 × 250 mm; 5 µm/300 Å; Grace, 
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Deerfield, IL, USA) by using two different linear gradient systems of 0.1% (v/v) TFA in 
water and 0.08% (v/v) TFA in either acetonitrile (ACN) or methanol. Analytical data are 
summarized in Table 3. 
Table 3:  Analytics of PrRP20 used for structural and biological investigations 
Peptide Sequence 
Mass [M+H]+ HPLC 
Calc. Exp. ACN [%] 
MeOH 
[%] Purity [%] 
PrRP20 TPDINPAWYASRGIRPVGRF-NH2 2272.6 2273.7 40.3a 65.5 b >99 
PrRP4-20 INPAWYASRGIRPVGRF-NH2 1959.3 1960.4 40.5 a 66.9 b >99 
PrRP8-20 WYASRGIRPVGRF-NH2 1562.9 1563.9 38.3 a 61.6b >92 
PrRP14-20 IRPVGRF-NH2 842.5 843.5 33.8 a 52.6 b >96 
A15PrRP20 TPDINPAWYASRGIAPVGRF-NH2 2186.1 2187.2 42.9 a 71.7 b >96 
A19PrRP20 TPDINPAWYASRGIRPVGAF-NH2 2187.5 2188.4 41.6a 70.8c >99 
A20PrRP20 TPDINPAWYASRGIRPVGRA-NH2 2196.5 2196.2 37.7a 61.6b >99 
a 10% to 60% ACN (0.08% TFA) in water (0.1% TFA) over 30 min. b 20% to 100% MeOH 
(0.08% TFA) in water (0.1% TFA) over 40 min. c 30% to 100% MeOH (0.08% TFA) in water 
(0.1% TFA) over 30 min. 
 
Cloning of the RF-amide peptide receptors in eukaryotic expression vectors 
To obtain genomic DNA from SMS-KAN cells, approximately 1 million cells 
were digested overnight at 55°C with 500 µL lysis buffer (1 M NaCl, 20% SDS, 0,5 M 
EDTA, 1 M Tris, pH 8.5) containing 50 µg proteinase K (Promega, Mannheim, 
Germany). Genomic DNA was extracted using phenol/chloroform and precipitated from 
the aqueous phase with isopropanol, washed with ethanol, and then dissolved in water. 
The coding sequence of the human PrRP receptor was obtained by PCR amplification 
from the genomic DNA of SMS-KAN cells. Cloning of cDNA into the eukaryotic 
expression vector pEYFP-N1 (Clontech, Heidelberg, Germany) C-terminally fused to 
EYFP was performed, using the XhoI and BamHI site to result in the constructs phPrRP 
receptor_EYFP-N1. Mutations were introduced with the QuikChange™ site-directed 
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mutagenesis method (Stratagene). The residues are numbered according to the system of 
Ballesteros and Weinstein (38). The correctness of all constructs was confirmed by 
sequencing of the entire coding sequence.  
 
Cell culture 
Cell culture material was supplied by PAA Laboratories GmbH (Pasching, 
Austria). COS-7 cells (African green monkey, kidney) were cultured in Dulbecco’s 
Modified Eagle’s Medium containing 10% (v/v) heat-inactivated fetal calf serum (FCS), 
100 units/mL penicillin and 100 µg/mL streptomycin. SMS-KAN cells (human 
neuroblastoma cells) were maintained in nutrient mixture Ham’s F12/Dulbecco’s 
modified Eagle medium (1:1) with 15% (v/v) FCS, 4 mM glutamine, 0.2 mM non 
essential amino acids, 10 units/mL penicillin, and 10 µg/mL streptomycin. Cells were 
grown as monolayers at 37°C in a humidified atmosphere of 5% CO2 and 95% air. 
 
Signal transduction assay 
For signal transduction (inositol phosphate accumulation) assays, COS-7 cells 
were seeded into 24-well (1.0 × 105 cells/well) or 48-well plates (6.0 × 104 cells/well) 
and transiently transfected with 0.4 µg plasmid DNA using 1.2 µL metafectene (Biontex 
Laboratories GmbH, Martinsried/Planegg, Germany). Incubation with 2 µCi/mL 
[3H]myo-inositol (GE Healthcare Europe GmbH, Braunschweig, Germany) in DMEM 
supplemented with 10% (v/v) FCS was performed one day after transfection and 16 h 
before stimulation. Labeled cells were washed once and stimulated with increasing 
concentrations of each peptide for 1 h at 37°C in DMEM containing 10 mM LiCl (Sigma-
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Aldrich, Taufkirchen, Germany) as described previously (171, 172). Receptor stimulation 
and IP accumulation were stopped by aspiration of medium, and cell lysis was performed 
with 0.1 M NaOH (24-well plate: 150 µL/well; 48-well plate: 100 µL/well) for 5 minutes. 
After neutralizing with 0.2 M (24-well plate: 50 µL/well) or 0.13 M (48-well plate: 50 
µL/well) formic acid, IP dilution buffer (5.0 mM Na-borate + 0.5 mM Na-EDTA; 24-
well plate: 1 mL/well; 48-well plate: 750 µL/well) was added to each well. 
Intracellular IP levels were determined by anion-exchange chromatography on 
Bio-Rad AG 1-X8 resin either by manual pipetting or using an automated pipetting robot 
system (USK-UTZ GmbH, Limbach-Oberfrohna, Germany). Radioactivity was measured 
by a scintillation counter (Win Spectral 1414 Liquid Scintillations Counter Wallac) (173, 
174). Data were analyzed with GraphPad Prism 3.0 program (GraphPad Software, San 
Diego, USA) and EC50-values were obtained from concentration response curves. The 
EC50-determinations were performed in duplicate and signal transduction assays were 
repeated at least twice independently.  
 
Radioligand binding studies  
For radioligand binding studies, 1.5 × 106 COS-7 cell were seeded into 25 cm2 
flasks. At 60-70% confluency, cells were transiently transfected using 4 µg vector DNA 
and 15 µL of Metafectene™ (Biontex Laboratories GmbH, Martinsried/Planegg, 
Germany). Approximately 24 hours after transfection, binding assays were performed on 
intact cells using N[propionyl3H]hPrRP20. Binding was determined with 1 nM 
N[propionyl3H]hPrRP20 in the absence (total binding) or in the presence (non-specific 
binding) of 1 µM unlabeled hPrRP20, respectively, as described previously(172, 175). 
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N[propionyl3H]hPrRP20 was obtained by selective labeling as described previously and 
resulted in a KD-value of 0.58 nM (176). Specific binding of each PrRP receptor mutant 
was compared to specific binding of the PrRP wt receptor. IC50-values and KD-values 
were calculated with GraphPad Prism 3.0 (GraphPad Software, San Diego, USA), fitted 
to a one-site competition or a one-site binding model, respectively. Each experiment was 
performed in triplicate. 
 
CD spectroscopy 
CD measurements of 40 µM peptide solutions buffered with 10 mM phosphate 
buffer at pH 5.5 or 7 were performed in the far ultraviolet region from 250 to 190 nm 
using a Jasco J-715 spectropolarimeter. Additionally, CD spectra of 10 mM phosphate 
buffered peptide solutions were measured in either 25% TFE or 100 mM SDS-containing 
solutions. Cuvettes with 2 mm path length (quartz cuvette; Hellma, Jena, Germany), as 
well as the following parameters, were used: 50 nm·min-1 scanning speed, 4 s response, 
0.2 nm step resolution, 2 nm bandwidth, temperature of 22°C. Peptide concentration was 
determined from the aromatic spectrum determined in aqueous solution and calculated 
using the molar extinction coefficient of the peptides at 280 nm (6990 M-1 cm-1). For 
PrRP14-20, the pure lyophilized peptide was weighed and diluted to 40 µM, considering 
that the final peptide mass results from the salt with TFA as counterion for both arginine 
residues. Spectra were measured in a constant nitrogen stream of 15 L·min-1. The final 
spectra were averaged from 6 to 9 baseline-corrected scans without any smoothing. The 
raw CD signal [mdeg] was converted to mean residue ellipticity, [Θ], by [Θ] = 
[Θ]observed(MRW/l·c·10), where MRW is the mean residue weight (molecular mass divided 
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by number of peptide bonds), l is path length [cm] and c is the concentration of peptide in 
mg/mL. Graphs were processed using GraphPad Prism 3.0 program (GraphPad Software, 
San Diego, USA), Microsoft Excel 2011™, as well as with the Jasco-715 
spectropolarimeter-related Jasco software. 
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Results 
Previous NMR studies of C-terminally amidated PrRP20 reveal a helical C-terminal 
region. 
RosettaNMR (106, 136, 168) was employed to construct a model of C-terminally 
amidated PrRP from 38 previously reported inter-proton distances (NOEs) and 13 Hα 
chemical shifts, which were collected at pH 5.5 in 100 mM sodium dodecyl sulfate, or 
SDS (Table 1 and Table 2) (35). These NMR data were obtained for PrRP20. We chose 
to construct structural models for residues 8-20 of PrRP20 because the structural 
restraints cover mainly these residues, implying that residues 1-7 are conformationally 
flexible. However, because only a partial dataset was available, the herein discussed 
peptide model ensemble serves only as a starting point for further structural 
characterization of the PrRP/PrRP receptor interaction. The generated models were 
further confirmed with CD spectroscopy (see Structural investigations of PrRP by CD 
spectroscopy studies indicate a decreased helical propensity for PrRP8-20). 
 The NOEs and chemical shifts occurring within residues 8-20 are indicative of a 
combination of α- and 310-helical secondary structure. The presence of αN(i,i+2) NOEs is 
often associated with i(i+3) hydrogen bonding characteristic of 310-helices. Further, the 
ratio of αβ(I,i+3) to αN(i,i+3) NOEs, as well as the lack of αN(i,i+4) NOEs, support the 
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idea that the peptide exists in an equilibrium of α- and 310-helix in SDS micelles (177-
179) (see D’Ursi et al. for original figures). An ensemble of twenty low-energy models of 
the PrRP20 residues 8-20 consistent with the NMR data obtained for the full-length 
peptide was generated and deposited in the Protein Model Database (180) (Figure 4 
PMID: 0078404). 
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Figure 4:  The conformational ensemble of PrRP8-20 generated using RosettaNMR 
A) The primary sequence of PrRP8-20. The three arginines are in bold. B) The twenty lowest-
energy models resulting from full-atom refinement that had a RosettaNMR restraint score ≤ 1.0 
Rosetta Energy Unit (REU). Briefly, ten thousand models were de novo folded in the presence of 
38 distance restraints. Energetically favorable models that satisfied the NMR data were then 
refined to atomic detail using the same 38 restraints. Notice that all three arginine residues are on 
one side of the amphipathic helix. #
Secondary structural analysis of PrRP20 models implies a conformational equilibrium. 
The final ensemble of PrRP models was chosen based on the models’ overall 
energy according to the RosettaNMR full-atom soluble protein scoring function (110), as 
well as their agreement with the NMR distance restraints for the full-length peptide 
(Table 4 and Table 5) (35). Define Secondary Structure of Proteins (DSSP)(181, 182) 
analysis indicates that these models are mainly α-helical, especially between residues 10-
90° 
N 
C 
 PrRP8-20:  WYASRGIRPVGRF 
                              10         15           20 
A 
B 
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13 and 15-19, with the other residues being coil or bend/turn (Figure 5A). Note the often-
observed non-ideal helical character around residue I14. This is likely due to the inability 
of the nitrogen of P16 to hydrogen bond with the carbonyl oxygen on R12 (distance = 4.98 
± 0.27Å), thus disrupting the hydrogen bond between G13 and V17 (distance = 5.00 ± 
0.26Å) (Figure 5B). The models exhibit ϕ and ψ angles (torsion angles around the N-Cα 
bond and the Cα-C bond, respectively) characteristic of both α- and 310-helix, where α-
helices have an average ϕ angle of −57° and an average ψ angle of −70°. 310-helicies 
typically have average ϕ angles of approximately −49° and average ψ angles of −26° 
(Figure 5C) (183-185). Interestingly, residues 10-13 appear to usually form an α-helical 
turn, but they can also adopt a 310-helical structure (Table 6, Models 10 and 11). 
Furthermore, the DSSP secondary structure analysis reveals that approximately 15% of 
all models de novo folded and refined with RosettaNMR contained both α- and 310-
helical conformation, but the majority of models were primarily α-helical (Figure 6). 
These results match D’Ursi et al.’s NOE data, which support an unambiguously α-helical 
C-terminal region (residues 15-19), whereas the N-terminus of PrRP20 appeared to be in 
a conformational equilibrium, fluctuating between α-helix, 310-helix, and nascent helix or 
coil. It is noteworthy that the new ensemble agrees well with D’Ursi et al. considering the 
sparseness of the available data, which recapitulates RosettaNMR’s sampling efficiency.  
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Table 4:  Statistics for restraints, structural calculations, and structural quality for final 
ensemble of PrRP models 
NMR)distance)restraints)used)during)folding)and)refinement#Total#restraints# 51#Chemical#shiftsa# 13#Distance#restraints# #Total#NOE# 38#Intra_residue# # 0#Inter_residue# 38#Sequential#(|i−j|#=#1)# 27#Medium_range#(|i−j|#<#5)# 11#Long_range#(|i−j|#≥#5)# 0#
) #
Structural)statistics# #Violations#of#distance#restraints#(Å)b# 0.08#±#0.11#Deviations#from#idealized#geometry# #Bond#lengths#(Å)# 0.024#Bond#angles#(°)# 0.8#Main#chain#RMSD#to#the#mean#structure#(Å)# 0.83#Average#main#chain#pairwise#RMSD#(Å)# 1.10#Ramachandran#plot#statistics#(%)# #Most#favored#regions# 85.6#Additionally#allowed#regions## 14.4#
a Chemical shifts were used only during fragment generation and were not used during de novo 
folding and refinement. b For analysis, a violation of a restraint was counted if the inter-proton 
distance was > 5.5Å (weak) or 3.5Å (strong). There are no distance restraint violations greater 
than 0.4Å. 
 
 
 
Table 5:  NMR distance restraints violated by final ensemble of PrRP models 
Residue 
Pair 
NOE 
Type 
NOE 
Strengtha 
Number of 
Models 
Violatingb 
This Restraint 
Average Violation Distance (Å) 
17-18 Hα-HN strong 14 0.06 ± 0.002 
19-20 Hβ-HN strong 6 0.30 ± 0.11  
a During folding and refinement, NOEs were classified as either “weak” (proton-proton distance ≤ 
5Å) or “strong” (proton-proton distance ≤ 3Å). b For analysis, a violation of a restraint was 
counted if the inter-proton distance was > 5.5Å or 3.5Å, respectively). 
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Figure 5:  Evidence of helical secondary structure in the PrRP ensemble of models 
A) WebLogo (http://weblogo.berkeley.edu/) summarizing the consensus secondary structure 
information obtained by DSSP; C=coil, T=turn, H=α-helix. B) Close-up view of backbone 
interactions between residues 12-18. Oxygens are colored in red, nitrogens in blue, and hydrogens 
in white. C) Ramachandran plot of ϕ/ψ angles of the models as computed by DSSP; gray=angles 
obtained for all models generated; black=angles for final ensemble. 
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Table 6:  Secondary structure analysis of PrRP8-20 models by DSSPa analysis 
State) Secondary)Structure)
#)
Residues)
αDHelix)
(H))
#)
Residues)
310DHelix)
(G))
#)
Residues)
Turn)(T))
#)
Residues)
Bend)(S))
#)
Residues)
Coil)(D))1# __HHHHSHHHHH_# 9# 0# 0# 1# 3#2# _HHHHHTHHHHH_# 10# 0# 1# 0# 2#3# _HHHHHTHHHHH# 10# 0# 1# 0# 1#4# _HHHHHTHHHHH_# 10# 0# 1# 0# 2#5# _HHHHHTHHHHH_# 10# 0# 1# 0# 2#6# _THHHHTHHHHH_# 9# 0# 2# 0# 2#7# _THHHHTHHHHH_# 9# 0# 2# 0# 2#8# _THHHHTHHHHH_# 9# 0# 2# 0# 2#9# _THHHHTHHHHH_# 9# 0# 2# 0# 2#10# __GGGGTHHHHT_# 4# 4# 2# 0# 3#11# __GGGGTHHHHT_# 4# 4# 2# 0# 3#12# _THHHHTHHHHH_# 9# 0# 2# 0# 2#13# _HHHHHTHHHHH_# 10# 0# 1# 0# 2#14# __HHHHTHHHH__# 8# 0# 1# 0# 4#15# __HHHHTHHHH__# 8# 0# 1# 0# 4#16# __HHHHTHHHH__# 8# 0# 1# 0# 4#17# __HHHHTHHHH__# 8# 0# 1# 0# 4#18# _THHHHTHHHHH_# 9# 0# 2# 0# 2#19# _HHHHTTHHHHH_# 9# 0# 2# 0# 2#20# _HHHHTTHHHHH_# 9# 0# 2# 0# 2#
a For more information, go to http://swift.cmbi.ru.nl/gv/dssp/. In this case, H=alpha-helix, G=3-
10 helix, S=bend, T=hydrogen-bonded turn, (-)=random coil. ####
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Figure 6:  Secondary structure of PrRP models generated with RosettaNMR 
DSSP was used to determine the secondary structural make up of all models (left) generated, as 
well as the final ensemble submitted to the Protein Model Database (right). All models contained 
at least 1-2 residues having non-helical character (i.e., unstructured, turn, bend, etc.). 
 
Structural investigations of PrRP by CD spectroscopy indicate a decreased helical 
propensity for PrRP8-20.  
To elucidate the structural and functional requirements for PrRP20 binding and 
receptor activation, a set of PrRP analogs was synthesized and characterized (Table 3). 
Because the C-terminal region of the peptide is presumably responsible for receptor 
binding and activation (28, 30, 34, 36), we focused primarily on N-terminal truncation of 
PrRP20 to PrRP4-20, PrRP8-20, and the shortest reported full agonist, PrRP14-20 (30). 
CD spectra of PrRP20 and PrRP4-20 recorded in aqueous phosphate buffered solution at 
pH 7.0 and 22°C show significantly more intense signal between 200-230 nm in 
comparison to PrRP14-20, which is expected to be flexible and mostly disordered. 
Further, the CD spectrum of PrRP8-20 in phosphate buffer also suggests a primarily 
disordered peptide; the slight maximum at approximately 228 nm suggests the presence 
of some poly-proline II helix conformation as well (186, 187) (Figure 7, left panel). 
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Interestingly, according to the spectra of PrRP20 and PrRP4-20, the peptides may contain 
some ordered secondary structural character, including 310-helix (Table 7); note the deep 
minima at ~205 nm and the shoulder at ~222 nm. This is also supported by the peptides’ 
R222/208 values of 0.46 ± 0.01 and 0.37 ± 0.02, respectively. According to Toniolo et al., 
this ratio is expected to be between 0.15 and 0.40 for 310-helical peptides and ~1.0 for α-
helical peptides (188, 189). 
 
#
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Figure 7:  Influence of different solvents on the structure of wildtype and mutant PrRP 
Left panel: Truncation mutants of PrRP20 (PrRP4-20, PrRP8-20, and PrRP14-20). Right panel: 
Single-mutant PrRP20 analogs (A15PrRP20, A19PrRP20, and A20PrRP20). CD spectra are 
represented in mean residue ellipticity, measured in 40 µM peptide in 10 mM phosphate buffered 
solution at pH 7 and 22°C. (A) CD spectra measured without additives, (B) in 100 mM micellar 
SDS solution, and (C) 25% TFE-containing solution. All curves were calculated with the baseline 
corrected for buffer effects. 
A 
B 
C 
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Table 7:  Characterization of CD data 
Peptide)
Condition) Ratio)[R])±)SD)
pH)7,)10)mM)pb) [θ]222)[θ]208)PrRP20# aqueous# 0.46#±#0.01#PrRP4_20# aqueous# 0.37#±#0.02#PrRP8_20# aqueous# NC#PrRP14_20# aqueous# NC#PrRP20# 100#mM#SDS# 0.54#±#0.01#PrRP4_20# 100#mM#SDS# 0.63#±#0.01#PrRP8_20# 100#mM#SDS# NC#PrRP14_20# 100#mM#SDS# 0.40#±#0.05#PrRP20# 25%#TFE# 0.68#±#0.01#PrRP4_20# 25%#TFE# 0.65#±#0.01#PrRP8_20# 25%#TFE# 0.45#±#0.08#PrRP14_20# 25%#TFE# 0.54#±#0.03#
pb = phosphate buffered; SD = standard deviation; NC = not considered for reasons of missing 
characteristic helical CD spectra. 
 
Next, we investigated the peptide in solvents mimicking the partially apolar 
membrane environment while retaining a certain biocompatibility. We will label the three 
experimental conditions as “aqueous,” “SDS,” and “TFE” throughout the remainder of 
the manuscript. For PrRP20 tested in 100 mM SDS solution, a well-known membrane 
mimicking detergent, we observe a maximum at 195 nm, a minimum at 205 nm, and a 
shoulder around 222 nm (Figure 7B, left panel); the latter two spectral features are 
indicative of a 310-helical component to the conformational ensemble. The characteristic 
minima for solely α-helically structured peptides are at 208 nm and 222 nm (190). 
However, the R222/208 value of 0.54 ± 0.01 is higher than expected for a pure 310-helix. 
We therefore conclude that, in SDS, PrRP20 adopts a partially α-helical conformation, 
with 310-helix and other secondary structural components also being present. Similar 
observations were observed for PrRP4-20 (R222/208 = 0.63 ± 0.01). The CD spectra of 
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PrRP14-20 has 310-helix character, (R222/208 = 0.40 ± 0.05), whereas PrRP8-20 appears to 
remain primarily coil/poly-proline II helix under these conditions (Figure 7B, left panel; 
Table 7).  
Fluorinated alcohols, such as trifluoroethethanol, or TFE, are organic solvents that 
induce environmental constrains; TFE/water mixtures exhibit helix-inducing 
biocompatible conditions. For CD spectroscopy of PrRP20 and PrRP4-20 measured in 
TFE/water, R222/208 values of 0.68 ± 0.01 and 0.65 ± 0.01, respectively, were calculated. 
These values support the assumption that the peptides are primarily α-helical (Table 7). 
Indeed, in TFE/water, the helical content of the full-length peptide increased, with the 
spectrum exhibiting deep minima at 208 nm and 222 nm. These minima are more 
pronounced than those seen in the CD spectra obtained in SDS micelles. In contrast, the 
spectra of PrRP8-20 and PrRP14-20 in TFE are more reminiscent of that of a mixture of 
helices with a strong 310-helix component. Both peptides exhibit a minimum at 
approximately 202 nm and a shoulder at about 220 nm (Figure 7C, left panel). Further, 
the R222/208 values for these peptides were 0.45 ± 0.08 and 0.54 ± 0.03, respectively 
(Table 7). The experiments in TFE were repeated at various pH-values and temperatures 
of 25°, 37°, and 50° for both PrRP20 and PrRP8-20 in order to confirm that the spectra 
were largely independent of these parameters (Figure 8). 
#
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Figure 8:  Structural effects of pH and temperature 
CD spectra were recorded from 190–250 nm with 40 µM PrRP8-20 and PrRP20 in 10 mM 
phosphate buffered solution (Materials and methods), and mean residue ellipticity was calculated. 
(A) Measurement performed at pH 7 and 5.5. (B) PrRP20 was tested at different temperatures and 
showed no change. 
 
Single-substituted PrRP20 analogs do not exhibit different secondary structure from wt 
PrRP20. 
Single alanine mutants of PrRP20 at R15, R19, and F20 positions have been 
previously implicated with peptide activity (30, 34, 36) and were also tested here. Note 
that the highly conserved C-terminal residues, R19 and F20, make PrRP a member of the 
RF-amide peptide family. To study the influence of the conserved RF-amide motif and 
the impact of charged amino acids at the hydrophilic side of the helix on the overall 
peptide structure, we performed CD spectroscopy on A15PrRP20, A19PrRP20, and 
A20PrRP20 compared to wt PrRP20 (Figure 7, right panel; Table 7). Interestingly, all 
tested conditions (aqueous, SDS, TFE) resulted in almost identical CD spectra for 
PrRP20 and all alanine mutants. Although CD spectroscopy is not sensitive to identify 
small, local rearrangements in the peptide, we conclude that the modified single side-
chains at positions 15, 19, and 20 have no impact on the overall secondary structure of 
A B 
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the peptide. Therefore, any loss of activity when interacting with the receptor results from 
a change in the interaction with the receptor rather than a change in structure or dynamics 
of the peptide (see Binding to and activation of the wt PrRP receptor is primarily 
mediated by direct interactions with PrRP). 
#
Binding to and activation of the wt PrRP receptor is primarily mediated by direct 
interactions with PrRP. 
To evaluate the biological relevance of the PrRP20 analogs, binding and signal 
transduction capabilities were investigated in COS-7 cells transiently transfected with the 
PrRP receptor. In a displacement assay with the wt PrRP receptor using 1 nM 
N[propionyl3H]hPrRP20, an IC50-value of 4.1 ± 0.7 nM was obtained, where IC50 is the 
inhibition concentration of the ligand at half maximum biological activity of the receptor. 
A dissociation constant, or KD, value of 0.58 nM was computed using established 
methods(191). The activity of PrRP20 was determined using an IP, or inositol phosphate, 
accumulation assay (see Materials and methods) and resulted in an EC50-value of 2.2 ± 
0.3 nM (Table 8). The EC50 is the effective concentration of the ligand at half maximum 
biological activity. 
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Table 8:  Effects of mutation of PrRP on binding and signaling 
Peptide 
Binding Assay Signal Transduction Assay 
IC50 [nM]a x-foldb EC50 [nM]c x-foldd 
PrRP20 4.1 ± 0.7 1 2.2 ± 0.3 1 
PrRP4-20 1.2 ± 0.1 0.3 1 ± 0.2 0.5 
PrRP8-20 7 ± 1.8 1.7 2.3 ± 0.5 1 
PrRP14-20 430 ± 16 105 14 ± 2 6 
A15PrRP20 882 ± 376 215 49 ± 12 22 
A19PrRP20 > 10000 > 2440 1198 ± 231 545 
A20PrRP20 870 ± 288 212 20 ± 5 9 
Values are the standard deviation (± SD) of parameters deduced by using GraphPad Prism 3.0 
software. IC50 and EC50 values were obtained from resulting concentration-response curves. All 
signal transduction assays were performed in duplicates and repeated at least twice 
independently. a COS-7 cells were transiently transfected with PrRP receptor. The IC50 value was 
determined by competition assays using N[propionyl3H]hPrRP20. b Ratios with respect to the IC50 
values of wt peptide: IC50 (peptide)/IC50 (PrRP20). c COS-7 cells were transiently transfected with 
wt hPrRP receptor. EC50-values were obtained from IP accumulation assay. d Ratios with respect 
to the EC50 values of wt peptide: EC50 (peptide)/ EC50 (PrRP20). 
 
The radioligand binding assays revealed IC50-values of 1.2 ± 0.1 nM and 7 ± 1.8 
nM for PrRP4-20 and PrRP8-20, respectively. These values are comparable to PrRP20 
(4.1 ± 0.7 nM, The heptapeptide, PrPR14-20, exhibited a 105-fold reduction in binding 
compared to PrRP20. Loss of binding was even more dramatic in the single mutant 
analogs: an IC50-value of 870 ± 288 nM was obtained for A20PrRP20, whereas for 
A19PrRP20, no IC50-value could be determined for concentrations of up to 10 µM of the 
ligand. A15PrRP20 behaved similarly to A20PrRP20, resulting in a 215-fold decrease in 
binding (Table 8). 
In the signal transduction assays with the wt receptor, A19PrRP20 revealed a 545-
fold increase in EC50-values (1198 ± 231 nM) over unmodified PrRP20 (2.2 ± 0.3 nM). 
A20PrRP20 and A15PrRP20 had a lower impact in IP accumulation. The EC50-values were 
only 9- and 22-fold increased compared to the unmodified PrRP20, respectively. Apart 
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from PrRP14-20, which exhibited a 6-fold increased EC50-value of 14 ± 2 nM, the 
truncated analogs, PrRP4-20 and PrRP8-20, showed wildtype-like signaling properties 
(Table 8). 
#
PrRP8-20’s is unable to activate extracellular loop 1 PrRP receptor mutants. 
Next, we investigated the interaction of PrRP8-20 and PrRP20 with different 
receptor mutants. Because extracellular loop 1, referred to as EL1 for the remainder of 
this discussion, of other peptide receptors is known to be important for interactions with 
the ligands (192, 193), we assumed that charged or aromatic amino acids of the EL1 
region may be involved in ligand recognition via hydrophobic, ionic, or π-cationic 
interactions. Therefore, we substituted all such residues between position 2.64 and 2.73 to 
alanine (Table 9). The single-substituted F2.66A, E2.67A, R2.69A, and F2.73A receptor 
mutants behaved like wt PrRP receptor after treatment with PrRP20 in an IP 
accumulation assay. However, Y2.64A and W2.71A PrRP receptor variants resulted in 
significantly increased EC50-values when stimulated with PrRP20 (50 ± 7.5 nM and 593 
± 78 nM, respectively). Stimulation of receptor mutants Y2.64A and W2.71A with PrRP8-
20 revealed a further right-shifted concentration-response curve when compared to 
activation with PrRP20 (Figure 9) and hence elevated EC50-values (434 ± 96 nM and 
2119 ± 390 nM, respectively, Table 9). We hypothesized that changes in structure or 
dynamics of the ligand might cause this difference in receptor activation, as 
mutation/deletion studies of residues 1-7 did not suggest a direct contact point between 
this part of the ligand and the receptor.  
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Table 9:  Signaling properties of PrRP8-20 with respect to PrRP receptor 
Receptor 
Mutants 
PrRP20 PrRP8-20 
EC50  
[nM]a x-fold
b EC50 [nM]a x-fold
b 
wt PrRP receptor 2.2 ± 0.3 1 2.3 ± 0.5 1 
Y2.64A 50 ± 7.5 23 434 ± 96 197 
F2.66A 6.2 ± 3.3 3 NT - 
E2.67A 7.2 ± 3.4 3 NT - 
R2.69A 4.2 ± 2.5 2 NT - 
W2.71A 593 ± 78 270 2119 ± 390 963 
F2.73A 4.4 ± 2 2 NT - 
NT = not tested; Values are the standard deviation (± SD) of parameters deduced by using 
GraphPad Prism 3.0 software. EC50 values were obtained from resulting concentration-response 
curves. All signal transduction assays were performed in duplicate and repeated at least twice 
independently. a COS-7 cells were transiently transfected with wt hPrRP receptor. EC50-values 
were obtained from IP accumulation assay. b Ratios with respect to the EC50 values of wt peptide: 
EC50 (peptide)/ EC50 (PrRP20). 
 
 
 
 
Figure 9:  IP accumulation of PrRP and truncated analogs test at PrRP receptor mutants 
COS-7 cells were transiently transfected with DNA coding for the wt, Y2.64A, or W2.71A receptor. 
The signal transduction assay was performed with PrRP20, PrRP8-20, as well as with PrRP14-20 
for wt PrRP receptor. All experiments performed with PrRP8-20 lead to a significantly right 
shifted curve, whereas PrRP8-20 behaves like PrRP20 with respect to wt receptor. ##
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Discussion 
Structure-activity/affinity studies are needed to understand PrRP receptor activation.  
The objective of this study is to better understand the structural determinants of 
PrRP receptor activation, an important milestone towards the development of potent 
small-molecule agonists given the increasing prevalence for the physiological role of 
PrRP20 and its receptor (171). This is a formidable challenge, as structure-activity 
relationship studies of PrRP/PrRP receptor system are rare. Initial investigations of the 
truncated PrRP20 analogs, PrRP4-20 and PrRP8-20, exhibited wildtype-like binding and 
IP accumulation behavior. Further, in our assay system, a reduced affinity of the full 
agonist, PrRP14-20, is in accordance with recent studies (30, 34). We hypothesized that 
the structure and dynamics of PrRP’s interaction with the receptor is altered through the 
truncation, rather than single point mutation, of the peptide. This hypothesis was tested 
through CD and NMR spectroscopic studies that assert the secondary structure of the 
peptide. To mimic the amphipathic environment of the peptide when it is interacting with 
the receptor, the additives SDS and TFE were used (194, 195). 
 
CD and NMR spectroscopic studies support a mainly helical peptide conformation.  
While SDS is an accepted membrane mimic, TFE mainly induces secondary 
structure (196). SDS micelles provide a non-isotropic, apolar environment in which the 
membrane interactions of the biomolecules can be investigated. A molecular dynamics 
study has shown that, in a TFE/water mixture, the organic co-solvent aggregates around 
the peptide, forming a matrix that partly excludes water. This process stabilizes the 
secondary structure, as the formation of proximate interactions is assisted.38 We suggest 
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that, to some extent, both solvents mimic the membrane surface thought to contribute to 
the transition of the peptide from a random coil to a helical conformation that is 
recognized by the receptor (197). Accordingly, we assume that PrRP20 will adopt a 
conformation more similar to the bioactive form when interacting with these solvents. 
According to our CD spectroscopic studies, the single mutant PrPR20 analogs, 
A15PrRP20, A19PrRP20, and A20PrRP20, fully maintained their PrRP20-like α/310-helical 
conformation in SDS and TFE. This is especially remarkable because all of them display 
significantly reduced binding and signaling properties with respect to the wt receptor. It is 
noteworthy that the binding and signaling studies herein are in agreement with recently 
published structure-activity studies that describe the importance of R15, as well as the RF-
amide motif (30, 34). PrRP20 and PrRP4-20, while exhibiting some 310-helical character 
in phosphate buffer, became increasingly α-helical in SDS and TFE. In contrast, PrRP8-
20 appears to be primarily disordered, or nascent helix at most, in SDS. Its 310-helix 
component does increase in TFE, but it is almost undoubtedly not an α-helix, unlike the 
full-length peptide. Our results indicate that the peptide length of PrRP is a significant 
determinant in its ability to form an α-helix. It appears that the N-terminus, which 
exhibits increased flexibility, is nevertheless involved in stabilizing the C-terminal helical 
segment. Even though PrRP8-20 fully activates the wt receptor (Figure 9), it shows little 
α-helical propensity in SDS and TFE when compared to PrRP20.  
Earlier CD studies could not clearly distinguish between 310- and α-helical peptide 
structures, which were investigated using a set of seven peptides ranging in length from 
10 to 21 amino acid residues (198). In contrast, a recent report describes the standard CD 
spectrum of a 310-helial octapeptide (188). Indeed, evidence of this combination of coil 
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and helical secondary structure can be seen in the CD spectra of the PrRP analogs, which 
were collected in SDS micelles or TFE (Figure 7, left panel). The shape of PrRP20 and 
PrRP4-20 in TFE fits to the former described spectrum for an α-helical peptide (188, 
199). In the case of PrRP8-20, the membrane-mimicking SDS micelles are not capable of 
inducing α- or 310-helical conformation, in contrast to the longer peptides. For the analogs 
PrRP8-20 and PrRP14-20, the shape of the curves is altered, having a lower Cotton effect 
and different minima. 
The combination of CD and computational modeling results, as well as analysis 
of the 13 C-terminal residues of PrRP20, imply a structural model for the full-length 
peptide, in which the peptide forms an extended helix. According to a secondary structure 
analysis of the final ensemble with DSSP (181, 182), it appears that, in most low-energy 
RosettaNMR models, 8-9 of the 13 residues tend to be α-helical. The ideal helical 
geometry is broken around residue I14. This is expected due to the lack of ideal α-helix 
hydrogen bonding between R12 and P16, as well as between G13 and V17. In our model, the 
helix bulges and bends in this area. Interestingly, the helical character of the models can 
either consist of all α-helix or a combination of approximately half α-helix and half 310-
helix (Table 6, Models 10 and 11); this matches observations from CD investigations of 
PrRP20 and PrRP4-20, as well as the combination of i(i+2) and i(i+3) NOEs obtained by 
D’Ursi et al. on PrRP20 (Table 2). According to these data, PrRP20 in solution is not 
solely α-helical, nor is it completely random coil.  
The presence of potential 310-helical character in the PrRP20 models may be a 
result of its amphipathic nature and the fact that the NMR data were also collected in 
SDS micelles at high PrRP20 concentration (0.5−15 mM) (35). Indeed, there is evidence 
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that amphipathic helices can assume extended (often 310) helical conformations in certain 
mediums, such as in detergent micelles (200, 201). Remarkably, it has been proposed that 
the R1xxR2xxR3xxR4xxR5xxR6 motif in the Kv1.2- and Kv2.1-chimeric potassium ion 
channel structures form an extended 310-helix, which allows the arginine residues to sit 
on the same side of the helix (202, 203). This is also often observed in our models of 
PrRP, which contains three arginine residues in an R1xxR2xxxR3 motif. Further, the 
conformational equilibrium between nascent, α-, and 310-helix is seen in other systems. 
Another neuropeptide, the galanin-like peptide (GALP) has been shown to be only 
loosely ordered in solution, but in TFE, it forms stable helical structures. Indeed, its CD 
spectrum resembles that of a 310-helix and is similar to our CD spectra obtained for 
PrRP20 in buffer and SDS and PrRP8-20 in TFE (204). The 16 amino acid sequences of 
the C-terminal helices of two bacterial cytochromes were synthesized and characterized 
by CD and NMR spectroscopy. These peptides’ spectra also imply a dynamic equilibrium 
between α- and 310-helix (205). It is possible that this conformational equilibrium is due 
to folding and unfolding of the free (as opposed to receptor-bound) peptide in solution; 
the 310-helix is often considered to be a kinetic intermediate when forming an α-helix 
from coil (184, 206, 207). 
#
Receptor residues Y2.64 and W2.71 may induce ligand helicity and facilitate binding and 
activation.  
To further elucidate the role of N-terminal PrRP20 truncations with respect to 
ligand binding, we chose to study the EL1 of the receptor because this region is known to 
be a prominent agonistic binding region in GPCRs. With respect to receptor activation, 
the alanine scan of selected amino residues within EL1 of the PrRP receptor identified the 
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aromatic residues Y2.64 and W2.71 to be important. Both residues might contribute to a 
hydrophobic cluster, as described for the neurotensin receptor 1, where EL1 is described 
to be stabilized by π-stacking clusters and was proved to be important for agonist binding 
(208). In addition, Y2.64 in particular has already been identified to participate in ligand 
binding in the Y1 receptor (209) and is thought to be part of a formed cluster in the 
binding-site crevice at the aminergic GPCR (210). PrRP20 stimulation resulted in 
increased EC50-values in Y2.64A and W2.71A PrRP receptor mutants. This fits to the 
reported ligand-binding and receptor-activating role of EL1 in GPCRs (192, 193, 211). In 
particular, W2.71 is located in the previously described WxGF-motif (212), which is 
necessary for receptor activation. Activation by a ligand occurs most likely by inducing 
movement of the transmembrane helices. While PrRP20 and PrRP8-20 exhibit identical 
potency for the wt receptor, PrRP8-20 was less potent at theY2.64A or W2.71A PrRP 
receptor. 
Combining these findings, we expect that the receptor assists PrRP in forming its 
bioactive α-helical conformation. This conformation is induced by the wt receptor for 
PrRP20, as well as PrRP8-20, even though its α-helical propensity is reduced due to the 
missing residues 1-7. However, the mutations Y2.64A and W2.71A partially impair the 
helix-inducing capabilities of the receptor. This leads to a reduced activity for both 
peptides PrRP20 and PrRP8-20. The reduced helical propensity of PrRP8-20 results in a 
more dramatic loss of activity for its interaction with the mutant receptors. The results 
obtained from our structure-activity and spectroscopic studies suggest that Y2.64 and W2.71 
provide part of the hydrophobic framework that induces helicity in the ligand.  
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Conclusion 
The C-terminal segment of PrRP20 was shown by NMR and CD spectroscopy to 
adopt a combination of α- and 310-helical conformation in SDS micelles and becomes 
primarily α-helical in TFE. Moreover, the decreased stability of the helical segment 
generated by shorter PrRP20 analogs resulted in reduced biological activity. In contrast, 
single amino acid replacement of crucial residues led to significantly decreased binding 
and activity, while the overall peptide structure was maintained. With respect to future 
structure/activity studies, we disclose that a stable C-terminal α-helix facilitates the 
ligand recognition by its receptor. By making a three-dimensional structure of PrRP 
publicly available, the structure-function studies can now be performed more effectively 
with the ability to look at the structure of the peptide itself. Additionally, the 
identification of the important residues Y2.64 and W2.71 with respect to ligand binding and 
receptor activation offers an initial step, as comprehensive structure/activity studies are 
rare and no antagonist of the PrRP receptor is known. Due to the involvement of PrRP20 
in energy and body weight homeostasis and food intake, it provides a remarkable target 
for future drugs (171). The Cartesian coordinates of the ensemble of structures of the 
PrRP20 C-terminal segment discussed herein has been included in the Supplementary 
Information, as well as deposited in the Protein Model Database (PMID: PM0078404) for 
other researchers to use to further their own studies. 
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CHAPTER III 
 
INTEGRATING SOLID STATE NMR AND COMPUTATIONAL MODELING 
TO INVESTIGATE THE STRUCTURE AND DYNAMICS OF MEMBRANE-
ASSOCIATED GHRELIN 
 
This work is based on the manuscript submitted to PLoS ONE of the same title by 
Gerrit Vortmeier*, Stephanie H. DeLuca*, Sylvia Els-Heind, Constance Chollet, Holger 
A. Scheidt, Annette G. Beck-Sickinger, Jens Meiler, and Daniel Huster. *These authors 
contributed equally. 
 
Summary 
The peptide hormone ghrelin activates the growth hormone secretagogue receptor 
1a (GHS-R1a), also known as the ghrelin receptor. This 28-residue peptide is acylated at 
Ser3 and is the only peptide hormone in the human body that is lipid-modified. Little is 
known about the structure and dynamics of membrane-associated ghrelin. We carried out 
solid-state NMR studies of ghrelin in lipid vesicles, followed by computational modeling 
of the peptide using Rosetta. Spin diffusion experiments of ghrelin indicate that the 
peptide binds to membranes via its lipidated Ser3. Further, Phe4, as well as electrostatics 
involving the peptide’s positively charged residues and lipid polar headgroups, may 
contribute to the binding energy. Other than the lipid anchor, ghrelin is highly flexible 
and mobile in solution. This observation is supported by our model, which is in good 
agreement with experimentally determined chemical shifts. In the final ensemble of 
models, residues 8-17 form an α-helix, while residues 21-23 and 26-27 often adopt a 
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polyproline II helical conformation. These helices appear to assist the peptide in forming 
an amphipathic conformation so that it can bind to the membrane. 
 
Introduction 
Ghrelin, a 28-amino acid peptide hormone, is the endogenous ligand of the 
growth hormone secretagogue receptor 1a (GHS-R1a or GHSR), a G protein-coupled 
receptor (GPCR) (41, 213, 214). In addition to stimulating the release of growth hormone 
from the pituitary (41, 213, 214), it has been implicated in appetite stimulation (215), 
insulin and glucagon secretion levels (216), decreased blood pressure (217), inhibition of 
apoptosis in cardiomyocytes and endothelial cells, and cell proliferation and 
differentiation (218). Further, circulating ghrelin levels have been found to change in 
patients with diseases involving perturbed energy balance, such as obesity (54, 219-222) 
and diabetes (223). See reference (224) for thorough review. Given the current 
prevalence and rapidly increasing rates of obesity and related conditions, it is of 
importance to understand the mechanism of action of ghrelin in order to eventually 
contribute to the understanding of the molecular basis of these diseases. 
Ghrelin carries a fatty acid (FA) modification at position Ser3 and represents the 
only hormone in the human body that is lipid modified. Although the desacylated form of 
ghrelin is the most abundant in the bloodstream, the FA modification proves necessary 
for receptor binding and activation. The initial identification of acylated ghrelin revealed 
an octanoyl group at Ser3 (41), but ghrelin O-acyltransferase can add FA groups of 
varying lengths to the peptide (58-60). Remarkably, the length of the lipid side-chain has 
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a demonstrated effect on the ability of ghrelin to activate GHSR and on levels of 
adiposity in mice (225). 
Bednarek, et al. identified a short N-terminal segment, spanning from Gly1 to 
Phe4, including the octanoylated Ser3, that is able to activate the GHSR in vitro (226), but 
this active core neither displaces ghrelin from its receptor nor stimulates growth hormone 
release in vivo (227). This may be due to the influence of the membrane surface on 
transport and receptor binding. Membrane binding of a ligand is a crucial step for 
membrane-receptor activation. The limitation of ligand diffusion to two dimensions, as 
well as structural pre-orientation and pre-organization of the ligand, may lead to 
enhanced peptide-receptor interaction probability (228). However, more structural and 
dynamic information of the peptide in solution, membrane-bound, and receptor-bound 
states is needed to further examine this so-called “membrane catalysis”. 
Our current understanding of the structure of membrane-bound ghrelin is 
fragmentary at best. Spectroscopic studies from proton nuclear magnetic resonance (1H 
NMR) and circular dichrosim (CD) of ghrelin in solution revealed a highly flexible 
peptide without a distinct structure, regardless of whether or not Ser3 was acylated (61). 
CD experiments conducted in the membrane mimics, sodium dodecyl sulfate (SDS) and 
trifluoroethanol (TFE), showed formation of an α-helix with increasing TFE content (62), 
and molecular dynamics (MD) simulations in water and in 1,2-dihexanoyl-sn-glycero-3-
phosphocholine (DMPC)-lipid bilayer/water systems suggest that this helix extends from 
Pro7 to Gln13 (63). Chemical shift (CS) data from 1H NMR experiments performed in 
phosphate buffered saline and in live cells also indicated a putative α-helix between 
residues Glu8 and Lys20, while the peptide remained seemingly unstructured in water 
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(64). A structure of desacyl-ghrelin solved with CS data from 1H NMR experiments 
performed in a water/hexafluoroacetone (HFA) mixture supports the presence of a stable 
α-helix spanning from Pro7 to Gln14 (229). Furthermore, controversial results were 
published about the membrane binding segment. While simulations propose a C-terminal 
loop that mediates binding, with the octanoyl moiety pointing towards the aqueous phase 
(63), solution NMR experiments suggested that the peptide binds to detergent micelles 
via Phe4 and the lipid-modified Ser3 (230). 
Lipid modifications typically serve as membrane anchors (231, 232). However, a 
short octanoyl chain is only weakly hydrophobic, and the strength of its interaction with 
the membrane has yet to be determined. In order to characterize the structure and 
dynamics of octanoylated ghrelin and how it interacts with the membrane, we employed 
solid-state NMR spectroscopy (ssNMR), which has been demonstrated to be a useful and 
versatile tool for studying membrane-associated proteins and peptides (233-235). We 
show that ghrelin binds to large unilamellar vesicles (LUVs) via its octanoyl chain and 
assumes a highly mobile structure at the membrane surface. 
Previous research indicates that ghrelin is highly flexible, even in the presence of 
membranes, and its secondary structure propensities in LUVs remain unknown. 
Therefore, the CSs obtained from ssNMR were used in combination with the Rosetta 
molecular modeling software (100, 101, 103), which has been widely used for protein 
structure prediction. NMR CSs can be used to enhance Rosetta’s ability to sample native-
like structures (106, 107, 236, 237), with modeling of membrane and membrane-
associated proteins becoming more feasible. Recently, the structure of hepatitis C virus 
protein p7, a small, helical membrane protein, was determined using the 
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RosettaMembrane environment (105, 156) with NMR CS, residual dipolar coupling 
(RDC), and paramagnetic relaxation enhancement (PRE) structural data (238). In 
addition to the extensive ssNMR studies mentioned above, we present a new, detailed 
protocol for elucidating the structural ensemble of membrane-associated ghrelin that is 
consistent with sparse CS data. 
 
Materials and methods 
Materials 
1,2-Dimyristoyl-sn-glycero–3-phosphocholine (DMPC), 1,2-dimyristoyl(d54)-sn-
glycero–3-phosphocholine (DMPC-d54), 1,2-dimyristoyl(d54)-sn-glycero–3-
phosphocholine–1,1,2,2-d4-N,N,N-trimethyl-d9 (DMPC-d67), 1,2-dimyristoyl-sn-glycero–
3-phosphatidylserine (DMPS), 1,2-dimyristoyl(d54)-sn-glycero–3-phosphatidylserine 
(DMPS-d54), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG) were purchased from Avanti 
Polar Lipids, Inc. (Alabaster, AL) and used without further purification. 13C/15N Fmoc-
protected amino acids and deuterated octanoic acid were obtained from Euriso-Top 
GmbH, Saarbrücken, Germany. All other materials were purchased from Sigma, 
Deisenhofen, Germany. 
 
Peptide synthesis 
Ghrelin analogs were synthesized automatically on a Wang resin by solid-phase 
peptide synthesis (SPPS) using Fmoc/tBu protection group strategy on a robot system 
(SyroI, MultiSynTech, Bochum, Germany) as described previously.(239) 13C/15N-labeled 
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amino acids were introduced via manual peptide coupling using 5 equiv Fmoc-amino 
acid, 5 equiv DIC and 5 equiv HOBt in DMF. To enable the incorporation of octanoic 
acid or perdeuterated octanoic acid, Ser3 was introduced with the labile Trt side-chain 
protecting group. The ester bond was formed by incubation of 5 equiv octanoic acid, 5 
equiv DMAP, and 5 equiv DCC in NMP with the resin. The final peptides were cleaved 
from the resin in one step, and purification was achieved by preparative HPLC on a 
reversed-phase C18 column (Phenomenex Jupiter 10u Proteo 90 Å: 250 × 21.2 mm; 7.8 
µm; 90 Å). Peptides were analyzed by MALDI-TOF MS (UltraflexII, Bruker, Bremen, 
Germany) and by analytical reversed-phase HPLC on columns VariTide RPC (Varian: 
250 × 4.6 mm; 6 µm; 200 Å) and Phenomenex Jupiter 4u Proteo 300 Å (Phenomenex: 
250 × 4.6 mm; 4 µm; 300 Å)_ENREF_20. The observed masses were in full agreement 
with the calculated masses, and peptide purity ≥ 95% could be obtained, according to the 
analytical RP-HPLC. 
 
Sample preparation 
Aliquots of lipids were co-dissolved in chloroform; the solvent was evaporated, 
and the lipid film was suspended in 10 mM MES buffer (100 mM NaCl, pH 6) to reach a 
final concentration of 20 mM. After freeze-thaw cycles, the suspension was extruded 
across 100 nM polycarbonate membranes to produce LUVs (240). Aliquots of ghrelin 
were added to the LUVs to reach the desired peptide/lipid ratio. Samples were incubated 
for 2 h while shaking it at 190 rpm at 37 °C. Binding to the inner membrane leaflet was 
achieved after performing another five freeze-thaw cycles. The sample was 
ultracentrifuged at ~90.000 g for 8 h. After lyophilization, the precipitate was hydrated to 
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35 WT% water content, mixed with 5 freeze-thaw cycles, and transferred into 4 mm MAS 
rotors with Teflon inserts. 
 
Membrane binding assay 
For membrane binding analysis of ghrelin, 5 µM peptide solutions were 
ultracentrifuged with various amounts of 176 mM sucrose-loaded POPC/POPG vesicles 
(5:1, mol/mol). For each vesicle concentration, 10 µL of a 50 µM peptide solution in H20 
were added to 740 µL of iso-osmolar 1 mM MOPS buffer at pH 7, containing 100 mM 
KCl. Vesicle solutions of various lipid concentrations ranging from 0 mM to 10 mM 
were added to reach a final volume of 1 mL. Each concentration was prepared in 
duplicate, and lipid-only samples were taken to determine background signals. After 
vortexing and 30 min incubation at room temperature, samples were ultracentrifuged 
overnight at ~90.000 g and 4 °C. Immediately after centrifugation, ~900 µL supernatant 
were transferred into Eppendorf tubes. Pellets were resuspended in the remaining solution 
(~100 µL) and diluted by adding 900 µL buffer. 600 µl of both the supernatant and the 
pellet solutions were used to determine peptide concentration using a fluorescamine assay 
(241). The remaining volumes were used to measure the lipid concentration. 
The pH of the samples was elevated to 10 using 5 µL 0.1 M KOH. 250 µL of a 
fluorescamine stock solution in acetone (1 mg/mL) was added to the samples, and the 
fluorescence was measured after ~5 min with excitation at 390 nm and emission at 475 
nm. Background fluorescence determined from the lipid-only samples was subtracted, 
and the percentage of bound peptide was calculated according to the equation: 
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The final lipid concentration was determined by phosphate analysis. 
Approximately 90% of the lipids were in the pellet fraction. Further, half of the lipids are 
not accessible for the peptide because the molecules are on the inside of the vesicles. 
Accordingly, the lipid concentrations were corrected with the factor 0.45 to deliver the 
effective lipid concentration [L]eff (242). 
 
Solid-state NMR Spectroscopy 
2H NMR spectra were acquired using an Avance 750 MHz NMR spectrometer 
(Bruker Biospin, Rheinstetten, Germany) operating at a resonance frequency of 115.0 
MHz for 2H using a quadrupolar-echo pulse sequence, a 90°-pulse length of 2.8 µs, an 
echo time of 60 µs, and a relaxation delay of 0.75 s. Smoothed chain order parameter 
profiles were calculated from the quadrupolar splittings after dePaking, as described in 
reference (243). Standard 31P NMR spectra were acquired on a Bruker DRX300 NMR 
spectrometer operating at a resonance frequency of 121.4 MHz using a standard Hahn 
echo pulse sequence with a 90° pulse length of 10.75 µs, a delay between pulses of 50 µs, 
and a relaxation delay of 2.5 s. The 13C magic angle spinning (MAS) NMR spectra were 
acquired using a Bruker Avance III 600 NMR spectrometer at resonance frequencies of 
600.1 MHz and 150.9 MHz for 1H and 13C, respectively. Typical 1H and 13C 90° pulse 
lengths were 4 and 5 µs, respectively, while the decoupling filed during acquisition was 
~65 kHz using Spinal64. Standard CP (contact time 700 µs), directly excited, and INEPT 
excitation schemes were used. All CSs were referenced to external crystalline glycine at 
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176.46 ppm (equivalent to TMS). Standard 2D HetCor (244) and PDSP (245) spectra 
were acquired, with a total evolution time of 7.1 ms and 1.7 ms in the 1H and 13C indirect 
dimensions, respectively. Constant time DIPSHIFT experiments (246) were carried out at 
a MAS frequency of 4 kHz with FSLG homonuclear decoupling. Dipolar dephasing 
curves were simulated as described in the literature (247). The ratio of the motional 
averaged and full dipolar coupling (248) defined the molecular order parameter, S.  
Spin diffusion experiments from the lipid into ghrelin were carried out using the 
pulse sequence from the literature (249). A T2 filter of 6 ms and spin diffusion times from 
0.01 to 900 ms were used. Peak intensities were corrected for relaxation using measured 
T1 relaxation times. Intensities were normalized to 1 for the longest spin diffusion time of 
900 ms. Spin diffusion build-up curves were simulated as a function of mixing time using 
a one-dimensional lattice model (250). In this model, the magnetization of a given spin 
(Mi) is transferred to the neighboring spins (Mi-1 and Mi+1) according to:  
112 −+ Ω+Ω+Ω−=ΔΔ iiimi MMMtM # # (2)#
The rate of magnetization transfer, 2/ aD=Ω  depends on the spin diffusion 
coefficient, D, and the distance between spins, a. Simulations were carried out using D = 
0.001 nm2/s and a = 2 Å. 
 
Overview of structure determination using Rosetta 
The Rosetta Topology Broker framework (107, 108, 251) was employed to fold 
ghrelin de novo, or from the sequence, in the presence of the implicit RosettaMembrane 
environment (105, 156). The traditional Rosetta fragment-based assembly algorithm for 
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soluble proteins was employed (100, 102). The modeling and analysis protocol is 
summarized in Figure 10, and full details are available in Appendix C. 
 
 
Figure 10:  Flowchart of computational modeling and analysis protocol 
The above flowchart outlines the protocol used to elucidate the structure of ghrelin based on 
ssNMR CS data. 
 
Definition of membrane location in Rosetta 
In order to fold membrane-associated proteins using Rosetta, transmembrane 
helical (TMH) regions must be specified. Therefore, because the modeling objective was 
to fold ghrelin at the membrane interface, a comparative model of GHS-R1a was created 
based on an alignment of nineteen different GHSR sequences and the sequences of 
twenty GPCRs of known structure (Figure 11). This receptor model was only used as a 
proxy to define the membrane location; that is, no interaction between receptor and 
peptide occurs. In the starting conformation for peptide folding, the receptor was placed 
more than 50 Å away from the peptide. During selection of the final ensemble, only 
models having a minimum interatomic receptor-to-peptide distance of 5 Å were analyzed 
and compared to experimental CSs.  
Build comparative model of 
GHS-R1a 
Fold ghrelin in presence of 
membrane environment 
Predict CSs for each model 
Filter for models in proximity to 
membrane 
Determine best CS prediction 
method 
Find ensemble of models that 
best fit experimental data 
Assess final ensemble quality 
Compute models’ secondary 
structure using DSSP 
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Generation of GHSR comparative model to define membrane location in Rosetta 
In order to fold a peptide at the membrane surface, for technical reasons, Rosetta 
requires at least one transmembrane span to define the location of the membrane. We 
decided to construct a comparative model of growth hormone secretagogue receptor 1a 
(GHSR) as we expect to leverage it in future studies. We then used this model to define 
the membrane location but ensured that no interaction between receptor and peptide 
occurs for the present study.  
The comparative model was based on the sequence alignment in Figure 11 and 
generated according to the protocol described previously (19, 252-254). Briefly, GHSR 
amino acid sequences from nineteen species were aligned using ClustalW (19, 252-257), 
resulting in a sequence alignment profile. Next, twenty GPCRs of known structure, 
henceforth referred to as templates, were structurally aligned in Mustang (19, 254, 257-
259), which resulted in a structural alignment profile. Then, a profile-profile alignment 
was performed in ClustalW, and the resulting alignment was manually adjusted to 
minimize gaps in TMH regions and maximize alignment of regions conserved across 
GPCRs (Figure 11).  
The sequence of human GHSR was isolated from the final profile-profile 
alignment and threaded onto the backbone of the bovine rhodopsin structure (PDB: 1U19 
(259-261)). Next, all loops and areas of missing electron density (from alignment gaps) 
were built in for one hundred models using the Rosetta cyclic coordinate descent (CCD) 
loop modeling algorithm (255, 257). The five lowest-energy models that did not contain 
chainbreaks were used as starting models for constructing extracellular loops (ECLs). For 
each starting structure, ECLs 1–3 were constructed for 185–200 models, resulting in a 
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total of approximately 985 complete comparative models. Finally, the lowest energy 
model after building the ECLs was selected to define the membrane in the ghrelin folding 
protocol. 
 
Figure 11:  Sequence alignment of GHSR and GPCRs of known structure 
The sequences of twenty GPCR templates of known structure and nineteen GHSR sequences 
were used manually aligned in Aline (260, 262) 
(http://crystal.scb.uwa.edu.au/charlie/software/aline/) such that gaps in the predicted TMH 
consensus ranges (dark gray helices) were minimized and conserved prolines (white triangles) 
and cysteines (open gray triangles) remained in alignment. 
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Fragment selection of ghrelin in Rosetta 
A complete set of CSs can greatly increase the quality of fragments selected for 
Rosetta de novo structure prediction (106, 263). Fragment selection for de novo folding in 
Rosetta heavily prioritizes peptide fragment conformations that have the same secondary 
structure as that indicated by CS analysis (106, 264, 265). In the case of ghrelin, however, 
the CS dataset is incomplete, i.e. CS assignments are not available for every residue. This 
leads to inconsistencies in fragment selection, where CSs of a few residues can determine 
the secondary structure of the entire fragment. In the present case, the CS data suggest 
that residues 2-5 have β-strand torsion angles. Accordingly, these residues are often 
constructed from fragments that stem from β-hairpins (Figure 12). In result, even though 
the fewer CSs obtained for residues 8-28 are indicative of a random coil region with a 
slight helical tendency, the vast majority of Rosetta models generated from fragments 
selected based on the sparse CS dataset exhibited a β-hairpin fold (data not shown). 
Therefore, we elected to fold with fragments not generated using CS data, thereby 
sampling the complete conformational space reasonable for a peptide of this sequence. 
We then employed CS data to filter, from a large pool of models, an ensemble that agreed 
best with the CS data. This approach has another advantage in the case of highly flexible 
peptides in that the ensemble average CSs, not the CS of a single model, must conform to 
the experimental data.  
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Figure 12:  Secondary structure prediction of ghrelin 
A) Secondary structure prediction for the primary sequence of ghrelin. B) Secondary structure 
composition of 3mer and 9mer amino acid fragments used in de novo folding. These fragments 
were generated based either on the primary sequence of the peptide alone (+CS and –CS). For all 
predictions, α-helices (H) are in green, β-strands (S) are in blue, and random coil (C) are in black.  
 
De novo folding of ghrelin in Rosetta 
During folding in the Topology Broker framework, 3- and 9-amino acid peptide 
fragments were inserted into an extended backbone of the peptide in a Monte Carlo 
fashion. The resulting conformations were scored with the RosettaMembrane (105, 130) 
potentials according to the Metropolis criterion (266). Ten thousand models were 
generated in the presence of the membrane and relaxed within the all-atom membrane 
potential. 
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Prediction of chemical shifts of de novo-folded models 
Predicted CSs for the models generated from de novo folding were obtained by 
running PROSHIFT (253), SPARTA+ (261), SHIFTX (256), and SHIFTX2 (258). When 
running PROSHIFT, the temperature and pH were set to 303 K and 6.0, respectively. 
SPARTA+, SHIFTX, and SHIFTX2 were run using default settings. During CS analysis, 
CSs obtained for Gly1 were disregarded. (See Protocol Capture in Appendix C). 
 
Selection of models that are of low energy and in contact with membrane 
To maintain close contact between Ser3 and the membrane, all 10,000 models 
were filtered so that the Ser3 Cα of the filtered models were within the polar region of the 
RosettaMembrane implicit membrane environment. The remaining pool of 3,692 models 
was screened to filter out those models in which any peptide atoms found within 5 Å of 
any receptor atoms. All 3,692 of these models passed the filter and were further culled by 
keeping only those models whose Rosetta energies were within the top 10% of all 10,000 
model energies, leaving a fully filtered pool of 355 models. This percentage was chosen 
after testing various ensemble sizes (Table 10). 
Table 10:  Ensemble average RMSDs (in ppm) resulting from filtering strategies 
 
Top 10% 
by Rosetta 
Energy 
Top 25% by 
Rosetta Energy 
Top 50% by 
Rosetta Energy 
Top 75% 
by Rosetta 
Energy 
All 
PROSHIFTb 0.385 (22) 0.381 (18) 0.379 (26) 0.378 (26) 0.377 (26) 
SHIFTXc 0.716 (18) 0.713 (28) 0.707 (23) 0.707 (17) 0.709 (13) 
SHIFTX2d 0.722 (29) 0.719 (26) 0.718 (26) 0.702 (26) 0.717 (11) 
SPARTA+e 0.718 (29) 0.717 (20) 0.711 (30) 0.711 (24) 0.718 (12) 
# models in pool 355 856 1,790 2,683 3,692 
a Ensemble size in parentheses 
b References (19, 252-254) 
c References (19, 254-257) 
d References (19, 254, 257-259) 
e References (259-261) 
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Generation of model ensembles in agreement with experimental chemical shifts 
Ensembles of 10-30 models consistent with the experimental CSs were 
constructed from the resulting low-energy pool according to the algorithm summarized in 
Figure 13. PROSHIFT (253) was used to predict CSs for all models. The selection 
algorithm generates a random ensemble of 10 models. It then computes the average CS of 
each Cα, Cβ, CO, and Hα atom for which an experimental CS was determined (excluding 
those for Gly1). After all average CS values are determined, the root mean square 
deviation (RMSD) of the ensemble average-predicted CSs relative to the experimental 
CSs is calculated and reported. In order to avoid the average and RMSD being dominated 
by the larger magnitude of carbon CS values, carbon CSs were scaled down by a factor of 
4. Next, the algorithm randomly chooses to add another model from the bigger pool to 
the ensemble (if not at the specified maximum ensemble size of 30), swap models 
between the ensemble and the pool, or remove a model from the ensemble (if not at the 
minimum ensemble size of 10). The process is repeated for 5,000,000 cycles.  
 
Figure 13:  Outline of model ensemble selection algorithm 
The above flowchart outlines the process by which the agreement with experimental data is 
determined for an ensemble of models selected from a large pool. 
 
Select random ensemble 
of 10 from pool 
Compute RMSD of 
ensemble CSs to 
experimental CSs 
Add to ensemble 
from pool 
if 10 ≤ ensemble size ≤ 30:!
add, remove, or swap models 
between ensemble and pool 
Reject move 
Yes No 
Accept move 
RMSD 
decrease? 
5,000,000 cycles 
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Structural analysis of final ensemble 
The final ensemble of models was initially evaluated by the Protein Structure 
Validation Software suite (PSVS, http://psvs–1_5-dev.nesg.org/). The secondary 
structure information, including ϕ/ψ torsion angles, was obtained by running Define 
Secondary Structure of Proteins (DSSP (182), http://swift.cmbi.ru.nl/gv/dssp/). In 
addition, the DSSP analysis was modified to take into account polyproline II (PPII) 
helical structure using the same parameters presented by Adzhubei, Sternberg, and 
Makarav (267). Briefly, residues were only assigned PPII structure if they met the 
following conditions: 1) formerly assigned random coil (-) by DSSP, 2) ϕ = –75 ± 29 
degrees, 3) ψ = 145 ± 29 degrees, 3) conditions 1) and 2) were met for two sequential 
residues. 
 
Results 
Ghrelin binds to negatively charged membranes 
First, binding of ghrelin and desacyl-ghrelin to POPC/POPG (5/1, mol/mol) 
membranes was measured using an ultracentrifugation assay. Upon addition of sucrose 
loaded vesicles and ultracentrifugation, bound ghrelin co-precipitates with the liposomes 
and the percentage of bound peptide is measured with a fluorescamine assay, as shown in 
Figure 14. While about ~65% of the octanoylated ghrelin binds to the acidic liposomes 
with a KD value of 100 ± 24 µM, only ~10% desacyl ghrelin is associated to the 
membranes at a lipid concentration of 5 mM without reaching saturation, indicating the 
importance of the octanoyl modification. The KD-derived ΔG value for the binding of 
ghrelin to membrane surfaces is –28.6 kJ/mol. To confirm that the lipid membranes used 
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in this study were in a lamellar liquid crystalline phase state, static 31P NMR spectra were 
recorded. All preparations showed the typical axially symmetric powder pattern, with a 
Δσ = 45 ppm (data not shown).  
 
 
Figure 14:  Binding isotherm of ghrelin and desacyl ghrelin to POPC/POPG membranes 
The amount of bound ghrelin (black squares) and desacyl ghrelin (red circles) as a function of 
lipid concentration is given. The ghrelin binding curve was fitted according to Equation (1). No 
significant membrane binding is observed for desacyl ghrelin.  
 
To understand the dynamics of the membrane lipids and the lipid modification of 
membrane-associated ghrelin, the properties of the lipid chains in four different samples 
were compared: 1) pure DMPC-d54/DMPS, 2) DMPC-d54/DMPS/ghrelin at a 30:1 molar 
lipid-to-peptide molar ratio, 3) DMPC-d54/DMPS/desacyl-ghrelin, and 4) 
DMPC/DMPS/ghrelin-d15, where ghrelin featured a perdeuterated octanoyl-d15 chain at 
Ser3. This combination of samples allowed us to determine the effect of ghrelin on the 
bilayer properties of the host membrane. Typical 2H NMR spectra of the DMPC-d54 and 
the ghrelin-d15 component of the mixtures are shown in Figure 15, panels A and B. The 
NMR spectrum of DMPC shows the typical superposition of Pake dubletts, which is 
typical for the lamellar liquid crystalline phase state of the membrane. A small isotropic 
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peak, as well as the bigger line width, indicate the presence of ghrelin. The 2H NMR 
spectrum of ghrelin with a perdeuterated octanoyl chain also shows the features of a well-
inserted peptide lipid chain, i.e., well dissolved Pake dublets. In addition, an isotropic 
peak that accounts for ~10% of the intensity is shown, indicating that about 10% of the 
octanoyl chain of ghrelin is isotropically mobile, or not inserted into the membrane. 
 
 
Figure 15:  2H NMR spectra and order parameters of DMPC-d54/DMPS membranes 
2H NMR spectra in DMPC-d54/DMPS membranes (5/1, mol/mol) in the presence of ghrelin (A) 
and ghrelin-d15 in DMPC/DMPS membranes (B). C) 2H NMR order parameters of 
DMPC-d54/DMPS (5:1, mol/mol) membranes in the presence or absence of ghrelin (1:30 protein 
to lipid molar ratio) at a temperature of 30°C and a buffer content of 35 wt%.  #
From the 2H NMR powder spectra of the four samples mentioned above, the 
segmental chain order parameters were determined. Smoothed chain order parameter 
profiles showing the dependence of the order parameter on the position of the carbon 
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segment in the acyl chain are presented in Figure 15C. The segments are numbered 
consecutively starting at the carbonyl group of the lipid or the Cβ of ghrelin’s Ser3. 
Striking differences between the chain order parameters of DMPC-d54 and ghrelin-d15 are 
observed. The ghrelin octanoyl chain shows significantly lower order parameters than the 
host membrane for all carbon positions. In contrast, the order parameters of the host 
membrane are very similar in the absence and presence of both ghrelin and desacyl 
ghrelin. Virtually no differences are observed for DMPC-d54/DMPS in the absence or 
presence of desacyl-ghrelin, confirming that there was no binding of the desacylated 
peptide to the membrane. Slightly higher order parameters are observed for the upper 
eight chain methylenes of the membrane in the presence of ghrelin. Using the mean 
torque model (268), the structural parameters of these lipid chains were calculated. The 
length of the DMPC chains in the mixture in the absence and presence of ghrelin was 
11.1 Å and 11.3 Å, respectively. The length of the octanoyl chain of ghrelin was 4.8 Å. 
 
13C Chemical shifts were collected to study the structure of membrane-bound ghrelin 
Next, the secondary structure of membrane-bound ghrelin was investigated. To 
this end, six peptides with varying labeling scheme were synthesized (Table 11). 13C 
MAS NMR measurements were carried out in DMPC/DMPS (5:1, mol/mol) membranes. 
A comprehensive set of directly excited 13C MAS NMR spectra, CP MAS spectra, and 
INEPT-based techniques were employed to find the most sensitive excitation scheme for 
membrane-bound ghrelin (269); the CP MAS technique with a contact time of 700 µs 
provided the most sensitivity. A typical 13C CP MAS NMR spectrum of a ghrelin peptide 
in membranes is shown in Figure 16A. As membrane-bound peptides often aggregate at 
#79#
high concentrations (248), the dependence of ghrelin CSs on peptide concentration was 
determined; ghrelin/lipid preparations of 1:30, 1:50, and 1:100 molar ratios were used. In 
all cases, there were no observable altered CSs, so a 1:30 ghrelin/lipid preparation was 
used for the remainder of this study. 
 
Table 11:  Overview of ghrelin peptide constructs and labeling schemes* GHR1:#H2N_#GSS(nDoctanoyl)FL#SPEHQ#RVQQR#KESKK#PPAKL#QPR#_OH# M#=#3398,96#Da#GHR2:#H2N_#GSS(n_octanoyl)FL#SPEHQ#RVQQR#KESKK#PPAKL#QPR#_OH# M#=#3384,96#Da#GHR3:#H2N_#GSS(n_octanoyl)FL#SPEHQ#RVQQR#KESKK#PPAKL#QPR#_OH# M#=#3385,96#Da#GHR4:#H2N_#GSS(n_octanoyl)FL#SPEHQ#RVQQR#KESKK#PPAKL#QPR#_OH# M#=#3388,96#Da#GHR5:#H2N_#GSS(n_octanoyl)FL#SPEHQ#RVQQR#KESKK#PPAKL#QPR#_OH# M#=#3385,96#Da#GHR6:#H2N_#GSS(n_octanoyl)FL#SPEHQ#RVQQR#KESKK#PPAKL#QPR#_OH# M#=#3379,96#Da###############∑:#H2N_#GSS(nDoctanoyl)FL)SPEHQ#RVQQR#KESKK#PPAKL#QPR#_OH# #
* Several ghrelin peptides were synthesized having 17 of the 28 amino acids that were 13C/15N 
labeled. The peptides were allowed to bind to LUVs having a diameter of 100 nm and a 
composition of 80% DMPC-d67 and 20% DMPS-d54. Experiments were performed with 35 wt% 
of 10 mM MES buffer containing 10 mM NaCl at pH 6. 
 
 
 
#80#
 
Figure 16:  Ghrelin sequence showing the isotopic labeling scheme of the different molecules 
and ssNMR spectra of membrane-embedded ghrelin 
Labeling scheme is shown in color (see Table 11). A) 13C CP MAS NMR spectrum of ghrelin 
(with Gly1, Leu5, and Ser6 labeled) in DMPC-d67/DMPS-d54 (5:1, mol/mol) membranes at a 
ghrelin concentration of 3.3 mol%. B) 1H-13C MAS HetCor spectrum of the same preparation, all 
at 30°C and a MAS frequency of 7 kHz. 
 
To achieve the full assignments of the ghrelin signals, 1H–13C HetCor and 13C–
13C PDSP experiments were conducted. The basic connectivities within the labeled amino 
acid were determined in PDSP experiments using a mixing time of 50 ms. As membrane-
associated ghrelin is relatively mobile (see below), the PDSP experiments were 
performed at –30°C. The high mobility of ghrelin helped in detecting 1H CSs in 1H–13C 
HetCor experiments, which were well-resolved, even without application of homo-
#81#
nuclear decoupling. Typical peptide signals had a 1H line width of 0.3–0.4 ppm. A 
characteristic 1H-13C HetCor NMR spectrum of membrane-associated ghrelin is shown in 
Figure 16B. A summary of the CS values determined for membrane-bound ghrelin is 
given in Table 12. The difference between 13Cα and 13Cβ values for determination of 
secondary structure are reported in Figure 17. 
 
!82!
Table 12:  Chemical shifts measured for acylated ghrelin bound to DMPC/DMPS membranes (5/1,mol/mol) using MAS ssNMR 
Residue CO Cα Cβ Cγ Cδ Hα Hβ Hγ Hδ 
Gly1 167.0 ± 0.4 40.9 ± 0.2 ! ! ! ! ! ! !
Ser2 172.1 ± 0.2 55.6 ± 0.5 62.5 ± 0.6 ! ! ! ! ! !
Ser3 ! 53.6 ± 0.1 63.3 ± 0.2 ! ! 4.5± 0.3 ! ! !
Phe4 172.1 ± 0.2 55.8 ± 1.2 37.0 ± 0.8 ! ! ! ! ! !
Leu5 174.8 ± 0.4 51.9 ± 0.2 40.7 ± 0.5 ! ! ! ! ! !
Ser6 169.3 ± 0.5 54.2 ± 0.5 61.2 ± 0.6 ! ! ! ! ! !
Pro7 174.9 ± 1.2 61.2 ± 0.5 30.8 ± 1.7 ! ! ! ! ! !
Glu8 174.1 ± 0.2 54.3 ± 0.9 25.8 ± 0.9 ! ! ! ! ! !
Gln10 177.3± 0.3 55.4 ± 0.4 27.0 ± 0.0  34.4 ± 0.9 ! 4.1± 0.3 ! ! !
Val12 174.1 ± 0.2 60.3 ± 0.9 30.0± 0.3 ! ! ! ! ! !
Gln13 173.4 ± 0.3 53.5 ± 0.2 27.0 ± 0.1 ! ! 4.3± 0.3 2.0± 0.3 ! !
Gln14 173.5± 0.3 53.4 ± 0.1 27.0 ± 0.1 33.7 ± 0.1 ! 4.3± 0.3 2.1± 0.3 2.4± 0.3 !
Ser18 171.8 ± 0.2 55.8 ± 0.1 61.3 ± 0.2 ! ! 4.4± 0.3 3.9± 0.3 ! !
Pro21 177.7± 0.3  59.0 ± 0.1 28.3 ± 0.0 24.8 ± 0.1 48.0± 0.3 4.7± 0.3 ! 2.0± 0.3 3.8± 0.3 
Pro22 173.7 ± 0.2 60.4 ± 0.2 29.4 ± 0.0 24.8± 0.3 47.9± 0.3 4.4± 0.3 ! ! !
Ala23 175.5 ± 0.5 50.5 ± 0.6 17.0± 0.3 ! ! ! ! ! !
Pro27 173.3 ± 0.0 60.8 ± 0.0 29.4 ± 0.1 24.8 ± 0.1 48.1± 0.3 4.4± 0.3 2.0± 0.3 2.0± 0.3 3.8± 0.3 
* Gray cells indicate that these CSs were used in structure determination. 
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Figure 17:  Chemical shift analysis of ghrelin based on MAS ssNMR data 
The 13Cβ−13Cα values for reach residue are plotted. Positive values greater than 1 ppm indicate a 
tendency for α-helical structure, whereas values less than −1 ppm suggest some β-sheet character. 
Amino acids with a CS index close to 0 ppm are considered to have no secondary structure. 
Asterisks indicate that no CSs were available for that residue. 
 
Dipolar couplings were measured to study the dynamics of membrane-bound ghrelin 
Next, the dynamics of membrane-associated ghrelin were studied via dipolar 
coupling measurements (246). From the measurement of 13C–1H dipolar couplings, we 
determined the backbone and side-chain order parameters needed to characterize the 
amplitude of motion for the C-H-bond vectors. A fully rigid C-H-bond exhibits the 
maximal dipolar coupling strength of 22.8 kHz, corresponding to an order parameter of 1. 
An order parameter value of 0 corresponds to fully isotropic motion, which is expressed 
by a vanishing dipolar coupling. Molecular motions with a given amplitude lead to partial 
averaging of the dipolar coupling strength and can be characterized by a specific order 
parameter. The 1H–13C order parameters sample all motions with correlation times 
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shorter than ~10 µs (269). Overall, the order parameters for ghrelin in membranes are 
relatively low--around 0.2 for the backbone--with smaller values obtained for the side-
chains. There are no significant differences in the order parameters for residues 1-12. 
However, the order parameter of Ala23 was significantly lower, indicating a large increase 
in the motional amplitude at the C-terminus (Figure 18). 
 
Figure 18:  1H-13C order parameters of ghrelin bound to DMPC/DMPS membranes 
Order parameters were determined for 3.3 mol% ghrelin bound to DMPC/DMPS membranes 
(5:1, mol/mol) at a temperature of 30°C and a water content of 35 wt%. 
 
Ghrelin interacts with membrane via Ser3 and Phe4 
Finally, the membrane topology of ghrelin was investigated by measuring spin 
diffusion from the lipid into the peptide (249). Ghrelin samples were prepared in DMPC-
d67/DMPS-d54 membranes in the presence of D2O. Thus, spin diffusion originating from 
the glycerol backbone and the PS headgroup was detected in the ghrelin backbone. 
Typical spin diffusion curves for Ser3, Phe4, Val12, and Ala23 are shown in Figure 19. At a 
mixing time of 0, all peptide magnetization was relaxed due to the T2 filter of 6 ms. 
However, as the mixing time increases, the intensity of the ghrelin signals also increases. 
Qualitatively, magnetization buildup is strongest in Ser3 and Phe4, while a significantly 
decreased magnetization buildup is detected for Val12 and Ala23. This means that Ser3 and 
!85!
Phe4 are in close proximity to the membrane surface, while Val12 and Ala23 have no 
membrane contact because spin diffusion has to migrate longer to reach these sites. 
!
Figure 19:  1H spin diffusion buildup curves of membrane-associated ghrelin 
Spin diffusion spectra were determined for 3.3 mol% membrane-associated ghrelin in DMPC-
d67/DMPS-d54 (5:1, mol/mol) at a D2O content of 35 wt%. Spin diffusion originates from the 
membrane’s glycerol and the PS headgroups. Solid lines represent best-fit simulations using a 
lattice model with a spin diffusion coefficient of D = 0.001 nm2/s and a distance between protons 
of 2 Å. 
 
Magnetization buildup was also simulated using a simple lattice model for spin 
diffusion (250). As the mobilities of the lipids and ghrelin are comparable (see Figure 15 
and Figure 18), a common spin diffusion coefficient of D = 0.001 nm2/s was used for 
spin diffusion within the lipid, from lipid to peptide, and within ghrelin. With these 
simple assumptions, the magnetization buildup could be modeled relatively well using a 
2-Å spacing between neighboring spins. In the lattice model, spin diffusion from the lipid 
reaches the peptide sites in close proximity to the membrane surface, Ser3 and Phe4, in 3 
and 4 steps, respectively. On the other hand, 6 to 8 steps are necessary for the 
magnetization to diffuse to residues Val12 and Ala23. 
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PROSHIFT predicts CS of de novo folded ghrelin with smallest deviation from 
experiment 
In order to construct an ensemble of ghrelin models in agreement with the 
experimental CS data (Table 12), an appropriate method for predicting CSs based on the 
de novo folded models was needed. We tested four CS prediction tools: PROSHIFT 
(253), SHIFTX (256), SHIFTX2 (258), and SPARTA+ (261). PROSHIFT employs an 
artificial neural network (ANN) trained on CS data from the Biological Magnetic 
Resonance Bank (BMRB). SHIFTX operates via a hybrid method, in which empirically 
derived CS hypersurfaces are combined with classical (i.e., Newtonian physics) or semi-
classical equations for parameters, such as ring current, hydrogen bond, and solvent 
effects. SHIFTX2, like SHIFTX, employs structure-based concepts used by SHIFTX, but 
the algorithm also takes sequence homology information into account, as is done by 
SHIFTY (270). SPARTA+ uses an ANN, but, being a newer method, the ANN was 
trained on an approximately two-fold larger protein database than was used for training 
the PROSHIFT ANN. We hypothesized that the fragment-based assembly in Rosetta 
samples the conformational space likely occupied by the biologically active peptide and 
that, therefore, some models within the final ensemble represent conformations that give 
rise to the observed CSs. Accordingly, one can argue that the CS prediction algorithm 
most suitable for this particular application should give the lowest CS-RMSD between 
experimental and predicted CS. Because not all of the CS prediction methods predict 
values for side-chain atoms, including protons, only CO, Cα, Cβ, and Hα CSs were used in 
the determination of the CS-RMSD. 
!87!
After using all four of the aforementioned methods to predict CSs for the 10,000 
Rosetta-generated models, the CS-RMSD (in ppm) of each model to the experimental 
data was computed. The Rosetta score, or energy, was plotted against CS-RMSD, as 
determined by each CS prediction method (Figure 20). Surprisingly, it was found that 
PROSHIFT systematically created lower CS-RMSD values. Manual inspection of one 
selected model that agreed well with predicted CSs from all methods confirmed that more 
accurate CSs were predicted throughout the peptide and not located in one particular 
region (Table 13). 
 
Figure 20:  Assessment of four chemical shift prediction methods 
Score vs. RMSD (in ppm) plot, where the RMSD of each model’s predicted CSs to experimental 
values were computed. The RMSD was computed over each of the experimentally determined 
CSs, excluding the two CSs determined for Gly1. 
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Table 13:  Detailed analysis of low-RMSD model from set of filtered models in top 10% by score 
Res$ Atom$ CSexp
a,b$ CSPROSHIFT$
|$CSPROSHIFT$–$
CSexp$|c$
CSSPARTA+$
|$CSSPARTA+$–$
CSexp$|$
CSSHIFTX$
|$CSSHIFTX$–$
CSexp$|$
CSSHIFTX2$
|$CSSHIFTX2–$
CSexp$|$Ser2! CO! 172.1!±!0.2! 173.0! 0.2! 176.5! 1.1! 174.9! 0.7! 176.28! 1.0!Ser2! Cα! 55.6!±!0.5! 57.0! 0.4! 61.0! 1.4! 58.83! 0.8! 61.08! 1.4!Ser2! Cβ! 62.5!±!0.6! 62.3! 0.0! 63.0! 0.1! 62.98! 0.1! 63.06! 0.1!Ser2! Cα! 53.6!±!0.1! 58.4! 1.2! 60.2! 1.7! 60.67! 1.8! 60.48! 1.7!Ser2! Cβ! 63.3!±!0.2! 61.4! 0.5! 62.6! 0.2! 63.78! 0.1! 62.65! 0.2!Ser2! Hα! 4.5!±!0.3! 4.2! 0.3! 4.4! 0.1! 4.27! 0.2! 4.33! 0.2!Phe4! CO! 172.1!±!0.2! 174.5! 0.6! 176.2! 1.0! 175.45! 0.8! 176.27! 1.0!Phe4! Cα! 55.8!±!1.2! 56.0! 0.1! 58.2! 0.6! 59.48! 0.9! 58.9! 0.8!Phe4! Cβ! 37.0!±!0.8! 38.0! 0.3! 39.0! 0.5! 38.85! 0.5! 39.36! 0.6!Leu5! CO! 174.8!±!0.4! 173.9! 0.2! 176.3! 0.4! 175.41! 0.2! 176.17! 0.3!Leu5! Cα! 51.9!±!0.2! 51.5! 0.1! 53.6! 0.4! 53.3! 0.4! 54.2! 0.6!Leu5! Cβ! 40.7!±!0.5! 39.8! 0.2! 43.3! 0.7! 43.13! 0.6! 43.52! 0.7!Ser6! CO! 169.3!±!0.5! 172.2! 0.7! 172.7! 0.8! 172.64! 0.8! 173.32! 1.0!Ser6! Cα! 54.2!±!0.5! 54.0! 0.1! 54.9! 0.2! 56.51! 0.6! 55.58! 0.3!Ser6! Cβ! 61.2!±!0.6! 62.8! 0.4! 64.1! 0.7! 63.58! 0.6! 63.85! 0.7!Pro7! CO! 174.9!±!1.2! 174.3! 0.2! 178.0! 0.8! 177.03! 0.5! 177.79! 0.7!Pro7! Cα! 61.2!±!0.6! 61.3! 0.0! 62.3! 0.3! 62.01! 0.2! 62.11! 0.2!Pro7! Cβ! 30.8!±!1.7! 30.9! 0.0! 32.9! 0.5! 33.75! 0.7! 33.42! 0.7!Glu8! CO! 174.1!±!0.2! 176.0! 0.5! 178.9! 1.2! 178.78! 1.2! 178.75! 1.2!Glu8! Cα! 54.3!±!0.9! 56.9! 0.7! 60.2! 1.5! 59.66! 1.3! 59.46! 1.3!Glu8! Cβ! 25.8!±!0.9! 27.4! 0.4! 29.0! 0.8! 29.09! 0.8! 29.23! 0.9!Gln10! CO! 177.3!±!0.3! 176.2! 0.3! 178.6! 0.3! 178.93! 0.4! 178.73! 0.4!Gln10! Cα! 55.4!±!0.4! 57.4! 0.5! 59.3! 1.0! 58.88! 0.9! 59.11! 0.9!Gln10! Cβ! 27.0!±!0.0! 27.0! 0.0! 28.5! 0.4! 28.72! 0.4! 28.58! 0.4!Gln10! Hα! 4.1!±!0.3! 3.9! 0.2! 3.8! 0.3! 3.93! 0.2! 3.98! 0.2!Val12! CO! 174.1!±!0.2! 175.5! 0.3! 177.0! 0.7! 177.75! 0.9! 178.15! 1.0!
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Val12! Cα! 60.3!±!0.9! 63.9! 0.9! 65.7! 1.3! 66.1! 1.5! 65.84! 1.4!Val12! Cβ! 30.0!±!0.3! 28.8! 0.3! 31.5! 0.4! 31.63! 0.4! 31.75! 0.4!Gln13! CO! 173.5!±!0.3! 175.2! 0.4! 178.7! 1.3! 177.83! 1.1! 176.87! 0.8!Gln13! Cα! 53.4!±!0.2! 56.3! 0.7! 57.1! 0.9! 58.16! 1.2! 57.74! 1.1!Gln13! Cβ! 27.0!±!0.1! 27.0! 0.0! 28.7! 0.4! 28.64! 0.4! 28.66! 0.4!Gln13! Hα! 4.3!±!0.3! 4.1! 0.2! 4.1! 0.2! 4.11! 0.2! 4.14! 0.2!Gln14! CO! 173.5! 173.9! 0.1! 176.3! 0.7! 176.43! 0.7! 176.36! 0.7!Gln14! Cα! 53.4!±!0.1! 55.0! 0.4! 56.6! 0.8! 57.55! 1.0! 57.21! 0.9!Gln14! Cβ! 27.0!±!0.1! 26.5! 0.1! 29.0! 0.5! 29.58! 0.7! 29.14! 0.5!Gln14! Hα! 4.3! 4.3! 0.0! 4.1! 0.2! 4.07! 0.2! 4.19! 0.1!Ser18! CO! 171.8!±!0.2! 173.2! 0.4! 174.8! 0.8! 174.27! 0.6! 173.9! 0.5!Ser18! Cα! 55.8!±!0.1! 56.4! 0.2! 57.9! 0.5! 57.89! 0.5! 58.23! 0.6!Ser18! Cβ! 61.3!±!0.2! 60.3! 0.3! 64.7! 0.8! 64.13! 0.7! 64.47! 0.8!Ser18! Hα! 4.4!±!0.3! 4.4! 0.0! 4.5! 0.0! 4.42! 0.0! 4.41! 0.0!Pro21! CO! 177.7!±!0.3! 173.4! 1.1! 175.1! 0.6! 174.84! 0.7! 175.33! 0.6!Pro21! Cα! 59.0!±!0.1! 59.1! 0.0! 61.8! 0.7! 61.79! 0.7! 62.32! 0.8!Pro21! Cβ! 28.3!±!0.0! 29.8! 0.4! 31.5! 0.8! 31.89! 0.9! 30.97! 0.7!Pro21! Hα! 4.7!±!0.3! 4.6! 0.1! 4.4! 0.3! 4.42! 0.3! 4.6! 0.1!Pro22! CO! 173.7!±!0.2! 174.3! 0.2! 176.1! 0.6! 176.41! 0.7! 177.46! 0.9!Pro22! Cα! 60.4!±!0.2! 60.7! 0.1! 62.6! 0.5! 62.68! 0.6! 62.72! 0.6!Pro22! Cβ! 29.4!±!0.0! 30.9! 0.4! 32.3! 0.7! 31.89! 0.6! 32.19! 0.7!Pro22! Hα! 4.4!±!0.3! 4.5! 0.1! 4.1! 0.4! 4.21! 0.2! 4.42! 0.0!Ala23! CO! 175.5!±!0.5! 175.0! 0.1! 177.1! 0.4! 177.18! 0.4! 177.2! 0.4!Ala23! Cα! 50.5!±!0.6! 50.2! 0.1! 51.4! 0.2! 51.51! 0.3! 51.62! 0.3!Ala23! Cβ! 17.0!±!0.3! 16.8! 0.0! 20.3! 0.8! 20.15! 0.8! 19.27! 0.6!Pro27! CO! 173.3!±!0.0! 175.0! 0.4! 176.0! 0.7! 176.67! 0.8! 177.01! 0.9!Pro27! Cα! 60.8!±!0.0! 61.7! 0.2! 63.1! 0.6! 62.73! 0.5! 63.13! 0.6!Pro27! Cβ! 29.4!±!0.1! 30.2! 0.2! 32.4! 0.7! 32.32! 0.7! 31.98! 0.6!
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Pro27! Hα! 4.4!±!0.3! 4.4! 0.1! 4.6! 0.1! 4.37! 0.1! 4.4! 0.0!
Average$Deviation$$
(±$S.E.M.)$$ 0.3$±$0.04$ 0.6$±$0.05$ 0.6$±$0.05$ 0.6$±$0.05$
RMSD$ 0.4$ 0.7$ 0.7$ 0.7$
a All values in ppm 
b Experimental and predicted values not scaled. Difference values take scaling into account.  
c All CS differences (in | |) are scaled. Scaling = CScarbon * 0.25 
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 Furthermore, the selection algorithm used to find the ensemble of models with 
the best overall agreement to the experimental CSs resulted in lower average RMSD 
values when the model CSs were predicted by PROSHIFT (Table 10 and Table 12). After 
running the selection algorithm over model pools of various sizes, each with PROSHIFT, 
SHIFTX, SHIFTX2, or SPARTA(+)-predicted CSs, it was determined that, for this 
system, the top 10% of models by total Rosetta score that had Ser3 Cα atoms in proximity 
to the membrane plane struck the best compromise between favorable Rosetta energy and 
agreement with experimental CSs. 
 
The final structural ensemble of ghrelin is highly flexible 
The final ensemble of 22 ghrelin models had a CS-RMSD of 0.4 ppm relative to 
the experimental CSs according to the selection algorithm outlined in Figure 13. 
However, the ensemble is highly flexible and mobile. The backbone RMSD to mean 
structure is 4.0 ± 0.8 Å (Table 14). There was no structural core by which the models 
could be aligned; therefore, the models’ Ser3 Cβ atoms were superimposed for 
visualization (Figure 21). 
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Figure 21:  Structure of ghrelin based on MAS ssNMR chemical shift data 
A) Final ensemble of ghrelin selected from the ensemble selection algorithm discussed in the 
main text. The Ser3 Cα of each model was superimposed on the others. Ser3 is shown as spheres. 
The ensemble was manually placed on the surface of a DMPC lipid bilayer, and the octanoic acid 
(spheres) was manually positioned in proximity to Ser3. B) Model from the final ensemble. 
Residues predicted to be PPII helix (21-23 and 26-27) are colored in orange. Residues predicted 
to be helical according to Figure 12A (4, 8, 10, and 12) are colored in green. Positively charged 
residues (Arg and Lys), Ser3, Phe4, Val12, and Ala23 are displayed as lines. 
 
Table 14:  Statistics for restraints, structural calculations, and structural quality for final 
ensemble of ghrelin models 
NMR distance restraints used during folding and refinement 
Total restraints 55 
Chemical shiftsa 55 ! !
Structural(statistics!
Number of models in ensemble 22!
Deviations from idealized geometry !
Bond lengths (Å) 0.02 
Bond angles (°) 0.7 
Main chain RMSD to the mean structure (Å) 4.0 ± 0.8 
Ensemble average RMSD to chemical shifts (ppm) 0.4 
Ramachandran plot statistics (%) !
Most favored regionsb,c 95.2, 99.5 
Additionally allowed regionsb,c 4.8, 0.5 
a Chemical shifts were used during post-processing only; they were not used during fragment 
generation or de novo folding and refinement 
b As determined by PROCHECK (http://www.ebi.ac.uk/thornton-srv/software/PROCHECK/) 
c As determined by MolProbity (http://molprobity.biochem.duke.edu) 
 
Ala23
Val12Ser3
Phe4
A B
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Notice that the peptide exhibits an α-helical core but no β-strand character. After 
further inspection of the Ramachandran plot generated for all 10,000 models, as well as 
for the final ensemble, it appears that the final ensemble may exhibit some polyproline II 
helical character, which would be found in the ϕ = −75° / ψ = 150° area (Figure 22). 
Additionally, analysis of the ϕ/ψ angles using the PPII-DSSP method presented by 
Kabsch and Sander (182), residues 21–23 and 26–27 show significant PPII helical 
propensity (Figure 22B). The α-helical core agrees well with the secondary structure 
prediction of ghrelin based on PSIPRED (271), JUFO (104), SAM (272), and Figure 12. 
On the other hand, according to TALOS+ (143), which is based on the experimental CSs, 
the peptide, especially residues 21-23, is expected to be almost completely random coil. 
Ramachandran plots of residues 1-7, 8-12, 13-20, 21-28, and 21-28 indicate that the 
secondary structure of the final ensemble is not completely at odds with the secondary 
structure prediction or experimental CSs (Figure 22A).  
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Figure 22:  Secondary structure analysis of ghrelin 
A) Ramachandran plots of various subsets of residues as labeled at the top of the plots. The 
torsion angles of all models generated in Rosetta (gray) and the final ensemble of models (black) 
are plotted. B) Weblogo (http://weblogo.threeplusone.com) of PPII-DSSP analysis of final 
ensemble of ghrelin models. Color key:  black = random coil (C), blue = bend (S) or turn (T), and 
green = α-, 310-, or PPII helix (H, G, or P, respectively). 
 
Discussion 
Ghrelin interacts with the membrane via a small hydrophobic cluster 
According to our spin diffusion studies, ghrelin interacts with the membrane via 
residues Ser3 and Phe4, whose side-chains and the octanoyl chain insert into the 
membrane (Figure 19); this is also in agreement with solution NMR data performed in 
detergent micelles (230). Due to the deuteration scheme of the membrane, 1H spin 
diffusion can only originate from the glycerol backbone and the polar headgroup, 
suggesting localization of the Phe side-chain in this region. Generally speaking, the 
interface region of the membrane represents the preferred localization for membrane-
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bound lipidated peptides (273, 274). Spin diffusion into residues Val12 and Ala23 is 
significantly slower, implying that these residues have no membrane contact. Due to the 
highly dynamic ghrelin structure at the membrane surface and the fact that the octanoyl 
chain is in equilibrium between an inserted state (~90% of the time) and a desorbed state 
(~10% of the time), spin diffusion from the membrane into the peptide is significantly 
slower than what is observed for membrane proteins with a transmembrane segment 
(249). 
The small hydrophobic cluster of amino acids of octanoylated Ser3, Phe4, and 
Leu5 account for about –13.4 kJ/mol (275, 276) of the energy corresponding to the 
ghrelin-membrane interaction. At the lipid concentrations used in our experiments, this is 
insufficient for a permanent association with the membrane. Using a simple membrane 
partition model (232), this would only account for binding of ~8% of ghrelin. Clearly, a 
second mechanism is required for anchoring ghrelin to the membrane. This second 
mechanism is electrostatic attraction of the positively charged C-terminal two-thirds of 
the ghrelin sequence to the lipid headgroups. Indeed, ghrelin holds an electrostatic charge 
of +5.8 at pH 6, which was used for our studies to prevent the hydrolysis of the octanoyl 
chain. Numerous calculations based on the Gouy Chapman theory have been carried out 
to determine the electrostatic contribution to membrane binding of lipidated peptides 
(277). For instance, pentalysine binds to a slightly negatively charged membrane, as in 
our case, with a Gibbs free energy of approximately –12 kJ/mol (278). Together with the 
hydrophobic contribution from the N-terminus of ghrelin, we estimate a total membrane 
binding energy of ΔΔG0 about –25 kJ/mol, which corresponds to approximately 90% of 
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bound ghrelin. This corresponds relatively well with the value of –28.6 kJ/mol 
determined from the binding measurement.  
 
The octanoyl chain might play a role in a fine-tuned membrane association mechanism 
Given the above observations, why is ghrelin not modified with a longer lipid 
chain, which would provide the peptide much better membrane partitioning properties? 
Clearly, the short octanoyl chain is not optimal for membrane binding. Further, chemical 
biology studies have shown that longer lipid chains and even more bulky groups are 
accepted by the GHSR (226). However, a replacement of the octanoyl chain to Ser6 or 
Ser18 is not tolerated. Further, the lack of the octanoyl chain, as in descyl-ghrelin, poorly 
activates the receptor. This could, however, also be explained by the fact that desacyl-
ghrelin does not bind negatively charged membranes, as shown here and by others (62). 
However, a computer-generated model of the GHSR-ghrelin complex revealed 
hydrophobic contacts between the receptor and Phe4, as well as the octanoyl side-chain 
(279). Apparently, the short ghrelin octanoyl chain is responsible for a fine-tuned 
membrane association mechanism, which catalyzes receptor binding and activation (228). 
Although there is some disagreement about the exact hydrophopic contribution of ghrelin 
to membrane binding, most studies agree that desacyl-ghrelin does not significantly bind 
membranes (62, 230). It is obvious that the ghrelin octanoyl chain has not been optimized 
for the purpose of membrane binding; longer acyl chains or prenyl groups provide much 
more favorable membrane anchors (232). The octanoyl chain is therefore primarily 
needed for receptor activation. 
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Previous studies of membrane-associated ghrelin and related peptides primarily indicate 
α-helical structure 
Earlier 1H studies of acylated and desacylated ghrelin in aqueous solution at low 
pH indicate that both forms of the peptide are highly unstructured in water. Indeed, the 
poor dispersion of CSs, as well as the lack of nuclear Overhauser effects (NOEs) 
typically seen of α-helices and β-sheets support the CD data (61). It is also possible that 
ghrelin experiences structural inter-conversion on a faster timescale than the NMR 
measurements, resulting in no detection of transient secondary structure. A 10-ns MD 
simulation performed in water at constant temperature and neutral pH (preceded by 2 ns 
of simulated annealing MD, or SAMD) provided evidence that ghrelin may sample a 
helix from residues 7 to 13 in both environments. MD studies in DMPC bilayers for 15 
ns, initiated with the energy-minimized final peptide from the previous 10-ns MD 
simulation in water, did not show any significant differences in secondary structure from 
the peptide in aqueous conditions. However, the presence of the membrane appeared to 
reduce ghrelin’s flexibility. Interestingly, the octanoyl side-chain, while initially pointed 
to the lipid bilayer, did not anchor the peptide to the membrane. Instead, during the 
simulation, residues 15–18 served as contact points with the lipid headgroups (63, 280). 
CD spectroscopy of ghrelin and desacyl-ghrelin performed in aqueous solution 
(20 mM Tris buffer) and in 100% TFE at pH 7.4 provide experimental support for the 
MD studies, in that the acylated peptide exhibits 12% helical character in aqueous 
solution and in TFE. Desacyl-ghrelin, on the other hand, showed a significant increase in 
helical character when going from an aqueous environment (23%) to TFE (48%) (281). 
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In contrast to the MD simulations performed by Beevers and Kukol (63), Staes, et 
al. showed via a variety of biochemical assays that, while ghrelin and desacyl-ghrelin 
both electrostatically interact with the membrane, only acylated ghrelin penetrates into 
negatively charged membranes. However, the interaction of ghrelin with membranes was 
not such that it otherwise significantly disturbed the membrane surface. The same authors 
also investigated the secondary structure of ghrelin and desacyl-ghrelin via in silico 
modeling and CD spectroscopy. Similar to previous MD studies (63), an α-helix spanning 
residues Pro7 to Ser18, which was flanked by two loops, for both acylated and desacylated 
ghrelin. The authors’ models were supported by CD data collected in water, 
dodecylphosphocholine (DPC) micelles, SDS micelles, and TFE. For both forms of 
ghrelin, the helicity increased significantly in SDS micelles and TFE (62). A similar trend 
was observed for the prolactin releasing peptide (PrRP), another peptide that plays a role 
in food intake and body weight homeostasis (37). In the case of PrRP, it was 
demonstrated that the peptide likely exists in a conformational equilibrium between α- 
and 310-helix, and the helical propensity of the peptide is essential for its ability to 
activate the PrRP receptor, another GPCR. Another peptide that is involved in the 
regulation of appetite, galanin-like peptide (GALP), also shows nascent helical character, 
which may increase upon binding to galanin receptors (204). More recently, the 
neuropeptide, substance P (SP), was also found to have α-helical character in negatively 
charged SDS micelles and DMPG liposomes. However, in aqueous solution and in sub-
micellar concentrations of SDS and DMPC liposomes, CD spectra indicate the presence 
of polyproline II (PPII) helix (282). 
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Ghrelin exhibits a highly flexible structure containing some polyproline II-, α-, and 310- 
helix 
Based on previous structural studies, structural characterization of related 
peptides, and secondary structure prediction based on the primary sequence (Figure 12), 
it was expected that our current ssNMR studies would point to a dynamic peptide having 
transient α- and/or 310-helical character in conformational equilibrium. Interestingly, 
13Cα−13Cβ CS values indicate helical propensity for residue 4, 8, 10, and 12, but according 
to CS index analysis with TALOS+ (143), only Arg11 exhibits a small amount of helical 
propensity (Figure 12). This is in agreement with the high mobility inferred from the low 
order parameters that have been measured for the peptide (Figure 18).  
The final ensemble of Rosetta-generated models in best agreement with the 
experimental CSs provides a set of three-dimensional (3D) structures that allow for the 
visualization of the information obtained by NMR. As expected from the order 
parameters, we modeled a very loose conformational ensemble (Figure 22A and Table 
14). Interestingly, while Rosetta sampled ϕ/ψ torsion angles expected for all common 
secondary structures (i.e., α-helix and β-sheet), the final ensemble exhibits a strongly 
helical core with what initially appeared to be “random coil” in the N- and C-terminal 
region, in agreement with previous studies (41, 62, 63, 213, 214). However, upon closer 
inspection of the Ramachandran plots and a modified DSSP analysis of these 22 models, 
it is probable that the final ensemble exhibits a small amount of 310-helical character, as 
well as a significant amount of PPII helix, especially for Pro21-Ala23 and Gln26-Pro27 
(Figure 21 and Figure 22). The helical character of ghrelin does appear to allow it to 
!100!
frequently adopt amphipathic conformations, thus allowing the basic residues to interact 
with the membrane’s polar headgroups (Figure 21). 
 
Polyproline II helical conformation in ghrelin may play a biologically significant role 
Pure PPII helix is left-handed, is often characterized as a triangular prism, and has 
a helical pitch of 9.3 Å/turn; it contains ϕ and ψ angles of –75° and 145°, respectively. 
However, other amino acids and combinations of amino acids can form PPII 
helices.(283) Stapley and Creamer state that, in addition to Pro, Gln and positively 
charged residues having an increased probability of existing in PPII helices, Gly and 
aromatic residues show decreased probability (284). Other analyses of proteins of known 
structure agree that Gly and aromatic residues have low propensities to form PPII helices 
and that Pro appears most often, the increased observation of Gln and positively charged 
residues in PPII helices is disputed (285). In addition to being sampled during protein 
folding and unfolding, PPII helical structure has been implicated in amyloid formation 
(286, 287), nucleic acid binding (288), and muscle tissue elasticity (289). Statistical 
analysis of a database of 274 non-homologous protein structures shows that, while only 
2% of residues are found in PPII helices, more than half of all polypeptide chains contain 
PPII helix of at least three residues in length (284). 
To our knowledge, ghrelin is the first membrane-associated peptide to have PPII 
helical character for some residues in the presence of lipid bilayers. We point out that this 
character is likely transient and involves only short stretches of 2-3 residues. However, it 
is possible that, like the aforementioned peptides, ghrelin’s α-helical content increases 
and extends into the ten C-terminal residues when it binds to GHSR. However, the PPII 
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helical character could allow for increased solvent accessibility while simultaneously 
providing for structural flexibility in areas such as flanking α-helices, linker regions, etc. 
Further, PPII helices have been found to be structural motifs involved in protein-protein 
interactions, which may result from their tendency to form amphipathic helices and to 
bind in a rapid and reversible fashion (267, 290). 
 
Reliance of peptide fragment selection on chemical shifts and secondary structure 
prediction 
While CSs can be used to guide fragment selection for de novo folding in Rosetta, 
we ultimately chose to utilize the original fragment selection protocol and filter by CS 
agreement after modeling was completed. Given that CS data for ghrelin is sparse, i.e. 
only for a subset of all residues secondary structure can be determined from the CSs, this 
protocol was chosen to prevent biases from residues with determined CSs on other 
regions of the peptide. In the case of ghrelin, Rosetta selects fragments based on 
agreement of CS for a subset of residues with little or no secondary structure information 
for other residues. When generating fragments for ghrelin, this led to a bias of β-hairpin 
fragments, which was not in agreement with other experimental data that pointed to a 
highly flexible and mobile peptide. We therefore opted to select fragments based on 
predicted secondary structure for all residues and filtered the models based on agreement 
of experimental CS later. Indeed, upon analysis of the secondary structure of fragments 
selected with and without experimental CSs, we see that the fragment selection scheme 
depends heavily on CS data when available, as is described in the literature.(106) On the 
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other hand, when CS data are not included in fragment selection, the secondary structure 
prediction of all residues is critical (Figure 12). 
 
PROSHIFT gives systematically best agreement between experimental and predicted CS 
values 
In order to compare the Rosetta-generated models with the experimentally 
determined CSs, we tested four CS prediction methods: PROSHIFT, SPARTA+, 
SHIFTX, and SHIFTX2. While SPARTA+, SHIFTX, and SHIFTX2 performed similarly, 
PROSHIFT appears to be the best method for prediction of CSs for ghrelin (Figure 20). 
To rule out systematic error and artifacts, one low-energy model that had minimal 
deviations between predicted and experimental CSs was chosen for in-depth analysis 
(Table 13 and Figure 23). This was also carried out on a few randomly selected models 
(data not shown). 
 
 
 
 
 
!103!
 
Figure 23:  In-depth analysis of chemical shiftx for one model 
A) The CSSPARTA+, CSSHIFTX, and CSSHIFTX2 deviations from CSexperimental values (Table 13) are 
plotted against CSPROSHIFT deviations from CSexperimental values. All values are in ppm. B) Structure 
of the model chosen for in-depth analysis. While it was not in the final ensemble of models 
reported in this work, it was within the top 10% by Rosetta energy and the best or second-best 
model with respect to CS-RMSD relative to experimental CSs. 
 
This result was somewhat surprising, given that PROSHIFT is an older method 
than the three to which it was compared. The reason for PROSHIFT’s superior 
performance is not obvious, especially considering that the same 55 (CO, Cα, Cβ, and Hα) 
CSs were used for all analysis. Our explanation for this phenomenon is that PROSHIFT 
might be less biased than other methods in predicting CSs for well-structured proteins 
with large amounts of secondary structure, thereby making it more suitable for prediction 
of CSs for peptides or intrinsically disordered proteins. 
 
 
 
0.0 0.5 1.0 1.5
0.
0
0.
5
1.
0
1.
5
0.0 0.5 1.0 1.5
0.
0
0.
5
1.
0
1.
5
0.0 0.5 1.0 1.5
0.
0
0.
5
1.
0
1.
5
SPARTA+ SHIFTX SHIFTX2
O
th
er
 M
et
ho
d 
C
S
 
D
ev
ia
tio
n 
(p
pm
)
PROSHIFT Method CS Deviation (ppm)
A
B
N
C
!104!
A combined ssNMR-Rosetta protocol for studying structure and dynamics of flexible 
peptides and proteins 
Due to the lack of regular inter-residue hydrogen bonding characteristic of α-
helices and β-strands, it is likely that PPII helices are often categorized as “random coil” 
by secondary structure analysis software, such as DSSP. Furthermore, while PPII helices 
are difficult to detect directly by NMR (285) there have been attempts using CS data 
(291, 292). More generally, determining the structural ensemble that best represents 
sparse NMR CSs is especially challenging for biomolecules expected to be highly 
flexible and potentially unstructured. In addition to presenting a 3D structural ensemble 
of the biologically active form of ghrelin, we provide a novel, thorough method for 
predicting membrane-associated peptides, as well as for selecting a set of models based 
on ssNMR CSs. As NMR is often used to characterize protein unfolding and intrinsically 
unstructured proteins (IUPs) (289, 292-294), we believe our approach of combing NMR 
with Rosetta and a Monte Carlo ensemble selection algorithm may be useful for future 
studies of other structurally flexible and mobile systems. 
 
Conclusion 
To date, the results on the structure and dynamics of ghrelin have been 
controversial and inconclusive. In order to elucidate the mechanism by which ghrelin 
interacts with the membrane, as well as its 3D structure and its dynamics in the 
membrane environment, CSs and order parameter data were collected via MAS ssNMR. 
The primary sequence of ghrelin was then used to de novo the peptide in Rosetta using 
the RosettaMembrane energy functions. A final ensemble of models was then selected 
!105!
based on the CS data. Unlike other peptides that activate GPCRs and in contrast to 
previous studies of ghrelin, our model of ghrelin is extremely flexible (4-Å RMSD) while 
strongly sampling both α- and PPII helical character. This unique secondary structure 
may allow the peptide to adopt an amphipathic structure, which would allow it to bind 
electrostatically to the membrane. Finally, the protocol employed to fold ghrelin and 
select the final ensemble of models can be used to structurally characterize other flexible 
proteins and peptides for which only sparse CS data are available, including those that act 
in a lipid environment. 
 
Availability 
The protocol capture for comparative modeling, CS prediction, and ensemble 
selection, can be found in Appendix C. The coordinates for the final ensemble will be 
available on a hard drive upon final submission of the dissertation. 
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CHAPTER IV 
 
ROSETTAEPR:  AN INTEGRATED TOOL FOR PROTEIN STRUCTURE 
DETERMINATION FROM SPARSE EPR DATA 
 
This work is based on publication (Hirst, Alexander, Mchaourab, and Meiler, 
2011). 
 
Summary 
Site-directed spin labeling electron paramagnetic resonance (SDSL-EPR) is often 
used for the structural characterization of proteins that elude other techniques, such as X-
ray crystallography and nuclear magnetic resonance (NMR). However, high-resolution 
structures are difficult to obtain due to uncertainty in the spin label location and 
sparseness of experimental data. Here, we introduce RosettaEPR, which has been 
designed to improve de novo high-resolution protein structure prediction using sparse 
SDSL-EPR distance data. The “motion-on-a-cone” spin label model is converted into a 
knowledge-based potential, which was implemented as a scoring term in Rosetta. 
RosettaEPR increased the fractions of correctly folded models (RMSDCα < 7.5Å) and 
models accurate at medium resolution (RMSDCα < 3.5Å) by 25%. The correlation of 
score and model quality increased from 0.42 when using no restraints to 0.51 when using 
bounded restraints and again to 0.62 when using RosettaEPR. This allowed for the 
selection of accurate models by score. After full-atom refinement, RosettaEPR yielded a 
1.7Å model of T4-lysozyme, thus indicating that atomic detail models can be achieved by 
combining sparse EPR data with Rosetta. While these results indicate RosettaEPR’s 
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potential utility in high-resolution protein structure prediction, they are based on a single 
example. In order to affirm the method’s general performance, it must be tested on a 
larger and more versatile dataset of proteins. 
 
 Introduction 
Protein modeling with Rosetta can serve as an alternative means of structure elucidation 
The vast majority of proteins in the Protein Data Bank (PDB) have been 
determined by X-ray crystallography or nuclear magnetic resonance (NMR) (1). 
However, a large number of biomedically relevant proteins continue to evade structural 
elucidation by these techniques due to membrane environment (295), high flexibility 
(296), and size (297). Alternative techniques, such as computational structure prediction 
methods, can be employed in order to define the structure of such proteins. The usual 
experimental bottlenecks, such as obtaining highly pure, concentrated samples of protein, 
are thereby avoided. Rosetta routinely folds soluble proteins of less than 150 amino acids 
correctly (298). It is generally among the top performers in the Critical Assessment of 
protein Structure Prediction (CASP) experiments (109, 111, 299-301). In addition, 
Rosetta’s ability to obtain the correct fold of membrane proteins of various sizes and 
topologies has been demonstrated (105, 117, 130). More recently, Das, et al. introduced 
RosettaFold-and-Dock, which allows for the de novo structure prediction of homomeric 
proteins (302). 
Rosetta’s sampling and scoring capabilities for protein folding have been 
reviewed extensively elsewhere (101, 102, 110, 303). Briefly, the Rosetta de novo protein 
structure prediction algorithm is divided into two steps: low-resolution protein folding to 
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obtain the overall topology and high-resolution refinement of the backbone and side-
chains. Metropolis Monte Carlo peptide fragment insertion is driven by a variety of 
knowledge-based potentials to rapidly predict protein folds. In high-resolution 
refinement, the protein backbone φ and ψ angles are perturbed while the overall fold is 
maintained. Side-chain conformations are predicted via a Metropolis Monte Carlo search 
of rotamer space, and all torsional degrees of freedom are subjected to gradient-based 
minimization. 
 
Sparse NMR restraints can be combined with Rosetta to obtain atomic detail structures 
While the algorithm described above performs well in the de novo prediction of 
relatively small, soluble proteins, effectively sampling protein conformational space 
remains the limiting factor in the accurate prediction of more complex proteins. To this 
end, distance and orientational restraints, such as those obtained by NMR, have been 
incorporated into the Rosetta protein folding protocol (106). Chemical shifts are 
converted into backbone torsional angle restraints, which are used in the generation of the 
peptide fragment libraries. Distance restraints from nuclear Overhauser effects (NOEs) 
are also employed in this process. Additionally, distance and orientaitonal restraints 
(NOEs and residual dipolar couplings, or RDCs, respectively) have been incorporated 
into the scoring function and are evaluated during protein folding. Bowers, et al. 
demonstrated that Rosetta, combined with a sparse set of NOEs (approximately one 
restraint per residue) and backbone chemical shifts, can produce models with atomic 
detail accuracy (168). Similarly, a combination of sparse RDCs and chemical shifts was 
used to produce correctly folded models (303). Shen, et al. have made significant 
!109!
progress in improving the robustness and accuracy of CS-Rosetta with incomplete 
chemical shift datasets, obtaining atomic detail models based on much data that would 
otherwise be considered unsuitable for high-resolution structure determination (139, 263, 
264). 
 
SDSL-EPR offers an advantage over traditional structure determination techniques 
Despite such advances, some proteins remain un-amenable to structure 
determination by these methods. Site-directed spin labeling electron paramagnetic 
resonance spectroscopy (SDSL-EPR) allows for structural studies of membrane proteins 
and large macromolecular assemblies in native or native-like environments (74, 146-148, 
304-306). SDSL involves mutating residues of interest to cysteines, which can be reacted 
with a paramagnetic spin label, such as methanethiosulfonate (MTS). A sensitive 
structural probe at a known sequence position is created, forgoing the need to “assign” 
signals in the spectrum as is necessary in NMR spectroscopy. Additionally, resolution of 
SDSL-EPR is not limited by the size of the system. Similar to fluorescence and NMR 
spectroscopy, however, SDSL-EPR generates information concerning both the local 
environment of the spin label and the overall global fold of the protein. SDSL-EPR has 
been used to characterize conformational changes, such as those seen in MsbA (74, 147), 
rhodopsin (307-309), and KcsA (77, 146, 310). More recently, it has been demonstrated 
that the fold of a protein can be determined by structural restraints derived from SDSL-
EPR data alone (134). 
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Atomic detail protein structure determination by SDSL-EPR is difficult and 
computationally demanding 
Challenges in using SDSL-EPR structural data arise from the possible 
perturbation of the system by introduction of the spin label, sparseness of datasets 
resulting from the need to construct a dedicated mutant for every data point collected, and 
uncertainty in the position and dynamics of the spin label relative to the protein 
backbone. In the past, proteins have displayed a surprising robustness with respect to the 
introduction of spin labels (151, 157, 161, 311, 312). Molecular dynamics simulations 
(162) and crystallography (161, 313) have been employed to explicitly model the spin 
label in order to help interpret SDSL-EPR structural data. However, these calculations are 
relatively slow and computationally demanding. In addition, most studies of this nature 
are designed to examine a specific protein and are not easily expanded to other systems. 
For the purpose of protein structure determination, a faster, broadly applicable approach 
to relate the spin label position to the protein backbone is needed. As an exhaustive 
experimental mapping of intra-protein distances is infeasible given time and the labor 
intensiveness of the SDSL-EPR method, a limited dataset that unambiguously defines the 
fold of the protein needs to be defined (314). 
 
RosettaEPR is designed specifically to work with sparse SDSL-EPR data 
In 2008, Alexander et al introduced the implicit “motion-on-a-cone” model, or 
cone model (Figure 26B), which is based on the structure of the MTS spin label (Figure 
26A) (134). This model was used to convert an observed spin label distance, dSL, into an 
“allowed” range for the distance of the Cβ atoms, dCβ ∈ [dSL–12.5Å, dSL+2.5Å] (Figure 
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26C). The authors demonstrate that these distance restraints are sufficient to determine 
the structure of T4-lysozyme to atomic detail accuracy from 25 SDSL-EPR restraints The 
present study introduces RosettaEPR, which replaces the soft interpretation of the 
distance constraints used in the previous study with a knowledge-based restraint potential 
optimized for SDSL-EPR distance data. Alexander, et al. utilized RosettaNMR, with the 
consequence that all dCβ distances falling within the allowed range were considered 
equally favorable during de novo folding. All other distances were disfavored using a 
quadratic penalty function (Figure 24). However, while the distance difference, dSL–dCβ, 
falls within a wide range, values between 0Å and 5Å are more likely than values outside 
this range. We used the cone model, in combination with the PDB, to derive a probability 
function for dSL–dCβ, which was then converted into a scoring function using the 
Boltzmann relation. We demonstrate that treatment of SDSL-EPR distance restraints with 
this scoring function is superior. Following the benchmarking presented in this paper, 
RosettaEPR will be made available to the scientific community. 
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Figure 24:  Comparison of the RosettaEPR knowledge-based potential with the bounded 
potential 
The bounded potential against which restraint violations are scored is defined according to the 
equation reported in the figure, where ub = upper bound, lb = lower bound, sd = standard 
deviation of 1.0, and rswitch = 0.5 
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Figure 25:  Flowchart outlining the currently described protocol 
(
Materials and methods 
The protocol described in the present work is outlined in Figure 25. It is divided 
into two subsections corresponding to the implementation and development of 
RosettaEPR and the prediction of the T4-lysozyme structure to atomic detail. 
 
Conversion of the motion-on-a-cone model into a knowledge-based potential 
The dSL−dCβ histogram (Figure 26D) was generated by placing a cone model-
based simulated spin label at every exposed amino acid position in 3,584 proteins from a 
non-redundant protein database (315). That is, the simulated spin label was placed at 
residue positions that had a neighbor count (316) of less than ten, resulting in over 140 
million measured distances. For every pairwise distance within each protein, the protein’s 
dCβ was subtracted from the simulated dSL and stored in 0.5Å-wide bins. Because the 
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highest frequency of dSL−dCβ values was on the order of 106, a pseudocount of 106 was 
added to the total counts computed so that less commonly observed values are also 
considered. 
The potential (Figure 26E) was calculated by taking the negative logarithm (−ln) 
of the propensity of each dSL−dCβ value, where the propensity is defined as:  
 
 
 
PseudoCount equals 106, and # bins equals 64. The resulting values were 
normalized and shifted such that they were all negative. This relationship is based on the 
Boltzmann relationship, which is used to correlate a population of a species to an 
associated energy. The potential was re-scaled to give a maximum bonus of −1.0 for 
dSL−dCβ values between −12.0 and 12.0 (observed by the cone model) and a 0.0 penalty 
for values outside this range. 
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Figure 26:  The "motion-on-a-cone" model 
A) Methanethiosulfonate (MTS) spin label. The Cβ-SL distance is approximately 8.5Å. B) In the 
cone model, the Cβ-SL distance (SLeffective) is assumed to be 6Å, and the cone has an opening 
angle of 90°. The Cα-Cβ-SLeffective angle is restrained to angles 135° ≤ (∠CαCβSLeffective) ≤ 180°. C) 
The cone model is used to calculate dSL–dCβ values. D) The normalized frequency of dSL–dCβ 
values for a database of proteins (black line, right y-axis) compared to experimentally observed 
values for T4-lysozyme and αA-crystallin (open and filled bars, respectively, left y-axis. E) The 
propensity of dSL–dCβ values can be converted into a knowledge-based potential according to the 
Boltzmann relation. The resulting energies were normalized such that the most favored dSL−dCβ 
value correlates with an energy of −1.0 Rosetta Energy Unit (REU), and the least favored dSL−dCβ 
value correlates with a Rosetta energy of 0.0 REU. 
!
Model quality was assessed according to RMSDCα relative to the 2LZM crystal structure 
In order to best assess the ability of RosettaEPR to recover native-like folds, only 
the α-helical core domain of T4-lysozyme (residues 58-164) was modeled, as 
experimental restraints for other regions of this protein were not available. The 
experimentally determined distances used as restraints are reported in Table 15 and are 
mapped onto the T4-lysozyme crystal structure in Figure 27. Models of the protein were 
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generated a) without restraints, b) with restraints using RosettaEPR’s knowledge-based 
potential, and c) with restraints defined by the same boundaries as those used by 
Alexander, et al. Model quality was assessed by computing the RMSDCα relative to the 
X-ray crystal structure of T4-lysozyme (PDBID: 2LZM (317)). Only core residues 70-
155, excluding loops, were considered in computing the RMSDCα (see Table 16).  
Table 15:  T4-lysozyme EPR distance restraints in comparison with the crystal structure 
AA1-AA2a dCβ (Å)b dSL (Å)c σSL (Å)d Reference 
061-135 37.7 47.2 2.2 Borbat, et al., 2002 
065-135 34.3 46.3 2.2 Borbat, et al., 2002 
061-086 34.5 37.5 2.0 Borbat, et al., 2002 
065-086 28.9 37.4 2.7 Borbat, et al., 2002 
080-135 26.7 36.8 1.0 Borbat, et al., 2002 
061-080 28.7 34.0 2.2 Borbat, et al., 2002 
065-080 22.6 26.5 3.8 Borbat, et al., 2002 
119-131 13.2 25.0 5.0 Alexander, et al., 2008 
123-131 14.6 23.0 5.0 Alexander, et al., 2008 
065-076 16.8 21.4 2.8 Borbat, et al., 2002 
116-131 11.1 19.0 10.0 Alexander, et al., 2008 
119-128 10.4 19.0 4.0 Alexander, et al., 2008 
140-151 15.5 18.0 9.0 Alexander, et al., 2008 
089-093 9.8 16.0 3.0 Alexander, et al., 2008 
086-119 10.0 15.0 3.0 Alexander, et al., 2008 
120-131 10.5 14.0 3.0 Alexander, et al., 2008 
127-151 9.6 14.0 2.4 Alexander, et al., 2008 
140-147 10.1 13.0 7.0 Alexander, et al., 2008 
131-150 8.7 5.7 0.4 Alexander, et al., 2008 
127-154 5.9 7.0 3.0 Alexander, et al., 2008 
131-154 9.5 6.5 4.0 Alexander, et al., 2008 
134-151 10.7 7.0 0.8 Alexander, et al., 2008 
131-151 10.4 9.0 8.0 Alexander, et al., 2008 
088-100 8.9 <6.0 3.0 Alexander, et al., 2008 
089-096 8.4 <6.0 3.0 Alexander, et al., 2008 
a Indices of spin labeled amino acids with respect to the crystal structure 
b Cβ distance as reported in the crystal structure 
c Spin label distance as observed by EPR 
d Standard deviation as observed by EPR 
 
 
 
 
!117!
!
 
Figure 27:  Map of EPR distance restraints on the T4-lysozyme crystal structure 
The 107 C-terminal residues of the T4-lysozyme crystal structure are shown in rainbow with 
inter-residue distances used as restraints in RosettaEPR depicted as black dotted lines. A full list 
of experimentally determined EPR distances used in the benchmarking of RosettaEPR for this 
protein is reported in Table 15. 
 
 
Table 16:  Residues over which RMSDs and rotamer recovery were computed 
RMSD( Rotamer(Recovery(70,80,!82,90,!93,106,!108,113,!115,123,!126,134,!137,141,!143,155! 74,75,! 78,! 84,! 87,88,! 91,! 94,104,! 106,!110,111,! 113,114,! 116,118,! 120,121,!125,126,! 128,130,! 132,134,! 136,! 138,139,!145,153,!156!
 
Weight optimization for the knowledge-based SDSL-EPR restraint potential 
To optimize the factor by which the RosettaEPR scoring function should be 
applied, 10,000 models of the α-helical region of T4-lysozyme were constructed for a 
wide variety of weights (Table 17). The fraction of models with RMSDCα values below 
7.5Å was taken as measure for the correct fold. The fraction of models with RMSDCα 
values below 3.5Å was employed to identify candidate models for successful atomic 
detail refinement; models generated with this level of accuracy are considered to be 
“native-like.” The knowledge-based potential was implemented as a spline approximation 
in the Rosetta AtomPairConstraint score. The bounded restraint uses the 
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AtomPairConstraint score as computed according to a bounded quadratic equation 
(Figure 24). 
 
Rosetta was used to de novo fold and refine T4-lysozyme 
Secondary structure prediction of the 107 C-terminal residues of T4-lysozyme 
was performed using Jufo (104), Psipred (271), and Sam (318). Peptide fragments to be 
used in de novo structure prediction were generated as previously described, and 
fragments based on homologous proteins were excluded during folding. Rosetta’s low-
resolution de novo protein folding algorithm was used to generate 10,000 models of T4-
lysozyme guided by experimental restraints (Table 15) (134) weighted to various extents, 
resulting in models containing structural information of the protein backbone only. 
During de novo folding, residues are represented as superatoms, or “centroids” (102). 
After determining that the RosettaEPR knowledge-based potential optimally predicts the 
fold of T4-lysoyzme when multiplied by a factor of 4.0, this weight was used in the 
generation of 500,000 models of the protein.  
The 500,000 models were filtered according to their overall Rosetta energy and 
the extent to which they satisfied the experimental restraints. Only the top 1% of models 
by total score that had a restraint score of at least 85% of the optimum value was included 
in the filtered ensemble. These 1,388 models were then refined to atomic detail, in which 
the centroids were replaced with side-chain rotamers based on a backbone-dependent 
rotamer library (319). During refinement, Rosetta’s full-atom scoring potentials are used 
to guide refinement through an iterative cycle of side-chain repacking and gradient-based 
minimization (110, 320). Each round of refinement yielded ten times the initial number 
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of models. That is, one round of refinement resulted in 13,880 new, refined models. All 
de novo folding and full-atom refinement computations were performed using Rosetta 
trunk revision 34586. 
 
Structure determination with RosettaEPR is computationally feasible 
All models were generated by independent simulations using Vanderbilt 
University’s Center for Structural Biology computing cluster and the university’s 
Advanced Computing Center for Research and Education (ACCRE). Computations were 
performed on a combination of AMD Opteron and Intel Nehalem processor nodes. The 
average time needed to fold one model of the 107 C-terminal residues of T4-lysozyme 
was approximately 240 seconds. The same time is required for a single round of high-
resolution refinement for one model. 
 
Results 
Knowledge-based potential reflects likelihood of model in light of observed SDSL-EPR 
distance 
Cone model-based statistics were collected over a database of non-redundant 
proteins (see Materials and methods) and compared to dSL−dCβ values determined 
experimentally for T4-lysozyme and αA-crystallin (Figure 26D). The set of cone model 
statistics recovers several features of the experimental data, including the range of 
dSL−dCβ values and a shift towards dSL−dCβ values greater than 0Å. The shift towards 
positive dSL−dCβ values indicates that spin labels are more likely to point away from each 
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other. This is expected for soluble proteins, where mutations of surface residues are not 
expected to destabilize the protein.  
For conversion into a knowledge-based potential, the negative logarithm (−ln) of 
the propensity of each dSL−dCβ value was computed such that less frequently seen dSL−dCβ 
values are considered less favorable than one that is more often observed (Figure 26E). In 
result, a restraint that is fulfilled in the most likely area of the distribution improves the 
total score by one point, and a restraint that is violated is not counted towards the total 
score. This knowledge-based potential was then incorporated into Rosetta’s low-
resolution scoring function where it is affiliated with a dedicated weight (see Knowledge-
based potential section below). The current model is an improvement upon the original 
implementation of the cone model, in that a) protein structures, not ellipsoids, were used 
to generate the statistics, and b) the knowledge-based potential considers the likelihood of 
dSL−dCβ values instead of a simple binary classification. 
 
Knowledge-based potential achieves up to 55% correctly folded T4-lysozyme models 
Ten thousand T4-lysozyme models were folded de novo in the presence of the 
same restraints used previously (Table 15 and Figure 27) (134). Restraints were 
incorporated with various weights, and the results were compared to the bounded 
potential used by Alexander, et al. (Table 17). The usage of restraint scoring functions 
results in more native-like folds than when folding with no restraints at all (Figure 28 and 
Table 18). This reaffirms that experimental data increases sampling of more native-like 
structures. RosettaEPR recovers the native topology of the T4-lysozyme α-helical region 
in up to 55% of the models. This compares to 7% if no restraints are used and 42% when 
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using bounded restraints. Furthermore, folding with bounded restraints consistently 
resulted in approximately 1.0-1.5% of all built models having native-like conformations, 
compared to 2.1% when using the EPR knowledge-based potential with an optimal 
weight of 4.0. This improvement is significant, as additional starting structures for high-
resolution refinement increase the chance of successfully obtaining atomic detail models 
(see Ten-fold enrichment of low-RMSD models). Further, conversion to a knowledge-
based potential enabled fine-tuning of the weight of the SDSL-EPR potential for optimal 
performance, while the bounded potential provided constant suboptimal performance 
over wide ranges of the weight.  
 
Table 17:  Benchmarking results of T4-lysozyme using no restraints, 25 restraints scored 
according to the RosettaEPR knowledge-based potential, and 25 bounded restraints 
Weight % Models with RMSDCα < 3.5Å 
% Models with 
RMSDCα < 7.5Å 
% Models with 
RMSDCα < 3.5Å 
% Models with 
RMSDCα < 7.5Å 
0 0.03 7.17   
     
RosettaEPR Bounded 
1 0.73 21.98 0.89 37.56 
2 1.41 31.07 1.18 40.95 
3 2.01 37.20 1.58 41.84 
4 2.05 42.08 1.62 41.09 
5 1.83 45.65 1.43 40.44 
6 1.60 47.29 1.40 39.50 
7 1.35 49.60 1.40 38.42 
8 1.31 51.21 1.62 38.01 
9 0.87 50.89 1.59 37.42 
10 1.02 52.70 1.57 37.22 
20 0.51 54.89 1.44 34.02 
30 0.46 53.28 1.22 32.77 
40 0.25 49.74 1.27 32.16 
50 0.17 47.43 1.12 32.27 
60 0.07 43.86 1.01 31.07 
70 0.03 43.95 1.29 31.67 
80 0.02 43.07 1.34 31.05 
90 0.01 40.92 1.39 31.22 
100 0.01 41.11 1.12 30.62 
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Figure 28:  Comparison of the RosettaEPR knowledge-based potential to the bounded 
potential 
T4-lysozyme was folded de novo in Rosetta guided by 25 experimental restraints. Restraint 
violations were scored according to either a bounded potential or the EPR knowledge-based 
potential. The RMSDCα distributions of the resulting models when folded with optimally 
weighted restraint energies are compared to folding without restraints. !
Table 18:  Summary of benchmarking results of T4-lysozyme using no restraints, 25 
restraints scored according to the optimally weighted RosettaEPR knowledge-based 
potential, and 25 bounded restraints with a weight of 4.0a 
Restraint Type % Models with RMSDCα < 3.5Å 
% Models with 
RMSDCα < 7.5Å 
Enrichmentb 
none 0.03 7.17 --c 
knowledge-based 
potential (weight = 4.0) 2.05 42.08 7.0 
bounded restraints 
(weight = 4.0) 1.62 41.09 5.3 
a Results for all tested weights reported in Table 17 
b Enrichment = (fraction of low-RMSD models in filtered ensemble) ÷ (fraction of low-RMSD 
models of all models generated); filtered ensemble = within the top 1% of models by total score, 
the top 35% of models according to restraint score 
c Enrichment could not be computed as with the other data sets due to lack of restraint score 
!
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Knowledge-based function improves correlation of score and model quality  
The correlation of the scoring function with model quality is key to selection of 
native-like models when the structure is not known. The correlation coefficient improves 
from 0.42 in the absence of restraints to 0.51 when using the bounded function and 
further to 0.62 when using RosettaEPR (Figure 29). To quantify the value of the score for 
filtering native-like models, the enrichment for each optimized scenario was also 
computed (see Table 18). For the knowledge-based potential weighted by a factor of 4.0, 
the benchmark resulted in an enrichment of 7.0. The same analysis was performed on the 
models folded with the equally weighted bounded restraint potential, resulting in an 
enrichment of 5.3. The ensemble of models generated with no restraints contained only 
three native-like models, all of which were among the 10% best-scoring models, but this 
method was unable to produce enough native-like models to justify any high-resolution 
refinement. 
 
Figure 29:  Correlation between total Rosetta energy and RMSDCα of de novo folded models 
Score vs. RMSDCα for 10,000 models de novo folded A) with no restraints, B) with 25 bounded 
restraints, and C) with 25 restraints guided by the RosettaEPR knowledge-based potential !
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Ten-fold enrichment of low-RMSD models through knowledge-based SDSL-EPR score 
for high-resolution refinement 
500,000 models of T4-lysozyme were de novo folded in Rosetta guided by 25 
EPR distance restraints (weight equals 4.0). From the 1% best-scoring models, models 
achieving at least 85% of the optimal knowledge-based restraint score were selected for 
high-resolution refinement. The enrichment of native-like models in the filtered pool was 
10.6, while the enrichment of correctly folded models was 2.3, where enrichment was 
defined as the fraction of native-like or correctly folded models in the filtered pool 
divided by the fraction of native-like or correctly folded models in the entire ensemble. 
Filtering decreases the number of models considered for high-resolution refinement to a 
more manageable ensemble and enriches the fraction of low-RMSD models such that 
more native-like folds are refined to full-atom detail. 
 
High-resolution refinement of T4-lysozyme yields structural model that is accurate at 
atomic detail  
The resulting 1,388 models of T4-lysozyme were refined to high-resolution using 
Rosetta’s full-atom potentials, which include knowledge-based van der Waals attraction, 
repulsion, hydrogen bonding, solvation, and electrostatic terms (110). Each input model 
was refined ten times without experimental restraints, resulting in 13,880 models. Ideally, 
low-RMSD models would be considered energetically favored according to Rosetta’s 
scoring function. Therefore, the models were then filtered such that only the top 10% by 
total score were carried on to the next round of refinement. This process was repeated 
through eight 
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total score of each model was plotted against its RMSDCα (Figure 30A). The correlation 
between energetically favorable and low-RMSD models improves after each round of 
refinement until it converges after the eighth iteration. The lowest energy model 
produced with this strategy had an RMSDCα of 1.76Å relative to the native (Figure 31), 
and the lowest RMSDCα observed was 1.73Å. The previously reported model was 
determined to have an RMSDCα of 1.66Å. 
 
!
Figure 30:  Correlation between Rosetta energy and RMSDCα of refined models 
A) Score vs. RMSDCα plot of T4-lysozyme models for eight cycles of full-atom refinement. Each 
cycle of refinement resulted in ten times the number of input models. After each cycle, the refined 
models were filtered by total Rosetta energy, and the top 10% were refined again. Color key: 
refined crystal structure – black; round 1 = sky blue; round 2 = bright blue; round 3 = dark blue; 
round 4 = light green; round 5 = dark green; round 6 = yellow; round 7 = orange; round 8 = red. 
B) Percent of incorrectly predicted side-chains of core residues (see Table 16) as a function of 
total Rosetta score. The same coloring scheme in Panel A was used. !!
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Figure 31:  Atomic detail model of T4-lysozyme de novo folded with RosettaEPR 
A) Superimposition of the lowest-scoring model of T4-lysozyme (rainbow) with the 2LZM 
crystal structure (gray). The RMSDCα for the lowest-scoring model to the native is 1.76Å. Side-
chains are displayed as sticks. B) Residues 86-104. C) Residues 126-154 !
The ability of Rosetta to recover native-like side-chain conformations was tested 
by comparing side-chain rotamer agreement of refined models of T4-lysozyme with the 
X-ray crystal structure. A rotamer of a given amino acid residue is defined by its χ1-4 
angles. Side-chain conformations are classified by assigning them to the closest rotamer 
in terms of χ1-4 angle deviation (319, 321). The total Rosetta energy is plotted as a 
function of the percentage of incorrectly predicted side-chain rotamers (Figure 30). In 
general, the Rosetta energy correlates well with rotamer agreement, with the percent of 
correct rotamers predicted increasing after each round of refinement. 
 
Discussion 
The RosettaEPR knowledge-based potential proves to be superior to the bounded 
potential during de novo folding 
We have demonstrated the advantages of using a knowledge-based potential to 
convert EPR distance data into structural restraints. The potential is derived from the 
cone model (134) and has been shown to perform better than a simple bounded potential. 
A B C 
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From a conceptual standpoint alone, the energetic bonus correlates with the likelihood of 
observing dSL−dCβ values. As a result, the knowledge-based potential inherently uses the 
structural information from SDSL-EPR data more completely compared to the bounded 
scoring function used by Alexander, et al. Furthermore, the knowledge-based potential, 
in combination with Rosetta’s low-resolution scoring function and de novo folding 
algorithm, proves more robust in obtaining low-RMSD models of T4-lysozyme, from 
which atomic detail structures can be generated through full-atom refinement.  
 
The correlation between score and RMSD improves through multiple rounds of 
refinements 
The Rosetta full-atom scoring function allows the most native-like model to be 
identified unambiguously by its overall score, if model accuracy is better than 2.0Å. This 
model should have the lowest overall Rosetta energy and therefore exhibit not only the 
correct topology, but also native-like side-chain and backbone conformations. Similarly, 
less favorable conformations should have higher computed energies; these models will 
also have higher computed RMSDs relative to the native structure. One therefore expects 
to observe an energy “funnel” after several rounds of full-atom refinement, where both 
the score and RMSD of the models converge to the native structure. The overall scores of 
the predicted models of T4-lysozyme are plotted against their RMSDCα relative to the 
crystal structure in Figure 30. The correlation improves after each round of filtering and 
refinement, resulting in several atomic detail models with Rosetta energies comparable to 
the 2LZM crystal structure, which was refined using the same potentials as the predicted 
models. 
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RosettaEPR will be developed continuously as more data become available 
Although a larger benchmarking set would be ideal, there are a limited number of 
systems for which both experimentally determined three-dimensional structures and EPR 
data can be obtained. However, the resulting atomic detail models of T4-lysozyme 
generally satisfy the experimental EPR data, and benchmarking will be expanded to more 
diverse systems as more data become available. In the mean time, a larger benchmark on 
a variety of proteins of known structure using simulated data will be performed to assess 
the general performance of the method. The current work serves as a proof of principle. It 
will be interesting to test whether the similar results will be obtained for other proteins. It 
has already been shown that NMR restraints greatly aid Rosetta’s ability to recover 
native-like models (106, 136, 168, 303, 322), a method which is widely applicable to 
other biological systems, including the fumarate sensor DcuS (137) and a chordin-like 
cysteine-rich (CR) repeat from procollagen IIA (323). It is believed that the same will be 
true with RosettaEPR after further testing and refinement. 
!
Sparse SDSL-EPR distance data alone are not able to yield atomic detail models 
SDSL-EPR affords several advantages over other structure determination 
techniques, such as X-ray crystallography and NMR. No crystallization is required, there 
are few size constraints, proteins, and membrane proteins in particular, can be studied in 
a native-like environment, and there is no need to assign resonance signals. Thereby, 
SDSL-EPR overcomes some experimental limitations in the high-resolution structure 
determination of proteins that are large, highly flexible, or natively reside in lipid 
bilayers.  
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However, while quantitative in nature, the structural information obtained by 
SDSL-EPR is limited due to the flexibility of the spin label, which adds large 
uncertainties to the distances determined. Introduction of spin labels into proteins 
requires removal of native cysteine residues without affecting the protein structure and 
assumes that the spin label does not perturb the structure. Datasets obtained by SDSL-
EPR remain sparse due to the requirement to create a dedicated double-mutant for each 
distance to be measured. Therefore, SDSL-EPR a) will be applied to systems where 
crystallography and NMR spectroscopy are not applicable and b) will be combined with 
crystallography and other techniques to study structural dynamics of proteins. 
The current work and the results presented by Alexander, et al. (134) provide the 
first indication that sparse (approximately 0.25 restraints per residue) SDSL-EPR 
distance data can be combined with Rosetta for de novo protein structure elucidation with 
atomic detail accuracy. While RosettaEPR can be applied to soluble proteins, it is 
expected that the need and applicability of RosettaEPR will be highest for the structure 
determination of membrane proteins, the majority of which continue to evade more 
traditional techniques. A benchmark of RosettaEPR involving more proteins and 
membrane proteins in particular will be executed as suitable datasets become available 
 
RosettaEPR will be accessible to the scientific community 
Other researchers will have access to RosettaEPR via software licenses granted by 
the RosettaCommons (www.rosettacommons.org). These licenses are free for academic 
and non-profit institutions. To encourage usage of RosettaEPR, web tutorials will be 
made available. 
!130!
Conclusion 
RosettaEPR is the first tool designed to generate high-resolution protein structures 
from sparse EPR data. It can also be used in combination with an optimized restraint-
selecting algorithm (314) to assist experimentalists in determining protein structures to 
high-resolution. In the future, RosettaEPR will be modified such that it can be used to 
effectively determine the structures of membrane proteins, an EPR accessibility 
knowledge-based potential will be implemented, and high-resolution modeling of the 
MTS spin label will be included. The ultimate goal of this research is to optimize the 
structural information that can be achieved through EPR spectroscopy. RosettaEPR will 
enable the high-resolution structure elucidation of a plethora of proteins for which 
structures have, until now, not yet been determined. 
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CHAPTER V 
 
ROSETTATMH:  MEMBRANE PROTEIN STRUCTURE ELUCIDATION BY 
COMBINING EPR DISTANCE RESTRAINTS WITH ASSEMBLY OF 
TRANSMEMBRANE HELICES 
 
This work is based on the manuscript submitted to PLoS ONE of the same title by 
Stephanie DeLuca, Samuel DeLuca, Andrew Leaver-Fay, and Jens Meiler 
 
Summary 
Membrane proteins make up approximately one third of all proteins, and they 
play key roles in a plethora of physiological processes. Even though significant advances 
have been made in structure determination methods, such as X-ray crystallography, 
nuclear magnetic resonance spectroscopy, and cryo-electron microscopy, integral 
membrane proteins make up less than 2% of experimentally determined structures. 
Furthermore, few computational methods for de novo folding of integral membrane 
proteins have been presented. One potential alternative means of structure elucidation is 
to combine computational methods with experimental EPR data. In 2011, Hirst and 
others introduced RosettaEPR; the authors showed that this approach could be 
successfully applied to soluble proteins. In this work, we present RosettaTMH, a novel 
algorithm for structure prediction of helical membrane proteins. A benchmark set of 34 
proteins, in which the proteins ranged in size from 91 to 565 residues, was used to 
compare RosettaTMH to Rosetta’s two existing membrane protein folding protocols:  the 
published RosettaMembrane folding protocol (“MembraneAbinitio”) and folding from an 
extended chain (“ExtendedChain”). In the absence of EPR restraints, RosettaTMH folds 
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more models having the correct topology than MembraneAbinitio in 8 cases, whereas it 
performs better in 9 cases in comparison with ExtendedChain. When EPR distance 
restraints are used, RosettaTMH+EPR outperforms MembraneAbinitio for 30 proteins 
and ExtendedChain+EPR for 14 proteins. RosettaTMH+EPR is capable of achieving 
native-like topologies for the majority of proteins tested, including receptors and 
transporters. For example, a model of rhodopsin of 4.9Å RMSD100SSE accuracy to the 
crystal structure was achieved, and a model of 6.7Å accuracy was obtained for the 565-
residue Na+/galactose transporter, vSGLT. The addition of RosettaTMH and 
RosettaTMH+EPR to the Rosetta family of de novo folding methods broadens the scope 
of helical membrane proteins that can be accurately modeled with this software suite. 
 
Introduction 
Approximately one-third of all proteins are integral membrane proteins (MPs) 
(324), and, due to their prevalence in a wide variety of biological functions, MPs 
comprise more than half of all drug targets (25, 26, 325). However, of the > 100,000 
proteins with experimentally determined three-dimensional (3D) structures in the Protein 
Data Bank (PDB) (1), only about 2,000 are MPs (295). Further, according to Stephen 
White’s database of MPs of known structure (http://blanco.biomol.uci.edu/mpstruc/), 
fewer than 500 unique MP structures have been determined. This disparity between the 
importance of MPs and the available 3D structures reflects the technical difficulties 
associated with MP structure determination by X-ray crystallography and nuclear 
magnetic resonance (NMR) spectroscopy. To study MPs in their biologically relevant 
native conformation(s), a membrane mimic must be present during the experiment. While 
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X-ray crystallographers have developed techniques to obtain diffracting crystals, such as 
the use of femto-second crystallography (326, 327), robotics (328), and antibodies (66, 
329, 330), MP crystallization remains a bottleneck. Line broadening due to slow 
tumbling times of large MPs embedded in membrane mimics and decreased sensitivity 
due to the presence of additional nuclei are often limiting factors for solution NMR 
spectroscopy. Cryo-probes, increasingly powerful NMR magnets, selective labeling, and 
the development of solid-state NMR techniques (331) are continuously pushing the MP 
NMR field forward, but challenges remain here as well (72, 332-334). 
 
EPR spectroscopy can serve as an alternative means of membrane protein structural 
characterization 
Site-directed spin labeling electron paramagnetic resonance (SDSL-EPR) 
spectroscopy may serve as another means of MP structure determination because it has a 
number of advantages compared to more traditional methods. For example, proteins can 
be studied in their native environment, such as in lipid bicelles or vesicles, and no 
crystallization is required. Further, it does not require large amounts of protein, which is 
important in the case of MPs that are often difficult to express and purify. EPR is also an 
extremely sensitive technique because it measures the resonance of two unpaired 
electrons, so the signal-to-noise ratio is largely uninterrupted, unlike in NMR 
spectroscopy (148, 154, 311, 335, 336). 
However, EPR is not without its disadvantages. Like NMR spectroscopy, 
structure determination is indirect in that the spectroscopic data are first converted to 
structural restraints (134, 135). Also, for distance measurements, SDSL requires the 
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removal of all endogenous cysteines in the protein and the mutation of the residues of 
interest into cysteines. As a result, in contrast to NMR spectroscopy, only one inter-
residue distance can be measured per experiment. This results in low throughput and 
sparse datasets. In addition, the spin label itself introduces uncertainty, as the distance 
between the paramagnetic spin labels, which are at the tips of long and flexible side-
chains, is measured. This distance then needs to be converted into a structural restraint 
based on MP backbone coordinates (134, 135).  
 
There is a need for novel de novo membrane protein structure prediction tools 
In order to aid in MP structure determination, several computational methods 
have been developed. These methods can be divided into two categories:  template-based, 
or comparative modeling, and de novo folding. Template-based methods, such has 
Modeller (95, 337), Rosetta (96), SWISS-MODEL (338), and I-TASSER (339), are 
commonly used when the structure of a homologous protein exists. Template-based 
modeling methods are so named because they require a structural template onto which a 
target sequence can be threaded. For the sequence in question, a template structure, 
whether it is a sequence homolog or a structure exhibiting the same expected topology, 
must first be identified. Next, often after performing one or more sequence alignments, 
the target sequence is threaded onto the 3D coordinates of the template structure, thus 
replacing the sequence of the template with that of the target (252). 
In the case of MPs, it is often difficult to identify a suitable template structure. As 
mentioned previously, there are a limited number unique MP structures available in the 
PDB. Additionally, even though templates having a similar fold may exist, it is possible 
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that the sequence homology between the target and the template is too low to be 
confidently detected. For example, of the more than 20 experimentally determined 
structures of G-protein coupled receptors (GPCRs), the majority are of class A, or class 1 
(http://gpcr.scripps.edu/index.html) (23), even though there are probably 5 or 6 GPCR 
classes (13). Similarly, while there are some structures of transporters, such as LeuT 
(340), vSGLT (341), BetP (342), and GadC (343), MPs having the LeuT fold perform a 
large variety of functions and diverge in sequence significantly and can belong to a 
number of different protein superfamilies (344). While comparative modeling based on 
an evolutionarily distant template can be useful for hypothesis generation, especially 
when combined with experimental methods in an iterative fashion (254), de novo 
structure prediction of MPs is needed when no structural template is available. 
Additionally, de novo folding methods allow for an unbiased exploration of the 
conformational space, which is one disadvantage of using template-based methods. 
 Even though significant advances are being made in the structure determination 
of GPCRs, progress appears slower for other MP folds. The MP structural biology 
community is still striving for the structure determination of biomedically significant 
proteins, such as hERG, hSERT, the NPY receptor, etc. 
(http://blanco.biomol.uci.edu/mpstruc) It is possible, or perhaps even likely, that these 
structures will be determined in the future, but in the mean time, the need for advances in 
computational methods for MP structure prediction persists. 
Compared to template-based MP modeling methods, there are only a handful of 
tools for de novo folding of MPs. RosettaMembrane was introduced in 2006 (105) and 
was later expanded to include full-atom scoring potentials (130), but its capabilities were 
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limited to MPs of fewer than 150 amino acids. The addition of limited restraints derived 
from sequence conservation allowed for accurate modeling of larger proteins (117), but 
this method could only account for one restraint at a time. Furthermore, the utility of 
RosettaMembrane in its current state is limited. For technical reasons that originate in the 
RosettaMembrane code base, it is not possible to de novo fold MPs with multiple 
restraints, such as those obtained from NMR and EPR.  
Other methods to predict membrane protein structure, such as FILM3, exhibited 
mild success for predicting large MPs, but they rely on correlated mutational information 
to score MP models. Of 71 MP sequences, FILM3 was able to correctly predict 100% of 
inter-helix contacts for 17 proteins. Upon, comparison with two-dimensional slices of the 
experimental structures, 9 predicted structures had the correct topology (119). 
EVfold_membrane is also a promising method for MP structure determination but again 
relies on information from evolutionary covariation (118). On the other hand, BCL::MP-
Fold does not depend on mutational information. It reduces the conformational search 
space by assembling secondary structure elements (SSEs) combined with knowledge-
based potentials (KBPs) to assess model quality (345). The disadvantage of BCL-
generated models is the lack of inter-helix loop regions and, because they are comprised 
of idealized α-helices, it under-predicts secondary structural features often present in 
MPs, such as helical kinks. 
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RosettaTMH allows for folding of membrane proteins, both with and without 
experimental restraints 
To address the limitations of previously reported MP de novo folding methods, 
we have developed RosettaTMH, which, like BCL::MP-Fold, assembles MP topologies 
via rigid body perturbations of transmembrane helices (TMHs). Further, 3- and 9-amino 
acid fragment insertions, as used in the traditional Rosetta de novo folding algorithm 
(100), are used to more thoroughly sample helical orientations and introduce bends and 
kinks. Throughout the de novo folding process, RosettaMembrane’s MP-specific scoring 
functions are used (105, 130). However, in contrast to previously published 
RosettaMembrane folding protocols, RosettaTMH can be combined with multiple 
experimental restraints, such as inter-residue distance information from EPR. This 
additional feature allows for improved sampling of native-like topologies that are in 
agreement with empirical information. 
In this work, RosettaTMH was benchmarked on 34 MPs of known structure. It 
was compared to the original RosettaMembrane folding algorithm, “MembraneAbinitio” 
(105) and the traditional fragment assembly-only method used for folding soluble 
proteins in Rosetta, “ExtendedChain” (100) (but using the RosettaMembrane scoring 
function). In order to assess the performance of combining RosettaTMH with 
experimentally obtained structural data, EPR distance restraints were simulated for all 
MPs in the benchmark set. The purpose of the benchmark was to determine if these 
restraints increase the sampling of native-like MP folds. The simulated distance restraints 
were generated using the BioChemical Library (BCL, 
http://bclcommons.vueinnovations.com/bclcommons) and the restraint-picking algorithm 
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introduced by Kazmier, et al. (314). We show that, by implementing the ability to fold 
MPs with structural restraints, native-like folds can be obtained for 33 MPs in the 
benchmark set. 
 
Materials and methods 
Setup of RosettaTMH parameterization and benchmarking datasets 
Thirty-four α-helical MPs and MP subunits of known structure were chosen to 
test the RosettaTMH folding algorithm (Table 19). Nine of these proteins (in italics in 
(Table 19) were used for the initial testing and parameter optimization of the 
RosettaTMH protocol. The benchmarking set exhibits a wide range of sizes and 
topological complexity. The number of EPR distance restraints simulated was computed 
as: 
# restraints = 0.2* #aaTMH , 
where #restraints refers to the number of simulated EPR restraints generated, and #aaTMH 
refers to the amino acids in TMHs defined in the experimental structures. This number of 
restraints was chosen because it is on the order of the maximal number of distance 
restraints that have been obtained for several MPs (145-147, 346). Further, it is a good 
compromise between prediction accuracy and plausibility. The input files used (i.e., 
fragments, secondary structure prediction, span, lipophilicity, and native PDB files) were 
the same or based on those employed for benchmarking of BCL::MP-Fold (345). 
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Table 19:  Proteins used for benchmarking 
PDB( Protein(Name( Domain( #(Res( #(TMH(
Absolute(
Contact(
Order(
#(
Restraints(
Small(MPs(
3SYO! subunit!of!G!protein,gated!inward!rectifier!K+!channel!GIRK2!(Kir3.2)! 76–197! 122! 2! 14.4! 12!
2BG9! subdomain!of!nicotinic!acetylcholine!receptor! A:!211–301! 91! 3! 6.9! 16!
1J4N! subdomain!of!aquaporin!water!channel,!AQP1! 4–119! 116! 3! 15.2! 17!
2KSF! subdomain!of!histidine!kinase!receptor,!KdpD! 396–502! 107! 4! 11.9! 13!
1PY6a! subdomain!of!bacteriorhodopsin! 77–199! 123! 4! 13.3! 20!
2PNO! human!leukotriene!C4!synthase! A:!2–131! 130! 4! 13.6! 22!
2BL2! subdomain!of!V,type!Na,ATPase! 12–156! 145! 4! 20.7! 25!
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Medium(MPs(
2K73! disulfide!bond!formation!protein,!DsbB! 1–164! 164! 4! 15.5! 19!
2ZW3! subdomain!of!connexin!26!gap!junction!channel! A:!2–217! 216! 4! 25.7! 24!
1IWG! subdomain!of!multidrug!efflux!transporter,!AcrB! 336–498! 163! 5! 17.4! 26!
1RHZ! subdomain!of!protein,conducting!channel,!SecYE! A:!23–188! 166! 5! 19.8! 21!
2YVX! subdomain!of!magnesium!transporter,!MgtE! A:!284–471! 188! 5! 20.6! 26!
1OCC! subdomain!of!cytochrome!C!oxidase,!aa3! C:!71–261! 191! 5! 24.1! 29!
4A2N! isoprenylcysteine!carboxyl!methyltransferase! 1–192! 192! 5! 22.4! 24!
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1KPL! subdomain!of!H+/Cl,!!!exchange!transporter,!CIC! 31–233! 203! 5! 23.4! 31!
2BS2! subdomain!of!quinol:fumarate!reductase! C:!21–237! 217! 5! 17.5! 29!
3P5N! S!component!of!the!ECF,type!riboflavin!transporter! 10–188! 179! 6! 17.9! 22!
2IC8! rhomboid!peptidase,!GlpG!(E.!coli)! 91–272! 182! 6! 17.9! 23!
1PV6! subdomain!of!lactose!permease!transporter! 1–190! 189! 6! 28.3! 33!
2NR9! rhomboid!peptidase,!GlpG!(H.!influenzae)! 4–195! 192! 6! 17.6! 24!
Large(MPs(
1OKCb! mitochondrial!ADP/ATP!carrier! 2–293! 292! 6! 25.8! 34!
3B60! subdomain!of!lipid!flippase,!MsbA! A:!10–328! 319! 6! 25.7! 52!
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2KSY! sensory!rhodopsin!II! 1–223! 223! 7! 20.1! 37!
1PY6! bacteriorhodopsin!(full!length)! 5–231! 227! 7! 25.2! 36!
3KCU! formate!channel,!FocA! 29–280! 252! 7! 29.7! 33!
1FX8!
!
glycerol!facilitator!channel,!GlpF! 6–259! 254! 7! 28.6! 38!
1U19! rhodopsin! 33–310! 278! 7! 25.0! 41!
3KJ6! methylated!β2!adrenergic!receptor! A:!35–346! 311! 7! 39.5! 31!
Very(large(MPs(
3HD6! human!Rh!C!glycoprotein,!RhCG! 6–448! 403! 12! 43.6! 59!
3GIA!
amino!acid,!polyamine,!and!organocation!transporter,!ApcT! 3–435! 433! 12! 62.5! 64!
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3O0R! nitric!oxide!reductase!subunit!B! B:!10–458! 449! 12! 30.6! 69!
3HFX! carnitine!transporter,!CalT! 12–504! 493! 12! 68.0! 63!
2XUT! peptide!transporter,!PepT1!and!PepT2! A:!13–500! 488! 14! 42.8! 71!
2XQ2! K294A!mutant!of!Na+/galactose!transporter,!VSGLT! A:!9–573! 565! 15! 71.8! 79!
a Referred to as 1PY7 in this chapter; b Italicized PDB IDs indicate that this protein was used in 
RosettaTMH parameter optimization.  
 
Modification of BCL::MP-Fold benchmark models for comparison with Rosetta 
In order to compare the performance of BCL::MP-Fold with Rosetta, Rosetta loop 
definition files based on the models resulting from the BCL::MP-Fold benchmark for the 
34 proteins in Table 19 were generated using the BCL 
(http://www.meilerlab.org/index.php/bclcommons/show/b_apps_id/1). Next, the model 
PDB files were converted to be compatible with the Rosetta cyclic coordinate descent 
(CCD) loop modeling application, according to the protocol outlined by Combs, et al. 
(252). The resulting PDB files were then used as input for fragment-based loop building 
in Rosetta. Only one output model was generated per input. That is, for 1,000 models that 
!144!
were input for a given protein, only 1,000 models with loops were constructed. This 
procedure allowed for the calculation of RMSD100SSE (Cα RMSD100 (347) in predicted 
native SSEs) over the same residues as that computed over Rosetta-built models. 
 
Loop building on RosettaTMH-generated models 
Because RosettaTMH makes cuts in the protein fold tree in order to perform rigid 
body sampling (see The RosettaTMH de novo folding algorithm), the TMHs needed to be 
reconnected with loops. Therefore, the models built using RosettaTMH with and without 
restraints were subjected to Rosetta fragment-based loop building, as described in the 
previous section. 
 
Modification of Rosetta radius of gyration score for folding membrane proteins 
In addition to implementing the ability to fold MPs with multiple experimental 
restraints, a modified version of the Rosetta radius of gyration (RG) scoring term was 
introduced to help keep the TMHs from drifting too far away in 3D space, as well as to 
prevent the TMHs from collapsing into the membrane. Generally, the RG of a protein is 
directly proportional to the extent to which it is “spread out” in Cartesian space (348). 
The existing RG scoring term in Rosetta is computed over all residues in the protein 
(100). For MPs, the new RG scoring term takes only the TMH centers of mass (CoMs) 
into account and is computed over only those residues’ coordinates in the membrane, or 
X-Y, plane. In result, the scoring term, which is an energetic penalty, will disfavor 
conformational changes that cause the TMH CoMs to move, either laterally or along the 
membrane normal, far away from one another. 
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Weight optimization of Rosetta default radius of gyration score 
Preliminary testing data indicated that the default weight for the Rosetta RG score 
was sub-optimal for folding MPs. Therefore, multiple weighting factors, ranging from 0.0 
to 10.0 in increments of 0.25 (as well as 0.01), were tested. For each simulation, 1,000 
models of the 9 MPs italicized in Table 19 were folded using the RosettaTMH and 
ExtendedChain protocols, as both protocols have not yet been optimized. 
 
Determination of sampling efficiency for de novo folding 
 In order to measure sampling efficiency, or how many models need to be 
constructed for reliable benchmarking, 5,000 models based on the 1FX8, 1U19, and 
3O0R primary sequences were folded with the MembraneAbinitio folding algorithm, 
with RosettaTMH with and without simulated EPR distance restraints (weightKBP = 20.0, 
weightquadratic = 1.0), and from an ExtendedChain with and without simulated EPR 
distance restraints (weightKBP = 50.0, weightquadratic = 20.0). After this was completed, the 
average RMSD100SSE and standard deviation of a randomly selected subset of the 5,000 
models were computed. 
 
Simulation of EPR distance restraints using the BCL 
For the benchmark in this chapter, 10 sets of EPR distance restraints were 
generated for each protein. This was done to avoid bias resulting from using any single 
restraint set. The restraint selection algorithm developed by Kazmier, et al. (314) was 
used employed. The algorithm optimizes the information content of the restraint set by 
maximizing the sequence separation between spin labeling sites. At the same time, the 
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algorithm finds restraint sets that link all pairs of SSEs in the protein. In order to convert 
the resulting restraint sets to EPR-like distance restraints for testing during de novo 
folding, the Euclidian distances between the specified residues were determined from the 
MP experimental structures. Next, a spin label uncertainty was added to each distance, 
based on the cone model-based spin label statistics generated for the RosettaEPR KBP 
(135). These statistics were generated by placing a pseudo-spin label in the form of a 
right-angle cone (based on methanethiosulfonate, or MTS) on exposed residue pairs in a 
database of over 3,500 proteins. The frequency of observed values for the calculated 
difference between spin label distance and Cβ distance (dSL–dCβ) were collected in a 
histogram, which was shown to match relatively well to experimentally determined dSL–
dCβ values for T4-lysozyme and αA-crystallin. This histogram of spin label statistics 
quantifies the expected uncertainty associated with EPR distances measured on proteins 
spin labeled with MTS. 
 
Optimization of EPR distance restraint scoring term weighting 
The EPR distances for the residue pairs were simulated as described in the 
previous section. Preliminary benchmarking indicated that the EPR score used for the 
folding of T4-lysozyme (135) was insufficient to improve MP model quality of large 
MPs, such as rhodopsin. Instead, it was determined that a two-component scoring term 
was needed. 
 The modified EPR restraint potential for folding MPs consists of an energetic 
bonus derived from the aforementioned cone model statistics. Indeed, this energetic 
bonus is the same KBP used in the de novo folding of T4-lysozyme by Hirst, et al. (135). 
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However, in addition to the KBP energetic bonus, the EPR restraint score contains an 
energetic penalty characterized by the equation: 
f (x) =
x - lb
sd
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where x is the currently measured distance within the model, lb is the restraint lower 
bound, ub is the restraint upper bound, sd is the restraint standard deviation, and rswitch 
is set to 0.5. This quadratic penalty is similar to that used for nuclear Overhauser effect 
(NOE)-derived distance restraints in NMR structure calculations. The EPR scoring 
potential is designed such that the quadratic penalty is enforced if, during folding, the 
simulated model’s dSL–dCβ value for a given residue pair is greater than –12.0Å and less 
than 12.0Å.  
The weight of each EPR scoring term component was optimized separately. One 
thousand models of each protein were folded using RosettaTMH for each EPR restraint 
weighting scheme. For each protein under each of 49 weighting schemes, the percentage 
of models having RMSD100SSE < 8Å was computed, and the average of these values 
across the 9 proteins used for optimization are reported in Table 20. In addition, the 
enrichment was computed based on the models obtained from each weight scheme (Table 
21). Enrichment was computed as: 
enrichment = TPTP + FP *
P + N
P , 
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where the (P+N) / P ratio = 10, limiting the maximum obtainable enrichment to 10.0. 
The models were sorted according to Rosetta score. Models that fell within the top 10% 
by score were counted as “positive,” (P), and all models whose scores fell into the bottom 
90% by score were counted as “negative” (N). The positives were then sorted by 
RMSD100SSE relative to the native structures, and those models that fell within the top 
10% by RMSD100SSE were labeled “true positives” (TPs). All other low-scoring models 
were considered “false positives” (FPs).  
During EPR restraint weight optimization, the default Rosetta RG score weighted 
at 4.25 was used (see Weight optimization of Rosetta default radius of gyration score). 
Further, each restraint is scored independently, and the sum of individual restraint scores 
constitutes the total raw restraint score. The total restraint score was multiplied by a 
normalization factor that is equal to: 
weightcst = log(# cst)# cst *#aa , 
where weightcst is the weight by which the entire restraint score is multiplied before it is 
added to the total Rosetta score, or energy, #cst is equal to the number of simulated EPR 
restraints used, and #aa is the number of residues in the protein. Because the total 
restraint score is the sum of individual restraint scores, the weighted restraint score can be 
represented by: 
cst _ scoreweighted = average(cst _ scoreraw)* log(# cst)*#aa . 
 
The RosettaTMH de novo folding algorithm 
The RosettaTMH MP folding algorithm differs significantly from both the 
Rosetta folding algorithm for soluble proteins, “ExtendedChain” (100), as well as the 
!149!
published RosettaMembrane folding protocols (105, 117). It allows for enhanced 
sampling of MP topologies by treating TMHs as rigid bodies. Each helix can be rotated 
or translated, or transformed, as an independent entity. In order to implement this new 
algorithm in Rosetta folding, the model’s fold tree was modified. The fold tree of a model 
is a directed acyclic graph--a data structure that represents the connectivity of the model 
in internal coordinate space. This connectivity is distinct from chemical connectivity and 
thus enables Rosetta to rapidly move large sections of the protein without disturbing 
other parts (138). In the case of a helical MP, a radial, or star, fold tree is used, in which 
the CoM of each helix is connected to a central node (Figure 32). 
 
!
Figure 32:  Generation of membrane protein fold tree in RosettaTMH 
This schematic outlines how RosettaTMH generates a radial fold tree for a 5-helix membrane 
protein. In preparation for generating the fold tree, the primary sequence of the protein is read in 
and used to create an idealized α-helix. RosettaTMH utilizes user-defined TMH definitions to 
divide the idealized helix and insert each individual TMH into the implicit membrane. It then 
calculates each helix’s center of mass (CoM). The CoMs connect the helices to a central root 
residue (open circle) in internal coordinate space.  
 
N C
1 2 3 4 5
insert TMHs
find TMH centers of mass
make cuts in loops
make jumps between 
CoMs and virtual root 
residue
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Before de novo folding begins, each helix is inserted into the implicit 
RosettaMembrane environment (105). The CoM of each helix is set at the membrane 
center, and the helices are aligned along the membrane normal such that each helix is 
antiparallel to its sequential neighbors. The helices are arranged in a hexagonal grid and 
are initially separated from each other by 15Å. This grid point separation value was 
chosen after briefly testing distances of 5Å, 10Å, and 20Å and was selected based on the 
qualitative observation that, when TMHs were placed 5-10Å apart, they were more likely 
to “clash” into each other in sterically hindered conformations. On the other hand, a 
distance of 20Å caused the TMHs to never “see” each other during the first stage of de 
novo folding, making scoring by the Rosetta energy function difficult. The starting 
topology of the model is randomized; that is, the arrangement of helices in the hexagonal 
grid is different for each starting model (Figure 33). 
 
Figure 33:  Initial placement of transmembrane helices before de novo folding 
Schematic outlining initialization of protein model conformation before sampling. In this case, a 
5-helix MP is inserted in the RosettaMembrane implicit membrane such that the TMHs run 
antiparallel to one another and aligned along the membrane normal. A hexagonal grid is 
computed, such that the vertices are aligned along the membrane center plane and are 15Å away 
from one another and from the origin. Then, for each grid point, a TMH is chosen randomly, and 
the helix is transformed to that grid point such that its CoM is aligned with the origin. The 
hexagonal grid can be expanded as needed, depending on the number of TMHs in the protein. 
Setup for rigid body sampling
N C
1 2 3 4 5
place helices into grid 
points before sampling
flip helices N-terminus to C-terminus
pre-compute
grid points
15Å
origin
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Stages of de novo folding with RosettaTMH 
The pre-processing and de novo folding stages of RosettaTMH are summarized in 
Figure 34. Folding begins after the initialization of the model. The first stage of de novo 
folding consists entirely of rigid body transformations performed in a Monte Carlo 
Metropolis (MCM) fashion (266). For each MCM move, the helix is allowed to either 
rotate by up to 0.1° about any axis or translate up to 0.5Å in any direction from its current 
position. These values were selected based on preliminary testing and qualitative 
observation of the resulting models. The conformation resulting from each transformation 
is scored according to the RosettaMembrane centroid-based scoring function and, if 
specified, the MP-specific RG score (see Modification of Rosetta radius of gyration score 
for folding MPs). Stage 1 of folding consists of 2,000 MCM moves, and the RG and 
RosettaMembrane-specific “density” term and are turned on (105). These scoring terms 
aid in improving the compactness of the model. After the first stage, the model undergoes 
9- and 3-amino acid fragment insertions using a protocol analogous to the one used for 
soluble proteins (100). Briefly, in Stage 2, 2,000 MCM cycles are performed, during 
which 9mer fragments are inserted onto the helical protein backbone. The density scoring 
term is turned off, and residue pairing, membrane environment, and membrane-specific 
penalties are added (105). The density term is re-introduced in Stage 3, which consists of 
10 inner cycles; during these inner cycles, the scoring function can be alternated if 
desired. However, for MPs, the scoring function is the same for each of two inner cycle 
sub-stages. Each sub-stage consists of 2,000 MCM cycles for inserting 9mer fragments, 
resulting in a total of 20,000 fragment insertions. Finally, the density term is up-weighted 
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in Stage 4, and 4,000 MCM cycles of 3mer fragment insertions are performed (see 
Appendix E). 
 
Figure 34:  Outline of stages for RosettaTMH de novo folding 
Benchmarking of RosettaTMH in the absence and presence of simulated EPR restraints 
The generation of input files for this benchmark, except for the simulated 
restraints, is described in Weiner, et al. ‘s work on BCL::MP-Fold (345). Briefly, the 
primary sequence of each protein listed in Table 19 was used to generate 3- and 9-amino 
acid fragment files required for de novo folding in Rosetta. The Rosetta spanfiles 
containing the TMH definitions were obtained by using predictions from OCTOPUS 
(349). Rosetta lipophilicity files were also generated for each protein using the LIPS 
algorithm (350). One thousand models were folded from the primary sequence, using 
TMH information and the RosettaMembrane centroid-based scoring function (105). 
When multiple EPR restraint sets were used, the number of total models generated per 
restraint set was equal to the total number of models generated divided by the number of 
different restraint sets (i.e., 10 sets of 100 models for each protein). All computations 
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were performed on the Vanderbilt University Advanced Computing Cluster for Research 
and Education (ACCRE) using Rosetta revision numbers d592380 and d7b5a70 for 
RosettaTMH parameter optimization and benchmarking, respectively. The source code is 
available in the Rosetta3 master branch, which is available to developers in the 
RosettaCommons via https://github.com/RosettaCommons. The complete protocol 
capture for this work is described in Appendix E. 
 
Results 
Modified radius of gyration score does not significantly affect folding with RosettaTMH 
Development of MP de novo folding methods often has a distinct advantage in 
that the membrane environment imposes a spatial constraint on the orientation of the 
protein. One way to leverage this constraint is to modify MP-specific scoring terms. In 
the case of RosettaTMH, an MP-specific RG scoring term (“new RG”) was tested. This 
RG scoring term computes the RG over X- and Y- Cartesian coordinate values, 
disregarding the Z-coordinates that indicate vertical position of the MP in the membrane 
bilayer. The objective of this scoring term is to compress the model in the X/Y plane but 
not, or less drastically, along the Z-axis. This is different than the Rosetta default RG 
scoring term, which computes the RG over all three Cartesian dimensions. However, 
after testing this new RG score on the 9 MPs italicized in Table 19, it was found that the 
modified RG score did not affect overall performance for de novo folding with 
RosettaTMH (Figure 35). Therefore, the default Rosetta RG score was used for all further 
simulations in this chapter. 
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Figure 35:  Comparison of RosettaTMH de novo folding with the original and modified 
radius of gyration scores 
The mean RMSD100SSE (± S.E.M) of the top 10% of total models built for 9 MPs is plotted as a 
function of the factor by which the RG score is weighted (beyond the default Rosetta weight of 
0.3). 
 
Weight optimization for default radius of gyration score  
Preliminary testing of de novo folding of MPs with RosettaTMH indicated that 
the weight of the Rosetta default RG score needed optimization. For each of 42 RG 
weighting factors ranging from 0.0 to 10.0, 1,000 models of the 9 proteins italicized in 
Table 1 were folded using RosettaTMH. The average enrichment and standard error of 
the mean (S.E.M.) were computed for each folding simulation (Figure 36). Based on 
these results, a weighting factor of 4.25 was used for the benchmarking of RosettaTMH. 
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It should be noted that, by default, the RG score is already multiplied by 0.3, thus 
resulting in an overall RG score weight of 1.275. 
 
Figure 36:  Optimization of the default Rosetta radius of gyration score weighting factor for 
de novo folding with RosettaTMH 
The average enrichment (± S.E.M) obtained for folding 9 MPs with RosettaTMH is plotted as a 
function of RG weighting factor. The blue box indicates the optimum value for that folding 
method. Further benchmarking was performed with an RG weight of 4.25 for all folding 
protocols. 
 
The sampling efficiency of Rosetta de novo folding methods is similar 
To test how quickly de novo folding results of Rosetta for MPs converge, i.e., 
sampling efficiency, 5,000 models of 3 large MPs were folded using MembraneAbinitio, 
ExtendedChain, and RosettaTMH protocols. The latter two methods were also tested in 
the presence of simulated EPR restraints (“ExtendedChain+EPR” and 
“RosettaTMH+EPR,” respectively). Then, randomized subsets of varying sizes were 
A B
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selected, and the average RMSD100SSE and standard deviation was computed for that 
fraction of models. The standard deviation was then plotted as a function of fraction of 
total models built (Figure 37). Interestingly, all five folding methods’ results appear to 
converge at around 3,750 – 5,000 models.  
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Figure 37:  Sampling efficiency of various Rosetta de novo folding methods for three membrane proteins 
Ratio between the mean standard deviation of RMSD100SSE (SDRMSD) of a subset of 5,000 models and the mean SDRMSD of all 5,000 models is 
plotted as a function of the fraction of total models built. 
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Optimal EPR restraint potential weighs both knowledge-based potential and quadratic 
penalty equally 
De novo folding of soluble proteins with EPR restraints in Rosetta had been 
optimized previously (134, 135). However, it was found that, for MPs, a quadratic 
penalty was needed in addition to the EPR KBP energetic bonus to sufficiently improve 
conformational sampling of native-like folds. After rigorous weight optimization of this 
hybrid scoring term, it was determined that, for folding with RosettaTMH, the optimal 
weight scheme for the EPR distance restraint score was to multiply the EPR KBP by a 
factor of 1.0 and multiply the quadratic penalty by a factor of 1.0. This was based on the 
observation that, of the weights tested, the mean percentage of models with RMSD100SSE 
< 8Å across 9 proteins was highest with this weighting scheme (Table 20). The 
enrichment for folding with this set of weights was 2.93 (Table 21). Interestingly, the 
enrichment for de novo folding with EPR restraints was generally lower than folding with 
no restraints. By definition, this is because the number of false positives, or low-scoring, 
high-RMSD models, was higher when folding with simulated restraints. This is perhaps 
due to the higher promiscuity of the EPR restraints, which are broader than distance 
restraints resulting from NMR NOEs. Therefore, models that fulfill the simulated 
restraints and are lower-scoring do not necessarily have native-like topologies. 
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Table 20:  Percentage of correctly folded models obtained for folding nine membrane 
proteins with RosettaTMH using a variety of restraint score weighting schemes 
! Percent'of'Models'RMSD100SSE'<'8Å'Quadratic'Penalty'0! 1! 10! 20! 30! 40! 50!
EPR'KBP'
0! 0.02! 1.00! 0.91! 0.89! 0.81! 0.82! 0.78!1! 1.56! 4.03! 3.74! 3.26! 3.48! 3.41! 3.51!10! 1.58! 5.24! 4.21! 4.03! 4.28! 4.01! 4.03!20! 1.54! 4.53! 4.03! 3.84! 3.96! 3.67! 3.64!30! 1.63! 4.34! 4.02! 3.94! 3.99! 3.98! 3.72!40! 1.30! 4.28! 3.99! 3.81! 3.82! 3.60! 3.57!50! 1.33! 4.07! 3.73! 3.50! 3.79! 3.72! 3.66!
 
 
Table 21:  Enrichment obtained for folding nine membrane proteins with RosettaTMH 
using a variety of restraint score weighting schemes !! Enrichment'Quadratic'Penalty'0! 1! 10! 20! 30! 40! 50!
EPR'KBP'
0! 3.16! 2.41! 2.54! 2.51! 2.47! 2.28! 2.44!1! 3.40! 2.93! 2.58! 2.66! 2.71! 2.64! 2.54!10! 3.06! 1.99! 2.09! 2.01! 1.99! 2.23! 2.12!20! 2.87! 1.76! 2.00! 1.70! 1.93! 1.78! 1.89!30! 2.54! 1.54! 1.84! 1.90! 1.60! 1.70! 1.83!40! 3.12! 1.67! 1.69! 1.78! 1.82! 1.90! 1.73!50! 2.73! 1.78! 1.64! 1.71! 1.57! 1.66! 1.86!
 
The data in Table 22 and Table 23 compares the enrichment and quality of models 
generated by MembraneAbinitio (105), ExtendedChain (100), ExtendedChain+EPR, 
RosettaTMH, and RosettaTMH+EPR. We also compare the various Rosetta MP folding 
methods to BCL::MP-Fold, another MP de novo folding method that forms 3D protein 
conformations via assembly of SSEs (345). There are no significant or apparent trends in 
the enrichment data, other than that enrichments for datasets generated with RosettaTMH 
are often higher for small- to medium-sized MPs. The addition of EPR restraints results 
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in a general decrease in enrichment for all but the largest MPs, which was unexpected 
(Table 22). 
Table 22:  Enrichment obtained for folding thirty-four membrane proteins with and 
without simulated EPR distance restraints* 
PDB'
Folding'Method'
MembraneAbinitio' ExtendedChain' +EPR' RosettaTMH' +EPR' BCL'3SYO! 1.2! 1.0! 0.8!±!0.9! 3.2! 2.1!±!1.3! 1.5!2BG9! 1.5! 0.7! 2.5!±!1.4! 4.1! 2.9!±!1.0! 2.2!1J4N! 1.6! 1.1! 2.1!±!1.5! 0.0! 3.0!±!1.1! 0.4!2KSF! 1.0! 0.9! 1.0!±!1.5! 3.2! 2.4!±!2.0! 1.5!1PY7! 2.9! 2.7! 4.1!±!2.1! 4.0! 3.1!±!1.4! 1.8!2PNO! 1.0! 2.3! 1.7!±!0.9! 3.7! 2.1!±!1.2! 0.8!2BL2! 3.5! 3.2! 3.9!±!1.7! 4.3! 2.6!±!1.7! 1.1!2K73! 1.5! 1.6! 1.4!±!1.2! 3.1! 2.3!±!1.7! 1.5!2ZW3! 2.4! 1.3! 1.5!±!0.7! 3.1! 1.8!±!0.9! 0.5!1IWG! 1.9! 1.0! 2.4!±!0.7! 2.9! 1.8!±!1.5! 0.6!1RHZ! 1.9! 1.7! 2.2!±!0.9! 2.9! 2.3!±!0.9! 0.9!2YVX! 2.3! 0.4! 1.3!±!0.8! 2.5! 2.0!±!1.1! 0.7!1OCC! 2.5! 2.5! 1.8!±!1.4! 3.8! 2.1!±!1.1! 1.1!4A2N! 3.1! 1.1! 1.2!±!1.1! 3.5! 2.7!±!1.5! 0.7!1KPL! 1.7! 2.3! 1.3!±!0.9! 1.8! 1.3!±!1.2! 0.6!2BS2! 1.9! 2.9! 2.3!±!1.1! 3.6! 2.0!±!1.4! 1.5!3P5N! 2.8! 2.6! 3.0!±!1.9! 3.4! 2.3!±!1.2! 1.5!2IC8! 1.8! 1.6! 1.6!±!1.5! 2.3! 2.0!±!1.2! 1.3!1PV6! 1.4! 2.5! 2.8!±!0.8! 3.0! 2.3!±!1.6! 1.2!2NR9! 2.6! 0.6! 1.5!±!1.0! 2.6! 2.0!±!1.1! 1.5!1OKC! 3.4! 4.0! 2.2!±!0.9! 2.6! 2.9!±!1.3! 0.7!3B60! 2.0! 3.5! 4.1!±!1.0! 2.3! 2.2!±!1.1! 0.0!2KSY! 1.0! 0.9! 1.0!±!1.5! 3.2! 2.4!±!2.0! 1.5!1PY6! 1.3! 3.1! 3.5!±!1.4! 3.3! 2.9!±!1.0! 1.4!3KCU! 1.4! 1.1! 1.1!±!0.9! 2.2! 1.4!±!1.2! 0.5!1FX8! 2.5! 4.9! 2.4!±!1.3! 2.9! 1.7!±!0.9! 0.9!1U19! 5.2! 3.3! 1.9!±!1.7! 2.7! 1.9!±!1.1! 1.4!3KJ6! 1.2! 0.6! 0.8!±!0.6! 2.3! 1.3!±!0.9! 1.0!3HD6! 2.0! 5.7! 4.4!±!0.5! 1.9! 1.8!±!1.1! 0.4!3GIA! 2.7! 4.2! 2.3!±!1.2! 1.6! 1.5!±!1.1! 0.0!3O0R! 2.2! 4.9! 3.2!±!1.2! 1.7! 2.3!±!1.1! 0.1!3HFX! 3.5! 1.9! 2.1!±!0.9! 1.2! 1.8!±!1.4! 0.4!2XUT! 2.4! 1.1! 1.3!±!1.2! 1.6! 2.1!±!1.3! 0.0!2XQ2! 2.7! 1.1! 1.3!±!1.4! 0.8! 1.1!±!0.9! 0.1!Mean!! 2.2! 2.2! 2.1!±!1.2! 2.7! 2.1!±!1.3! 0.9!std.!dev.! 0.9! 1.3! 1.0!±!0.4! 1.0! 0.5!±!0.3! 0.6!
* Enrichment values with standard deviations were obtained from de novo folding 1,000 models 
with 10 different EPR distance restraint sets. 
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Addition of EPR restraints significantly improves sampling for RosettaTMH and 
ExtendedChain 
In order to assess the overall sampling capability of each folding protocol, the 
average RMSD100SSE of the top 10% of models by RMSD100SSE (µ10%RMSD) was 
computed relative to the experimental, or native, structure. Additionally, we computed 
the percentage of models having an RMSD100SSE < 8Å, which serves as a cutoff for 
determining if models have the correct topology. We also report the best RMSD100SSE 
(BestRMSD) obtained for each method and the mean RMSD100SSE of the five lowest-
scoring models (µ5modelscore). As was observed with T4-lysozyme (135), the addition of 
EPR restraints increases the likelihood of obtaining the correct MP fold for both 
RosettaTMH and ExtendedChain. When looking at the percentage of models with 
RMSD100SSE < 8Å, for 12 of 34 proteins, RosettaTMH performs worse than 
ExtendedChain, while RosettaTMH+EPR performs better than ExtendedChain+EPR. 
Several of these proteins consist of over 200 residues, indicating RosettaTMH’s ability to 
fold large MPs in the presence of restraints. Further, when compared to other Rosetta MP 
folding methods, RosettaTMH+EPR obtains the highest percentage of correctly folded 
models for 4 of the 13 medium-sized proteins, 5 of the 8 large proteins, and 5 of the 6 
very large proteins. However, BCL::MP-Fold out-performs all Rosetta methods for the 
vast majority of benchmark cases – a fact that requires further research outside the scope 
of the present work (Table 23). 
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Table 23:  Overall performance of de novo folding membrane proteins with Rosetta and BCL::MP-Fold 
PDB$ Metric$
Folding$Method$
MembraneAbinitio$ ExtendedChain$ +EPR$ RosettaTMH$ +EPR$ BCL$
3SYO! μ5modelscorea! 11.6! 8.0! 7.7! 6.3! 5.2! 4.0!BestRMSDb! 6.9! 2.5! 2.0! 2.9! 2.3! 1.6!μ10%RMSDc! 9.5! 4.9! 3.5! 5.1! 3.4! 3.0!%!<!8Åd! 0.4! 43.5! 74.6! 30.4! 71.3! 100.0!
2BG9! μ5modelscore! 8.7! 10.4! 7.2! 8.3! 7.3! 6.4!BestRMSD! 4.2! 4.1! 3.9! 5.5! 2.9! 2.7!μ10%RMSD! 5.8! 5.3! 5.6! 8.4! 5.1! 3.6!%!<!8Å! 28.1! 22.1! 40.0! 3.0! 32.7! 50.7!
1J4N! μ5modelscore! 10.0! 8.2! 7.6! 11.2! 10.0! 9.2!BestRMSD! 4.9! 4.8! 3.1! 6.6! 5.7! 4.6!μ10%RMSD! 7.0! 6.1! 4.5! 8.9! 7.9! 6.0!%!<!8Å! 12.3! 28.8! 44.7! 1.4! 4.4! 32.3!
2KSF! μ5modelscore! 8.5! 9.2! 10.0! 8.8! 9.6! 6.6!BestRMSD! 5.6! 4.8! 4.0! 5.5! 3.9! 3.2!μ10%RMSD! 6.9! 6.4! 5.8! 9.1! 5.9! 4.2!%!<!8Å! 18.8! 27.0! 28.8! 1.3! 20.6! 41.3!
1PY6*! μ5modelscore! 4.5! 7.3! 2.3! 9.6! 6.6! 8.0!BestRMSD! 2.5! 1.9! 1.9! 6.0! 2.9! 3.8!μ10%RMSD! 3.9! 3.5! 2.6! 9.4! 5.0! 4.8!%!<!8Å! 63.7! 70.7! 57.9! 0.9! 31.0! 57.4!
2PNO! μ5modelscore! 7.9! 8.1! 7.9! 10.4! 7.8! 59.6!BestRMSD! 4.1! 3.3! 2.8! 7.2! 4.4! 4.5!μ10%RMSD! 6.0! 5.7! 4.1! 10.1! 6.0! 7.2!%!<!8Å! 29.0! 26.0! 56.6! 0.5! 23.3! 13.6!2BL2! μ5modelscore! 6.7! 3.9! 5.4! 9.9! 7.3! 38.7!BestRMSD! 2.3! 2.3! 2.5! 6.7! 3.4! 3.0!
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μ10%RMSD! 3.6! 3.4! 3.7! 9.8! 5.0! 4.0!%!<!8Å! 70.1! 54.8! 70.9! 1.0! 53.8! 79.9!
2K73! μ5modelscore! 10.1! 6.9! 5.7! 10.6! 5.9! 31.4!BestRMSD! 6.4! 3.1! 2.8! 6.3! 3.1! 2.8!μ10%RMSD! 8.7! 4.5! 4.2! 9.0! 4.9! 3.8!%!<!8Å! 1.1! 43.5! 55.2! 1.6! 48.3! 72.3!
2ZW3! μ5modelscore! 11.8! 12.1! 9.7! 10.5! 7.7! 48.3!BestRMSD! 10.1! 5.2! 5.2! 5.7! 3.7! 3.1!μ10%RMSD! 11.9! 8.3! 6.8! 8.8! 5.4! 4.5!%!<!8Å! 0.0! 2.7! 16.4! 1.8! 30.2! 73.2!
1IWG! μ5modelscore! 8.1! 10.4! 8.4! 11.5! 7.2! 8.6!BestRMSD! 5.8! 5.0! 4.8! 7.6! 4.2! 4.2!μ10%RMSD! 7.3! 11.2! 5.8! 10.0! 5.9! 5.9!%!<!8Å! 12.2! 9.0! 42.6! 0.3! 27.0! 41.9!
1RHZ! μ5modelscore! 9.8! 9.4! 8.2! 11.9! 7.7! 9.4!BestRMSD! 7.1! 5.2! 3.9! 7.5! 5.4! 4.9!μ10%RMSD! 8.8! 7.1! 5.2! 10.1! 7.0! 7.2!%!<!8Å! 0.7! 11.9! 44.4! 0.2! 12.9! 12.6!
2YVX! μ5modelscore! 8.9! 14.3! 8.1! 11.3! 6.6! 9.4!BestRMSD! 6.7! 6.0! 4.1! 7.5! 3.8! 5.8!μ10%RMSD! 7.9! 8.2! 5.6! 10.4! 6.6! 7.3!%!<!8Å! 4.8! 3.5! 35.8! 0.1! 17.6! 13.3!
1OCC! μ5modelscore! 9.8! 10.1! 9.1! 9.1! 6.9! 7.4!BestRMSD! 5.9! 7.0! 5.9! 7.8! 4.1! 4.5!μ10%RMSD! 9.1! 8.8! 7.9! 10.0! 5.4! 6.2!%!<!8Å! 0.8! 1.2! 5.0! 0.3! 45.9! 49.0!
4A2N! μ5modelscore! 9.9! 14.0! 8.7! 9.6! 8.0! 8.7!BestRMSD! 6.4! 5.6! 3.8! 6.4! 4.5! 3.8!μ10%RMSD! 8.2! 7.8! 5.5! 9.3! 6.7! 5.6!
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%!<!8Å! 3.4! 5.0! 32.2! 1.3! 10.9! 29.2!
1KPL! μ5modelscore! 13.3! 13.8! 13.8! 13.9! 11.5! 145.4!BestRMSD! 10.3! 9.9! 6.9! 11.2! 7.3! 9.9!μ10%RMSD! 13.0! 12.5! 9.0! 13.0! 9.8! 11.3!%!<!8Å! 0.0! 0.0! 1.0! 0.0! 0.1! 0.0!
2BS2! μ5modelscore! 9.9! 9.0! 8.1! 10.6! 9.1! 8.1!BestRMSD! 6.0! 6.3! 5.1! 6.4! 4.1! 4.9!μ10%RMSD! 8.8! 9.0! 6.7! 10.2! 6.1! 6.4!%!<!8Å! 1.5! 1.0! 15.1! 0.1! 26.9! 31.4!
3P5N! μ5modelscore! 9.0! 9.4! 7.3! 12.0! 9.1! 114.9!BestRMSD! 5.5! 5.1! 3.8! 7.5! 4.6! 4.5!μ10%RMSD! 8.3! 7.4! 5.4! 10.0! 7.0! 6.5!%!<!8Å! 2.0! 7.1! 36.6! 0.1! 16.3! 23.6!
2IC8! μ5modelscore! 10.1! 9.3! 9.7! 10.1! 8.3! 9.6!BestRMSD! 5.2! 4.9! 3.5! 7.8! 5.0! 5.1!μ10%RMSD! 7.9! 7.3! 5.6! 10.2! 6.8! 6.8!%!<!8Å! 3.6! 8.0! 30.0! 0.1! 13.0! 16.7!
1PV6! μ5modelscore! 10.5! 9.9! 8.0! 11.7! 7.8! 9.3!BestRMSD! 5.7! 6.9! 4.2! 7.5! 4.2! 5.7!μ10%RMSD! 8.2! 8.6! 6.3! 10.7! 5.9! 7.3!%!<!8Å! 3.5! 1.5! 20.6! 0.1! 23.8! 10.5!
2NR9! μ5modelscore! 9.6! 9.6! 9.0! 11.3! 9.1! 8.6!BestRMSD! 6.1! 5.6! 3.7! 8.3! 5.3! 5.1!μ10%RMSD! 8.3! 7.8! 5.6! 10.2! 7.1! 6.8!%!<!8Å! 2.5! 4.5! 27.8! 0.0! 10.9! 16.7!
1OKC! μ5modelscore! 13.1! 10.5! 10.6! 12.0! 9.2! 78.9!BestRMSD! 9.0! 8.4! 6.9! 8.0! 5.1! 5.7!μ10%RMSD! 11.6! 12.1! 8.6! 10.7! 7.3! 7.8!%!<!8Å! 0.0! 0.0! 2.1! 0.1! 9.5! 5.9!
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3B60! μ5modelscore! 9.4! 9.4! 4.3! 11.0! 8.6! 74.4!BestRMSD! 5.5! 6.0! 3.2! 7.8! 4.8! 9.2!μ10%RMSD! 8.3! 8.3! 4.7! 10.2! 6.3! 11.1!%!<!8Å! 2.2! 3.2! 48.0! 0.1! 30.7! 0.0!
2KSY! μ5modelscore! 7.7! 10.0! 8.4! 11.7! 6.6! 8.2!BestRMSD! 4.3! 3.6! 3.9! 8.2! 4.2! 5.1!μ10%RMSD! 6.0! 6.2! 5.3! 10.9! 5.8! 6.7!%!<!8Å! 27.9! 17.8! 33.4! 0.0! 28.6! 17.7!
1PY6! μ5modelscore! 8.4! 7.1! 5.8! 12.3! 7.7! 8.4!BestRMSD! 4.6! 4.0! 4.2! 8.3! 4.1! 4.7!μ10%RMSD! 6.3! 6.6! 5.9! 10.6! 5.8! 6.2!%!<!8Å! 29.3! 16.5! 23.9! 0.0! 32.7! 24.4!
3KCU! μ5modelscore! 10.0! 11.7! 10.9! 12.2! 11.1! 100.7!BestRMSD! 6.8! 6.8! 4.7! 8.8! 5.9! 6.5!μ10%RMSD! 8.9! 9.2! 7.6! 11.1! 7.6! 8.5!%!<!8Å! 0.4! 0.7! 6.1! 0.0! 6.6! 1.0!
1FX8! μ5modelscore! 11.3! 11.5! 11.6! 11.5! 9.3! 210.4!BestRMSD! 7.7! 7.0! 6.2! 9.6! 6.7! 7.2!μ10%RMSD! 10.1! 11.2! 8.8! 10.9! 8.8! 8.3!%!<!8Å! 0.1! 0.1! 1.2! 0.0! 0.7! 1.9!
1U19! μ5modelscore! 11.9! 15.8! 10.8! 12.1! 8.3! 8.5!BestRMSD! 9.7! 12.7! 7.3! 8.3! 4.9! 5.3!μ10%RMSD! 12.5! 15.0! 9.2! 10.7! 6.6! 7.0!%!<!8Å! 0.0! 0.0! 0.5! 0.0! 16.8! 14.2!
3KJ6! μ5modelscore! 15.1! 13.0! 10.1! 10.8! 8.6! 152.6!BestRMSD! 12.4! 7.5! 5.1! 6.2! 3.6! 4.4!μ10%RMSD! 13.7! 10.3! 7.2! 9.6! 6.4! 5.9!%!<!8Å! 0.0! 0.1! 10.8! 0.6! 20.0! 43.9!3HD6! μ5modelscore! 10.6! 16.5! 11.1! 19.2! 10.8! 10.2!
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BestRMSD! 6.8! 13.1! 8.3! 9.7! 7.2! 7.0!μ10%RMSD! 9.6! 19.4! 10.9! 12.2! 9.4! 8.5!%!<!8Å! 0.1! 0.0! 0.1! 0.0! 0.6! 1.6!
3GIA! μ5modelscore! 14.0! 25.9! 13.5! 15.0! 14.0! 122.3!BestRMSD! 11.6! 20.4! 8.0! 11.2! 8.8! 9.1!μ10%RMSD! 14.0! 24.4! 10.2! 13.2! 10.5! 10.8!%!<!8Å! 0.0! 0.0! 0.2! 0.0! 0.0! 0.0!
3O0R! μ5modelscore! 10.2! 24.1! 9.9! 14.5! 9.5! 51.3!BestRMSD! 6.5! 20.2! 6.0! 10.3! 6.2! 6.9!μ10%RMSD! 8.6! 24.6! 9.2! 12.3! 7.6! 8.7!%!<!8Å! 2.2! 0.0! 1.3! 0.0! 6.8! 1.6!
3HFX! μ5modelscore! 13.2! 24.7! 12.2! 15.1! 9.9! 77.8!BestRMSD! 10.0! 15.2! 7.0! 8.4! 5.7! 6.0!μ10%RMSD! 12.8! 20.5! 9.1! 10.1! 7.9! 8.0!%!<!8Å! 0.0! 0.0! 0.8! 0.0! 4.4! 4.2!
2XUT! μ5modelscore! 14.5! 48.2! 12.8! 16.1! 9.5! 75.1!BestRMSD! 12.5! 22.6! 8.3! 12.1! 6.5! 7.4!μ10%RMSD! 13.6! 29.4! 11.4! 13.6! 8.5! 9.4!%!<!8Å! 0.0! 0.0! 0.1! 0.0! 2.7! 0.3!
2XQ2!!
μ5modelscore! 17.2! 52.3! 13.1! 17.5! 11.5! 103.7!BestRMSD! 13.8! 31.7! 9.8! 12.1! 6.7! 8.2!μ10%RMSD! 15.6! 39.5! 11.5! 13.6! 8.6! 10.3!%!<!8Å! 0.0! 0.0! 0.1! 0.0! 1.8! 0.0!Mean!±!std.!dev.!
μ5modelscore! 10.4!±!2.6! 13.9!±!10.6! 9.0!±!2.6! 11.8!±!2.6! 8.6!±!1.8! 48.1!±!46.0!BestRMSD! 7.0!±!2.8! 8.2!±!6.8! 4.9!±!2.0! 7.9!±!2.0! 4.9!±!1.4! 5.3!±!2.0!μ10%RMSD! 9.1!±!2.9! 11.2!±!8.2! 6.7!±!2.4! 10.4!±!1.7! 6.8!±!1.5! 6.9!±!2.2!%!<!8Å! 9.4!±!17.6! 12.1!±!18.0! 25.4!±!22.5! 1.3!±!5.3! 20.1!±!16.6! 26.0!±!26.8!
a µ5modelscore = mean RMSD100SSE to native structure of the top five models by score; b BestRMSD = RMSD100SSE of the best model by 
RMSD100SSE compared to the native structure; c µ10%RMSD = mean of the top 10% of models by RMSD100SSE compared to the native structure; d 
% < 8Å = percentage of total models folded having an RMSD100SSE < 8Å 
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De novo folding with RosettaTMH improves sampling over other methods for large 
proteins 
 For ease of visualization, a representative set of 7 proteins was chosen from the 
34-protein benchmark set for further RMSD100SSE analysis. For each protein and for 
each folding method, the RMSD100SSE values were sorted from lowest to highest, and 
the top 5% of models by RMSD100SSE were selected. Next, RMSD100SSE vs. 
RMSD100SSE plots comparing RosettaTMH and RosettaTMH+EPR with the other 
Rosetta and BCL MP folding methods were generated. This analysis clarifies a few key 
conclusions concerning RosettaTMH. First, RosettaTMH+EPR samples lower-RMSD 
conformations for larger MPs when compared to RosettaTMH, MembraneAbinito, and 
ExtendedChain. Also, when comparing RosettaTMH with MembraneAbinito and 
ExtendedChain, the latter two methods are more suitable for structure prediction when 
the proteins are small- to medium-sized. Finally, RosettaTMH performance is 
comparable to MembraneAbinitio and ExtendedChain for 2K73 and 1FX8, respectively 
(Figure 38). 
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!
Figure 38:  Sampling performance for de novo folding with RosettaTMH compared to other 
folding methods 
For each panel, the RMSD100SSE of the top 5% of models by score were selected for 7 proteins. 
A) MembraneAvinitio vs. RosettaTMH. B) Folding from an extended chain vs. RosettaTMH. C) 
RosettaTMH with EPR restraints vs. RosettaTMH (without EPR restraints). D) BCL::MP-Fold 
vs. RosettaTMH. E) MembraneAbinitio vs. RosettaTMH with EPR restraints. F) Folding from an 
extended chain with EPR restraints vs. RosettaTMH with EPR restraints. 
 
 
Addition of EPR restraints primarily responsible for improvement seen in RosettaTMH 
folding 
The MembraneAbinitio folding algorithm was first benchmarked on a dataset of 
relatively small proteins and performed best with small helical bundles (105). However, it 
was found that MPs having more complex topologies posed a much more difficult 
challenge, which RosettaTMH could possibly address. Indeed, 6 of the 34 proteins tested 
in this benchmark set show improved quality when using RosettaTMH over folding with 
MembraneAbinitio or ExtendedChain. Further, the addition of the EPR distance restraint 
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potential improves sampling of native-like folds significantly. This appears to be 
primarily due to the influence of the EPR restraints, as folding with ExtendedChain+EPR 
also increases sampling efficiency to include the correct fold. In order to test this 
hypothesis, rhodopsin (PDB ID: 1U19 (260)) was selected for an in-depth analysis of the 
relationship between the number of EPR restraints and overall conformational sampling 
ability.  
Rhodopsin was folded using all of the Rosetta methods listed in Table 22. 
However, for RosettaTMH+EPR and ExtendedChain+EPR, multiple sets of models were 
generated based on whether 0, 10, 20, 40, 80, or 160 simulated EPR distance restraints 
were used. Unlike in the 34-protein benchmark, only one EPR restraint set for each 
scenario was generated, and 1,000 models were folded for each case. Box-and-whisker 
plots of the resulting RMSD100SSE distributions are displayed in Figure 39. When no 
restraints are used, MembraneAbinitio and folding from an extended chain perform 
similarly, while RosettaTMH generally appears to generate lower-RMSD models. When 
using 10 restraints, RosettaTMH+EPR and ExtendedChain+EPR exhibit similar median 
RMSD100SSE values, but RosettaTMH+EPR samples a wider range of conformations. 
However, when 20 or more restraints are used, RosettaTMH+EPR is consistently better 
in sampling the correct fold. As expected, the number of outliers correlates inversely with 
the number of restraints (Figure 39). 
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Figure 39:  Sampling performance of RosettaTMH with various EPR restraint set sizes for 
folding rhodopsin 
Box-and-whisker plot indicating the breadth of model accuracy obtained for folding rhodopsin 
with RosettaTMH with 10, 20, 40, 80 and 160 simulated EPR distance restraints. The thick line 
indicates the median RMSD100SSE obtained, while the boxes indicate the interquartile range. The 
highest and lowest RMSD100SSE values, excluding outliers, are indicated by the “whiskers,” and 
outliers are shown as open circles. 
 
Detailed analysis of individual de novo folding stages indicate rigid body sampling not 
necessary 
In addition to studying the overall performance of RosettaTMH with and without 
EPR restraints, the ability of the protocol to sample MP topologies during each stage of 
folding (see Figure 34) was also analyzed. As with the above experiment, rhodopsin was 
chosen as an example protein, and, when indicated that EPR restraints were employed, 
only one set of 41 optimally weighted restraints was used. For each folding method, 
1,000 individual trajectories were run, and the conformations before folding began and 
after each stage of folding were output. Then, similar to in Figure 39, the RMSD100SSE 
distributions for each folding stage were plotted. The single, high-scoring conformations 
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observed at folding initiation, or Stage 0, are all an extended chain, which is how both the 
default Rosetta folding algorithm, and MembraneAbinitio, begin. Accordingly, for 
MembraneAbinitio and ExtendedChain model quality significantly improves from 
initiation to Stage 1 and then from Stage 1 to Stage 2. In contrast, RosettaTMH-generated 
model accuracy decreases during Stage 1 of folding. That is, the rigid body sampling 
causes the quality of rhodopsin models to decrease. The RMSD100SSE values do not 
improve significantly for Stages 2-4 when no restraints are used. When EPR restraints are 
used, the models’ accuracy improves from Stage 1 to Stage 2 but does not change 
significantly thereafter. This was also observed for ExtendedChain+EPR (Figure 40). 
!
Figure 40:  Sampling performance of various Rosetta methods during each stage of de novo 
folding using rhodopsin as an example 
Box-and-whisker plot indicating the breadth of model accuracy obtained during each stage of 
folding with MembraneAbinitio, folding from an extended chain with and without EPR restraints, 
and folding with RosettaTMH with and without restraints. The thick line indicates the median 
RMSD100SSE obtained, while the boxes indicate the interquartile range. The highest and lowest 
RMSD100SSE values, excluding outliers, are indicated by the “whiskers,” and outliers are shown 
as open circles. 
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RosettaTMH-generated models exhibit large inter-helical distances 
RosettaTMH assembles MP folds by breaking up the proteins into individual 
TMHs and allowing these helices to move as rigid bodies. Therefore, the resulting 
arrangements could feature distances between subsequent SSEs that cannot be connected 
by a loop. In order to determine the extent to which this is true, a representative set of 7 
proteins chosen from the 34-protein benchmark was selected, and the Euclidian distance 
between subsequent SSEs was measured for 1,000 models generated with RosettaTMH in 
the presence and absence of restraints. The log10 of the Euclidian distance was plotted as 
a function of log10 of the number of amino acids in the loop (Figure 41). The distance-
loop length relationship for the 7 native proteins, as well as the maximum Euclidian 
distance possible ( 3.8*(loop_ length −1) ), were also determined and plotted. According 
to the information in Figure 41, it appears that, especially for shorter loops, RosettaTMH 
often places TMHs too far away in 3D space. Similarly, RosettaTMH fails to reflect the 
dependence of Euclidean distance from loop length accurately. Indeed, for all proteins, 
excluding 3HFX, the inter-helix distances of the vast majority of models generated can 
theoretically be spanned by a loop, but only a small percentage—if any--exhibits native-
like inter-helix distances (Table 24). 
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Figure 41:  Analysis of inter-SSE distances for RosettaTMH-folded models 
The log10 of the inter-SSE Euclidian distance (i.e., loop distance) as a function of the log10 of the 
number of residues in the loop is plotted for a representative set of membrane proteins. The long-
dashed line indicates the maximum Euclidian distance possible for n residues, and the short-
dashed line indicates the Euclidian distances for n residues found in the proteins’ native 
structures. 
 
 
Table 24:  Percentage of models having loops that can or are likely to be closeable 
PDB$
%$Models$with$Loop$
Distance$<$Maximum$
Possible$
%$Models$with$Loop$
Distance$<$Native$
+$EPR$
Restraints$
–$EPR$
Restraints$
+$EPR$
Restraints$
–$EPR$
Restraints$1FX8! 91.1! 76.4! 0.2! 0.0!1U19! 99.8! 80.7! 0.0! 0.0!2BG9! 99.3! 96.7! 11.2! 2.4!2K73! 97.7! 76.0! 4.4! 0.2!3B60! 79.2! 62.5! 0.0! 0.0!3HFX! 42.6! 26.7! 0.0! 0.0!3O0R! 76.9! 41.9! 0.0! 0.0!
 
Discussion 
EPR restraints significantly assist in obtain models with the correct topology 
The results in Table 23, Figure 38, Figure 39, and Figure 40 indicate that, for 
large and very large MPs, the conformational search space of MP structures must be 
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limited in order to obtain de novo-folded models with native-like folds. The 
MembraneAbinitio protocol attempts to accomplish this by folding MPs “from the inside 
out.” That is, a helix in the middle of the protein sequence is inserted into the implicit 
membrane environment first. Next, either helices N- or C-terminal to the initially inserted 
helix are folded into the membrane via fragment-based assembly, beginning with the 
helix adjacent to the starting helix. Then, the helices on the other side (in terms of 
sequence) are folded in the same manner (105).  
While MembraneAbinitio is able to generate models with RMSD100SSE < 8Å for 
over half of the 34 proteins tested, the majority of these success cases have fewer than 
200 residues and 7 TMHs. Indeed, for 12 proteins, the MembraneAbinitio protocol 
performs better than RosettaTMH and folding from an extended chain when EPR 
restraints are not used. However, when EPR restraints were used, the additional restraints 
result in more models having the correct fold (Table 23). This is important because 
MembraneAbinitio, unlike RosettaTMH, cannot take EPR restraints into account. 
Therefore, for MPs of more than 4 TMHs and 145 residues, it is advantageous to include 
structural restraints, such as those available from NMR, EPR, etc. If one does employ 
such restraints, the traditional folding method, ExtendedChain, appears to be better suited 
for medium-sized MPs, whereas RosettaTMH may be the best method for de novo 
folding larger MPs, such as GPCRs, channels, and transporters. 
Optimization of RosettaTMH folding protocol may lead to further improvement 
Even though Rosetta is now capable of folding MPs that have the correct fold and 
is sometimes able to recover intra-helical features, these models are not yet accurate 
enough to be used as input for full-atom refinement using the RosettaMembrane all-atom 
 ! 175!
scoring functions (130). Typically, models of approximately 2.0Å RMSD100SSE relative 
to the native structure are required in order to successfully obtain atomic detail 
information (134, 135).  
Based on the information in Figure 40, one obvious next step in protocol 
optimization would be to forego the rigid body sampling in Stage 1 of RosettaTMH 
folding. It is expected that the initial set of rigid body transformations results in less 
viable MP conformations (e.g., helix out of the membrane, lying too orthogonal to the 
membrane normal, or too far apart in 3D space). The fragment insertions in Stages 2-4 
are then not able to recover the correct fold. This is supported by the lowest-RMSD 
models displayed in Figure 42, which show that there is a general lack of inter-helical 
packing and native-like placement that is not remedied by fragment insertions. Not 
surprisingly, the addition of EPR restraints assists in improving packing and even in the 
recovery of helical features (Figure 42). 
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Figure 42:  Most accurate model resulting from RosettaTMH folding for six proteins 
The most accurate models obtained from folding with RosettaTMH without EPR restraints (left 
model) and with EPR restraints (right model) are colored in rainbow. The native structures are 
colored in gray. The RMSD100SSE of the model compared to native is reported in angstroms. 
 
Implementation of loop closure filter and knowledge-based potential for de novo folding 
with RosettaTMH could improve inter-helix packing 
In order to create a radial fold tree for each model, the original simple fold tree 
must be “cut” to maintain the data structure’s acyclic nature. For folding with 
RosettaTMH, these cutpoints are chosen within the MP loops (Figure 32). However, now 
that the TMHs can move independently from one another, another external force must be 
applied to keep the helices in relatively close proximity, as the helices appear to drift 
apart and not exhibit native-like packing (Figure 41 and Figure 42). One possible means 
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of doing this is to implement and optimize a loophash filter, which would ensure that 
helices that would normally be connected by a loop remain close enough in Cartesian 
space such that the inter-helical loop can be successfully rebuilt at a later stage. 
The loophash filter is based on work recently published by Tyka, Jung, and Baker 
(351). In the protocol introduced by the authors, the loophash algorithm allows for 
extremely fast rebuilding of protein segments by rapidly determining if a loop of a given 
sequence length can span the distance defined by two endpoints. A hash lookup table is 
generated for a loop of a given sequence length, and the hashes in the table refer to 
specific protein segments found in a database of non-homologous proteins of known 
structure. In addition to the loophash, or loop closure, filter, the implementation of a loop 
distance KBP, such as that used by BCL::Fold (352, 353) could also be useful. While the 
loop closure filter would assist in ruling out models where helices could not theoretically 
be connected, and the loop distance KBP would provide an energetic incentive to place 
TMHs in more native-like conformations. 
 
Increased sampling may be needed in order to better observe RosettaTMH’s performance 
Even though the RosettaTMH folding protocol remains under development, it 
appears to be a much more rapid means of folding MPs than MembraneAbinitio and 
fragment-based assembly alone ( 
Figure 43). This is probably a result of the lack of fragment insertions, and thus 
recalculation of torsion angles, during the first stage of folding. However, this decreased 
amount of fragment insertion may be the cause of the generation of lower-quality models. 
In any case, the significant speedup in model production allows for the generation of 
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many more models. This increased sampling speed will likely prove beneficial for 
obtaining higher quality models from RosettaTMH for large MPs. 
 
Figure 43:  Average time required for de novo folding 
The mean time in minutes (± std. dev.) required to de novo fold 1,000 models for 34 MPs with 
different Rosetta folding methods. When the use of EPR restraints is indicated (+EPR), the EPR 
KBP bonus weight = 1.0, and the quadratic penalty weight = 1.0. 
 
 
Conclusion 
RosettaTMH is a novel de novo folding protocol that assembles MP topologies 
from the rigid body movements of TMHs, followed by peptide fragment insertions. This 
approach, along with the significantly decreased time required to fold models, allows for 
increased sampling of conformational space. In addition, complicated topologies can be 
sampled more efficiently, which is important for the structure prediction of more 
complex proteins, such as GPCRs, transporters, and channels. Finally, RosettaTMH, 
unlike MembraneAbinitio, allows for the folding of MPs with experimental restraints. 
Further, while the new folding protocol alone improves sampling, the addition of 
experimental restraints may be necessary to obtain native-like topologies, which is 
especially important for determination of proteins for which there is no structure. 
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Availability 
The RosettaTMH source code is available in the Rosetta3 master branch, which is 
available to developers in the RosettaCommons via https://github.com/RosettaCommons. 
Protocol captures used for generating the data in this paper are available in Appendix E. 
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CHAPTER VI !
CONCLUSION !
Summary of this work 
In an effort to understand the structural basis of disease, as well as aid in the 
development of novel drugs and therapeutics, structural biologists have worked tirelessly 
to determine the three-dimensional (3D) conformations and dynamics of 
biomacromolecules. This is evidenced by the explosion of structures deposited in the 
PDB (1, 317). However, the structural characterization of membrane proteins, referred to 
as MPs in this dissertation, has proven to be especially challenging. It is therefore not 
surprising that atomic-detail information about this important class of proteins is limited 
compared to that for soluble proteins (110, 354, 355). While a number of technological 
and methodological advances have made MP structure determination more feasible than 
ever before, the vast majority of MPs, including members of the ever-prominent GPCR 
superfamily, continue to elude both experimental and computational structural biologists.  
The primary purpose of this body of work was to implement, test, and apply 
methods that combine the power of both experiment and computation. This hybrid 
approach has allowed, and will allow, for the elucidation of protein structures, including 
transporters, peptide GPCRs, and their ligands. The concept of computational modeling 
in the presence of experimental restraints was applied, via the Rosetta molecular 
modeling suite, to the structural determination of the prolactin releasing peptide, or PrRP 
(Chapter II) (37, 135), and ghrelin (Chapter III) (Vortmeier, DeLuca, et al., submitted), 
both of which are endogenous agonists of GPCRs. In these cases, the experimental 
 ! 181!
restraints were derived from NMR spectroscopic data. However, with the introduction of 
RosettaEPR (Chapter IV) (107, 108, 135, 251), it was shown that even the relatively 
broad distance information from EPR spectroscopy can be used to enhance the 
conformational search space of the Rosetta protein folding algorithm. Finally, 
RosettaEPR was combined with a novel MP de novo folding algorithm, RosettaTMH, 
which further improves sampling of native-like topologies for large MPs (Chapter V) 
(S.H. DeLuca, S.D. DeLuca, A. Leaver-Fay, and Meiler, submitted). Other versions of 
RosettaMembrane folding protocols have been reported previously (105, 115, 117, 345), 
but neither method could be combined with EPR or NMR experimental data to the extent 
that is enabled by RosettaTMH.  
!
Improving our understanding of the structural basis of PrRP receptor activation by PrRP 
The prolactin releasing peptide, or PrRP, is a peptide hormone that activates the 
prolactin releasing peptide receptor, which is a GPCR that is primarily located in the 
pituitary (28, 105). PrRP, and to some extent, its receptor, are implicated in regulating 
body weight homeostasis, metabolism, and energy expenditure (29-31, 33, 135). Even 
though two groups had reported structural ensembles of PrRP based on NMR data (1, 35, 
36, 356), no coordinates of the models were made publicly available, hindering further 
exploration of this biologically significant interaction.  
In order to overcome the obstacle of the lack of structural data, RosettaNMR 
(106, 167, 168, 354, 355) was used to de novo fold PrRP using NMR chemical shifts 
(CSs) and NOE distances reported in the literature (35, 37, 357). More specifically, the 
13 C-terminal residues of PrRP (PrRP8-20) were folded using 3- and 9-amino acid 
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fragments that were generated using the 13 available CSs and the inter-proton distances 
resulting from backbone hydrogen NOEs. These fragments were assembled according to 
the Rosetta protein folding algorithm (100, 102, 135, 358, 359), during which 
conformations agreeing with all 38 backbone and side-chain NOE distances were 
energetically favored. The models were assessed according to the Rosetta soluble protein 
energy function during both folding and full-atom refinement (100, 105, 110, 117, 360-
364).  
After filtering for conformations with both low global energies and maximal 
satisfaction of the NMR distance restraints, an ensemble of 20 models having a backbone 
root mean square deviation (RMSD) of 0.83Å was obtained. As was expected based on 
the work by D'Ursi, et al. and Danho, et al. (28, 35, 36, 365), the final ensemble revealed 
an amphipathic helical structure, in which all three arginine side-chains were arranged on 
one side of the helix. Furthermore, Rosetta appeared to sample both α- and 310-helical 
conformations, indicating that the peptide exists in a dynamic equilibrium between the 
two. This hypothesis was supported by CD spectroscopic data collected in SDS and TFE, 
which were provided by the Beck-Sickinger laboratory at Leipzig University. 
Importantly, the final ensemble of PrRP models was deposited in the Protein Model 
Database (29-31, 33, 180, 366) (PM ID:  0078404). The models were also used in further 
computational modeling guided by structural restraints derived from receptor activation 
data. The peptide ensemble was docked into a comparative model of the PrRP receptor, 
and the combination of modeling and experimental data allowed for the elucidation of a 
dual-binding mode of PrRP to the PrRP receptor (19, 367-370) (Appendix A). 
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In addition to the determination and deposition of the 3D structure, PrRP and 
various analogs thereof were tested for their ability to activate the wildtype and selected 
point mutants of the PrRP receptor. Specifically, [R15A]PrRP20, [R19A]PrRP20, 
[F20A]PrRP20, as well as PrRP4-20, PrRP8-20, PrRP14-20, and full length PrRP20 were 
tested and their secondary structure analyzed by CD spectroscopy in water, 100 mM SDS 
micelles, and 25% TFE solution. While the PrRP point mutants' EC50 values were 
markedly decreased compared to wildtype, their CD spectra were practically identical in 
all three solvent conditions. PrRP4-20 and PrRP8-20 also activated the wildtype receptor 
to a similar extend as PrRP20, but the helicity of the two shorter truncation mutants was 
reduced.  
Further, when signal transduction assays of [Y2.64A]PrRPR and [W2.71A]PrRPR 
were performed with PrRP20 and PrRP8-20, it was found that PrRP8-20 exhibited 
significantly decreased agonism on the receptor mutants compared to full-length PrRP20 
(197-fold and 963-fold higher EC50 over PrRP20 for [Y2.64A]PrRPR and [W2.71A]PrRPR, 
respectively). This is in stark contrast to PrRP20's EC50 values, which were 23-fold and 
270-fold higher for [Y2.64A]PrRPR and [W2.71A]PrRPR, respectively. These results 
ndicate that the reduced helical character of PrRP8-20, while not affecting the truncated 
peptide's ability to activate the wildtype receptor, severely impaired activation for certain 
receptor mutants. The authors of the publication proposed that the two conserved receptor 
residues, Y2.64 and W2.71, assist PrRP in forming a more α-helical conformation upon 
binding to the receptor, which then allows for its activation. Even though PrRP8-20 
exhibits a decreased propensity to form an α-helix, it could also activate the wildtype 
receptor. However, when Y2.64 and W2.71 were no longer available to help PrRP8-20 
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adopt a helical binding conformation, the truncated peptide could not stimulate the 
receptor (37, 371) (Chapter II).  
 
Elucidation of ghrelin structure, dynamics, and interaction with the membrane 
Ghrelin is also a peptide hormone; it is synthesized in the gut and activates the 
GHSR1a, or ghrelin receptor, which is primarily located in the hypothalamus (40-42, 
372-376). Ghrelin, which is 28 residues in length, has an origenic effect, meaning that its 
presence is associated with increased food intake, but it appears to be involved in other 
physiological processes, such as memory, energy homeostasis, and reward mechanisms 
in the brain (45-49). A 3D structure of ghrelin and/or its receptor would therefore be 
desirable for the purposes of drug discovery, but unfortunately, but one has not been 
made publicly available. Therefore, in collaboration with the Huster laboratory at Leipzig 
University, the structural ensemble of the peptide was determined using Rosetta. In 
addition to providing CSs of ghrelin bound to lipid vesicles, our collaborators also 
performed further ssNMR studies of ghrelin that yielded information on peptide 
dynamics and its interaction with the membrane bilayer.  
Because ghrelin is acylated at its third residue, Ser3, and because the ssNMR CSs 
were collected for acylated ghrelin bound to vesicles, it was important for the modeling 
to take place in the Rosetta MP-specific energy function and implicit membrane 
environment (105, 130). In order to perform de novo folding in RosettaMembrane, a 
comparative model of the ghrelin receptor was created based on the rhodopsin crystal 
structure (PDB ID: 1U19 (260)). The receptor model was not of interest in this study and 
was only present for logistical purposes. However, it may be useful for future studies. 
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Ghrelin was folded using fragment-based assembly without the use of the 
experimental CSs. The resulting models were filtered such that Ser3 was located within 
the RosettaMembrane "polar" layer of the implicit membrane, which would be expected 
for ghrelin's octanoyl chain help anchor it to the membrane. Next, PROSHIFT (253), 
SPARTA+ (261), SHIFTX (256), and SHIFTX2 (258) were used to predict CSs based on 
all Rosetta-generated models. For ensemble selection, the RMSD between the 
experimental CSs and the predicted CSs for a randomly chosen ensemble of models was 
computed, and the ensemble was altered in a Monte Carlo fashion until the RMSD was 
minimized. This process was conducted for predicted CSs resulting from all four tools 
mentioned above starting from models within the top 10%, 25%, 50%, 75%, and 100% of 
all de novo folded models by Rosetta energy (that contained proper placement of Ser3). 
After careful analysis, it was determined that, for this peptide and dataset, PROSHIFT 
was the most effective CS prediction method, and the set of models selected from the 
Monte Carlo algorithm that was generated using the top 10% of models by Rosetta score 
(and passed previous filters) was chosen as the final representative conformational 
ensemble. This ensemble's RMSD of predicted CSs relative to the experimental CSs was 
0.4 ppm. The conformations in the final ensemble exhibited a core, flanked by more 
flexible N- and C-terminal tails. They also exhibited strong polyproline II (PPII) helical 
propensity for residues 21-23 and 26-27, but this was not predicted by TALOS+ (143), 
which does not account for PPII helix. 
Interestingly, this final ensemble was highly flexible, having a backbone RMSD 
of 4.0Å relative to the mean structure, according to the PSVS analysis tool (http://psvs–
1_5-dev.nesg.org). This is in agreement with the NMR order parameters, which indicate 
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that the C-terminal region of the peptide is mobile. However, experiments measuring 
ghrelin binding to lipid membranes provide evidence that the octanoyl group on Ser3 is 
not enough to account for the peptide/membrane interaction. Rather, because ghrelin is 
positively charged at the pH used for NMR studies (pH = 6), it is hypothesized that the 
basic residues on ghrelin also contribute. Further, spin diffusion studies showed that 
ghrelin binds to, but does not insert deep into, membranes via residues Ser3 and Phe4. The 
remainder of the peptide is therefore expected to be highly mobile and flexible, but not 
necessarily "random coil." This work has been submitted to PLoS ONE. 
 
Development of RosettaEPR, a computational tool that integrates EPR distance 
information for the structure determination of proteins in atomic detail 
Because EPR spectroscopy cannot currently yield atomic-detail information of a 
protein, as is possible with X-ray crystallography or NMR spectroscopy, computational 
methods that combine EPR data with modeling for protein structure determination would 
be desirable. In 2008, Alexander, et al. presented the first attempt at de novo folding 
soluble proteins in Rosetta using sparse EPR data (134). EPR distance data were 
simulated using a pseudo-spin label “motion-on-a-cone” model, in which the Cβ of the 
MTS-based spin label was attached to a simple ellipsoid. The cone model, allowed for the 
relating of EPR spin label distances (dSL) to protein Cβ distances (dCβ), but distribution of 
simulated dSL–dCβ values did not align well with experimentally determined values for 
T4-lysozyme and αA-crystallin. The authors were nevertheless able to generate atomic-
dtail models of the two soluble proteins. 
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Hirst, et al. built on Alexander and colleagues’ work and introduced RosettaEPR 
in 2011 (135) (Chapter IV). An EPR distance knowledge-based potential (KBP) was 
generated, in which statistically common dSL values for a given dCβ were correlated with 
the energy of a Rosetta-folded model. During fragment assembly, the model's dSL–dCβ 
value for a residue pair of interest (i.e., experimental distance restraint provided for that 
residue pair) was measured, and the corresponding energy according to the KBP was 
added to the model's total restraint score. This was, in turn, added to the model's overall 
Rosetta energy. 
As a proof of concept, RosettaEPR was tested on the α-helical core domain of T4-
lysozyme, which consists of 107 residues. Twenty-five experimentally determined EPR 
distances were provided by the Mchaourab laboratory at Vanderbilt University. These 
data were used as structural restraints during in silico folding. In addition, RosettaEPR's 
performance was compared to folding with no restraints and to folding with "bounded" 
distance restraints. The upper and lower bounds of the bounded restraints were defined 
such that (dSL − σSL − 12.5Å) ≤ dCβ ≤ (dSL + σSL + 2.5Å), where σSL is the experimental 
error associated with each measurement. For dCβ values that did not fall within the 
allowed range, a quadratic energy penalty similar to that used for NOE distance 
violations in NMR was applied to the model's restraint score. After weight optimization 
of the RosettaEPR KBP, the potential weighted by a factor of 4.0 was more able to 
recover correctly folded models (RMSDCα < 7.5Å relative to the crystal structure (PDB 
ID:  2LZM (317)) and models with native-like conformations (RMSDCα < 3.5Å) than 
when folding with bounded restraints or no restraints. Further, the correlation between 
Rosetta energy and model accuracy increased from 0.42 to 0.51 and then to 0.62 for 
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folding with no restraints, with bounded restraints, and with RosettaEPR, respectively. 
This supports the hypothesis that the incorporation of an energy term specifically 
designed for EPR distance data improved Rosetta de novo folding for a small, soluble, 
helical protein. 
After establishing the RosettaEPR de novo folding protocol for soluble proteins, 
500,000 models of T4-lysozyme were generated in the presence of the 25 aforementioned 
EPR distance restraints. Of the resulting models, those that fell within the top 1% by total 
Rosetta energy that satisfied at least 85% of the optimal EPR restraint score were chosen 
for full-atom refinement using Rosetta's all-atom scoring function for soluble proteins. 
This scoring function includes KBPs for van der Waals interactions, hydrogen bonding, 
and solvation (110). Of the 500,000 models folded, fewer than 1,400 were selected for 
refinement. During this step, the amino acid side-chains are added, as opposed to treating 
them as "superatoms." Next, the protein undergoes eight cycles of side-chain repacking 
and energy minimization, in which backbone torsion angles are sampled. The EPR 
restraints were not used during refinement because it was anticipated that the protein 
backbone would not change enough to be captured by the broad EPR KBP. 
Ten all-atom models were generated for each de novo folded input model, 
resulting in over 13,000 models. The top 10% of these models according to Rosetta 
energy were then carried forth to the next iteration of refinement. This process was 
repeated until a total of eight iterations were complete. After the final cycle, the lowest-
energy model had an RMSDCα of 1.76Å relative to the crystal structure and a side-chain 
rotamer recover of approximately 60% over the core residues. The high accuracy of this 
low-scoring model is remarkable because it was produced by folding directly from the 
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primary sequence with the assistance of a dataset of approximately one EPR distance 
restraint per four residues. This is evidence that RosettaEPR can be a useful tool for 
protein structure determination when sparse EPR distance information is available (135). 
 
Membrane protein structure determination made possible via the combination of a novel 
de novo folding algorithm and EPR distance information 
RosettaEPR appeared to be an effective method for obtaining atomic-detail 
models of small, soluble proteins, with demonstrated ability on the helical domain of T4-
lysozyme. However, ultimate goal of the development of RosettaEPR is to be able to 
apply it to the structure determination of large MPs, such as GPCRs, channels, and 
transporters. After thorough and rigorous testing of the currently available MP folding 
protocols in Rosetta, both with and without simulated EPR restraints, it was apparent that 
a more efficient sampling of conformational space was necessary. The originally reported 
RosettaMembrane folding algorithm, as well as a newer method that allowed for folding 
larger MPs, were more sophisticated than the default soluble protein folding protocol in 
Rosetta. Unfortunately, they could not be combined with experimental restraints for 
scoring during fragment assembly. Therefore, RosettaTMH was developed to address the 
lack of MP-specific Rosetta folding methods amenable to being combined with 
experimental data (Chapter V). 
Because the Rosetta folding infrastructure has been highly optimized for 
fragment-based assembly, RosettaTMH is a novel approach to folding proteins in this 
software suite. Firstly, the RosettaTMH algorithm was implemented within the Rosetta 
Topology Broker framework, which was initially developed for folding of proteins with 
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sparse NMR data (107, 108, 251) and allows for the creation of innovative and flexible 
de novo folding methods. RosettaTMH folds helical MPs by treating individual, idealized 
α-helices, which are defined by the user, as rigid bodies during the first stage of folding. 
This increases the number and types of protein topologies sampled. Subsequent stages of 
folding take place via the more traditional Rosetta method of peptide fragment insertion, 
which allows for the potential recovery of intra-helical features, such as bends and kinks. 
These structural features are under-sampled by BCL::Fold and BCL::MP-Fold (115, 
345). Further, RosettaTMH can be paired with experimental information. To demonstrate 
this, a set of 34 MPs were chosen for de novo folding with RosettaTMH, and EPR 
distance restraints were simulated using the BCL 
(http://bclcommons.vueinnovations.com). RosettaTMH's performance, both with and 
without simulated EPR restraints, was compared to that of the Rosetta MembraneAbinitio 
folding protocol (105), folding from an extended chain, as is done with soluble proteins, 
and folding from an extended chain with EPR restraints. The Rosetta methods were also 
compared to models previously generated by Weiner, et al., for benchmarking of 
BCL::MP-Fold (345). 
 The weight of the EPR restraint score was optimized on 9-protein subset of the 
34-protein benchmark set. Weight optimization was performed in a similar manner to that 
described by Hirst, et al. for folding of T4-lysozyme (135). However, the process was 
more complex in that, in addition to the EPR KBP, a quadratic energetic penalty was 
used to further discourage conformations in which the dSL–dCβ values fell outside of the 
energetically favored region outlined by the RosettaEPR KBP. Therefore, each of these 
components for scoring restraint agreement was weighted individually. The optimal 
 ! 191!
weight combination was chosen based on the overall performance across all nine 
proteins. That is, for each protein, the percentage of models having an RMSD100SSE < 
8Å was computed, and the mean of all 9 resulting values was reported. This value was 
computed for 49 EPR score weighting schemes, and the weighting scheme with the 
highest mean valuepercent<8 was considered optimal. 
Generally speaking, if a model's RMSD100SSE is less than 8Å relative to the 
native structure, it is considered to have the correct topology. Of the 34 benchmark MPs, 
RosettaTMH yielded more correctly folded models in 8 cases compared to 
MembraneAbinitio and in 9 cases compared to folding from an extended chain. However, 
upon the addition of EPR restraints, both RosettaTMH and folding from an extended 
chain improved topology recovery in most cases, indicating that the addition of 
experimental information is the driving force for achieving the correct fold. This is the 
case, at least, for this set of proteins and for these simulated restraints.  
RosettaTMH with EPR restraints generally performed better than the other 
methods for proteins having more than 200 residues. Further, RosettaTMH folds proteins 
much more rapidly than the other Rosetta folding methods, which allows for increased 
sampling due to the decreased computational time required per model. In summary, 
RosettaTMH enables folding MPs with experimental restraints and may also be the 
preferred folding method in Rosetta when no restraints are available if the protein's 
topology is more complex than a typical helical bundle. This work is reported in detail in 
Chapter V has been submitted to the Rosetta special issue of PLoS ONE. 
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Implication of results 
The work presented herein serves as an example of how an interdisciplinary 
approach to biomedical investigation can enhance the scientific community's 
effectiveness when it comes to research and method development. For example, in the 
case of the work presented on ghrelin and PrRP, the collaboration between 
computationalists and experimentalists led to the structural elucidation of two 
biologically significant peptide hormones. This information can now be used for future 
studies designed to explore the mechanism(s) of GPCR activation and, hopefully, the 
molecular basis of disease. In addition, the development of RosettaEPR, a novel protein 
folding method that incorporates EPR data to improve conformational sampling, would 
have not been possible without the collaboration of the Mchaourab laboratory, the 
personnel of which provided the experimental expertise to make the project a success. 
RosettaEPR is now available for the determination of soluble protein (and soon for MP) 
conformations that agree with experimental data.  
By developing computational methods that take experimental information into 
account for the structural characterization of proteins and peptides, we can model inter-
molecular interactions. These models then serve as the starting points for hypothesis 
generation. Experimental data resulting from those hypotheses can then be used to guide 
refinement of the models. This iterative process enables scientists to study biologically 
significant and interesting systems more in depth and with a structural biological 
perspective. 
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Towards the development of anti-obesity therapeutics 
The structural characterization of two peptide hormones, PrRP and ghrelin, was 
possible due to the close collaboration of the Meiler laboratory with the Beck-Sickinger 
laboratory (PrRP) and the Huster laboratory (ghrelin). The interdisciplinary approach 
taken to study these two peptides has led to insight into not only their structures, but also 
their mechanism of binding and activation to their respective receptors. This is especially 
important given the ever-increasing rates of obesity, type II diabetes, and other metabolic 
problems, especially in the United States. Specifically, by providing the conformational 
ensembles of PrRP and ghrelin for other researchers to use, we may be able to better 
probe the means by which the peptides interact with their GPCRs and perhaps develop 
drugs and therapeutics that target these receptors.  
The anorexigenic effect that injected PrRP has on rodents (167), as well as the 
observation that PrRP receptor-knockout mice incur obese phenotypes after sixteen 
weeks (357), points to the PrRP receptor as a possible anti-obesity drug target. Between 
January 2001 and March 2004, the U.S. Patent Office issued one patent, in which the 
inventors developed pharmacological approaches to study and develop drugs that activate 
(or inhibit) PrRPR (358, 359), indicating that this receptor is an attractive drug target. 
Publishing and providing the structure of PrRP, as well as further characterizing the 
peptide’s ability to stimulate the PrRP receptor, enables further informing of future 
pharmacological studies and drug discovery. 
Because ghrelin, which acts as an agonist of the ghrelin receptor, is an orexigenic 
hormone, compounds and peptides that are antagonists of GHSR1a would be one 
possible means of treating obesity. Indeed, while there are several known agonists of 
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GHSR1a (developed for stimulating growth hormone release), the design and 
optimization of ghrelin receptor antagonists is underway (360-364). (See Chollet, et al. 
for an in-depth review of agonists, antagonists, and inverse agonists of the ghrelin 
receptor (365).) Interestingly, ghrelin receptor agonist and inverse agonist radiotracers for 
positron emission tomography (PET) were developed in order to track receptor ligands in 
vivo (366). By being able to structurally describe how ghrelin activates its receptor, it 
may be possible to develop, not only future drugs, but also ligands that serve as tracers 
for imaging studies. 
 
Newly established de novo folding protocols open doors for structural characterization 
of non-globular polypeptides 
In addition to small molecules (150-500 Da), the design of peptide ligands and 
peptidomimetics is playing an increasingly prominent role in the discovery of new drugs 
and therapeutics, especially when the drug target is a GPCR that is naturally activated by 
a peptide (367-370). However, unlike small-molecule ligand docking methods, there are 
relatively few tools for predicting the binding mode of peptides and peptidomimetics in 
silico. This is further complicated by the tendency of peptides to adopt multiple--often 
rapidly changing--conformations in solution. Some methods attempt to address with mild 
success (371). Rosetta, though optimized for de novo folding proteins, also allows for 
predicting the structures of peptides in the presence of NMR CSs and NOEs. Therefore, 
protocols for folding peptides in solution and in the implicit environment were developed 
and used to generate conformational ensembles of PrRP and ghrelin.  
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In this work, ghrelin posed an interesting problem because it is a membrane-
bound peptide, and only sparse CSs from ssNMR were available. However, there now 
exists a method for de novo folding flexible peptides that are consistent with NMR data, 
which can be used for soluble or membrane-associated biomolecules. This could be 
especially useful for the generation of models of unstructured peptides and proteins, 
which serve a variety of biological functions, such as transcription regulation, translation, 
and cell signaling (372-376). Because intrinsically disordered proteins, or IDPs, are 
difficult to characterize by X-ray crystallography and NMR alone, computational 
structure prediction that incorporates NMR data into the modeling may be a suitable 
means of generating 3D conformational ensembles. This information can then be used to 
help provide insight into information obtained via "low-resolution" methods, such as CD 
spectroscopy. 
!
RosettaEPR can be used to determine three-dimensional protein structures using sparse 
EPR distance datasets 
The challenges associated with protein structure determination by NMR, such as 
molecular weight limitations on the system under study (including micelles, bicelles, etc. 
for MPs), can sometimes be discouraging. At the same time, crystallization remains a 
perpetual challenge. On the other hand, EPR spectroscopy offers several advantages. No 
crystallization is required; further, due to its sensitivity, only pico-moles of the protein 
are required, and there are no size constraints. Importantly, the protein can be studied in 
its native environment.  
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EPR is not without its own challenges, however. It cannot yield atomic-detail 3D 
structures, as with NMR spectroscopy and X-ray crystallography. It is also an inherently 
low-throughput method, in which, for each EPR measurement, a cysteine-less mutant 
must be made, cysteines introduced at sites of interest, constructs tested for functionality, 
and the protein spin labeled. Aside from the sparseness of the data resulting from the 
method's low-throughput nature, the paramagnetic spin label often introduces ambiguity 
into the experimental measurements. For example, one commonly used spin label, 
methanethiosulfonate (MTS) spin label, is highly flexible, having five rotatable bonds, 
and is relatively long--about 8.5Å from the Cβ to the end of the molecule. This 
information must be taken into account when analyzing distance data from EPR.  
RosettaEPR was developed in order to serve both experimentalists and 
computationalists. For the EPR spectroscopist, RosettaEPR allows for the generation of 
3D models that agree with EPR distance data, which can sometimes be up to 70-80Å in 
magnitude (1, 335). A model can potentially be useful for interpretation of the data and 
how it correlates to biological function. On the other side, the addition of experimental 
data into computational methods is a useful means of decreasing the conformational 
space that needs to be sampled, thus improving the likelihood that a native-like structure 
is produced. Practically speaking, this means that, for a given number of generated 
models, a higher percentage of the models will exhibit the correct protein fold if 
experimental restraints are used. Therefore, RosettaEPR can be a valuable tool for 
structural biologists, who are interested in understanding the structure-function 
relationship of their systems of interest.  
!
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 RosettaTMH improves Rosetta's conformational sampling of membrane protein 
topologies and can be used with experimental data 
Even though Rosetta has been reported to predict the folds of MPs of varying 
sizes and levels of complexity (105, 117, 130, 354, 355), there has not been any recent 
development on RosettaMembrane. Further, the previously reported methods could not 
be used with the incorporation of experimental restraints to enhance sampling. 
Meanwhile, sthe default fragment-based assembly algorithm used for folding soluble 
proteins in Rosetta can be used with experimental restraints, but it is not suitable for 
folding MPs with high contact order, such as can be seen with α-helical MPs. On the 
other hand, in light of the difficulties encountered when using X-ray crystallography and 
NMR spectroscopy, computational methods for MP structure determination tightly 
integrating with experimental data are greatly needed. RosettaTMH was developed in 
order to meet this need. 
Like other MP folding methods, including BCL::MP-Fold (37, 345), FILM3 (119, 
135), and EVFold for MPs (105, 117, 118), RosettaTMH attempts to reduce 
conformational search space in order to improve the probability of obtaining native-like 
topologies. Unlike FILM3 and EVFold, however, RosettaTMH does not rely on multiple 
sequence alignments. Instead, it employs user-defined TMH-spanning information to 
divide the model into rigid bodies, which can then be translated or rotated in an extremely 
rapid, Monte Carlo fashion. These moves are scored according to the RosettaMembrane 
energy function. This is similar to what is done by BCL::MP-Fold. In contrast to the 
BCL, RosettaTMH then performs peptide fragment insertions, which can lead to the 
recovery of helical features, such as proline-induced kinks. 
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RosettaTMH can be combined with RosettaEPR to fold MPs in the presence of 
EPR distance data. It also expands upon RosettaEPR in that a more sophisticated scoring 
function for EPR restraints was optimized, as discussed in Chapter V and in Summary of 
this Work. Because there are only a few examples of MPs for which both experimental 
structures and EPR distances are available, EPR restraints were simulated using the BCL. 
When compared to folding with RosettaTMH alone, the addition of the EPR restraints 
greatly improved the algorithm's performance. This was also true for folding from an 
extended chain, but RosettaTMH with EPR data produced slightly better results for MPs 
having high contact order, which included the Na+/galactose transporter, VSGLT (PDB 
ID:  2XQ2), and the carnitine transporter, CalT (PDB ID:  3HFX). More than 15% of 
rhodopsin models (PDB ID:  1U19) generated with RosettaTMH with EPR restraints 
exhibited the correct GPCR topology, which is also encouraging. These results suggest 
that RosettaTMH combined with EPR data--a popular structural biological technique for 
studying MPs--can serve as a starting point for MP structure determination. This could be 
especially helpful for experimentalists, who wish to have the assistance of a 3D model to 
interpret their data, propose new hypotheses, and postulate about protein functionality. 
!
Future directions 
Within the past decade, several new computational methods of protein and 
peptide structure determination have been developed and reported, especially within the 
Rosetta framework. The abilities of CS-Rosetta and RosettaNMR have been enhanced so 
that protein structures can be predicted from incompletely assigned CSs, and 
RosettaNMR can be used in an iterative fashion to fold proteins of up to 40 kDa in size 
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(35, 37, 108, 251, 263, 264, 322). RosettaEPR expanded upon the software suite's de 
novo folding capabilities to include the possibilty of folding proteins in the presence of 
EPR distance data. RosettaTMH has now been implemented in order to fold large, 
complex MPs, which is greatly assisted by the inclusion of experimental restraints. 
However, to understand the structural biological basis of disease and further advance 
molecular modeling technology, computationalists and experimentalists will likely need 
to work ever more closely and collaboratively moving forward. A few specific examples 
of where such partnerships could be advantageous are given below.  
 
Further exploration of the structural mechanism of activation of the PrRP receptor 
In Chapter II, the structure of PrRP, as well as how the propensity of the peptide 
to form an α-helix relates to its ability to activate the PrRP receptor, was described in 
detail. Notably, the less helical, truncated PrRP8-20 was much less stimulatory of the 
receptor when Y2.64 or W2.71 were mutated to alanine. The authors hypothesized that these 
two residues assisted the peptide ligand in forming its activating conformation, and, in 
their absence, PrRP8-20, unlike PrRP20, was not able to form the helical structure 
necessary. Even though stimulation with the full-length peptide was significantly 
decreased for the receptor mutants compared to wildtype, the EC50 was 4-5 times even 
greater when the same experiment was performed with PrRP8-20. Additional modeling 
of the full-length and truncated peptide in the wildtype and mutant receptor binding site 
could provide more insight into whether this hypothesis is correct. With the current 
knowledge concerning using Rosetta, this modeling could be performed in the implicit 
membrane environment, as was done with ghrelin (Chapter III). 
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More generally speaking, it is postulated that Y2.64 and W2.71, which are conserved 
residues in this receptor family, form a hydrophobic interaction that plays a role in 
causing a conformational change in the receptor (100, 102, 135, 377). One way to 
determine if these two residues are in close contact with one another is to perform a 
cross-linking experiment, in which the two residues of interest are mutated to cysteine. 
The general supposition is that, assuming the protein backbone and surrounding 
conformation remains relatively undisturbed, upon the addition of a cross-linking agent 
that is able to form disulfide bonds, the two residues will become cross-linked if they lie 
within the distance covered by the cross-linker. After separating the intra-molecularly 
cross-linked protein, usually by SDS-PAGE or size exclusion chromatography, the 
protein can be digested and analyzed via mass spectrometry. The sequences 
corresponding to the cross-linked peptide fragments is determined using computer 
software, and this information can be used to generate intra-molecular distance 
constraints on the protein (100, 105, 110, 117, 378). Another possibility for determining 
if the Y2.64 and W2.71 interact is to employ EPR spectroscopy, which can yield 
quantitative information on spin label distances. 
On the modeling side, a more up-to-date comparative model of the PrRP receptor 
could be built, followed by extensive loop rebuilding and all-atom refinement. Further, 
Dr. Steven Combs in the Meiler laboratory has developed a scoring function that takes 
atomic orbitals based on valence shell electron pair repulsion (VSEPR) theory into 
account. After re-optimization of this scoring function for MPs, it could be used to refine 
the receptor model. In the case of soluble proteins, the new orbitals scoring function 
appears to recover π-π interactions better than the default Rosetta all-atom scoring 
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function. It is possible that this could be true for MPs as well; in this case, it may be 
informative for studying a possible interaction between Y2.64 and W2.71. 
 
Ghrelin modeling based on experimental data collected in the presence of the ghrelin 
receptor 
A conformational ensemble of ghrelin based on CSs from ssNMR was presented 
in Chapter III. This set of models, while exhibiting high flexibility, was in agreement 
with not only the experimental CSs, but also with results from spin diffusion 
experiments. However, distance restraints in the form of NOEs are highly desirable for 
the production of a higher quality model (or ensemble of models, rather). Unfortunately, 
NOEs would be likely be obtained by performing solution NMR NOESY experiments of 
ghrelin in detergent micelles, whereas the CSs reported in Chapter III were resultant from 
ssNMR in lipid vesicles. Similarly, secondary structural information of the peptide from 
CD spectroscopy could be informative but would also need to be collected in a micellar 
environment. 
It would also be interesting to determine the conformation of ghrelin in the 
presence of the ghrelin receptor. CS information of the peptide based on ssNMR 
experiments--performed with both ghrelin and the ghrelin receptor in lipid vesicles--
could be especially useful for understanding how the peptide changes when binding to 
the receptor. Further, the ensemble of ghrelin models, either from the current study or 
future studies, could be docked into an updated comparative model of GHSR1a, and, as 
with PrRP / PrRPR, could be used to propose additional mutants for analysis via signal 
transduction assays. (See reference (19, 28, 35, 36) and Appendix A for more information 
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on this process.) The resulting data can then be used to further refine the model for 
peptide / receptor interaction. 
One of the main goals for the structural characterization of both PrRP and ghrelin 
is to improve our understanding of the mechanism of activation and function of their 
receptors. With that knowledge in hand, new therapeutics, most likely in the form of 
small-molecules or peptidomimetics, can be synthesized, tested in vitro, in vivo, and 
eventually in clinical trials for the treatment of a number of disorders, including obesity 
and type II diabetes in humans. 
 
Expanding the capabilities of RosettaEPR to fold membrane proteins 
The introduction of RosettaEPR (29-31, 33, 135, 180) (Chapter IV) served as a 
proof of concept that a) an EPR distance KBP based on the MTSSL can be used to 
improve sampling of native-like folds for small, soluble proteins, and b) it has the 
capability to be used for full-atom modeling of relatively small proteins to atomic detail 
accuracy. However, the reported work serves only as a starting point for the development 
of RosettaEPR. It has already been expanded by the addition of an all-atom 
representation of the MTS spin label, which can be used with the Rosetta soluble protein 
scoring function (19, 379), though this has not yet been tested on MPs. In order to more 
accurately model MPs with RosettaEPR, the statistics used to generate the EPR KBP 
should be re-calculated over a database of MPs. Futher, the spin label roatmer library 
should be tested on the leucine transporter, LeuT, for which a crystal structure of the spin 
labeled protein is available (37, 380). It should be noted that the EPR KBP and spin label 
rotamer library are specifically based on the MTS spin label. However, KBPs and 
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rotomaer libraries based on other spin labels, such as 2-Carboxyanthracene MTSEA 
amide (MTSEA), can also be created in a similar manner. 
It is expected that the implementation of an EPR accessibility restraint in 
RosettaEPR would also improve its performance on MP modeling. This is because the 
spin label accessibility at a particular site can yield information on both the surrounding 
environment (40-42, 74, 381) and the membrane depth of the residue (45-49, 307, 381, 
382). Axel Fischer and Dr. Nathan Alexander have shown that the inclusion of EPR 
accessibility restraints taking into account only spin label exposure (as opposed to 
membrane depth) significantly improves the recovery of correctly predicted MPs using 
BCL::MP-Fold (submitted). This would probably be the case for RosettaEPR and 
RosettaTMH as well. 
Finally, it is important to remember that EPR distance data do not consist of 
single distance values. Rather, distances are reported as probability distributions, which 
can sometimes be broad, resembling a hill instead of a spike. Furthermore, when 
measuring inter-residue distances under different conditions, the average distance does 
not necessary change, but the shape of the probability distribution may shift, as was seen 
with LeuT (105, 130, 336, 383). Therefore, instead of a single model, it would be better 
to predict an ensemble of models consistent with the distribution of inter-residue 
distances observed experimentally. This is now possible thanks in large part to the work 
of Samuel DeLuca (Meiler laboratory) and Dr. Mathew O'Meara (Stoichet laboratory) in 
implementing MySQL database infrastructure into the Rosetta software suite.  
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Improvement of RosettaTMH and testing RosettaTMH's prediction accuracy using real 
experimental data 
The implementation of RosettaTMH, which was explained in detail in Chapter V, 
provides a foundation for the de novo folding of other types of proteins (e.g., β-barrels, α-
β proteins, etc.) using rigid body sampling and fragment-based assembly. However, the 
main focus of this work is on the accurate determination of 3D α-helical MP structures. 
More specifically, it would be most interesting to explore the synergistic effect that arises 
from pairing this new sampling method with EPR data.  
One of the main challenges with the de novo folding of native-like MP topologies 
via rigid body assembly is the tendency of the secondary structural elements (SSEs) to 
move increasingly farther away from one another. This results in poorly packed 
structures. In order to prevent this from occurring, a loophash filter could be implemented 
in RosettaTMH, the intention of which would be to assist in generating TMH 
arrangements that could later be connected by loops. A loop length KBP similar to that 
used in BCL::Fold (115, 260) and BCL::MP-Fold (253, 345) would likely improve the 
performance of RosettaTMH because, once helices are in relatively close proximity to 
one another (via the loophash filter), the new energetic term would favor conformations 
that resemble inter-SSE orientations observed in nature.  
In order to truly and rigorously test RosettaTMH's ability to accurate predict MPs 
in the presence of EPR restraints, it would be important to use distances obtained from 
actual EPR measurements. There are only a few MPs for which such a benchmark would 
be possible, including the ABC transporter MsbA, the K+ ion channel KcsA, and 
rhodopsin, which is a GPCR. This is because there are EPR data and at least one 
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experimentally determined 3D structure, for these proteins (74, 145-147, 260, 261, 308, 
309, 384-386). This benchmark would also require that RosettaTMH be able to fold 
symmetric MPs, which it does not currently do. The Rosetta Symmetric FoldAndDock 
algorithm (256, 302) allows for the folding of symmetric homo-oligomeric soluble 
proteins. It is expected that this framework can also be used for MPs.  
A blind test, in which the answer (i.e., correct structure) is not known, would be 
an excellent means of ascertaining the ability of RosettaTMH to fold MPs. This would 
probably require collaboration with at least one research group, who would be willing to 
provide EPR experimental data. Ideally, a set of experimental data would be used to 
generate models with RosettaTMH. These models would then be cross-validated with 
additional EPR experiments. If there is no X-ray or NMR structure of the MP of interest 
in the pipeline, an iterative approach to model validation similar to that used for the PrRP 
/ PrRPR system (19, 258) (Appendix A) could be taken. This would be especially 
exciting for the field of MP structural biology because it would be a novel means of 
determining the 3D structures of MPs using the power of both computational methods 
and EPR spectroscopy. 
 
Concluding remarks 
Structural biologists have traditionally been categorized according to their method 
of choice for studying biomolecules. That is, one is often referred to as an X-ray 
Crystallographer, an NMR Spectroscopist, an Electron Microscopist, a Computationalist, 
etc. This dissertation serves as an example of how the field is moving away from these 
individualistic titles in the direction of the more generally and aptly named Structural 
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Biologist. By leveraging the advantages of multiple techniques and methodologies for 
structural elucidation, as was demonstrated by the herein reported work, the structural 
biological community can progress to a better understanding of how 3D structure affects 
inter-molecular interactions, dynamics, and ultimately, biological function. Dr. Stephen 
Harrison at Harvard University articulated such a vision for structural biology in a 
commentary published in Nature Structural and Molecular Biology: 
 
"...[S]tructural biology must seek to understand information transfer in 
terms of its underlying molecular agents by analyzing the molecular 
hardware that executes the information-transfer software. Unlike most 
man-made computers, the hardware and software of physiological 
regulation co-evolved. The possibilities for storage, retrieval, transfer and 
destruction of information are not independent of the molecular devices 
that execute these functions." (143, 297) 
 
Thus, a marriage of structural and systems biology appears to be a promising 
means of reaching this goal, and many researchers are already making great strides to this 
end. The work of Andrej Sali at the University of California-San Francisco in the 
structure determination of macromolecular assemblies by combining modeling with 
multiple types of experimental data serves as a prime example (135, 387). This 
dissertation work, which has focused on using computational, EPR, and NMR hybrid 
techniques, is just one small step towards achieving a full structural characterization of 
physiological processes. 
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The experiments described in this chapter would be only first steps leading 
towards a better understanding of GPCR / peptide interactions and improved 
computational de novo folding of helical membrane proteins. However, broader, more 
challenging questions face the structural biological—and the general biomedical—field. 
In recent years, one of the main questions the protein structure prediction community 
asks itself is:  Why are the capabilities of protein modeling methods plateauing? This is 
especially true for large proteins with complicated topologies, such as those that exhibit 
the LeuT fold. A key drawback of modeling proteins with Rosetta in its current state is 
that it does not take protein dynamics into account. Further, the surroundings in which the 
proteins reside, be they aqueous or hydrophobic, are only a statistically based implicit 
representation of reality. Finally, proteins do not exist in isolation, but rather in highly 
fluid, crowded environments. The numerous interactions that these biomolecules 
encounter play an important role in their conformations. 
Ideally, we would model the plethora of inter-molecular interactions in full detail, 
including computing molecular orbitals from first principles. It is possible that this 
approach would render an accurate picture of what goes on at the single molecule level. 
Unfortunately, this is computationally intractable, and likely will be for a long time to 
come. Scientists interested in predicting molecular structure have worked around this by 
including empirical data and statistics in their methods. The problem is that these 
approaches are difficult to dissect, troubleshoot, and improve. Therefore, we do not have 
a robust, analytical explanation of why, Rosetta for instance, does or does not fold certain 
proteins accurately. However, the same could be said for other processes and areas of 
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study, including protein crystallization, neuroscience and connectomics, and even dark 
matter and dark energy (in physics).  
In order to make headway on these known unknowns, as well as even more 
unknown unknowns, the scientific community--and society as a whole—must work 
together more closely than ever. Both pure and use-inspired basic research, often referred 
to as Bohr’s and Pasteur’s quadrants, respectively, ought to remain a national priority if 
the United States is to maintain its competitive economic edge (437, 438). This would 
require significant investments in both scientific discovery and method development, 
which seems infeasible given the current funding and political environment. Fortunately, 
we can leverage already existing resources and personnel via government-university-
industry partnerships (438). Moving in this direction necessitates continued and incresed 
effective communication across disciplines and sectors. !  
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APPENDIX A 
 
LIGAND-MIMICKING RECEPTOR VARIANT DISCLOSES BINDING AND 
ACTIVATION MODE OF PROLACTIN RELEASING PEPTIDE 
 
This work is based on the publication (Rathmann*, Lindner*, DeLuca*, 
Kaufmann, Meiler, and Beck-Sickinger, 2013). *These authors contributed equally. 
! !
Summary 
The prolactin-releasing peptide receptor (PrRPR) and its bioactive RF-amide 
peptide (PrRP20) have been investigated to explore the ligand binding mode of peptide 
G-protein coupled receptors (GPCR). By receptor mutagenesis we identified the 
conserved aspartate in the upper transmembrane helix 6 (D6.59) of the receptor as the first 
position that directly interacts with arginine 19 of the ligand (R19). Permutation of D6.59 
with R19 of PrRP20 led to D6.59R, which turned out to be a constitutively active receptor 
mutant (CAM). This suggests that the mutated residue at the top of transmembrane helix 
6 mimics R19 by interacting with additional binding partners in the receptor. Next, we set 
up a comparative model of this CAM because no ligand docking is required, and selected 
a next set of receptor mutants to find the engaged partners of the binding pocket. In an 
iterative process we identified two acidic residues and two hydrophobic residues that 
form the peptide ligand binding pocket. As all residues are localized on top or in the 
upper part of the transmembrane domains we clearly can show that the extracellular 
surface of the receptor is sufficient for full signal transduction for PrRP, rather than a 
deep membrane binding pocket. This contributes to the knowledge of the binding of 
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peptide ligands to GPCR and might facilitate the development of GPCR ligands, but also 
provides new targeting of CAM involved in hereditary diseases.  
 
Introduction 
Identification of direct receptor-ligand interactions for the approximately 800 
identified G protein-coupled receptors (GPCR) is as challenging as it is important for 
drug discovery (25), as 50% of all currently available drugs target the specific 
manipulation of GPCR activity (24, 388). The PrRP receptor superfamily is expressed in 
almost all cells/tissues, is involved in a plethora of different signalling pathways, and 
plays an important role in a large variety of physiological processes.  
The prolactin-releasing peptide receptor (PrRPR) was originally isolated from rat 
hypothalamus (389). PrRPR has been detected widely throughout the human and rat brain 
(31) and most commonly activates the Gq protein-coupled signalling pathway (390). Its 
eponymous endogenous ligand, the prolactin-releasing peptide (PrRP), was identified in 
1998 by a reverse pharmacology approach on the basis of orphan GPCR (28, 391). PrRP 
features two equipotent isoforms, PrRP31 (31 residues) and an N-terminally truncated 
PrRP20 (20 residues) (28, 390). PrRP is an RF-amide peptide, consisting of a common 
carboxy-terminal arginine (R) and an amidated phenylalanine (F) motif and plays a role 
in energy metabolism, stress responses, circadian rhythm, analgesia, and in anorexigenic 
effects (391, 392). Structure-activity relationship studies of PrRP using N-terminally 
truncated mutants and alanine substitution within these constructs (30, 34, 36) 
demonstrated the biological significance of the C-terminal R and F residues, and the 
amidation of the C-terminus.  
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Site-directed mutagenesis is a powerful and widely used tool to study receptor 
activation. This approach alone can provide insight in the function of GPCR, but it is 
often used in combination with information provided by other techniques, such as 
crystallography or molecular modeling, in order to relate receptor function to a tertiary 
structure (393). The conserved D6.59 residue of the Y receptor (YR) family was shown to 
interact with a specific R of either human pancreatic polypeptide or neuropeptide Y 
(NPY) in a subtype-specific manner (394, 395). The numbering of receptor residues has 
been performed as suggested by Ballesteros and Weinstein (38). PrRPR shares its 
phylogenic origin with Y receptors (396), leading to sequence similarities (Figure 44A) 
and a number of conserved residues, including D6.59 (Figure 44C). Furthermore, the 
ligands of these receptors are structurally similar (35) and share a similar C-terminal 
sequence (Figure 44B). While the RF-amide motif was previously identified as a major 
requirement for PrRP-induced agonist activity (30, 34), the critical residues on the 
receptor remain unknown, and the ligand binding mode is still poorly understood. 
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Figure 44:  Identification of the conserved D6.59 residue in the hPrRPR sequence as potential 
spot of interaction 
 A) Conservation of D6.59 shown in the amino acid sequence alignment. The region of upper 
transmembrane helix (TMH) 6 and the beginning of the subsequent extracellular loop (EL) 3 of 
the four human Y receptor subtypes and the PrRPR is presented. Sequence alignment and 
description was taken from: http://www.gpcr.org/7tm/. B) Comparison of the C-terminal amino 
acids of the Y receptor ligands and the PrRP20. C) Snake plot representing the sequence of the 
human PrRPR. Residues highlighted in black were investigated as double mutants in the D6.59R 
construct. Selective alanine-scan was performed on residues pictured in grey, resulting in no 
functional alteration. Residues with white letters in grey correspond to the X.50 nomenclature (38). D) IP accumulating signal transduction assay performed for 1h with COS-7 cells in a 
concentration-response dependent manner reveals an impact of D6.59A PrRPR in comparison to 
the wt PrRP receptor. Data represent the mean ± s.e.m. of multiple independent experiments (n = 
32 for hPrRPR, and n = 12 for D6.59A PrRPR). Receptor activity is expressed as percentage of the 
full response of PrRP20 at the wt PrRP receptor. 
 
Here, we describe the first mutagenesis study of the human PrRP receptor 
(PrRPR). We used the extracellular region to elucidate the binding site and the molecular 
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mechanism of GPCR activation. Considering the relevance of the C-terminal R and F 
residues of PrRP for receptor binding, we applied the concept of double cycle 
mutagenesis approach (395, 397, 398) and identified the first direct contact point between 
PrRP20 and the PrRPR, consisting of the conserved D6.59 and the R19 residue of PrRP20. 
To prove the existence of this interaction, we switched the residues involved in the salt 
bridge formation and created D6.59R PrRPR and D19PrRP20. This newly introduced R in 
the receptor variant D6.59R might serve as surrogate for the absent R19 of the ligand as it 
led to a new type of constitutive activity. Given the lack of data of experimentally 
determined structures of peptide GPCR, we developed a comparative model of the human 
PrRPR. By combining molecular modelling with double cycle mutagenesis experiments 
in the framework of this constitutively active mutant (CAM), we conceived an effective 
strategy to explore structural determinants of ligand recognition on a molecular level. 
More specifically, we were able to identify Y5.38, W5.28, E5.26, and to some extend F6.54 to 
be involved in receptor activation and ligand binding. This combinatory approach 
enabled us to clarify the double binding mode of R19 of the peptide ligand, which has two 
putative interaction partners within the PrRPR, E5.26 and D6.59. The assembled 
experimental data were used to generate a model of the PrRP/receptor interaction in 
molecular detail. Furthermore our data describe the binding mode of a peptide ligand to 
GPCR by solely interacting with residues localized in the extracellular domain or upper 
part of the TM helices. In our approach we identified a receptor mutant with constitutive 
activity, which most likely relies on mimicking a direct ligand-receptor interaction. This 
provides knowledge on the function of an active mode of GPCR and may be applied to 
other peptide GPCR. More specifically, we were able to identify Y5.38, W5.28, E5.26, and to 
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some extend F6.54 to be involved in receptor activation and ligand binding. This 
combinatory approach enabled us to clarify the double binding mode of R19 of the peptide 
ligand, which has two putative interaction partners within the PrRPR, E5.26 and D6.59. The 
assembled experimental data were used to generate a model of the PrRP/receptor 
interaction in molecular detail. Furthermore our data describe the binding mode of a 
peptide ligand to GPCR by solely interacting with residues localized in the extracellular 
domain or upper part of the TM helices. In our approach we identified a receptor mutant 
with constitutive activity, which most likely relies on mimicking a direct ligand-receptor 
interaction. This provides knowledge on the function of an active mode of GPCR and 
may be applied to other peptide GPCRs. 
 
Materials and methods 
Peptide synthesis  
Rink amide resin (NovaBiochem; Läufelfingen, Switzerland) was used to 
synthesize PrRP20, A19PrRP20, D19PrRP20, and A20PrRP20 by automated solid phase 
peptide synthesis (Syro; MultiSynTech, Bochum, Germany) as previously described, 
using the orthogonal Fmoc/tBu (9-fluorenyl-methoxycarbonyl-tert-butyl) strategy (399). 
Purification and verification of the peptides was achieved as previously described (Table 
25) (171).  
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Table 25:  Binding affinity of single amino acid replacements of PrRP20 at the human PrRP receptor wildtype. COS-7 cells were 
transiently transfected with wildtype PrRP receptor ! ! ! mass$(m/z)! HPLC! Binding&assayd!
No.! Peptide! Sequence! calcd.&
[M]+! exp.%[M+H]+! ACN$[%]! MeOH%[%]! purity'[%]! IC50! IC50(peptide)!! ! ! [nM]% IC50(PrRP20)!
1% PrRP20! TPDINPAWYASRGIRPVGRF%NH2! 2272.6! 2273.7! 40.3a! 65.5!b! >99! 3.6$±$0.5! 1!
2% A19PrRP20! TPDINPAWYASRGIRPVGAF%NH2! 2187.5! 2188.4! 41.6a! 70.8c! >99! >"10"000! >"2"700!
3% D19PrRP20! TPDINPAWYASRGIRPVGDF%NH2! 2231.5! 2231.4! 38.5a! 67.4b! >99! >"10"000! >"2"700!
4% A20PrRP20! TPDINPAWYASRGIRPVGRA%NH2! 2196.5! 2196.2! 37.7a! 61.6b! >99! 869$±$577! 241!
a 10 % to 60 % ACN (0.08 % TFA) in water (0.1 % TFA) over 30 min. 
b 20 % to 100 % MeOH (0.08 % TFA) in water (0.1 % TFA) over 40 min. 
c  30 % to 100 % MeOH (0.08 % TFA) in water (0.1 % TFA) over 30 min. 
d The IC50 value was determined by competition assays using N [propionyl3H] hPrRP20. 
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DNA extraction from SMS-KAN 
To obtain genomic DNA from SMS-KAN cells (human neuroblastoma cells, 
DSMZ, Braunschweig, Germany), approximately 1 million cells were digested overnight 
at 55°C with 500 µl lysis buffer (1 M NaCl, 20% SDS, 0.5 M EDTA, 1 M Tris, pH 8.5 
was adjusted using hydrochloric acid (HCl)) containing 50 µg proteinase K (Promega, 
Mannheim, Germany). Genomic DNA was extracted using phenol/chloroform and 
precipitated from the aqueous phase with isopropanol, washed with ethanol and then 
dissolved in water. 
 
Cloning and mutagenesis of the PrRP receptors in eukaryotic expression vectors  
The coding sequence of the human PrRPR was obtained by PCR amplification 
from the isolated genomic DNA of SMS-KAN cells and cloned into the eukaryotic 
expression vector pEYFP-N1 (Clontech, Heidelberg, Germany) C-terminally fused to 
EYFP, using the XhoI and BamHI restriction site to result in the construct 
phPrRPR_EYFP-N1. The correctness of the entire coding sequence was confirmed by 
DNA sequencing using the dideoxynucleotide (ddNTP) termination method developed by 
Sanger (23). Plasmids encoding single point mutations (Table 26 and Table 28) were 
prepared by using the QuikChange™ site-directed mutagenesis method (Stratagene, CA, 
USA) with the desired mutagenic primers. For intermolecular double-cycle mutagenesis 
approaches, the single alanine mutated receptor constructs were investigated, using single 
alanine modified PrRP20 analogs. Plasmids encoding double mutations containing 
Y2.64A, W2.71A, E5.26A, E5.26R; W5.28A, D6.59A, F6.54A or Q7.35A as a second mutation, 
respectively, were prepared by using the QuikChange™ site-directed mutagenesis 
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approach with the D6.59R or D6.59A construct as template. In addition, all PrPR receptor 
constructs were also generated N-terminally fused to the coding sequence of the 
hemagglutinin (HA)-tag. The entire coding sequence of each resulting receptor mutant 
was proven by sequencing.  
 
Cell culture 
Cell culture material was supplied by PAA Laboratories GmbH (Pasching, 
Austria). Culture of COS-7 (African green monkey, kidney), HEK293 (human embryonic 
kidney), and SMS-KAN cells was done as recommended by the supplier (DSMZ, 
Braunschweig, Germany). Briefly, cells were grown as monolayers at 37°C in a 
humidified atmosphere of 5% CO2 and 95% air. COS-7 cells were cultured in Dulbecco’s 
Modified Eagle’s Medium containing 10% (v/v) heat-inactivated fetal calf serum (FCS), 
100 units/ml penicillin and 100 µg/ml streptomycin and HEK293 cells were grown in 
DMEM / Ham’ F12 (1:1) without L-glutamine containing 15% (v/v) heat-inactivated 
FCS as previously described (395, 400). SMS-KAN cells were maintained in nutrient 
mixture Ham’s F12 / Dulbecco’s modified Eagle medium (1:1) with 15% (v/v) FCS, 4 
mM glutamine, and 0.2 mM non-essential amino acids (401).  
 
Fluorescence microscopy  
HEK293 cells (1.2 x 105) were seeded into 8-well chamber slides (ibidi, Munich, 
Germany). The transient transfection of HEK293 cells were performed using 0.1 µg to 
1µg vector DNA and 1 µl Lipofectamin™ 2000 transfection reagent (Invitrogen GmbH, 
Karlsruhe, Germany) according to the manufacturer’s instructions. The nuclei were 
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visualized with Hoechst 33342 (1 µg/ml; Sigma Aldrich, Taufkirchen, Germany) for 10 
min after 1h of starving with OPTI®-MEM I Reduced Serum Medium (Invitrogen GmbH, 
Karlsruhe, Germany). Fluorescence images were obtained using an ApoTome Imaging 
System with an Axio Observer microscope (Zeiss, Jena, Germany). All investigated 
receptors were correctly integrated in the membrane as confirmed by live-cell 
microscopy (Figure 45A). 
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Figure 45:  Surface localization of PrRPR variants in HEK293 cells 
A) Cell surface expression of wt PrRPR and investigated PrRPR mutants. HEK293 cells were 
transiently transfected with different PrRPR mutants, C-terminally fused to eYFP. The nuclei 
were visualized with Hoechst 33342. Scale bars represent 10 µm. B) Quantification of cell 
surface and total receptors by ELISA. The amount of cell surface receptors was measured as 
described under Materials and methods. Data are shown as mean ± s.e.m. of four independent 
experiments, each performed in triplicate. C) Relative cell surface expression levels of each 
receptor construct as percentage of each total receptor expression by ELISA. Data shows the 
capability of the individual receptor mutants to be exported to the plasma membrane, 
independently from the transfection efficiency. Data is calculated from Panel B and presented as 
mean ± s.e.m. of four independent experiments, each performed in triplicate. 
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Quantification of receptor cell surface localization by cell surface ELISA 
To quantify plasma-membrane receptors, a cell surface ELISA was performed 
using an antibody directed against the native 15 N-terminal amino acids of the PrRPR. 
50,000 HEK293 cells were grown in 96-well plates and transfected with the PrRP wt 
receptor or its mutants after reaching 75-85% of confluence. The cells were starved with 
OPTI®-MEM I (30 min) 17 hours post-transfection and fixed in 4% paraformaldehyde 
(30 min). For immune-staining, cells were blocked with 2% BSA and permeabilized with 
0.5% Triton X-100, 2% BSA in Dulbecco’s Modified Eagle’s Medium for 1 hour (37°C) 
to determine total receptor amounts, whereas surface expressed receptors were quantified 
without permeabilization. Incubation was performed with the primary antibody (1:2000 
dilutions) for 2 hours (25°C) and followed by 1.5 hour (25°C) incubation with the 
secondary antibody (1:5,000). Receptors were detected by using rabbit anti-N-terminus 
(GPR10 antibody [N1], GTX108137, GeneTex) followed by horseradish peroxidase-
conjugated goat anti-rabbit IgG (sc-2004, Santa Cruz, Heidelberg, Germany). The results 
were fully confirmed in a second independent ELISA set up, using a peroxidise-
conjugated anti-HA-antibody (1:1000 dilutions, 12CA5, Roche, Mannheim, Germany) 
versus the N-terminally fused HA-tag of the generated PrRPR constructs (data not 
shown). Quantification of the bound peroxidase was performed as described and analysis 
performed with the GraphPad Prism 5.03 program (14). Values are presented as mean 
values ± s.e.m. of four individual experiments, measured in triplicate. 
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Radioligand binding studies  
For radioligand binding studies, 1.5 × 106 COS-7 cells were seeded into 25 cm2 
flasks. At 60-70% confluency, cells were transiently transfected using 4 µg vector DNA 
and 15 µl of Metafectene™ (Biontex Laboratories GmbH, Martinsried/Planegg, 
Germany). Approximately 24 h after transfection binding assays were performed on 
intact cells using N [propionyl3H] hPrRP20. Binding was determined with 1 nM N 
[propionyl3H] hPrRP20 in the absence (total binding) or in the presence (non-specific 
binding) of 1 µM unlabeled hPrRP20, respectively, as described previously (172, 175). 
Our former evaluated protocol (176) was used to obtain N [propionyl3H] hPrRP20 by 
selective labelling with a specific activity of 3.52 TBq/mmol and resulting in a Kd-value 
of 0.58 nM. Specific binding of each PrRP receptor mutant was compared to specific 
binding of the PrRP wt receptor. IC50-values and the Kd-value were calculated with 
GraphPad Prism 5.03 (GraphPad Software, San Diego, USA), fitted to a one-site 
competition or a one-site binding model, respectively. Triplicates were measured in at 
least two independent experiments for the determination of IC50-values, whereas one 
experiment in triplicate was made for Kd-value estimation. 
 
Signal transduction assay  
Signal transduction (inositol phosphate, or IP, accumulation) assays were 
performed as previously described with minor modifications (171). The time of 
incubation was increased to 3 h for the double mutants of PrRPR and reduced to 1h for 
measurement of concentration-response curves. To test for constitutive activity, COS-7 
cells were incubated without agonist for 1 h, 3 h, and 6 h at 37°C. Each ligand-receptor 
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interaction was analyzed with the GraphPad Prism 5.03 program by establishing the 
corresponding data set from different experiments. All signal transduction assays were 
repeated at least twice independently and measured in duplicate. The global curve fitting 
function of GraphPad Prism 5.03 was asked to determine given EC50-ratios. The 
statistical significance of relevant samples was computed by using the unpaired student’s 
t-test, based on the means, values with P < 0.05 were considered to be significant. 
 
Multiple sequence alignment  
ClustalW (257) was used to align the primary sequence of the PrRPR with the 
sequences of mammalian Y and PrRP receptors. Next, the transmembrane regions of six 
GPCR of known structure were structurally aligned with Mustang (259). The profiles 
resulting from these first two steps were then aligned to one another with ClustalW, and 
the human PrRPR sequence alignment used for modelling was taken from this final 
profile-profile alignment. The C-terminal 310 residues of the PrRPR primary sequence 
were threaded onto the 3D coordinates of six available GPCR experimental structures; 
PDBIDs: 1U19 (260), 3CAP (402), 3DQB (403), 2RH1 (67), 2VT4 (404), 3EML (405).  
 
Construction of the comparative models  
Extracellular loop regions were reconstructed using kinematic loop closure (406) 
and cyclic coordinate descent (CCD) (255) as implemented in the Rosetta v3 software 
suite. The models were refined with the Rosetta v3 all-atom energy function. 
Energetically favourable models were grouped into 15 structurally similar groups by k-
means clustering, and the lowest scoring models of each cluster were analysed. Models 
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based on the template PDB 3DQB had the lowest energy and were used to inform the 
mutagenesis studies. 
 
Model refinement and peptide docking  
The comparative model constructed in light of the new mutagenesis data was 
generated using the original multiple sequence alignment. To model the PrRPR/ligand 
complex, an iterative peptide docking and loop remodeling procedure was performed: 
Energetically favorable changes in orientation were determined using the 
RosettaMembrane all-atom energy function (130). The PrRP8-20 model was docked into 
the putative binding site of the receptor while allowing remodeling of ELs 1, 2, and 3. 
Using the RosettaDock protocol (407), translational movements of the peptide of up to 
4Å were allowed in three dimensions and the peptide was allowed to rotate along its x, y, 
and z-axes by up to 10°. Loop regions were constructed using CCD (255). The 
conformational search was enhanced by conducting the modeling in the presence of loose 
distance restraints where models that placed D6.59, E5.26, W5.28, and Y5.38 within 10Å of 
R19 of the peptide were more energetically favorable than those that did not. The PrRP8-
20 model was generated by de novo folding the peptide using RosettaNMR with sparse 
NMR chemical shift and distance data (106). Of 19,241 PrRP/receptor complex docked 
models, the top ten by total score were analyzed. Two of these models were considered 
structurally redundant, leaving eight unique models that agree with the experimental data 
presented herein (Figure 52). 
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Results 
R19 of the endogenous ligand PrRP20 interacts with the D6.59 of PrRPR  
Based on the data of the NPY/YR system (394, 395), we hypothesized D6.59 to be 
the interaction partner of R19 in the PrRP/PrRPR system. To test this hypothesis, charge 
and size prerequisites in position D6.59 were elucidated by systematic substitution to 
D6.59A, D6.59E, D6.59N, D6.59R, and D6.59K (Table 26). The expected impact on function 
was confirmed by the right-shifted concentration-response curve of D6.59A, compared to 
the wildtype (wt) receptor after stimulation with PrRP20 (Figure 44D). The increased 
EC50-value (26 nM) of the D6.59A mutant confirms the importance of the D6.59 side-chain. 
In addition, the results obtained for the other D6.59 single mutants support the hypothesis 
of an ionic interaction; D6.59E behaves similarly to wt, the oppositely charged D6.59K 
shows strong effects in potency and the bulkier, more positively charged D6.59R is not 
tolerated (Table 26). The impact of the substitutions increases as follows: E<A<N<K<R, 
showing that the lack of charge is a first critical component. This is followed by 
necessities in space and strength of the opposing charged K and R at position 6.59, 
showing different and increasing repulsion of the substitutions by PrRP20 stimulation 
(Table 26). Therefore, the charge seems to be a major prerequisite at position 6.59. 
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Table 26:  Functional characterization of wildtype and D6.59 PrRP receptor mutants with different PrRP analogs 
IP accumulating signal transduction assay was performed for 1 hour with different concentrations of modified PrRP20 peptides to determine EC50-
values from concentration-response curves. 
PrRPR 
mutants 
PrRP20 A
19
PrRP20 D
19
PrRP20 
EC50 [nM]a  
(pEC50 ± SEM) 
EC50-ratiob (mut/wt) 
Emax ± SEM 
[%]c N 
EC50 [nM]a  
(pEC50 ± SEM) 
EC50-ratiob 
(analog/wt) N 
EC50 [nM]a  
(pEC50 ± SEM) 
N 
wt 1.66 (8.78 ± 0.04) 1 100 32 1202 (5.92 ± 0.08) 736 11 1318 (5.88 ± 0.12) 5 
D
6.59
A 26 (7.59 ± 0.15) 15 98 ± 7 12 166 (6.78 ± 0.17) 0.16 3 6456 (5.19 ± 0.16) 4 
D
6.59
R ND
d NDe 60 ± 13 4 > 10 000 (< 5) NDe 2 138 (6.86 ± 0.23) 3 
D
6.59
K 1380 (5.86 ± 0.20) 847 90 ± 10 3 NT - - 115 (6.94 ± 0.17) 2 
D
6.59
E 3.98 (8.4 ± 0.19) 2 106 ± 10 2 NT - - NT - 
D
6.59
N 36.3 (7.44 ± 0.25) 22 105 ± 20 2 NT - - NT - 
E5.26A 537 (6.27 ± 0.09) 361 81 ± 6 8 > 10 000 (< 5) 21 3 NT - 
E5.26R > 10 000 (< 5) NDe 70 ± 6 2 NDd NDe 2 > 10 000 (< 5) 2 
E5.26A/ D6.59A NDd NDe 58 ± 7 2 NDd NDe 2 NT - 
E5.26R/ D6.59R NR NDe 8 ± 2 2 NR NDe 2 NDd 2 
NT represents not tested, NR indicates no response after stimulation with 10 µM and N displays the number of individual experiments.  
a EC50-/pEC50-values were calculated from the mean ± s.e.m. of N independent experiments, measured in duplicate. 
b Efficacy was determined as percentage compared to full PrRP20 response at wt  
c The ratio was determined using the Prism 5.03 global fitting function for EC50 shift determination. 
d ND, not determined because of lack of efficacy. The plateau of the curve was not reached. 
e ND, not determinable 
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The signal transduction results obtained for PrRPR stimulation with peptide 
analogs A19PrRP20 and A20PrRP20 confirmed the essential influence of the formerly 
described RF-amide motif with respect to binding and signaling (Table 25, Table 26, and 
Table 27) (30, 34, 36). Circular dichrosim (CD) spectroscopy showed that these 
variations have no influence on the PrRP20 overall structure, at least, not detectable by 
CD (data not shown).  
Table 27:  Functional characterization of wildtype and D6.59 PrRP receptor mutants with 
A20PrRP 
IP accumulating signal transduction assay was performed for 1 hour with different concentrations 
of A20PrRP to determine EC50-values from concentration-response curves. 
 A
20PrRP20 
PrRPR mutants 
EC50 [nM] (pEC50 ± SEM) N 
  
wt 17.8 (7.75 ± 0.11) 8 
D6.59A NDa 2 
D6.59R NR 2 
E5.26R/ D6.59R NR 2 
NR indicates no response after stimulation with 10 µM, and N displays the number of individual 
experiments. 
a ND, not determined because of lack of efficacy. The plateau of the curve was not reached.  
Double cycle mutagenesis suggests additional receptor region “X” critical for peptide 
binding.  
The concentration-response curve of the D6.59A receptor with PrRP20 reveals a 
15-fold elevated EC50-value (Figure 46A and Table 26), whereas the wt receptor 
stimulated with A19PrRP20 results in a 736-fold elevated EC50-value (Figure 46B and 
Table 26). This finding suggests that R19 has one or more additional interaction partner, 
“X,” which explains the increased importance of R19 for receptor activity. Stimulation of 
the D6.59A receptor with A19PrRP20 resulted in a 0.16-fold elevated EC50-value, 
compared to PrRP20 stimulation. This non-additive effect of the double cycle 
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mutagenesis experiment implies that the effects of the individual replacements are not 
independent of each other. Among more complicated mechanisms, such as indirect 
interactions of the two residues, the effect may also be due to a direct interaction between 
D6.59 of PrRPR and R19 of PrRP20 (Figure 46C and Table 26).  
 
 
Figure 46:  Functional characterization of PrRP receptor mutant D6.59A with PrRP20 and 
the modified ligand A19PrRP20 
Schemes represent the postulated mode of ligand binding. Due to the different relevance of D6.59 
and the R19, a second contact point for R19 can be assumed. Complementary mutagenesis 
approach was used in combination with the signal transduction assay on cells, expressing the wt 
PrRPR or the D6.59A mutant in order to observe concentration-response curves. Data represent the 
mean ± s.e.m. of multiple independent experiments (n = 32 for hPrRPR with PrRP20, n = 12 for 
D6.59A PrRPR with PrRP20, n = 11 for hPrRPR with A19PrRP20, and n = 3 for D6.59A PrRPR 
with A19PrRP20). Receptor activity is expressed as percentage of full PrRP20 response at the wt 
PrRP receptor. A) Modification of receptor side: D6.59A PrRPR in comparison with wt receptor 
was stimulated with PrRP20. B) Exploring the ligand side: both PrRP20 and A19PrRP20 were 
investigated using wt PrRPR. C) Complementary approach: A19PrRP20 stimulation of wt and 
mutant receptor resulted almost matching concentration-response curves, indicating an interaction 
between D6.59 of the receptor and R19 of the ligand. 
 
Reciprocal mutagenesis leads to a constitutive active receptor mutant 
To confirm the direct interaction between R19 and D6.59, the corresponding 
residues were swapped (Figure 47A). The herein performed reciprocal mutagenesis 
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approach assumes that a lost interaction between two residues induced by single mutation 
to the counter amino acid can partly be recovered by a second mutation that establishes 
the interaction in a reverse manner. We used this method to verify the salt bridge between 
D6.59 and R19 in the PrRP/PrRPR system by using the single peptide D19PrRP20 and the 
D6.59R receptor mutant (Figure 47C). The single peptide mutant D19PrRP20 shows a 
similar effect as A19PrRP20, with an increased EC50-value of 1318 nM (Table 26) 
without impact on the efficacy (Figure 47B). We conclude that all peptide-receptor 
interactions that involve position R19 have been disrupted (Figure 46B and Figure 47B). 
In the reverse experiment, PrRP20 barely stimulated the D6.59R receptor mutant with no 
determinable EC50-value (Figure 47C). In comparison to both single mutant experiments, 
the activation of the D6.59R but also D6.59K mutant with D19PrRP20 revealed a gain of 
function (EC50-values: D6.59R = 138 nM and D6.59K = 115 nM, Table 26, Figure 47C, and 
Figure 48C), confirming the direct interaction of R19 and D6.59. At the same time, the 
experiment provides further evidence in support of a second interaction site “X” for 
D6.59R, as the EC50-value is still elevated by a factor of 84 compared to the wt interaction. 
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Figure 47:  Reciprocal mutagenesis of the PrRPR 
A) This scheme displays the assumed wt situation with the direct interaction of ligand R19PrRP20 
and receptor D6.59PrRPR, as well as the second unknown interaction of the R19 to the receptor. B) 
The stimulation of wt receptor by D19PrRP20 and the corresponding concentration-response 
curves of the signal transduction assay. C) Reciprocal mutagenesis scheme is shown with related 
concentration-response curves. Interestingly, D6.59R mutant is partially basally active and can be 
activated by D19PrRP20. The latter is due to the established D-R interaction. IP accumulation 
presented in Panels B and C represent the mean ± s.e.m. of multiple independent experiments (n 
= 32 for hPrRPR with PrRP20, n = 5 for D6.59R PrRPR with PrRP20, n = 4 for hPrRPR with 
D19PrRP20, and n = 3 for D6.59R PrRPR with D19PrRP20). Receptor activity is expressed as 
percentage of full PrRP20 response at the wt PrRP receptor. 
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Figure 48:  Investigation of the constitutive activity of D6.59R PrRPR mutant 
A) Test of influence of transfection upon constitutive activity of wt PrRPR and D6.59 constructs. 
The IP accumulation of differently transient transfected COS-7 cells expressing the various 
PrRPR mutants was measured without any agonist after three hours [given as x-fold over eYFP 
expressing cells]. [Each bar represents the mean ± s.e.m. of two different experiments; at least in 
triplicates; * P < 0.05; ** P < 0.01; *** P < 0.001] B) Constitutive activity of wt PrRPR and D6.59 
mutant was investigated in a time-dependent manner. The IP accumulation of COS-7 cells 
expressing the different PrRPR variants was measured without any agonist after different time 
periods [given as x-fold over eYFP expressing cells]. C) Concentration-response curves of D6.59 
PrRP receptor munats. Data represent the mean ± s.e.m. of multiple independent experiments (n = 
5 for hPrRPR, n = 4 for D6.59A PrRPR, n = 3 for D6.59R PrRPR, and n = 2 for D6.59K PrRPR). 
Receptor activity is expressed as percentage of full PrRP20 response at the wt PrRP receptor. D) 
Scheme of assumed explanation for the agonist-independent activity of the D6.59R receptor 
mutant: We postulate that the D6.59R is a CAM because D6.59R mimics R19 of PrRP20 by intra-
molecular interaction with a receptor region “X,” inducing a partially active receptor 
conformation. 
 
A novel possibility to identify the missing interaction site “X” arose because the 
D6.59R receptor mutant presented a strongly increased basal activity, which is indicated 
by curves with higher initial IP accumulation (Figure 47C and Figure 48C). In contrast, 
D6.59A and D6.59K reveal solely slight elevated basal activity. This can be explained by 
more loosened constraints at this position and thus making it more susceptible for 
induced basal activity, whereas for D6.59K the spatial and more charged prerequisites are 
missing. The observed effect of constitutive activity is independent of transient 
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transfection, which is a critical component. Different amounts of transfected DNA 
resulted in essentially similar cellular responses (Figure 46A). Finally, the constitutive 
activity of the D6.59R receptor mutant was confirmed by an increased time-dependent IP-
accumulation compared to wt (Figure 46B; 1h, 3h = P < 0.05; 6h = P < 0.01). All 
investigated receptors were correctly integrated in the membrane as confirmed by live-
cell microscopy (Figure 44A) and revealed similar cell surface levels as determined by 
surface ELISA (Figure 44B and Figure 44C). 
 
Identification of “X” by modelling-guided double mutant analysis.  
We hypothesize that D6.59R PrRPR is a CAM caused by the interaction of D6.59R 
with residue “X.” D6.59R mimics R19 of PrRP20, inducing a partially active receptor 
conformation (Figure 48D). We further hypothesize that D6.59R/XX.XA double mutants 
will lose constitutive activity and most importantly, retain activation by D19PrRP20. In 
order to determine likely positions for “X,” a comparative model of the PrRPR was 
constructed using the Rosetta molecular modeling software suite. Details of the modeling 
protocol are given in the Materials and methods. According to the lowest-energy model 
based on the semi-active opsin structure (PDBID: 3DQB (33)). E5.26, W5.28, Y5.38, F6.54, 
and Q7.35 were found proximal to D6.59 and were proposed to be potential interaction 
partners for D6.59R (Figure 49A) or for R19PrRP20 when testing the wt receptor. The 
more distant residues, Y2.64 and W2.71, were chosen for control experiments. 
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Figure 49:  Molecular model of the PrRPR based on 3DQB and resulting double mutations 
based on the D6.59R PrRPR construct 
A) Residues in proximity to the extracellular side are shown in purple. These were investigated in 
double mutational analysis with D6.59R PrRPR. The D6.59 on top of TMH4 is colored in blue, and 
the suggested inward movement of the extracellular helical part of TMH6 is indicated by an 
orange dart. (B) A new approach to identify the missing interaction site, “X,” arose by insertion 
of a second alanine substitution of assumed interacting residues to the D6.59R PrRPR. The second 
mutation is expected to diminish the basal activity but retain the capability to be activated by 
D19PrRP20. IP accumulation assay of COS-7 cells transfected with eYFP as control and the 
following constructs of PrRPR: wt, D6.59R, Y2.64A/D6.59R, W2.71A/D6.59R, E5.26A/D6.59R, 
W5.28A/D6.59R, Y5.38A/D6.59R, F6.54A/D6.59R, Q7.35A/D6.59R, respectively. Incubation was performed 
for three hours without ligand, PrRP20 or D19PrRP20, and results are presented in IP 
accumulation as percentage of full PrRP20 response at the wt PrRP receptor. [Each bar represents 
the mean ± s.e.m. of at least duplicates of four different experiments; ** P < 0.01; *** P < 
0.001]. 
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With guidance from the receptor modeling data (Figure 49A), we generated and 
tested the double mutants Y2.64A/D6.59R, W2.71A/D6.59R, E5.26A/D6.59R, W5.28A/D6.59R 
Y5.38A/D6.59R, F6.54A/D6.59R, and Q7.35A/D6.59R of PrRPR. Interestingly, E5.26A/D6.59R, 
W5.28A/D6.59R, and Y5.38A/D6.59R receptor mutants completely lost their constitutive 
activity in a ligand-independent signal transduction assay (Figure 49B). The IP 
accumulation after three hours of these unstimulated receptors dropped to a PrRPR wt 
level. The F6.54A/D6.59R dropped as well but remained partially constitutively active 
(Figure 49B). These effects could be due to disruption of the hypothesized interaction to 
the R6.59 residue or to decisive structural alterations, resulting in generally non-functional 
mutants. The latter situation was excluded after activation of these constructs using 10 
µM D19PrRP20 as an agonist (Figure 49B; P<0.01). In concentration-response 
experiments the EC50-values were determined to be higher than 100 µM (Figure 50A). 
The fact that D19PrRP20, not wt PrRP20, was able to activate these constructs re-
emphasizes the direct interaction of D19 with D6.59R.  
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Figure 50:  Functional characterization of PrRPR mutants with impact on receptor 
activation and ligand binding 
A) COS-7 cells transfected with wt PrRPR or E5.26A/D6.59R, W5.28A/D6.59R, Y5.38A/D6.59R, 
F6.54A/D6.59R receptor mutants, were stimulated for three hours with different D19PrRP20 
concentrations using a signal transduction assay. Data represent the mean ± s.e.m. of 5 (PrRPR), 
3 (E5.26A/D6.59R, W5.28A/D6.59R, Y5.38A/D6.59R) or 2 (F6.54A/D6.59R) independent experiments, 
measured in duplicate. B) COS-7 cells transfected with wt (n = 32) and E5.26A (n = 8), W5.28A (n 
= 7), Y5.38A (n = 5), D6.59A (n = 12), and F6.54A (n =3) PrRPR mutants, respectively, were 
investigated in signal transduction assay, and data are presented in concentration-response curves 
as percentage of full PrRP20 response at wt PrRP receptor. Stimulation was performed for 1 hour. 
The height of the curves correlates with the efficacy of the mutants. Potency is given by the 
degree of shift to the right and its resulting EC50 value. C) COS-7 cells transfected with the 
mentioned constructs in Panel B were incubated for one hour in a signal transduction assay with 1 
x 10-5M (mutants) or 1 x 10-7M (wt) PrRP20, and without stimulus. Results are expressed as 
percentage of IP accumulation compared to the PrRPR, with lowest mean of value being 0% and 
highest 100%. [bars represent the mean ± s.e.m of duplicates of at least 3 different experiments; * 
P < 0.05; *** P < 0.001]. 
 
Other double mutants, such as Y2.64A/D6.59R or Q7.35A/D6.59R, showed slightly 
reduced constitutive activity but seem to be trapped in that state, as no further 
activation/stimulation was achieved. W2.71A/D6.59R appears to have structural restrictions 
because no significant receptor activation could be observed. From the plethora of 
residues in the upper TMHs and ELs of PrRPR, which may interact with D6.59R the initial 
comparative models and mutational studies clearly suggested seven residues to 
potentially interact with D6.59R. Of these seven potential interaction sites, we hypothesize 
E5.26, W5.28, Y5.38, and F6.54 to be engaged in D6.59R-induced basal activity. Therefore, we 
postulate the latter residues to be involved in ligand binding and/or receptor activation. 
The combination of mutagenesis and comparative modelling enabled us to extract three 
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residues of relevance from the plethora of residues in the upper transmembrane helices 
(TMHs) and extracellular loops (ELs) of the PrRPR. 
 
Confirmation of binding and activation site using single mutants.  
To clarify the exact impact of the identified positions E5.26, W5.28, Y5.38, and F6.54, 
single alanine mutants at these positions were generated. Signal transduction studies of 
the single alanine mutants E5.26A (331-fold over wt), W5.28A (580-fold over wt), Y5.38A 
(61-fold over wt), and F6.54A (15-fold over wt) confirm the impact of residues E5.26, 
W5.28, Y5.38, and F6.54 on ligand binding (Table 28 and Figure 50B). Their distribution in 
EL2 and TMH5 suggests that this region plays a significant role in ligand binding. 
Therefore, EL2 and TMH5 were studied systematically to identify additional interaction 
sites that might have been missed due to inaccuracies of the comparative model. All 
charged (R, K, E, D) and aromatic (W, F, Y) residues between positions 4.65 and 5.40 
were substituted to alanine (Table 28). None of the tested mutants resulted in 
significantly increased EC50-values (Table 28 and Figure 50B). This demonstrates that 
the model-guided intramolecular mutagenesis experiment, at least in this setting, was 
more effective than alanine scanning in selecting the critical interaction partners.  
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Table 28:  Signal transduction of the selected alanine of PrRP receptor mutants from 
extracellular loop 2 and top TMH5 
IP accumulating signal transduction assay was performed for 1 hour with different concentrations 
of modified PrRP20 peptides to determine EC50-values from concentration-response curves.  
PrRPR mutant Emax ± SEM [%] a P 
b pEC50 ± SEMc 
EC50 
[nM]c 
EC50-ratio 
(mut/wt)d 
N 
 
Wt 100 - 8.78 ± 0.04 1.66 1 32 
Y4.65A 63 ± 22 ns 8.03 ± 0.32 9.3 6 2 
E4.68A 93 ± 8 ns 8.19 ± 0.19 6.4 4 3 
K4.70A 111 ± 35 ns 8.41 ± 0.41 3.9 2 2 
D4.73A 146 ± 41 ns 8.75 ± 0.49 1.78 1 2 
R4.75A 87 ± 15 ns 8.32 ± 0.37 4.8 3 3 
E5.25A 124 ± 10 ns 7.99 ± 0.13 10 6 3 
E5.26A 81 ± 5 0.0094 6.26 ± 0.10 549 331 8 
F5.27A 122 ± 50 ns 8.14 ± 0.49 7.2 4 2 
W5.28A 48 ± 5 < 0.0001 6.02 ± 0.14 954 580 7 
E5.32A 114 ± 11 ns 8.62 ± 0.14 2.4 1 2 
R5.33A 115 ± 15 ns 8.57 ± 0.20 2.7 2 2 
R5.35A 81 ± 4 0.0122 8.35 ± 0.32 4.5 3 2 
Y5.38A 46 ± 6 < 0.0001 6.99 ± 0.14 102 61 5 
W5.40A 101 ± 38 ns 8.78 ± 0.49 1.7 1 2 
D6.59A 97 ± 6 ns 7.59 ± 0.15 26 15 12 
F6.54A 101 ± 3 ns 7.61 ± 0.10 25 15 3 
N represents the number of independent experiments. 
a Efficacy was determined as percentage compared to full PrRP20 response at wt.  
b Significance P was estimated using the unpaired t-test (ns represents no significantly different 
means with P ≥ 0.05). 
c EC50-/pEC50-values were calculated from the mean ± s.e.m. of N independent experiments, 
measured in duplicate. 
d The ratio was determined using the Prism 5.03 function of dose-response EC50 shift 
determination by global fitting. 
 
To verify the obtained results of potency of the PrRP wt receptor and its mutants, 
the cellular expression levels in the plasma membrane were investigated, because 
recently a constitutive internalization of the PrRP receptor has been reported (408). 
Binding studies of transiently transfected COS-7 cells revealed a sufficient number of 
surface wt receptors per cell (~95,000), calculated from the obtained Bmax-value (445 
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Bq), the specific activity (3.52 x 1015 Bq/mol) and cell number (6.6 x 105). All PrRP 
receptor constructs with impact on potency were shown to be surface exposed and 
quantified by surface ELISA (Figure 44). The deviation from the wt PrRPR surface 
expression levels (wt = 39.6 ± 1.1%) varies from 16.3% (W5.28A) to 59.6% 
(F6.54A/D6.59A).  
However, these differences, basically resulting from transient transfection, reveal 
minor effects in the IP accumulation signaling assay set up, as the receptor mutant F6.54A 
(20.9 ± 3.7%) shows reduced total surface expression levels (Figure 44B) but full wt like 
efficacy (Figure 49B/C). Additionally, all PrRPR mutants are properly exported to the 
cell surface in comparable amounts as the wt receptor (39.6%, Figure 44C). Therefore, 
the herein obtained results of potency of agonists at their receptor constructs do not result 
from altered expression or export levels.  
A reduced efficacy was observed in the concentration-response dependent signal 
transduction assay for W5.28A and Y5.38A (P<0.001) and – with decreased impact – also 
for E5.26A (P<0.0094, Figure 50C and Table 28). In summary, our findings support a 
binding mechanism in which E5.26, in addition to D6.59, directly engage R19 of PrRP20 
through ionic interactions. F6.54 might contribute to the overall global conformation of the 
binding pocket and positioning of TMH 6, as its single mutation is less invasive but still 
is in distance for direct ligand interactions. We further suggest that W5.28 and Y5.38 are 
possibly in direct contact with the ligand and are indeed critical for receptor activation 
and the transmission of an external signal into the cell. 
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Exploration of second interaction partner and dual binding mode at R19.  
We generated the E5.26A/D6.59A double mutant of the receptor, which lacks both 
putative binding partners to the R19. In addition, the reciprocal PrRPR mutants, 
E5.26R/D6.59R and E5.26R, were generated to test the interaction by swapping the putative 
binding residues. The E5.26A and the E5.26A/D6.59A receptor mutants were investigated in 
a double cycle mutagenesis study, where they were stimulated with A19PrRP20 and wt 
PrRP20 (Table 26 and Figure 51A). The E5.26A mutant stimulated with A19PrRP20 
resulted in a strongly increased EC50-value higher than 10 µM, 21-fold shifted compared 
to PrRP20 stimulation (537 nM). The enhanced EC50-value can be explained by the 
disruption of the second R19 interaction to receptor residue D6.59. Indeed, this effect 
agrees with a similar impact of the D6.59A mutation (15-fold shifted; Table 26), which 
also diminished the direct interaction to the R19 of the ligand to a similar extent (Figure 
46A and Figure 51A). Furthermore, the stimulation of the E5.26A/D6.59A receptor mutant 
with either PrPR20 or A19PrRP20 resulted in matching curves. As no additional loss in 
potency was observed compared to the E5.26A mutant tested with A19PrRP20 (Figure 
51B), the experiment provides evidence that E5.26 is involved in binding to R19.  
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Figure 51:  Stimulation analysis of E5.26 mutants reveals a preferential activation of R 
mutants by the reciprocal ligand D19PrRP20 
Functional investigation of PrRPR mutants E5.26A, E5.26R, and E5.26A/D6.59A with the ligands 
PrRP20, A19PrRP20, or D19PrRP20. The signal transduction assay was performed in COS-7 cells 
expressing the wt PrRPR or E5.26A, E5.26R, or E5.26A/D6.59A mutants to observe concentration-
response curves. Results of two independent experiments, each performed in duplicate, are 
presented as mean ± s.e.m of duplicates. A) E5.26A PrRPR was stimulated with both PrRP20 and 
A19PrRP20 and demonstrated an equipotent loss in potency compared to the D6.59A PrRPR 
mutation (Figure!46A). Additionally, this panel highlights the direct interaction between R19 and 
D6.59. B) Stimulation with of the E5.26A/D6.59A receptor with A19PrRP20 or PrRP20 revealed no 
further loss in potency and a slightly decreased efficacy compared to the E5.26A PrRPR. This 
indicates that E5.26 might be the second binding partner of R19. C) Functional characterization of 
the reciprocal E5.26R PrRPR mutant using R19-modified PrRP20 analogues. D) The scheme shows 
the assumed interplay of attraction and repulsion for the reciprocal interaction of the ligands 
R19PrRP20 and D19PrRP20 with the E5.26R PrRP receptor mutant from Panel C. E) IP 
accumulation assay of COS-7 cells transfected with eYFP as control and the following constructs 
of PrRPR: wt, E5.26A, E5.26A/D6.59A, E5.26R, E5.26R/D6.59R, D6.59R, respectively. Incubation was 
performed for one hour using 100 µM of PrRP20, D19PrRP20, A19PrRP20, and without ligand. 
[Each bar represents the mean ± s.e.m. of at least duplicates of 2 different experiments; *** P < 
0.001].  
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Next, the capability of receptor mutants E5.26A, E5.26A/D6.59A, E5.26R, E5.26R/ 
D6.59R, D6.59A, and wt PrRPR to transmit signalling was tested (Figure 51E). Importantly, 
the reciprocal receptor mutants E5.26R and E5.26R/D6.59R were significantly and best 
activated by D19PrRP20 (both: P<0.001). In fact, E5.26R/D6.59R was solely activated by 
D19PrRP20. Finally, the E5.26R mutant was stimulated with PrRP20, A19PrRP20, and 
D19PrRP20 in a concentration-response experiment (Figure 51C). This receptor mutant 
behaved similarly, when stimulated by PrRP20 and D19PrRP20 (both: EC50-value >10 
µM). Along with the experiments testing D19PrRP20 stimulation of wt PrRPR, we 
demonstrate an approximately equal repulsive effect of R19 to E5.26R or D19 to D6.59 
(Figure 51D). This strengthens our hypothesis of a dual binding mode of R19 to E5.26 and 
D6.59.  
 
Comparative model of PrRP/receptor complex provides structural information on mode 
of binding.  
The R19/E5.26 and R19/D6.59 contacts as restraints, a de novo-folded model of 
PrRP8-20 based on reported NMR data (35) was docked into an ensemble of comparative 
models of the PrRPR. The conformation of the EL regions was constructed 
simultaneously with ligand docking to accurately capture conformational changes 
induced by the peptide. Details of the modeling procedures are given in the Materials and 
methods and Appendix C. The lowest-energy Rosetta model features salt bridges between 
D6.59, E5.26, and R19. W5.28 and Y5.38 form π-stacking interactions that may be indicative of 
a “toggle-switch” mechanism (Figure 52A) (409). F6.54 appears to further apart from R19 
but might contribute to the positioning of TMH 6 via intra-molecular interactions and is 
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in distance for π-stacking interactions with the F20 of PrRP20. Additional interactions 
between peptide and receptor hold the peptide in an optimal binding conformation deeply 
buried in the upper TMH segments and supported by the ELs from above. 
 
Figure 52:  Comparative model of PrRPR docked to the thirteen C-terminal residues of 
PrRP20 
A) Selected comparative model generated by Rosetta in the presence of the PrRP ligand to 
support experimental data. The figure displays an ensemble of low-energy PrRP/receptor models 
generated in Rosetta, that agrees well with experimental data. Residue D6.59 is colored in blue, the 
peptide is presented in yellow, and residues in vicinity to PrRP are in purple. B) The eight non-
redundant low-energy comparative models of the PrRP/receptor complex. These eight models 
were generated in the presence of structural constraints derived from the mutagenesis data 
described (see main text) and are considered energetically favorable according to the Rosetta v3 
all-atom scoring function. The peptide is highlighted in yellow, D6.59 of the receptor in blue, EL1 
of the receptor in green, and EL2 of the receptor in magenta.  
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Discussion 
We have evolved a strategy to interrogate detailed molecular mechanisms of 
GPCR activation by combining reciprocal, double cycle, and intramolecular double 
mutagenesis with computational modelling. We apply this technique effectively to 
PrRPR and its CAM, D6.59R PrRPR, identifying distinct receptor residues involved in 
activation and/or ligand binding.  
This is the first comprehensive mutational study of the extracellular and 
transmembrane regions of the PrRPR. The double cycle mutagenic approach suggests the 
interaction (direct or indirect) between residues D6.59 and R19 and provides a first anchor 
point for receptor/ligand investigations. Interacting residues can be characterized by 
reciprocal mutagenesis, as shown before in an intramolecular study with the 
D2.61R/R7.39D swap in the gastrin-releasing peptide receptor (410) or the D6.44/N7.49 
residues of the thyrotropin (TSH) receptor (411). By applying this method to the 
PrRP/PrRPR system, the salt bridge of D6.59 to R19 was verified, and more importantly, 
by generating the D6.59R receptor, we identified the first CAM of the PrRPR. Up to now, 
numerous CAM were generated and investigated in a plethora of previous studies, 
emphasizing the increasing importance of CAMs. For example, CAM of the human 
angiotensin II type 1 receptor with N3.35Gly (412), the ß1B (413)/ ß 2-adrenergic receptor 
(414, 415), the cannabinoid receptor 1 (416), muscarinic m1 (417) and m5 receptors 
(418), among others, have been found. Interestingly, more than sixty naturally occurring 
CAM GPCR are known so far (419) and are often related to human disorders (420). 
Consequently, GPCR activated in an agonist-independent manner are of emerging 
importance for drug development(388). 
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CAM more readily undergo transition between active and inactive conformations 
due to removed conformational constraints of the inactive form (421). Because D6.59R in 
PrRPR is located at the top of TMH6, we hypothesize that this helix is involved in 
receptor activation via an inward movement of the upper helical region (Figure 48D). 
Similarly to the PrRPR D6.59R CAM, mutant-induced receptor activity was observed in 
the S6.58Y/T6.59P double mutant of m5 muscarinic receptors (422). These data indicate that 
the top of TMH6 is directly involved in the switch between the active and the inactive 
state of several GPCR and that the interaction with the ligand stabilizes the receptor in 
this active conformation – a notion that supports the “global toggle switch model” (377, 
423). This model suggests that activation results from an inward movement of the 
extracellular ends of TMHs 6 and 7 toward TMH3, concomitant with a movement of the 
intracellular part of the TMHs in the opposite direction, which enables signaling via G-
protein coupling. PrRPR represents an excellent model system to further investigate this 
hypothesis and gain insights to receptor activating mechanisms.  
Previous work on the TSH receptors showed the effects of spatially distant double 
mutants on constitutive activity (424, 425). However, we focus on the investigation of the 
molecular vicinity surrounding D6.59, as we suggest that specific inter-residue interactions 
of the generated CAM occur. To take advantage of the D6.59R CAM to elucidate the 
mechanism of ligand binding and PrRPR activation, we established an effective 
combination of intramolecular double and inter-molecular reciprocal mutagenic 
approaches to study PrRPR activation by wt PrRP20, A19PrRP20, and D19PrRP20. With 
guidance from the PrRPR comparative model, seven possible interacting residues were 
considered (Figure 49A), and the double mutants E5.26A/D6.59R, W5.28A/D6.59R, 
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Y5.38A/D6.59R, and F6.54A/D6.59R revealed an involvement of these residues in receptor 
activation. Importantly, these receptor mutants were significantly activated by D19PrRP20 
but not by wt PrRP20 (Figure 49B), proving that the receptor mutants were not miss-
folded and that D19 on the ligand is still able to interact with D6.59R. CAM are thought to 
mimic, at least partially, the active conformation of the wt receptor and to spontaneously 
adopt a structure able to activate G-proteins (426). Therefore, we hypothesize that in 
D19PrRP20, residue D19 takes over the role of the destroyed intra-molecular interaction of 
the double mutants, reactivating the “silenced” CAM. The conformation of a basally 
silenced GPCR might impair its intrinsic capacity for signaling compared to the wt 
receptor. Notably, further mutations within EL2/TMH5 had no considerable impact on 
receptor potency, in contrast to all three positions identified via intramolecular 
interactions (Table 28). This demonstrates the precision and usefulness of the modeling-
guided double mutational approach to identify interacting residues in close proximity to 
the ligand.  
In contrast, the W2.71A/D6.59R control turned out to be deficient in signaling. This 
is expected and in agreement with the high conservation of W2.70/W2.71 in most peptide 
GPCR, e.g. in the NPY receptor system (14). Furthermore, W2.71 is located in the 
structurally relevant WxGF-motif, which is suggested to be a key component in the 
activation mechanism in many GPCR in the rhodopsin family (427). Recent 
investigations on TMH2 of the CAM N3.35G hAT1 suggested TMH2 to pivot, bringing 
the top of TMH2 closer to the binding pocket (428). Our results obtained for the 
conserved Y2.64 on top of TMH2 do not support such a spatial approach to D6.59 and thus 
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to the binding pocket. This reflects the divergence of GPCR activation and accentuates 
that the detailed mode of activation is not a common mechanism. 
The results obtained from studies of the E5.26A mutation lead to the conclusion 
that this residue is predominantly responsible for ligand binding. Our initial double cycle 
mutagenic experiments at D6.59 support a more complex double binding role for R19 of 
PrRP20, which appears to be in contact with two sites on PrRPR. Accordingly, we 
suggest E5.26 to be the second binding partner for peptide residue R19 (Figure 51D). The 
extensive mutagenic studies of residue E5.26 strongly indicate the participation in binding 
to R19 and the constitutive activity of D6.59R supports the hypothesis of a second R-
specific interaction site in PrRPR that can be satisfied by the D6.59R but not the D6.59K 
mutant. A similar dual binding mode for arginine was recently reported for gonadotropin-
releasing hormone (GnRH) receptor (212). This has been supported by other studies, 
where substitution of R19 to lysine, citruline (Cit), α-amino-4-guanidino-butyric acid 
(Agb), or α-amino-3-guanidino-propionic acid (Agp) on the peptide lead to reduced 
binding affinities (36). Interestingly, the tight ensemble of models that is in agreement 
with the experimental data presented herein exhibits variability in ELs 1 and 2 while still 
maintaining the contacts between D6.59 and E5.26 with R19. Given this structural variability 
in our models, we emphasize that the presented approach is an iterative process, where 
initial models can be used to guide experimental design, and the resulting data allow for 
model refinement. The current PrRP/receptor model can only be considered valid in the 
light of the functional data. However, it provides insight into possible structural 
mechanisms of peptide/receptor interactions and receptor activation. 
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W5.28A and Y5.38A also showed lowered ligand potency, but both mutants 
revealed a strongly decreased ability to transmit signals compared to the wt receptor 
(Table 28). This effect may result from intramolecular structural alteration due to the lack 
of aromaticity at the Y5.38A site. Mutational studies reported for the nearby Y5.39 residue 
in both cannabinoid receptors (CB1 and CB2) revealed that the aromaticity at this position 
is crucial (429). The PrRP/receptor model places W5.28 in close proximity to Y5.38 (Figure 
52A). In this model, the residues form stacking interactions, but this remains to be proven 
experimentally. We speculate that, due to the effects observed for potency and efficacy, 
W5.28 and Y5.38 are related to receptor activation. In contrast, F6.54A mutant reveals full wt 
efficacy accompanied with reduced potency. From the docked modeling data, we 
speculate that this residue contributes to the correct conformation of the binding pocket 
and might interact with the F20 of the PrPR20. 
Evolutionary and structural studies revealed that the PrRPR belongs to the family 
of RF-amide peptide receptors, consisting of five discovered groups: the neuropeptide FF 
(NPFF) group, the prolactin-releasing peptide (PrRP) group, the gonadotropin-inhibitory 
hormone (GnIH) group, the kisspeptin group, and the 26RFa group (430-432). However, 
further phylogenic investigations revealed that the PrPRR shares an ancient receptor with 
the NPY receptors (396). The human PrRPR possesses high sequence identity with the 
human NPY2R, particularly in the upper and middle regions of TMH 4, TMH 5, and 
TMH 6. It is suggested that the PrRPR family began co-evolving with ancestral PrRP/C-
RF-amide peptide with a redundant NPY binding receptor (396). This explains the 
importance of the conserved D6.59 residue and in turn, might have been responsible for the 
development of a double binding mode for R19 in the PrRPR/PrRP system. It could be 
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speculated that other RF-amide receptors evolved similar binding modes for the crucial 
arginine within the RF-amide motif, especially for the closely related 26RF-amide 
receptor. In contrast, for the well investigated Y-receptor family, a double binding mode 
was not identified, neither for R33 at Y2/Y5R nor for R35 at Y1/Y4R (394, 395). However, 
the second interaction might occur via the second arginine 33 or 35, respectively.  
Regarding medical and physiological implications, the expression of CAM can 
entail oncogenic effects, such as tumor formation in nude mice (433). A variety of 
diseases are known to be triggered by elevated basal activity, including autosomal 
dominant hypocalcaemia (434) and ovarian hyperstimulation syndrome (435). Our 
findings provide insight into the harmful potential of CAM and demonstrate the need for 
applicable drugs that are able to diminish mutation-induced receptor activity. We are 
confident that our technique is a promising tool to investigate residues relevant for ligand 
binding and receptor activation because a CAM is used as a template. Our approach 
paves the way for obtaining specific structure/function information on a molecular level, 
which is of indispensible value, as no crystal structure for a peptide GPCR currently 
exists. This method will hopefully contribute to the elucidation of the structural 
mechanisms of harmful CAM and help to develop and increase the number of inverse-
agonist drugs that target these receptors. 
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APPENDIX B 
 
PROTOCOL CAPTURE FOR CHAPTER II: 
THE ACTIVITY OF PROLACTIN RELEASING PEPTIDE CORRELATES 
WITH ITS HELICITY 
!
This appendix contains the protocol capture for the modeling work published in 
(DeLuca*, Rathmann*, Beck-Sickinger, and Meiler, 2013), some of which is found in the 
manuscript’s Supplemental Information. *These authors contributed equally. 
 
Computational details 
All models were generated by independent simulations using Vanderbilt 
University’s Center for Structural Biology computing cluster and the university’s 
Advanced Computing Center for Research and Education (ACCRE). Computations were 
performed on a combination of AMD Opteron and Intel Nehalem processor nodes. The 
time required to fold one model of the 13 C-terminal residues of PrRP20 was less than 10 
seconds. The time required for a single round of high-resolution refinement of one model 
was less than 1 minute. All modeling was performed using Rosetta trunk revision 36905. 
 
Input files 
Before any modeling was performed, truncated peptide to residues 8 to 20 and 
renumbered 1-13. 
FASTA file 
>PrRP8&20)Sequence)
WYASRGIRPVGRF)
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Chemical shift file for fragment generation (must end in .chsft) 
#)AA)Res)))))))C)))))))))CA)))))))))CB))))))HA))))))))))N)))))))))
))W))))1)9999.00))))9999.00))))9999.00))))4.34))))9999.00)
))Y))))2)9999.00))))9999.00))))9999.00))))4.03))))9999.00)
))A))))3)9999.00))))9999.00))))9999.00))))4.14))))9999.00)
))S))))4)9999.00))))9999.00))))9999.00))))4.31))))9999.00)
))R))))5)9999.00))))9999.00))))9999.00))))4.18))))9999.00)
))G))))6)9999.00))))9999.00))))9999.00))))3.86))))9999.00)
))I))))7)9999.00))))9999.00))))9999.00))))4.12))))9999.00)
))R))))8)9999.00))))9999.00))))9999.00))))4.65))))9999.00)
))P))))9)9999.00))))9999.00))))9999.00))))4.46))))9999.00)
))V)))10)9999.00))))9999.00))))9999.00))))4.14))))9999.00)
))G)))11)9999.00))))9999.00))))9999.00))))3.94))))9999.00)
))R)))12)9999.00))))9999.00))))9999.00))))4.05))))9999.00)
))F)))13)9999.00))))9999.00))))9999.00))))4.60))))9999.00)
 
Constraints file for fragment generation with NOEs (must end in .cst) 
#)(NOTE:))No)side&chain)protons)were)taken)into)account))
NMR_v3.0)
data)set)used)in)DUrsi)et)al)PrRP820)strict)NOE)definitions)
38)
))))))1))H))))))2))H)))))))))5.00)))))))0.00)))))medium)
))))))2))H))))))3))H)))))))))5.00)))))))0.00)))))medium)
))))))3))H))))))4))H)))))))))5.00)))))))0.00)))))medium)
))))))4))H))))))5))H)))))))))5.00)))))))0.00)))))medium)
))))))6))H))))))7))H)))))))))5.00)))))))0.00)))))medium)
))))))7))H))))))8))H)))))))))5.00)))))))0.00)))))medium)
)))))10))H)))))11))H)))))))))3.00)))))))0.00)))))strong)
)))))11))H)))))12))H)))))))))3.00)))))))0.00)))))strong)
))))))1))HA)))))2))H)))))))))5.00)))))))0.00)))))medium)
))))))2))HA)))))3))H)))))))))5.00)))))))0.00)))))medium)
))))))3))HA)))))4))H)))))))))5.00)))))))0.00)))))medium)
))))))4))HA)))))5))H)))))))))5.00)))))))0.00)))))medium)
))))))5))HA)))))6))H)))))))))5.00)))))))0.00)))))medium)
))))))6))#HA))))7))H)))))))))5.00)))))))0.00)))))medium)
))))))7))HA)))))8))H)))))))))5.00)))))))0.00)))))medium)
))))))9))HA))))10))H)))))))))5.00)))))))0.00)))))medium)
)))))10))HA))))11))H)))))))))3.00)))))))0.00)))))strong)
)))))11))#HA)))12))H)))))))))5.00)))))))0.00)))))medium)
)))))12))HA))))13))H)))))))))3.00)))))))0.00)))))strong)
))))))1))#HB))))2))H)))))))))5.00)))))))0.00)))))medium)
))))))2))#HB))))3))H)))))))))5.00)))))))0.00)))))medium)
))))))4))#HB))))5))H)))))))))5.00)))))))0.00)))))medium)
))))))5))#HB))))6))H)))))))))5.00)))))))0.00)))))medium)
))))))7))HB)))))8))H)))))))))3.00)))))))0.00)))))strong)
))))))9))#HB)))10))H)))))))))5.00)))))))0.00)))))medium)
)))))10))HB))))11))H)))))))))5.00)))))))0.00)))))medium)
)))))12))#HB)))13))H)))))))))3.00)))))))0.00)))))strong)
))))))2))H))))))4))H)))))))))5.00)))))))0.00)))))weak)
))))))3))H))))))5))H)))))))))5.00)))))))0.00)))))weak)
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))))))4))H))))))6))H)))))))))5.00)))))))0.00)))))weak)
))))))2))HA)))))4))H)))))))))5.00)))))))0.00)))))weak)
))))))3))HA)))))5))H)))))))))5.00)))))))0.00)))))weak)
))))))4))HA)))))6))H)))))))))5.00)))))))0.00)))))weak)
))))))9))HA))))11))H)))))))))5.00)))))))0.00)))))weak)
))))))7))HA))))10))H)))))))))5.00)))))))0.00)))))weak)
))))))9))HA))))12))H)))))))))5.00)))))))0.00)))))weak)
))))))5))HA)))))8))#HB)))))))5.00)))))))0.00)))))weak)
))))))7))HA))))10))HB))))))))5.00)))))))0.00)))))weak)
)
Constraint file for folding 
#) (NOTE:) For) de# novo# folding,) side&chains) are) not) taken) into) account.)
Therefore,)any)distance)restraints)between)side&chain)protons)were)changed)to)
CB)and)the)upper)bound)(ub))was)increased)from)5Å)to)7Å)for)weak)restraints)
and)from)3Å)to)5Å)for)strong)restraints.))
#)type)))atom1))res1)atom2))res2)))function))))))lb))))))ub)))))sd))comment)comment)
AtomPair)))))H)))))1)))))H)))))2))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair)))))H)))))2)))))H)))))3))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair)))))H)))))3)))))H)))))4))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair)))))H)))))4)))))H)))))5))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair)))))H)))))6)))))H)))))7))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair)))))H)))))7)))))H)))))8))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair)))))H))))10)))))H))))11))))BOUNDED))))0.00))))3.00))))1.0))))NOE))))strong)
AtomPair)))))H))))11)))))H))))12))))BOUNDED))))0.00))))3.00))))1.0))))NOE))))strong)
AtomPair))))HA)))))1)))))H)))))2))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair))))HA)))))2)))))H)))))3))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair))))HA)))))3)))))H)))))4))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair))))HA)))))4)))))H)))))5))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair))))HA)))))5)))))H)))))6))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair)))1HA)))))6)))))H)))))7))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair))))HA)))))7)))))H)))))8))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair))))HA)))))9)))))H))))10))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair))))HA))))10)))))H))))11))))BOUNDED))))0.00))))3.00))))1.0))))NOE))))strong)
AtomPair)))1HA))))11)))))H))))12))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair))))HA))))12)))))H))))13))))BOUNDED))))0.00))))3.00))))1.0))))NOE))))strong)
AtomPair))))CB)))))1)))))H)))))2))))BOUNDED))))0.00))))7.00))))1.0))))NOE))))medium)
AtomPair))))CB)))))2)))))H)))))3))))BOUNDED))))0.00))))7.00))))1.0))))NOE))))medium)
AtomPair))))CB)))))4)))))H)))))5))))BOUNDED))))0.00))))7.00))))1.0))))NOE))))medium)
AtomPair))))CB)))))5)))))H)))))6))))BOUNDED))))0.00))))7.00))))1.0))))NOE))))medium)
AtomPair))))CB)))))7)))))H)))))8))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))strong)
AtomPair))))CB)))))9)))))H))))10))))BOUNDED))))0.00))))7.00))))1.0))))NOE))))medium)
AtomPair))))CB))))10)))))H))))11))))BOUNDED))))0.00))))7.00))))1.0))))NOE))))medium)
AtomPair))))CB))))12)))))H))))13))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))strong)
AtomPair)))))H)))))2)))))H)))))4))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))weak)
AtomPair)))))H)))))3)))))H)))))5))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))weak)
AtomPair)))))H)))))4)))))H)))))6))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))weak)
AtomPair))))HA)))))2)))))H)))))4))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))weak)
AtomPair))))HA)))))3)))))H)))))5))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))weak)
AtomPair))))HA)))))4)))))H)))))6))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))weak)
AtomPair))))HA)))))9)))))H))))11))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))weak)
AtomPair))))HA)))))7)))))H))))10))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))weak)
AtomPair))))HA)))))9)))))H))))12))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))weak)
AtomPair))))HA)))))5))))CB)))))8))))BOUNDED))))0.00))))7.00))))1.0))))NOE))))weak)
AtomPair))))HA)))))7))))CB))))10))))BOUNDED))))0.00))))7.00))))1.0))))NOE))))weak)
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Constraint file for full-atom refinement 
#) (NOTE:) For) full&atom) refinement,) side&chains) are) taken) into) account.))
Therefore,) any) distance) restraints) between) side&chain) protons) were) not)
altered,)and)the)upper)bound)(ub))was)5Å)for)weak)restraints)and)3Å)for)strong)
restraints.))
#)type)))atom1))res1)atom2))res2)))function))))))lb))))))ub)))))sd))comment)comment)
AtomPair))))1H)))))1)))))H)))))2))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair)))))H)))))2)))))H)))))3))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair)))))H)))))3)))))H)))))4))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair)))))H)))))4)))))H)))))5))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair)))))H)))))6)))))H)))))7))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair)))))H)))))7)))))H)))))8))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair)))))H))))10)))))H))))11))))BOUNDED))))0.00))))3.00))))1.0))))NOE))))strong)
AtomPair)))))H))))11)))))H))))12))))BOUNDED))))0.00))))3.00))))1.0))))NOE))))strong)
AtomPair))))HA)))))1)))))H)))))2))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair))))HA)))))2)))))H)))))3))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair))))HA)))))3)))))H)))))4))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair))))HA)))))4)))))H)))))5))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair))))HA)))))5)))))H)))))6))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair)))1HA)))))6)))))H)))))7))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair))))HA)))))7)))))H)))))8))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair))))HA)))))9)))))H))))10))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair))))HA))))10)))))H))))11))))BOUNDED))))0.00))))3.00))))1.0))))NOE))))strong)
AtomPair)))1HA))))11)))))H))))12))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair))))HA))))12)))))H))))13))))BOUNDED))))0.00))))3.00))))1.0))))NOE))))strong)
AtomPair)))1HB)))))1)))))H)))))2))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair)))1HB)))))2)))))H)))))3))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair)))1HB)))))4)))))H)))))5))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair)))1HB)))))5)))))H)))))6))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair))))HB)))))7)))))H)))))8))))BOUNDED))))0.00))))3.00))))1.0))))NOE))))strong)
AtomPair)))1HB)))))9)))))H))))10))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair))))HB))))10)))))H))))11))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))medium)
AtomPair)))1HB))))12)))))H))))13))))BOUNDED))))0.00))))3.00))))1.0))))NOE))))strong)
AtomPair)))))H)))))2)))))H)))))4))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))weak)
AtomPair)))))H)))))3)))))H)))))5))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))weak)
AtomPair)))))H)))))4)))))H)))))6))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))weak)
AtomPair))))HA)))))2)))))H)))))4))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))weak)
AtomPair))))HA)))))3)))))H)))))5))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))weak)
AtomPair))))HA)))))4)))))H)))))6))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))weak)
AtomPair))))HA)))))9)))))H))))11))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))weak)
AtomPair))))HA)))))7)))))H))))10))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))weak)
AtomPair))))HA)))))9)))))H))))12))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))weak)
AtomPair))))HA)))))5)))1HB)))))8))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))weak)
AtomPair))))HA)))))7))))HB))))10))))BOUNDED))))0.00))))5.00))))1.0))))NOE))))weak)
 
De novo folding options file 
&abinitio)
))))))))&increase_cycles)2.5)
))))))))&rg_reweight)0.0)
&fold_cst))
))))))))&force_minimize)
&constraints)
))))))))&cst_file)PrRP8&20.cst)
))))))))&cst_weight)1.0)
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))))))))&viol)
))))))))&viol_level)101)
&residues)
))))))))&patch_selectors)CENTROID_HA)
&in)
))))))))&path)
))))))))))))))))&database)./rosetta_database)
))))))))&file)
))))))))))))))))&frag3)aa3mers.txt)
))))))))))))))))&frag9)aa9mers.txt)
))))))))))))))))&fasta)PrRP8&20.fasta)
&out)
))))))))&nstruct)10000)
))))))))&prefix)PrRP_)
))))))))&output)
))))))))&sf)PrRP_fold.sc)
))))))))&file)
))))))))))))))))&silent)PrRP.out)
))))))))))))))))&silent_struct_type)binary)
&overwrite)
 
Full-atom refinement options file 
&relax)
))))))))&sequence)
&constraints)
))))))))&cst_fa_file)PrRP_fa.cst)
))))))))&cst_fa_weight)1)
))))))))&viol)
))))))))&viol_level)101)
&in)
))))))))&path)
))))))))))))))))&database)rosetta_database)
))))))))&file)
))))))))))))))))&l)pdb_list.txt)
))))))))))))))))&fullatom)
) ) ) &residue_type_set)centroid)
&out)
))))))))&output)
))))))))&nstruct)10)
))))))))&file)
))))))))))))))))&silent)PrRP_fa.out)
))))))))))))))))&silent_struct_type)binary)
))))))))))))))))&scorefile)PrRP_fa.fasc)
))))))))))))))))&fullatom)
&residues)
))))))))&patch_selectors)CTERM_AMIDATION)
&overwrite)
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Command lines 
Fragment generation 
rosetta/rosetta_fragments/make_fragments.pl)&id)PrRP_)&nosam)PrRP_.fasta)>&)
make_fragments.log)&)
 
De novo folding 
rosetta/rosetta_source/bin/AbinitioRelax.default.linuxgccrelease)–database)
rosetta/rosetta_database)@fold.options)
 
Full-atom refinement 
mpiexec)rosetta/rosetta_sourse/bin/relax.default.linuxgccrelease)
@refinement.options)
) )
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APPENDIX C 
 
PROTOCOL CAPTURE FOR CHAPTER III: 
INTEGRATING SOLID STATE NMR AND COMPUTATIONAL MODELING 
TO INVESTIGATE THE STRUCTURE AND DYNAMICS OF MEMBRANE-
ASSOCIATED GHRELIN 
 
This appendix contains the protocol capture for the modeling work in the 
manuscript submitted to PLoS ONE of the same title by (Vortmeier*, DeLuca*, Cholet, 
Scheidt, Beck-Sickinger, Meiler, and Huster.) *These authors contributed equally. 
Further details are also available in Chapter III, and more detailed information on 
comparative modeling in Rosetta can be found in reference (252). 
 
Computational details 
All models were generated by independent simulations using Vanderbilt 
University’s Center for Structural Biology computing cluster and the university’s 
Advanced Computing Center for Research and Education (ACCRE). Computations were 
performed on a combination of AMD Opteron and Intel Nehalem processor nodes. All 
Rosetta-related protocols were conducted using Rosetta version 3.4. 
!
Comparative modeling 
FASTA file of GHSR1a 
>gi|38455410|ref|NP_940799.1|)growth)hormone)secretagogue)receptor))
MWNATPSEEPGFNLTLADLDWDASPGNDSLGDELLQLFPAPLLAGVTATCVALFVVGIAGNLLTMLVVSR)
FRELRTTTNLYLSSMAFSDLLIFLCMPLDLVRLWQYRPWNFGDLLCKLFQFVSESCTYATVLTITALSVE)
RYFAICFPLRAKVVVTKGRVKLVIFVIWAVAFCSAGPIFVLVGVEHENGTDPWDTNECRPTEFAVRSGLL)
TVMVWVSSIFFFLPVFCLTVLYSLIGRKLWRRRRGDAVVGASLRDQNHKQTVKMLAVVVFAFILCWLPFH)
VGRYLFSKSFEPGSLEIAQISQYCNLVSFVLFYLSAAINPILYNIMSKKYRVAVFRLLGFEPFSQRKLST)
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LKDESSRAWTESSINT)
Transmembrane span prediction 
#)Used)HMMTOP,)TMHMM,)JUFO9D,)and)OCTOPUS)servers.)Also)ran)Meiler)lab’s)
YUFOPM)(Jeff)Mendenhall):)
yufopm)GHSR1.fasta 
 
Threading of GHSR1a sequence on template structure 
#)See)Chapter)III)for)sequence)alignment)information.)
/sb/meiler/scripts/sequence_util/thread_pdb_from_alignment.py)&&template)
$TEMPLATE_NAME_FROM_ALIGNMENT)&&target)$TARGET_NAME_FROM_ALIGNMENT)&&chain)A)&
&align_format)clustal)
)
 
Preparation for making fragments 
make_fragments.pl)–id)GHSR1)–nofrags)GHSR1.fasta)
)
Generating fragments with Rosetta fragment picker 
&in:file:fasta))))))))))GHSR1.fasta)
&in:path:database)))))))rosetta&3.4/rosetta_database)
&in:file:vall)))))rosetta&3.4/rosetta_tools/fragment_tools/vall.jul19.2011.gz)
&frags:n_candidates)))))1000)
&frags:n_frags))))))))))200)
&frags:frag_sizes)))))))3)9)
&out:file:frag_prefix)))GHSR1_)
&frags:scoring:config)))GHSR1.cfg)
&in:file:checkpoint)))))GHSR1.checkpoint)
&frags:write_ca_coordinates)
&frags:describe_fragments)GHSR1_score)
&frags:ss_pred)GHSR1.psipred_ss2)psipred)GHSR1.jufo_ss)jufo)GHSR1.rdb)sam)
 
 
Generation of lipophilicity file 
rosetta_source/src/apps/public/membrane_abinitio/run_lips.pl)<fasta)file>)
<span)file>)<path)to)blastpgp>)<path)to)nr)database>)<path)to)alignblast.pl)
script>)
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GHSR1 disulfide definition 
116) 198)
GHSR1 spanfile 
TM)region)consensus)for)Homo)sapiens)GHSR1a)
7)366)
antiparallel)
n2c)
))43))))66))))43))))66)
))80)))100))))80)))100)
)120)))140)))120)))140)
)162)))181)))162)))181)
)212)))233)))212)))233)
)263)))282)))263)))282)
)304)))325)))304)))325)
 
Fill in density by building loops 
#options)file)
&database)/blue/meilerlab/apps/rosetta/rosetta&3.4/rosetta_database)
&loops:timer)#output)time)spent)in)seconds)for)each)loop)modeling)job)
&loops:fa_input)#input)structures)are)in)full)atom)format)
&in:fix_disulf)GHSR1.disulfide)#read)disulfide)connectivity)information)
&in:file:spanfile)GHSR1.span)
&in:file:lipofile)GHSR1.lips4)
&loops:relax)fastrelax)#does)a)minimization)of)the)structure)in)the)torsion)
space)
&loops:extended)true)#force)phi&psi)angles)to)be)set)to)180)degrees)
independent)of)loop)input)file)(recommended)for)production)runs))
&loops:frag_sizes)9)3)1)
&loops:frag_files)GHSR1.200.9mers)GHSR1.200.3mers)none)
&loops:remodel)quick_ccd)
&loops:refine)refine_kic)
&out:file:silent_struct_type)binary)#output)file)type)
&membrane:no_interpolate_Mpair)#)membrane)scoring)specification)
&membrane:Menv_penalties)#)turn)on)membrane)penalty)scores)
&score:weights)membrane_highres_Menv_smooth.wts)
)
#)command)line)
rosetta&3.4/rosetta_source/bin/loopmodel.default.linuxgccrelease)&database)
rosetta&3.4/rosetta_database)@fill_gaps.options)&s)GHSR1_on_"$TEMPLATE".pdb)&
loops:input_pdb)GHSR1_on_"$TEMPLATE".pdb)&loops:loop_file)
GHSR1_on_"$TEMPLATE"_init.loops)&out:file:silent)
GHSR1_on_"$TEMPLATE"_fillgaps.out)&out:file:scorefile)
GHSR1_on_"$TEMPLATE"_fillgaps.sc)&nstruct)25)
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Filter for building ECLs 
Filtered out models based on template 1U19 so that only took models with no 
chainbreaks within the top 10 by total score. 
Rebuilding extracellular loops 
#Options)file)
&database)rosetta&3.4/rosetta_database)
&loops:timer)#output)time)spent)in)seconds)for)each)loop)modeling)job)
&loops:fa_input)#input)structures)are)in)full)atom)format)
&in:fix_disulf)GHSR1.disulfide)#read)disulfide)connectivity)information)
&in:file:spanfile)GHSR1.span)
&in:file:lipofile)GHSR1.lips4)
&in:detect_disulf)true)#NEW)
&loops:relax)fastrelax)#does)a)minimization)of)the)structure)in)the)torsion)
space)
&loops:extended)true)#force)phi&psi)angles)to)be)set)to)180)degrees)
independent)of)loop)input)file)(recommended)for)production)runs))
&loops:frag_sizes)9)3)1)
&loops:frag_files)GHSR1.200.9mers)GHSR1.200.3mers)none)
&loops:ccd_closure)
&loops:remodel)quick_ccd)
&loops:refine)refine_kic)
&ex1)
&ex2))
&relax:membrane)#set)up)membrane)environment)for)relax)
&relax:fast)
&out:file:silent_struct_type)binary)#output)file)type)
&out:file:fullatom)#output)file)will)be)fullatom)
&membrane:no_interpolate_Mpair)#)membrane)scoring)specification)
&membrane:Menv_penalties)#)turn)on)membrane)penalty)scores)
&score:weights)membrane_highres_Menv_smooth.wts)
)
#Command)
rosetta&3.4/rosetta_source/bin/loopmodel.default.linuxgccrelease)&database))
rosetta&3.4/rosetta_database)@rebuild_ecl.options)&s)
GHSR1_on_"$TEMPLATE"_"$RANK".pdb)&loops:input_pdb)
GHSR1_on_"$TEMPLATE"_"$RANK".pdb)&loops:loop_file)GHSR1_on_"$TEMPLATE".loops)&
out:file:silent)GHSR1_on_"$TEMPLATE"_0"$RANK"_rebuild_ecl.out)&
out:file:scorefile)GHSR1_on_"$TEMPLATE"_0"$RANK"_rebuild_ecl.sc)&nstruct)20)
 
Selecting final model 
The final model was selected by choosing the lowest scoring model overall. 
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Folding of ghrelin in the Rosetta membrane environment 
FASTA file 
>GHSRg_renumber)
APLLAGVTATCVALFVVGIAGNLLTMLVVSRFRELRTTTNLYLSSMAFSDLLIFLCMPLDLVRLWQYRPWNFGDLLCK
LFQFVSESCTYATVLTITALSVERYFAICFPLRAKVVVTKGRVKLVIFVIWAVAFCSAGPIFVLVGVEHENGTDPWDT
NECRPTEFAVRSGLLTVMVWVSSIFFFLPVFCLTVLYSLIGRKLWRRRRGDAVVGASLRDQNHKQTVKMLAVVVFAFI
LCWLPFHVGRYLFSKSFEPGSLEIAQISQYCNLVSFVLFYLSAAINPILYNIMSKKYRVAVFRLLGFGSSFLSPEHQR
VQQRKESKKPPAKLQPR)
 
Making fragments 
 See above section on making fragments for the receptor. 
Spanfile 
TM)region)consensus)for)Homo)sapiens)GHSR1)with)ghrelin)
7)329)
antiparallel)
n2c)
)))4))))27)))))4))))27)
))41))))61))))41))))61)
))81)))101))))81)))101)
)123)))142)))123)))142)
)173)))194)))173)))194)
)224)))243)))224)))243)
)265)))286)))265)))286)
 
Lipophilicity file 
 Generated as before but with the spanfile directly above. 
 
Rigid file (for Topology Broker) 
RIGID)1)301)
 
Topology broker setup file 
CLAIMER)MembraneTopologyClaimer)
END_CLAIMER)
CLAIMER)RigidChunkClaimer)
NO_USE_INPUT_POSE)
PDB)receptor.pdb)
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REGION_FILE))GHSRg.rigid)
END_CLAIMER)
 
Options file for de novo folding 
&in)
) &file)
) ) &native)receptor.pdb)
) ) &fasta)GHSRg.fasta)
) ) &frag3)GHSRg.200.3mers)
) ) &frag9)GHSRg.200.9mers)
) ) &spanfile)GHSRg.span)
) ) &lipofile)GHSRg.lips4)
&residues)
) &patch_selectors)CENTROID_HA)
&broker)
) &setup)GHSRg.tpb)
&run)
) &protocol)broker)
&score)
) &find_neighbors_3dgrid)
) &weights)membrane_highres_Menv_smooth)
&membrane)
) &no_interpolate_Mpair)
) &Menv_penalties)
&abinitio)
) &membrane)
) &rg_reweight)0.00)
) &stage2_patch)score_membrane_s2.wts_patch)
) &stage3a_patch)score_membrane_s3a.wts_patch)
) &stage3b_patch)score_membrane_s3b.wts_patch)
) &stage4_patch)score_membrane_s4.wts_patch)
&relax)
) &membrane)
) &fast)
&ex1)
&ex2)
&out)
) &output)
) &file)
) ) &fullatom)
) ) &silent_struct_type)binary)
&overwrite)
 
De novo command line 
rosetta&3.4/rosetta_source/bin/minirosetta.static.linuxgccrelease)&database)
rosetta&3.4/rosetta_database/)@fold_GHSRg.flags)&out::nstruct)${NSTRUCT})&
out:file:silent)GHSRg.out)&out:file:scorefile)output/GHSRg.sc)
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Analysis and ensemble selection 
Filter by proximity to membrane 
#XML)file)
<dock_design>)
))))<SCOREFXNS>)#defines)non&standard)score)functions)
))))</SCOREFXNS>)
))))<FILTERS>)
))))))))<MembraneDepth)name="membrane_depth")residue=304)depth_lb=48)
depth_ub=60/>)###)this)covers)polar)region.)Membrane)is)0&60)(inner)to)outer))
))))</FILTERS>)
))))<MOVERS>)
))))</MOVERS>)
))))<PROTOCOLS>)
))))))))<Add)filter_name=membrane_depth/>)
))))</PROTOCOLS>)
</dock_design>#
#command)
Rosetta/main/source/bin/rosetta_scripts.mpi.linuxgccrelease)&database)
Rosetta/main/database/)&in:file:l)pdb.ls)&parser:protocol)test.xml)&
out:file:score_only)&in:file:spanfile)GHSRg.span)&in:file:lipofile)GHSRg.lips4)
&membrane:no_interpolate_Mpair)&membrane:Menv_penalties)&out:file:scorefile)
MembraneDepth.sc)&out:no_nstruct_label)>&)MembraneDepth.log)&)
)
Run PROSHIFT and format for further analysis 
proshift.exe)${pdb})${pdb}.pro)303)6)
)
grep)SHIFT)${pro})|)grep)&v)PROSHIFT)>)${pro}.cs)
 
Run SPARTA+ and format for further analysis 
sparta/SPARTA+/sparta+)&in)input.pdb)&ref)GHSRg.tab)&out)outfile.out)&outS)
outfile.outstruct)&outCS)outfile.outcs)&offset)
)
tail)&n55)outfile.outcs)>)outfile.outcs.tmp)
)
cat)outfile.outcs.tmp)|)awk)'{print("SHIFT))))"NR"\t"$3"\t"$2")
A\t"$1"\t"$6"\tppm)+&)"$9")ppm")}')>)final.sparta.cs.out)
Run SHIFTX 
shiftx/./shiftx)1)${pdb})${pdb}.shiftx)>&)${pdb}_shiftx.log)
head)&n30)${pdb}.shiftx)|)tail)&n28)>)${pdb}.shiftx.tmp)
ls)*.shiftx.tmp)>)shiftx.ls)
./shiftx_to_proshift.py)&i)shiftx.ls)&&suffix)cs)–shiftx)
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Run SHIFTX2 
python)shiftx2&v107&linux/shiftx2.py)&i)${pdb})&f)TABULAR)&p)6)&t)303)>&)
${pdb}_shiftx2.log)
head)&n30)${pdb}.cs)|)tail)&n28)>)${pdb}.cs.shiftx2)
ls)*.shiftx2)>)shiftx2.ls)
./shiftx_to_proshift.py)&i)shiftx2.ls)&&suffix)cs)&&shiftx2)
 
Compare predicted chemical shifts to experimental chemical shifts 
#)list)all)predicted)chemical)shift)files)(one)method)at)a)time))
ls)*.cs)>)cs.ls)
awk)'{system("/home/hirstsj/scripts/compare_cs.py)&&exp_cs)GHSRg.tab.sd)&&
pred_cs)")$1)")&&outfile)")$1)".out)&&summary)&&no_sd)&&carbon_scale_factor)
0.25")}')cs.ls)
)
ls)*.cs.out.summary)>>)all_outputs.ls)
)
foreach)file)(`cat)all_outputs.ls`))
grep)&H)&v)MaxDiff)${file})|)awk)
'{split($1,a,":");print(a[1]"\t"a[2]"\t"$2"\t"$3"\t"$4"\t"$5"\t"$6"\t"$7"\t"$8
"\t"$9"\t"$10"\t"$11"\t"$12"\t"$13"\t"$14"\t"$15"\t"$16)}')|)awk)
'{split($1,a,".");print(a[1]"\t"$2"\t"$3"\t"$4"\t"$5"\t"$6"\t"$7"\t"$8"\t"$9"\
t"$10"\t"$11"\t"$12"\t"$13"\t"$14"\t"$15"\t"$16)}')>>)all_outputs.txt)
end)
)
echo)"PDB)))#yes))))#no)AvgDiff)sdDiff))MaxDiff)MaxRes#)MaxResn)MaxAtom)
MaxExpCS))))MaxExpLB))))MaxExpUB))))MaxProCS))))MaxProLB))))MaxProUB))))RMSD")
>)GHSRg_compare_cs.out)
)
cat)all_outputs.txt)>>)GHSRg_compare_cs.out)
 
Input experimental chemical shifts 
#))))1)G))))C))167.040) 0.4)
#))))1)G)))CA)))40.900) 0.2)
))))2)S))))C))172.100) 0.2)
))))2)S)))CA)))55.600) 0.5)
))))2)S)))CB)))62.500) 0.6)
))))3)S)))CA)))53.580) 0.10)
))))3)S)))CB)))63.270) 0.21)
))))3)S)))HA))))4.488) 9999)
))))4)F))))C))172.100) 0.2)
))))4)F)))CA)))55.800) 1.2)
))))4)F)))CB)))37.000) 0.8)
))))5)L))))C))174.800) 0.4)
))))5)L)))CA)))51.900) 0.2)
))))5)L)))CB)))40.700) 0.5)
))))6)S))))C))169.300) 0.5)
))))6)S)))CA)))54.250) 0.5)
 !! 263!
))))6)S)))CB)))61.250) 0.6)
))))7)P))))C))174.900) 1.2)
))))7)P)))CA)))61.250) 0.5)
))))7)P)))CB)))30.800) 1.7)
))))8)E))))C))174.100) 0.2)
))))8)E)))CA)))54.300) 0.9)
))))8)E)))CB)))25.800) 0.9)
)))10)Q))))C))177.300) 9999)
)))10)Q)))CA)))55.420) 0.35)
)))10)Q)))CB)))27.010) 0.02)
)))10)Q)))HA))))4.130) 9999)
)))12)V))))C))174.100) 0.2)
)))12)V)))CA)))60.300) 0.9)
)))12)V)))CB)))30.000) 9999)
)))13)Q))))C))173.350) 0.26)
)))13)Q)))CA)))53.530) 0.18)
)))13)Q)))CB)))26.950) 0.12)
)))13)Q)))HA))))4.310) 9999)
)))14)Q))))C))173.500) 9999)
)))14)Q)))CA)))53.440) 0.14)
)))14)Q)))CB)))26.950) 0.05)
)))14)Q)))HA))))4.296) 9999)
)))18)S))))C))171.760) 0.16)
)))18)S)))CA)))55.800) 0.1)
)))18)S)))CB)))61.300) 0.2)
)))18)S)))HA))))4.440) 9999)
)))21)P))))C))177.700) 9999)
)))21)P)))CA)))58.980) 0.09)
)))21)P)))CB)))28.320) 0.04)
)))21)P)))HA))))4.720) 9999)
)))22)P))))C))173.670) 0.18)
)))22)P)))CA)))60.430) 0.25)
)))22)P)))CB)))29.410) 0.03)
)))22)P)))HA))))4.440) 9999)
)))23)A))))C))175.500) 0.5)
)))23)A)))CA)))50.500) 0.6)
)))23)A)))CB)))17.000) 9999)
)))27)P))))C))173.320) 0.03)
)))27)P)))CA)))60.770) 0.021)
)))27)P)))CB)))29.420) 0.14)
)))27)P)))HA))))4.430) 9999)
 
Run ensemble selection script 
./find_best_ensemble.py)&&ncycles)5000000)&&min_ensemble_size)10)&&
max_ensemble_size)30)&&outfile)outfile.out)
/directory/to/predicted/cs/in/proshift/format/ending/in/*.cs)
 
Run DSSP and compute phi/psi angles for models 
./run_dssp.py)&i)pdb.ls)&&all)all.out)
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Find polyproline II helix residues 
Ls)*.dssp)>)dssp.ls)
foreach)file)()`cat)dssp.ls`)))
awk)'{if(($3>=&104.0)&&)$3<=&46.0))&&)($4>=116.0)&&)$4<=174.0))&&)
($2=="&"))print}')${file})>)${file}.pp2)
end)
)
) )
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APPENDIX D 
 
PROTOCOL CAPTURE FOR CHAPTER IV: 
ROSETTAEPR: AN INTEGRATED TOOL FOR PROTEIN STRUCTURE 
DETERMINATION FROM SPARSE EPR DATA 
 
This appendix contains the protocol capture for the modeling work published in 
(Hirst, Alexander, Mcaourab, and Meiler, 2011), some of which is found in the 
manuscript’s Supplemental Information. Further details are also available in the main text 
(Chapter IV). 
 
Computational details 
All Rosetta-related protocols were conducted using Rosetta version 3 revision 
number 34586. All models were generated by independent simulations using Vanderbilt 
University’s Center for Structural Biology computing cluster and the university’s 
Advanced Computing Center for Research and Education (ACCRE). Computations were 
performed on a combination of AMD Opteron and Intel Nehalem processor nodes. 
  
Input files 
FASTA file 
>)2LZM)Sequence)
ITKDEAEKLFNQDVDAAVRGILRNAKLKPVYDSLDAVRRCALINMVFQMGETGVAGFTNSLRMLQQKRWDEAAVNLAK
SRWYNQTPNRAKRVITTFRTGTWDAYKNL)
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Constraints file used in de novo folding with RosettaEPR 
AtomPair))))))))CB))))))32))))))CB))))))36))))))SPLINE))EPR_DISTANCE))))16.0))))4.0)))))0.5)
AtomPair))))))))CB))))))59))))))CB))))))74))))))SPLINE))EPR_DISTANCE))))19.0))))4.0)))))0.5)
AtomPair))))))))CB))))))62))))))CB))))))71))))))SPLINE))EPR_DISTANCE))))19.0))))4.0)))))0.5)
AtomPair))))))))CB))))))62))))))CB))))))74))))))SPLINE))EPR_DISTANCE))))25.0))))4.0)))))0.5)
AtomPair))))))))CB))))))63))))))CB))))))74))))))SPLINE))EPR_DISTANCE))))14.0))))4.0)))))0.5)
AtomPair))))))))CB))))))66))))))CB))))))74))))))SPLINE))EPR_DISTANCE))))23.0))))4.0)))))0.5)
AtomPair))))))))CB))))))83))))))CB))))))90))))))SPLINE))EPR_DISTANCE))))13.0))))4.0)))))0.5)
AtomPair))))))))CB))))))83))))))CB))))))94))))))SPLINE))EPR_DISTANCE))))18.0))))4.0)))))0.5)
AtomPair))))))))CB))))))8)))))))CB))))))19))))))SPLINE))EPR_DISTANCE))))21.4))))4.0)))))0.5)
AtomPair))))))))CB))))))8)))))))CB))))))78))))))SPLINE))EPR_DISTANCE))))46.3))))4.0)))))0.5)
AtomPair))))))))CB))))))4)))))))CB))))))78))))))SPLINE))EPR_DISTANCE))))47.2))))4.0)))))0.5)
AtomPair))))))))CB))))))8)))))))CB))))))29))))))SPLINE))EPR_DISTANCE))))37.4))))4.0)))))0.5)
AtomPair))))))))CB))))))4)))))))CB))))))29))))))SPLINE))EPR_DISTANCE))))37.5))))4.0)))))0.5)
AtomPair))))))))CB))))))4)))))))CB))))))23))))))SPLINE))EPR_DISTANCE))))34.0))))4.0)))))0.5)
AtomPair))))))))CB))))))8)))))))CB))))))23))))))SPLINE))EPR_DISTANCE))))26.5))))4.0)))))0.5)
AtomPair))))))))CB))))))23))))))CB))))))78))))))SPLINE))EPR_DISTANCE))))36.8))))4.0)))))0.5)
AtomPair))))))))CB))))))31))))))CB))))))43))))))SPLINE))EPR_DISTANCE))))6.0)))))4.0)))))0.5)
AtomPair))))))))CB))))))32))))))CB))))))39))))))SPLINE))EPR_DISTANCE))))6.0)))))4.0)))))0.5)
AtomPair))))))))CB))))))29))))))CB))))))62))))))SPLINE))EPR_DISTANCE))))15.0))))4.0)))))0.5)
AtomPair))))))))CB))))))70))))))CB))))))94))))))SPLINE))EPR_DISTANCE))))14.0))))4.0)))))0.5)
AtomPair))))))))CB))))))70))))))CB))))))97))))))SPLINE))EPR_DISTANCE))))13.0))))4.0)))))0.5)
AtomPair))))))))CB))))))74))))))CB))))))93))))))SPLINE))EPR_DISTANCE))))13.0))))4.0)))))0.5)
AtomPair))))))))CB))))))74))))))CB))))))94))))))SPLINE))EPR_DISTANCE))))9.0)))))4.0)))))0.5)
AtomPair))))))))CB))))))74))))))CB))))))97))))))SPLINE))EPR_DISTANCE))))10.0))))4.0)))))0.5)
AtomPair))))))))CB))))))77))))))CB))))))94))))))SPLINE))EPR_DISTANCE))))9.0)))))4.0)))))0.5)
)
Constraints file used in de novo folding with bounded restraints 
AtomPair))))))))CB))))))32))))))CB))))))36))))))BOUNDED)0.5)))))21.5))))1.0)))))NOE)))));dist)
AtomPair))))))))CB))))))59))))))CB))))))74))))))BOUNDED)0.0)))))31.5))))1.0)))))NOE)))));dist)
AtomPair))))))))CB))))))62))))))CB))))))71))))))BOUNDED)2.5)))))25.5))))1.0)))))NOE)))));dist)
AtomPair))))))))CB))))))62))))))CB))))))74))))))BOUNDED)7.5)))))32.5))))1.0)))))NOE)))));dist)
AtomPair))))))))CB))))))63))))))CB))))))74))))))BOUNDED)0.0)))))19.5))))1.0)))))NOE)))));dist)
AtomPair))))))))CB))))))66))))))CB))))))74))))))BOUNDED)5.5)))))30.5))))1.0)))))NOE)))));dist)
AtomPair))))))))CB))))))83))))))CB))))))90))))))BOUNDED)0.0)))))22.5))))1.0)))))NOE)))));dist)
AtomPair))))))))CB))))))83))))))CB))))))94))))))BOUNDED)0.0)))))29.5))))1.0)))))NOE)))));dist)
AtomPair))))))))CB))))))8)))))))CB))))))19))))))BOUNDED)6.1)))))26.7))))1.0)))))NOE)))));dist)
AtomPair))))))))CB))))))8)))))))CB))))))78))))))BOUNDED)31.6))))51))))))1.0)))))NOE)))));dist)
AtomPair))))))))CB))))))4)))))))CB))))))78))))))BOUNDED)32.5))))51.9))))1.0)))))NOE)))));dist)
AtomPair))))))))CB))))))8)))))))CB))))))29))))))BOUNDED)22.2))))42.6))))1.0)))))NOE)))));dist)
AtomPair))))))))CB))))))4)))))))CB))))))29))))))BOUNDED)23))))))42))))))1.0)))))NOE)))));dist)
AtomPair))))))))CB))))))4)))))))CB))))))23))))))BOUNDED)19.3))))38.7))))1.0)))))NOE)))));dist)
AtomPair))))))))CB))))))8)))))))CB))))))23))))))BOUNDED)10.2))))32.8))))1.0)))))NOE)))));dist)
AtomPair))))))))CB))))))23))))))CB))))))78))))))BOUNDED)23.3))))40.3))))1.0)))))NOE)))));dist)
AtomPair))))))))CB))))))31))))))CB))))))43))))))BOUNDED)0.0)))))11.5))))1.0)))))NOE)))));dist)
AtomPair))))))))CB))))))32))))))CB))))))39))))))BOUNDED)0.0)))))11.5))))1.0)))))NOE)))));dist)
AtomPair))))))))CB))))))29))))))CB))))))62))))))BOUNDED)0.0)))))20.5))))1.0)))))NOE)))));dist)
AtomPair))))))))CB))))))70))))))CB))))))94))))))BOUNDED)0.0)))))18.9))))1.0)))))NOE)))));dist)
AtomPair))))))))CB))))))70))))))CB))))))97))))))BOUNDED)0.0)))))21.5))))1.0)))))NOE)))));dist)
AtomPair))))))))CB))))))74))))))CB))))))93))))))BOUNDED)0.0)))))21.5))))1.0)))))NOE)))));dist)
AtomPair))))))))CB))))))74))))))CB))))))94))))))BOUNDED)0.0)))))19.5))))1.0)))))NOE)))));dist)
AtomPair))))))))CB))))))74))))))CB))))))97))))))BOUNDED)0.0)))))18.5))))1.0)))))NOE)))));dist)
AtomPair########CB######77######CB######94######BOUNDED#0.0#####17.5####1.0#####NOE#####;dist)
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De novo folding options file 
10,000 T4-lysozyme models with 25 EPR distance restraints scored according to 
the RosettaEPR knowledge-based potential 
&abinitio::increase_cycles)2.5)
&fold_cst::force_minimize)
&constraints::cst_file)./2LZM_dist_w4.cst)
&constraints::cst_weight)1.0)
&constraints::epr_distance)
&constraints::viol)
&constraints::viol_level)101)
&frags::scoring)
&frags::picking::selecting_rule)BestTotalScoreSelector)
&in::path::database)minirosetta_database_r34586)
&in::file::native)./2LZM_.pdb)
&in::file::fasta)./2LZM_.fasta))
&in::file:frag3)./aa2LZM_03_05.200_v1_3)
&in::file::frag9)./aa2LZM_09_05.200_v1_3)
&out::output)
&out::prefix)2LZM_)
&out::file::silent)./2LZM_.out)
&out::file::silent_struct_type)binary)
&out::file::scorefile)./2LZM_.sc)
&out::nstructs)10000)
&out::show_accessed_options)
!
Full-atom refinement options file 
One T4-lysozyme de novo folded model with no distance restraints, resulting in 
ten new models complete with amino acid side-chains 
&relax::sequence)
&in::path::database)./minirsetta_database_r34586)
&in::file::native)./2LZM_.pdb)
&in::file::fullatom)
&corrections::correct)
&out::output)
&out::prefix)2LZM_fa_)
&out::file::silent)./2LZM_fa.out)
&out::file::silent_struct_type)binary)
&out::file::scorefile)./2LZM_fa.fsc)
&out::nstructs)10)
&out::show_accessed_options)!
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Command lines 
Fragment generation 
make_fragments.pl)&id)2LZM_)&nohoms)2LZM_.fasta)
 
De novo folding 
/bin/AbinitioRelax.linuxgccrelease)@2LZM_w4_folding.options)
 
Full-atom refinement 
/bin/relax.linuxgccrelease)@2LZM_rlx.options)
 
RMSD histogram distribution 
perl)Smbins_RMSD_dist_from_score.pl)<file)with)rmsds>)<rmsd)col.)#>)
) )
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APPENDIX E 
 
PROTOCOL CAPTURE FOR CHAPTER V: 
ROSETTATMH:  MEMBRANE PROTEIN STRUCTURE ELUCIDATION BY 
COMBINING EPR DISTANCE RESTRAINTS WITH ASSEMBLY OF 
TRANSMEMBRANE HELICES 
 
This appendix contains the protocol capture for the modeling performed for the 
Chapter V, which is based on the manuscript submitted to PLoS ONE of the same title by 
Stephanie DeLuca, Sam DeLuca, Andrew Leaver-Fay, and Jens Meiler 
!
Preparation for folding 
Parameter optimization / testing PDBs 
1FX8A,)1KPLA,)1PY6A,)1U19A,)3B60A,)3GIAA,)3HD6A,)3HFXA,)3O0RB)
 
Benchmark set 
1FX8A,1IWGA,1J4NA,1KPLA,1OCCC,1OKCA,1PV6A,1PY6A,1PY7A,1RHZA,1U19A,2BG9A,2BL2A,
2BS2A,2IC8A,2K73A,2KSFA,2KSYA,2NR9A,2PNOA,2XQ2A,2XUTA,2YVXA,2ZW3A,3B60A,3GIAA,
3HD6A,3HFXA,3KCUA,3KJ6A,3O0RB,3P5NA,3SYOA,4A2NB)
 
FASTA files 
1FX8A)
>BCL):A|PDBID|CHAIN|SEQUENCE)
TLKGQCIAEFLGTGLLIFFGVGCVAALKVAGASFGQWEISVIWGLGVAMA)
IYLTAGVSGAHLNPAVTIALWLFACFDKRKVIPFIVSQVAGAFCAAALVY)
GLYYNLFFDFEQTHHIVRGSVESVDLAGTFSTYPNPHINFVQAFAVEMVI)
TAILMGLILALTDDGNGVPRGPLAPLLIGLLIAVIGASMGPLTGFAMNPA)
RDFGPKVFAWLAGWGNVAFTGGRDIPYFLVPLFGPIVGAIVGAFAYRKLI)
GRHL)
)
1IWGA)
>)1IWGA)
SIHEVVKTLVEAIILVFLVMYLFLQNFRATLIPTIAVPVVLLGTFAVLAAFGFSINTLTMFGMVLAIGLLVDDAIVVV
ENVERVMAEEGLPPKEATRKSMGQIQGALVGIAMVLSAVFVPMAFFGGSTGAIYRQFSITIVSAMALSVLVALILTPA
LCATMLK)
 !! 270!
1J4NA)
>BCL):A|PDBID|CHAIN|SEQUENCE)
EFKKKLFWRAVVAEFLAMILFIFISIGSALGFHYPIKSNQTTGAVQDNVK)
VSLAFGLSIATLAQSVGHISGAHLNPAVTLGLLLSCQISVLRAIMYIIAQ)
CVGAIVATAILSGITS)
)
1KPLA)
>BCL):A|PDBID|CHAIN|SEQUENCE)
TPLAILFMAAVVGTLTGLVGVAFEKAVSWVQNMRIGALVQVADHAFLLWP)
LAFILSALLAMVGYFLVRKFAPEAGGSGIPEIEGALEELRPVRWWRVLPV)
KFIGGMGTLGAGMVLGREGPTVQIGGNLGRMVLDVFRMRSAEARHTLLAT)
GAAAGLSAAFNAPLAGILFIIEEMRPQFRYNLISIKAVFTGVIMSSIVFR)
IFN)
)
1OCCC)
>BCL):C|PDBID|CHAIN|SEQUENCE)
HTPAVQKGLRYGMILFIISEVLFFTGFFWAFYHSSLAPTPELGGCWPPTG)
IHPLNPLEVPLLNTSVLLASGVSITWAHHSLMEGDRKHMLQALFITITLG)
VYFTLLQASEYYEAPFTISDGVYGSTFFVATGFHGLHVIIGSTFLIVCFF)
RQLKFHFTSNHHFGFEAGAWYWHFVDVVWLFLYVSIYWWGS)
)
1OKCA)
>BCL):A|PDBID|CHAIN|SEQUENCE)
DQALSFLKDFLAGGVAAAISKTAVAPIERVKLLLQVQHASKQISAEKQYK)
GIIDCVVRIPKEQGFLSFWRGNLANVIRYFPTQALNFAFKDKYKQIFLGG)
VDRHKQFWRYFAGNLASGGAAGATSLCFVYPLDFARTRLAADVGKGAAQR)
EFTGLGNCITKIFKSDGLRGLYQGFNVSVQGIIIYRAAYFGVYDTAKGML)
PDPKNVHIIVSWMIAQTVTAVAGLVSYPFDTVRRRMMMQSGRKGADIMYT)
GTVDCWRKIAKDEGPKAFFKGAWSNVLRGMGGAFVLVLYDEI)
)
1PV6A)
>BCL):A|PDBID|CHAIN|SEQUENCE)
MYYLKNTNFWMFGLFFFFYFFIMGAYFPFFPIWLHDINHISKSDTGIIFA)
AISLFSLLFQPLFGLLSDKLGLRKYLLWIITGMLVMFAPFFIFIFGPLLQ)
YNILVGSIVGGIYLGFCFNAGAPAVEAFIEKVSRRSNFEFGRARMFGCVG)
WALGASIVGIMFTINNQFVFWLGSGCALILAVLLFFAKT)
)
1PY6A)
>BCL):A|PDBID|CHAIN|SEQUENCE)
TGRPEWIWLALGTALMGLGTLYFLVKGMGVSDPDAKKFYAITTLVPAIAF)
TMYLSMLLGYGLTMVPFGGEQNPIYWARYADWLFTTPLLLLDLALLVDAD)
QGTILALVGADGIMIGTGLVGALTKVYSYRFVWWAISTAAMLYILYVLFF)
GFTSKAESMRPEVASTFKVLRNVTVVLWSAYPVVWLIGSEGAGIVPLNIE)
TLLFMVLDVSAKVGFGLILLRSRAIFG)
)
1PY7A)
>BCL):A|PDBID|CHAIN|SEQUENCE)
PIYWARYADWLFTTPLLLLDLALLVDADQGTILALVGADGIMIGTGLVGA)
LTKVYSYRFVWWAISTAAMLYILYVLFFGFTSKAESMRPEVASTFKVLRN)
VTVVLWSAYPVVWLIGSEGAGIV)
)
1RHZA)
>BCL):A|PDBID|CHAIN|SEQUENCE)
FKEKLKWTGIVLVLYFIMGCIDVYTAGAQIPAIFEFWQTITASRIGTLIT)
 !! 271!
LGIGPIVTAGIIMQLLVGSGIIQMDLSIPENRALFQGCQKLLSIIMCFVE)
AVLFVGAGAFGILTPLLAFLVIIQIAFGSIILIYLDEIVSKYGIGSGIGL)
FIAAGVSQTIFVGALG)
)
1U19A)
>BCL):A|PDBID|CHAIN|SEQUENCE)
EPWQFSMLAAYMFLLIMLGFPINFLTLYVTVQHKKLRTPLNYILLNLAVA)
DLFMVFGGFTTTLYTSLHGYFVFGPTGCNLEGFFATLGGEIALWSLVVLA)
IERYVVVCKPMSNFRFGENHAIMGVAFTWVMALACAAPPLVGWSRYIPEG)
MQCSCGIDYYTPHEETNNESFVIYMFVVHFIIPLIVIFFCYGQLVFTVKE)
AAAQQQESATTQKAEKEVTRMVIIMVIAFLICWLPYAGVAFYIFTHQGSD)
FGPIFMTIPAFFAKTSAVYNPVIYIMMN)
)
2BG9A)
>BCL):A|PDBID|CHAIN|SEQUENCE)
PLYFVVNVIIPCLLFSFLTVLVFYLPTDSGEKMTLSISVLLSLTVFLLVI)
VELIPSTSSAVPLIGKYMLFTMIFVISSIIVTVVVINTHHR)
)
2BL2A)
>BCL):A|PDBID|CHAIN|SEQUENCE)
MVFAVLAMATATIFSGIGSAKGVGMTGEAAAALTTSQPEKFGQALILQLL)
PGTQGLYGFVIAFLIFINLGSDMSVVQGLNFLGASLPIAFTGLFSGIAQG)
KVAAAGIQILAKKPEHATKGIIFAAMVETYAILGFVISFLLVLNA)
)
2BS2A)
>BCL):C|PDBID|CHAIN|SEQUENCE)
RMPAKLDWWQSATGLFLGLFMIGHMFFVSTILLGDNVMLWVTKKFELDFI)
FEGGKPIVVSFLAAFVFAVFIAHAFLAMRKFPINYRQYLTFKTHKDLMRH)
GDTTLWWIQAMTGFAMFFLGSVHLYIMMTQPQTIGPVSSSFRMVSEWMWP)
LYLVLLFAVELHGSVGLYRLAVKWGWFDGETPDKTRANLKKLKTLMSAFL)
IVLGLLTFGAYVKKGLE)
)
2IC8A)
>BCL):A|PDBID|CHAIN|SEQUENCE)
ERAGPVTWVMMIACVVVFIAMQILGDQEVMLWLAWPFDPTLKFEFWRYFT)
HALMHFSLMHILFNLLWWWYLGGAVEKRLGSGKLIVITLISALLSGYVQQ)
KFSGPWFGGLSGVVYALMGYVWLRGERDPQSGIYLQRGLIIFALIWIVAG)
WFDLFGMSMANGAHIAGLAVGLAMAFVDSLNA)
)
2K73A)
>BCL):A|PDBID|CHAIN|SEQUENCE)
MLRFLNQASQGRGAWLLMAFTALALELTALWFQHVMLLKPCVLSIYERAA)
LFGVLGAALIGAIAPKTPLRYVAMVIWLYSAFRGVQLTYEHTMLQLYPSP)
FATSDFMVRFPEWLPLDKWVPQVFVASGDCAERQWDFLGLEMPQWLLGIF)
IAYLIVAVLVVISQ)
)
2KSFA)
>BCL):A|PDBID|CHAIN|SEQUENCE)
MVQIQGSVVAAALSAVITLIAMQWLMAFDAANLVMLYLLGVVVVALFYGR)
WPSVVATVINVVSFDLFFIAPRGTLAVSDVQYLLTFAVMLTVGLVIGNLT)
AGVRYQA)
)
2KSYA)
>BCL):A|PDBID|CHAIN|SEQUENCE)
 !! 272!
MVGLTTLFWLGAIGMLVGTLAFAWAGRDAGSGERRYYVTLVGISGIAAVA)
YAVMALGVGWVPVAERTVFVPRYIDWILTTPLIVYFLGLLAGLDSREFGI)
VITLNTVVMLAGFAGAMVPGIERYALFGMGAVAFIGLVYYLVGPMTESAS)
QRSSGIKSLYVRLRNLTVVLWAIYPFIWLLGPPGVALLTPTVDVALIVYL)
DLVTKVGFGFIALDAAATLRAEH)
)
2NR9A)
>BCL):A|PDBID|CHAIN|SEQUENCE)
FLAQQGKITLILTALCVLIYIAQQLGFEDDIMYLMHYPAYEEQDSEVWRY)
ISHTLVHLSNLHILFNLSWFFIFGGMIERTFGSVKLLMLYVVASAITGYV)
QNYVSGPAFFGLSGVVYAVLGYVFIRDKLNHHLFDLPEGFFTMLLVGIAL)
GFISPLFGVEMGNAAHISGLIVGLIWGFIDSKLRKNSLELVP)
)
2PNOA)
>BCL):A|PDBID|CHAIN|SEQUENCE)
KDEVALLAAVTLLGVLLQAYFSLQVISARRAFRVSPPLTTGPPEFERVYR)
AQVNCSEYFPLFLATLWVAGIFFHEGAAALCGLVYLFARLRYFQGYARSA)
QLRLAPLYASARALWLLVALAALGLLAHFL)
)
2XQ2A)
>BCL):A|PDBID|CHAIN|SEQUENCE)
SFIDIMVFAIYVAIIIGVGLWVSRDKKGTQKSTEDYFLAGKSLPWWAVGA)
SLIAANISAEQFIGMSGSGYSIGLAIASYEWMSAITLIIVGKYFLPIFIE)
KGIYTIPEFVEKRFNKKLKTILAVFWISLYIFVNLTSVLYLGGLALETIL)
GIPLMYSILGLALFALVYSIYGGLSAVVWTDVIQVFFLVLGGFMTTYMAV)
SFIGGTDGWFAGVSKMVDAAPGHFEMILDQSNPQYMNLPGIAVLIGGLWV)
ANLYYWGFNQYIIQRTLAAKSVSEAQKGIVFAAFLALIVPFLVVLPGIAA)
YVITSDPQLMASLGDIAATNLPSAANADKAYPWLTQFLPVGVKGVVFAAL)
AAAIVSSLASMLNSTATIFTMDIYKEYISPDSGDHKLVNVGRTAAVVALI)
IAALIAPMLGGIGQCFQYIQEYTGLVSPGILAVFLLGLFWKKTTSKGAII)
GVVASIPFALFLKFMPLSMPFMDQMLYTLLFTMVVIAFTSLSTSINDDDP)
KGISVTSSMFVTDRSFNIAAYGIMIVLAVLYTLFWVNADAEITLIIFGVM)
AGVIGTILLISYGIK)
)
2XUTA)
>BCL):A|PDBID|CHAIN|SEQUENCE)
QIPYIIASEACERFSFYGMRNILTPFLMTALLLSIPEELRGAVAKDVFHS)
FVIGVYFFPLLGGWIADRFFGKYNTILWLSLIYCVGHAFLAIFEHSVQGF)
YTGLFLIALGSGGIKPLVSSFMGDQFDQSNKSLAQKAFDMFYFTINFGSF)
FASLSMPLLLKNFGAAVAFGIPGVLMFVATVFFWLGRKRYIHMPPEPKDP)
HGFLPVIRSALLTKVEGKGNIGLVLALIGGVSAAYALVNIPTLGIVAGLC)
CAMVLVMGFVGAGASLQLERARKSHPDAAVDGVRSVLRILVLFALVTPFW)
SLFDQKASTWILQANDMVKPQWFEPAMMQALNPLLVMLLIPFNNFVLYPA)
IERMGVKLTALRKMGAGIAITGLSWIVVGTIQLMMDGGSALSIFWQILPY)
ALLTFGEVLVSATGLEFAYSQAPKAMKGTIMSFWTLSVTVGNLWVLLANV)
SVKSPTVTEQIVQTGMSVTAFQMFFFAGFAILAAIVFA)
)
2YVXA)
>BCL):A|PDBID|CHAIN|SEQUENCE)
HKLGAVDVPDLVYSEAGPVALWLARVRWLVILILTGMVTSSILQGFESVL)
EAVTALAFYVPVLLGTGGNTGNQSATLIIRALATRDLDLRDWRRVFLKEM)
GVGLLLGLTLSFLLVGKVYWDGHPLLLPVVGVSLVLIVFFANLVGAMLPF)
LLRRLGVDPALVSNPLVATLSDVTGLLIYLSVARLLLE)
)
 !! 273!
2ZW3A)
>BCL):A|PDBID|CHAIN|SEQUENCE)
DWGTLQTILGGVNKHSTSIGKIWLTVLFIFRIMILVVAAKEVWGDEQADF)
VCNTLQPGCKNVCYDHYFPISHIRLWALQLIFVSTPALLVAMHVAYRRHE)
KKRKFIKGEIKSEFKDIEEIKTQKVRIEGSLWWTYTSSIFFRVIFEAAFM)
YVFYVMYDGFSMQRLVKCNAWPCPNTVDCFVSRPTEKTVFTVFMIAVSGI)
CILLNVTELCYLLIRY)
)
3B60A)
>BCL):A|PDBID|CHAIN|SEQUENCE)
WQTFRRLWPTIAPFKAGLIVAGIALILNAASDTFMLSLLKPLLDDGFGKT)
DRSVLLWMPLVVIGLMILRGITSYISSYCISWVSGKVVMTMRRRLFGHMM)
GMPVAFFDKQSTGTLLSRITYDSEQVASSSSGALITVVREGASIIGLFIM)
MFYYSWQLSIILVVLAPIVSIAIRVVSKRFRSISKNMQNTMGQVTTSAEQ)
MLKGHKEVLIFGGQEVETKRFDKVSNKMRLQGMKMVSASSISDPIIQLIA)
SLALAFVLYAASFPSVMDSLTAGTITVVFSSMIALMRPLKSLTNVNAQFQ)
RGMAACQTLFAILDSEQEK)
)
3GIAA)
>BCL):A|PDBID|CHAIN|SEQUENCE)
LKNKKLSLWEAVSMAVGVMIGASIFSIFGVGAKIAGRNLPETFILSGIYA)
LLVAYSYTKLGAKIVSNAGPIAFIHKAIGDNIITGALSILLWMSYVISIA)
LFAKGFAGYFLPLINAPINTFNIAITEIGIVAFFTALNFFGSKAVGRAEF)
FIVLVKLLILGLFIFAGLITIHPSYVIPDLAPSAVSGMIFASAIFFLSYM)
GFGVITNASEHIENPKKNVPRAIFISILIVMFVYVGVAISAIGNLPIDEL)
IKASENALAVAAKPFLGNLGFLLISIGALFSISSAMNATIYGGANVAYSL)
AKDGELPEFFERKVWFKSTEGLYITSALGVLFALLFNMEGVASITSAVFM)
VIYLFVILSHYILIDEVGGRKEIVIFSFIVVLGVFLLLLYYQWITNRFVF)
YGIIATFIGVLIFEIIYRKVTKRTFSNNMYVKS)
)
3HD6A)
>BCL):A|PDBID|CHAIN|SEQUENCE)
SAWNTNLRWRLPLTCLLLQVIMVILFGVFVRYDFENEFYYRYPSFQDVHV)
MVFVGFGFLMTFLQRYGFSAVGFNFLLAAFGIQWALLMQGWFHFLQDRYI)
VVGVENLINADFCVASVCVAFGAVLGKVSPIQLLIMTFFQVTLFAVNEFI)
LLNLLKVKDAGGSMTIHTFGAYFGLTVTRILYRRNLEQSKERQNSVYQSD)
LFAMIGTLFLWMYWPSFNSAISYHGDSQHRAAINTYCSLAACVLTSVAIS)
SALHKKGKLDMVHIQNATLAGGVAVGTAAEMMLMPYGALIIGFVCGIIST)
LGFVYLTPFLESRLHIQDTCGINNLHGIPGIIGGIVGAVTAASDWTARTQ)
GKFQIYGLLVTLAMALMGGIIVGLILRLPFWGQPSDENCFEDAVYWEMPE)
GNS)
)
3HFXA)
>BCL):A|PDBID|CHAIN|SEQUENCE)
PKVFFPPLIIVGILCWLTVRDLDAANVVINAVFSYVTNVWGWAFEWYMVV)
MLFGWFWLVFGPYAKKRLGNEPPEFSTASWIFMMFASCTSAAVLFWGSIE)
IYYYISTPPFGLEPNSTGAKELGLAYSLFHWGPLPWATYSFLSVAFAYFF)
FVRKMEVIRPSSTLVPLVGEKHAKGLFGTIVDNFYLVALIFAMGTSLGLA)
TPLVTECMQWLFGIPHTLQLDAIIITCWIILNAICVACGLQKGVRIASDV)
RSYLSFLMLGWVFIVSGASFIMNYFTDSVGMLLMYLPRMLFYTDPIAKGG)
FPQGWTVFYWAWWVIYAIQMSIFLARISRGRTVRELCFGMVLGLTASTWI)
LWTVLGSNTLLLIDKNIINIPNLIEQYGVARAIIETWAALPLSTATMWGF)
FILCFIATVTLVNACSYTLAMSTCREVRDGEEPPLLVRIGWSILVGIIGI)
VLLALGGLKPIQTAIIAGGCPLFFVNIMVTLSFIKDAKQNWKD)
 !! 274!
)
3KCUA)
>BCL):A|PDBID|CHAIN|SEQUENCE)
KHPLKTFYLAITAGVFISIAFVFYITATTGTGTMPFGMAKLVGGICFSLG)
LILCVVCGADLFTSTVLIVVAKASGRITWGQLAKNWLNVYFGNLVGALLF)
VLLMWLSGEYMTANGQWGLNVLQTADHKVHHTFIEAVCLGILANLMVCLA)
VWMSYSGRSLMDKAFIMVLPVAMFVASGFEHSIANMFMIPMGIVIRDFAS)
PEFWTAVGSAPENFSHLTVMNFITDNLIPVTIGNIIGGGLLVGLTYWVIY)
LR)
)
3KJ6A)
>BCL):A|PDBID|CHAIN|SEQUENCE)
GMGIVMSLIVLAIVFGNVLVITAIAKFERLQTVTNYFITSLACADLVMGL)
AVVPFGAAHILMKMWTFGNFWCEFWTSIDVLCVTASIETLCVIAVDRYFA)
ITSPFKYQSLLTKNKARVIILMVWIVSGLTSFLPIQMHWYRATHQEAINC)
YAEETCCDFFTNQAYAIASSIVSFYVPLVIMVFVYSRVFQEAKRQLQKID)
KSEGRFHVQNLSQVEQDGRTGHGLRRSSKFCLKEHKALKTLGIIMGTFTL)
CWLPFFIVNIVHVIQDNLIRKEVYILLNWIGYVNSGFNPLIYCRSPDFRI)
AFQELLCLRRS)
)
3O0RB)
>BCL):B|PDBID|CHAIN|SEQUENCE)
FASQAVAKPYFVFALILFVGQILFGLIMGLQYVVGDFLFPAIPFNVARMV)
HTNLLIVWLLFGFMGAAYYLVPEESDCELYSPKLAWILFWVFAAAGVLTI)
LGYLLVPYAGLARLTGNELWPTMGREFLEQPTISKAGIVIVALGFLFNVG)
MTVLRGRKTAISMVLMTGLIGLALLFLFSFYNPENLTRDKFYWWWVVHLW)
VEGVWELIMGAILAFVLVKITGVDREVIEKWLYVIIAMALISGIIGTGHH)
YFWIGVPGYWLWLGSVFSALEPLPFFAMVLFAFNTINRRRRDYPNRAVAL)
WAMGTTVMAFLGAGVWGFMHTLAPVNYYTHGTQLTAAHGHMAFYGAYAMI)
VMTIISYAMPRLRGIGEAMDNRSQVLEMWGFWLMTVAMVFITLFLSAAGV)
LQVWLQRMPADGAAMTFMATQDQLAIFYWLREGAGVVFLIGLVAYLLSF)
)
3P5NA)
>BCL):A|PDBID|CHAIN|SEQUENCE)
QQNKRLITISMLSAIAFVLTFIKFPIPFLPPYLTLDFSDVPSLLATFTFG)
PVAGIIVALVKNLLNYLFSMGDPVGPFANFLAGASFLLTAYAIYKNKRST)
KSLITGLIIATIVMTIVLSILNYFVLLPLYGMIFNLADIANNLKVIIVSG)
IIPFNIIKGIVISIVFILLYRRLANFLKR)
)
3SYOA)
>BCL):A|PDBID|CHAIN|SEQUENCE)
YRYLTDIFTTLVDLKWRFNLLIFVMVYTVTWLFFGMIWWLIAYIRGDMDH)
IEDPSWTPCVTNLNGFVSAFLFSIETETTIGYGYRVITDKCPEGIILLLI)
QSVLGSIVNAFMVGCMFVKISQ)
)
4A2NB)
>BCL):B|PDBID|CHAIN|SEQUENCE)
MNENLWKICFIVMFIIWVFVRKVYGTRAMKNKSKKKVRPNFEKSLVFLNF)
IGMVFLPLTAVFSSYLDSFNINLPDSIRLFALIVTFLNIGLFTKIHKDLG)
NNWSAILEIKDGHKLVKEGIYKNIRHPMYAHLWLWVITQGIILSNWVVLI)
FGIVAWAILYFIRVPKEEELLIEEFGDEYIEYMGKTGRLFPK)
 
 !! 275!
Fragment files 
 The fragment files and secondary structure prediction files are the same ones used 
for the modeling published in reference (345). Information on how this input was 
generated can be found in the publication’s Supplemental Information. 
#)Example)using)1U19.)Was)repeated)for)all)nine)proteins)in)benchmark)set)
rosetta&3.4/rosetta_tools/fragment_tools/make_fragments.pl)&id)1U19A)&
psipredfile)1U19A.psipred_ss2)–jufofile)1U19A.jufo)&nosam)&verbose)1U19A.fasta)
&nohoms)&nojufo)–nopsipred)!
Generation of spanfiles and lipophilicity files 
The spanfiles and lipophilicity files are the same ones used for the modeling 
published in reference (345). Information on how this input was generated can be found 
in the publication’s Supplemental Information. Span file generated using Rosetta version 
3.4 octopus2span.pl script and the SPOCTOPUS prediction as input. Lipophilicty files 
generated using run_lips.pl script. 
#)running)octopus2span.pl)
/rosetta&3.4/rosetta_source/src/apps/public/membrane_abinitio/octopus2span.pl)
<OCTOPUS)topology)file>)>)spanfile)
)
#)Example)spanfile)
TM)region)prediction)for)1U19A.octo_topo)predicted)using)OCTOPUS)
7)278)
antiparallel)
n2c)
)))7))))27)))))7))))27)
))43))))63))))43))))63)
))82)))102))))82)))102)
)120)))140)))120)))140)
)171)))191)))171)))191)
)221)))241)))221)))241)
)255)))275)))255)))275)
)
#)running)run_lips.pl)
/rosetta&3.4/rosetta_source/src/apps/public/membrane_abinitio/run_lips.pl)
1U19A.fasta)1U19A.span)/dir/blastpgp)/dir/alignblast.pl)!
 
 !! 276!
Generation of Topology Broker “rigid” files for computing RMSD100SSE 
Taken from secondary structure element definitions from DSSP and are similar to 
that used for evaluation of models in reference (345). 
#)example)rigid)file)for)1U19)
RIGID) 2) 32)
RIGID) 39) 57)
RIGID) 59) 68)
RIGID) 74) 107)
RIGID) 118) 136)
RIGID) 168) 178)
RIGID) 181) 193)
RIGID) 210) 245)
RIGID) 253) 262)
RIGID) 269) 276)
)
Residues over which RMSD100SSE was computed 
All native PDBs were renumbered starting at residue 1, as are all models folded 
with Rosetta. This is what the following lists of residues assume. 
#)1FX8A)
RIGID) 2) 29)
RIGID) 36) 58)
RIGID) 64) 73)
RIGID) 78) 114)
RIGID) 121) 130)
RIGID) 140) 162)
RIGID) 173) 192)
RIGID) 199) 212)
RIGID) 227) 253)
)
#)1IWGA)
RIGID) 2) 23)
RIGID) 31) 51)
RIGID) 57) 85)
RIGID) 93) 122)
RIGID) 129) 160)
#)1J4NA)
RIGID) 2) 31)
RIGID) 48) 70)
RIGID) 76) 85)
RIGID) 90) 115)
#)1KPLA)
RIGID) 2) 40)
RIGID) 48) 70)
RIGID) 79) 87)
 !! 277!
RIGID) 97) 111)
RIGID) 117) 136)
RIGID) 141) 160)
RIGID) 163) 174)
RIGID) 185) 202)
)
#)1OCCA)
RIGID) 3) 36)
RIGID) 59) 83)
RIGID) 86) 113)
RIGID) 122) 154)
RIGID) 163) 189)
)
#)1OKCA)
RIGID) 3) 36)
RIGID) 72) 98)
RIGID) 107) 141)
RIGID) 175) 198)
RIGID) 208) 239)
RIGID) 272) 290)
)
#)1PV6A)
RIGID) 7) 38)
RIGID) 42) 70)
RIGID) 74) 101)
RIGID) 104) 136)
RIGID) 140) 164)
RIGID) 166) 186)
)
#)1PY6A)
RIGID) 5) 29)
RIGID) 33) 58)
RIGID) 76) 97)
RIGID) 101) 123)
RIGID) 127) 158)
RIGID) 161) 187)
RIGID) 197) 221)
)
#)1PY7A)
RIGID) 4) 25)
RIGID) 29) 51)
RIGID) 55) 86)
RIGID) 89) 115)
)
#)1RHZA)
RIGID) 2) 20)
RIGID) 53) 67)
RIGID) 79) 107)
RIGID) 115) 141)
RIGID) 147) 165)
)
#)1U19A)
RIGID) 2) 32)
RIGID) 39) 68)
 !! 278!
RIGID) 75) 108)
RIGID) 118) 140)
RIGID) 168) 193)
RIGID) 210) 245)
RIGID) 253) 277)
)
#)2BG9A)
RIGID) 2) 28)
RIGID) 33) 60)
RIGID) 65) 90)
)
#)2BL2A)
RIGID) 2) 36)
RIGID) 41) 68)
RIGID) 75) 112)
RIGID) 117) 144)
)
#)2BS2A)
RIGID) 2) 33)
RIGID) 56) 80)
RIGID) 101) 129)
RIGID) 148) 174)
RIGID) 182) 216)
)
#)2IC8A)
RIGID) 5) 24)
RIGID) 58) 79)
RIGID) 81) 103)
RIGID) 111) 127)
RIGID) 137) 152)
RIGID) 161) 180)
)
#)2K73A)
RIGID) 12) 36)
RIGID) 42) 63)
RIGID) 68) 96)
RIGID) 142) 163)
)
#)2KSFA)
RIGID) 7) 25)
RIGID) 35) 48)
RIGID) 55) 66)
RIGID) 80) 103)
)
#)2KSYA)
RIGID) 3) 28)
RIGID) 33) 56)
RIGID) 70) 91)
RIGID) 95) 117)
RIGID) 122) 152)
RIGID) 154) 180)
RIGID) 190) 222)
)
)
 !! 279!
#)2NR9A)
RIGID) 7) 24)
RIGID) 60) 81)
RIGID) 83) 105)
RIGID) 112) 129)
RIGID) 140) 151)
RIGID) 163) 189)
)
#)2PNOA)
RIGID) 5) 32)
RIGID) 43) 73)
RIGID) 75) 98)
RIGID) 101) 129)
)
#)2XQ2A)
RIGID) 2) 21)
RIGID) 45) 72)
RIGID) 74) 101)
RIGID) 116) 150)
RIGID) 154) 172)
RIGID) 178) 204)
RIGID) 247) 267)
RIGID) 272) 305)
RIGID) 340) 378)
RIGID) 384) 409)
RIGID) 415) 439)
RIGID) 445) 464)
RIGID) 471) 493)
RIGID) 514) 536)
RIGID) 538) 564)
)
#)2XUTA)
RIGID) 3) 29)
RIGID) 39) 69)
RIGID) 73) 92)
RIGID) 97) 125)
RIGID) 132) 162)
RIGID) 165) 187)
RIGID) 217) 240)
RIGID) 246) 270)
RIGID) 283) 316)
RIGID) 326) 345)
RIGID) 361) 388)
RIGID) 397) 421)
RIGID) 430) 451)
RIGID) 468) 487)
)
#)2YVXA)
RIGID) 18) 45)
RIGID) 61) 84)
RIGID) 92) 121)
RIGID) 127) 155)
RIGID) 164) 182)
)
 !! 280!
#)2ZW3A)
RIGID) 22) 47)
RIGID) 72) 105)
RIGID) 125) 155)
RIGID) 184) 215)
)
#)3B60A)
RIGID) 15) 45)
RIGID) 52) 101)
RIGID) 112) 154)
RIGID) 156) 204)
RIGID) 214) 262)
RIGID) 274) 314)
)
#)3GIAA)
RIGID) 8) 35)
RIGID) 38) 63)
RIGID) 82) 114)
RIGID) 120) 140)
RIGID) 142) 170)
RIGID) 182) 208)
RIGID) 215) 244)
RIGID) 268) 303)
RIGID) 319) 335)
RIGID) 338) 362)
RIGID) 371) 395)
RIGID) 397) 421)
)
#)3HD6A)
RIGID) 9) 29)
RIGID) 37) 62)
RIGID) 67) 92)
RIGID) 104) 124)
RIGID) 130) 155)
RIGID) 163) 181)
RIGID) 197) 219)
RIGID) 225) 253)
RIGID) 261) 281)
RIGID) 285) 314)
RIGID) 322) 342)
RIGID) 345) 377)
)
#)3HFXA)
RIGID) 4) 20)
RIGID) 41) 60)
RIGID) 77) 106)
RIGID) 117) 149)
RIGID) 176) 209)
RIGID) 218) 237)
RIGID) 244) 266)
RIGID) 301) 327)
RIGID) 333) 364)
RIGID) 395) 422)
RIGID) 436) 455)
 !! 281!
RIGID) 458) 490)
)
#)3KCUA)
RIGID) 3) 28)
RIGID) 36) 57)
RIGID) 79) 107)
RIGID) 133) 156)
RIGID) 160) 177)
RIGID) 182) 198)
RIGID) 219) 250)
#)3KJ6A)
RIGID) 2) 24)
RIGID) 33) 56)
RIGID) 75) 102)
RIGID) 113) 129)
RIGID) 174) 197)
RIGID) 233) 252)
RIGID) 274) 292)
)
#)3O0RB)
RIGID) 2) 33)
RIGID) 44) 75)
RIGID) 82) 105)
RIGID) 132) 154)
RIGID) 160) 180)
RIGID) 186) 221)
RIGID) 225) 250)
RIGID) 258) 285)
RIGID) 296) 321)
RIGID) 333) 362)
RIGID) 371) 408)
RIGID) 417) 448)
)
#)3P5NA)
RIGID) 2) 21)
RIGID) 51) 69)
RIGID) 75) 95)
RIGID) 100) 122)
RIGID) 145) 175)
)
#)3SYOA)
RIGID) 16) 45)
RIGID) 92) 121)
)
#)4A2NB)
RIGID) 3) 30)
RIGID) 39) 62)
RIGID) 75) 99)
RIGID) 127) 143)
RIGID) 146) 175)!
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Topology Broker setup files 
#)Using)1U19)as)an)example)
#)extended)chain)
CLAIMER)MembraneTopologyClaimer)
END_CLAIMER)
)
#)extended)chain)+)EPR)
CLAIMER)MembraneTopologyClaimer)
END_CLAIMER)
CLAIMER)ConstraintClaimer)
FILE)1U19A.cst)
END_CLAIMER)
)
#)RosettaTMH)
CLAIMER)MembraneTopologyClaimer)
END_CLAIMER)
CLAIMER)TMHTopologySamplerClaimer)
END_CLAIMER)
)
#)RosettaTMH)+)EPR))
CLAIMER)MembraneTopologyClaimer)
END_CLAIMER)
CLAIMER)TMHTopologySamplerClaimer)
END_CLAIMER)
CLAIMER)ConstraintClaimer)
FILE)1U19A.cst)
END_CLAIMER)!
Simulating EPR distance restraints 
#)convert)Rosetta)native)PDB)file)to)BCL)format)
foreach)pdb)()`cat)pdb.ls`)))
))))))))sed)&i)'/CEN/d')${pdb}.pdb)
))))))))bcl.exe)protein:PDBConvert)${pdb}.pdb)&bcl_pdb)&output_prefix)${pdb}_)
>&)${pdb}_bcl.log)
end)
)
#)mutate.wts)
bcl::storage::Table<double>))))add_all)add_single)filter_aa_type_excl)
filter_sse_size)remove_single)))))))swap)distance_range_0)filter_exposure_0)
weights) 0) 1) 0) 0) 1) 1) 0) 0))
)
#)score.wts)
bcl::storage::Table<double>)data_density)aa_type_excl))))seq_sep)
data_set_size)sse_connection)))sse_size)))sse_term))))bipolar)sse_center)
triangulation_0)distance_range_0)exposure_0)
weights) 0) 0) 1) 1) 1) 0) 0) 0) 0) 0
) 10000) 10000)
 !! 283!
)
#)SSE)pool)for)1U19)
bcl::assemble::SSEPool)
HELIX))))1)))1)PRO)A))))2))GLN)A)))32))1))))))))))))))))))))))))))))))))))31)
HELIX))))2)))2)PRO)A)))39))HIS)A)))68))1))))))))))))))))))))))))))))))))))30)
HELIX))))3)))3)GLY)A)))74))VAL)A))107))1))))))))))))))))))))))))))))))))))34)
HELIX))))4)))4)GLU)A))118))LEU)A))140))1))))))))))))))))))))))))))))))))))23)
HELIX))))5)))5)ASN)A))168))GLN)A))193))1))))))))))))))))))))))))))))))))))26)
HELIX))))6)))6)THR)A))210))THR)A))245))1))))))))))))))))))))))))))))))))))36)
HELIX))))7)))7)PRO)A))253))MET)A))276))1))))))))))))))))))))))))))))))))))24)
END)
)
#)command)line)for)restraint)picking)
bcl.exe)restraint:OptimizeDataSetPairwise)&fasta)1U19A.fasta)&
pool_min_sse_lengths)3)0)&pool)1U19A_native.pool)&distance_min_max)10)50)&
nc_limit)10)&ensembles)pdb.ls)&mc_number_iterations)10000)10000)&prefix)1U19A)
&nmodels)10)&read_scores_optimization)score.wts)&read_mutates_optimization)
mutate.wts)&read_mutates_start)mutate.wts)&message_level)Standard)&
pymol_output)&data_set_size_range)10)40)&data_set_size_fraction_of_sse_resis)
0.2))
)
#)adding)spin)label)uncertainty)
bcl.exe)SimulateDistanceRestraints)&pdb)1U19A_bcl_format.pdb)&
simulate_distance_restraints)&output_file)1U19A_sim_epr.cst)&
add_distance_uncertainty)sl&cb_distances.histograms)&restraint_list)1U19A.data)
0)1)5)6)&random_seed)&write_rosetta_mini_restraints))
 
Restraint file format 
#)weighting)EPR)KBP)by)10.0)and)quadratic)penalty)by)1.0)
#)if)have)Gly)in)AtomPair,)replace)CB)with)1HA)or)2HA)
AtomPair)CB)67)CB)255)SCALARWEIGHTEDFUNC)1.0)SPLINE)EPR_DISTANCE) 28.9577)1.0)0.5)
AtomPair)CB)67)CB)255)SCALARWEIGHTEDFUNC)1.0)BOUNDED)16.9577)40.9577)1.0)NOE);dist)
 
Building loops on BCL and RosettaTMH files  
##Loops#file#format#–#residues#defined#in#loops#are#all#residues#not#covered#
by#spanfile#
#)EXAMPLE:))1FX8A))
LOOP) 1) 6)
LOOP) 26) 37)
LOOP) 57) 82)
LOOP) 102) 141)
LOOP) 161) 172)
LOOP) 192) 229)
LOOP) 249) 254)
)
#)convert)BCL)files)to)Rosetta)files)and)make)loops)files)for)Rosetta)loop)
building)
cd)1J4NA/pdbs)
foreach)pdb)(`cat)pdb.ls`))
 !! 284!
))))))))bcl.exe)protein:PDBConvert)${pdb}.pdb)&loop_file_rosetta)CCD)&
write_zero_coordinates)&bcl_pdb)Split)&output_prefix)../loops/${pdb})>&)
${pdb}_loops.log)
end)
 
##Build#loops#in#Rosetta#with#options#file#(see#fill_gaps.options)#–#from#
Rosetta#silent#file#
Rosetta/main/source/bin/loopmodel.mpi.linuxgccrelease)&database)
Rosetta/main/database/)@${DIR}/flags/fill_gaps.options)&in:file:silent)
${DIR}/${PDB}/test.out))&in:file:tags)${TAG000})&out:file:silent)
${DIR}/${PDB}/test_loops.out)&out:no_nstruct_label)&out:file:scorefile)
${DIR}/${PDB}/test_loops.sc)
#
##Build#loops#in#Rosetta#with#options#file#(see#fill_gaps.options)#–#from#a#
PDB#file#
Rosetta/main/source/bin/loopmodel.mpi.linuxgccrelease)&database)
Rosetta/main/database/)@${DIR}/flags/fill_gaps.options)&in:file:silent)
${DIR}/${PDB}/test.pdb)&out:pdb_gz)–out:prefix)test_)&out:no_nstruct_label)&
out:file:scorefile)${DIR}/${PDB}/test_loops.sc)
)
Restraint weights for folding in Rosetta 
pdb) weight_new)
1FX8A) 10.5596)
1IWGA) 8.8708)
1J4NA) 8.3960)
1KPLA) 9.7660)
1OCCA) 9.6317)
1OKCA) 13.1527)
1PV6A) 8.6969)
1PY6A) 9.8134)
1PY7A) 8.0013)
1RHZA) 10.4518)
1U19A) 10.9355)
2BG9A) 6.8484)
2BL2A) 8.1081)
2BS2A) 10.9428)
2IC8A) 10.7754)
2K73A) 11.0377)
2KSFA) 9.1686)
2KSYA) 9.4516)
2NR9A) 11.0417)
2PNOA) 7.9325)
2XQ2A) 13.5716)
2XUTA) 12.7241)
2YVXA) 10.2313)
2ZW3A) 12.4219)
3B60A) 10.5270)
3GIAA) 12.2199)
3HD6A) 12.0958)
3HFXA) 14.0806)
3KCUA) 11.5959)
 !! 285!
3KJ6A) 14.9617)
3O0RB) 11.9658)
3P5NA) 10.9224)
3SYOA) 10.9717)
4A2NB) 11.0417)
 
Options files for de novo folding 
#)MembraneAbinitio)
&in)
) &file)
) ) &native)${PDB}.pdb)
) ) &fasta)${PDB}.fasta)
) ) &frag3)aa${PDB}03_05.200_v1_3)
) ) &frag9)aa${PDB}09_05.200_v1_3)
) ) &spanfile)${PDB}.span)
) ) &lipofile)${PDB}.lips4)
&residues)
) &patch_selectors)CENTROID_HA)
&score)
) &find_neighbors_3dgrid)
#) &use_membrane_rg))####)use)this)flag)if)using)MP&specific)RG)score)
&membrane)
) &no_interpolate_Mpair)
) &Menv_penalties)
&abinitio)
) &membrane)
) &explicit_pdb_debug)#)if)want)to)output)at)stages)0&4)
) &rg_reweight)${RG_WEIGHT})
) &stage2_patch)score_membrane_s2.wts_patch)
) &stage3a_patch)score_membrane_s3a.wts_patch)
) &stage3b_patch)score_membrane_s3b.wts_patch)
) &stage4_patch)score_membrane_s4.wts_patch)
&evaluation)
) &gdtmm)
) &rmsd)NATIVE)_tm_sse)${PDB}_tm_sse_052814.txt)
&out)
) &output)
) &file)
) ) &output_virtual)
) ) &silent_struct_type)binary)
&overwrite)
)
#)extended)chain)(and)extended)chain)+)EPR)when)CST_WEIGHT)≠)0.0))
&in)
) &file)
) ) &native)${PDB}.pdb)
) ) &fasta)${PDB}.fasta)
) ) &frag3)aa${PDB}03_05.200_v1_3)
) ) &frag9)aa${PDB}09_05.200_v1_3)
) ) &spanfile)${PDB}.span)
) ) &lipofile)${PDB}.lips4)
 !! 286!
&residues)
) &patch_selectors)CENTROID_HA)
&broker)
) &setup)${CSTFILE}.tpb)####)will)follow)format)of)broker)setup)file)above)
&run)
) &protocol)broker)
&score)
) &find_neighbors_3dgrid)
#) &use_membrane_rg)####)use)this)flag)if)using)MP&specific)RG)score)
&membrane)
) &no_interpolate_Mpair)
) &Menv_penalties)
&abinitio)
) &membrane)
) &explicit_pdb_debug)#)if)want)to)output)at)stages)0&4)
) &rg_reweight)${RG_WEIGHT})
) &stage2_patch)score_membrane_s2.wts_patch)
) &stage3a_patch)score_membrane_s3a.wts_patch)
) &stage3b_patch)score_membrane_s3b.wts_patch)
) &stage4_patch)score_membrane_s4.wts_patch)
&constraints)
) &cst_file)${CSTFILE})
) &cst_weight)${CST_WEIGHT})
) &epr_distance)
&fold_cst)
) &force_minimize)
) &seq_sep_stages)1.0)1.0)1.2)
&evaluation)
) &gdtmm)
&rmsd)NATIVE)_tm_sse)${PDB}_tm_sse_052814.txt)
&out)
) &output)
) &file)
) ) &output_virtual)
) ) &silent_struct_type)binary)
&overwrite)
)
#)RosettaTMH)(and)RosettaTMH)+)EPR)when)cst_weight)!=)0.0))
&in)
) &file)
) ) &native)${PDB}.pdb)
) ) &fasta)${PDB}.fasta)
) ) &frag3)aa${PDB}03_05.200_v1_3)
) ) &frag9)aa${PDB}09_05.200_v1_3)
) ) &spanfile)${PDB}.span)
) ) &lipofile)${PDB}.lips4)
&residues)
) &patch_selectors)CENTROID_HA)
&broker)
) &setup)${CSTFILE}.tpb)
) &large_frag_mover_stage1_weight)0.0)
) &small_frag_mover_stage1_weight)0.0)
) &rb_mover_stage1_weight)5.0)
&run)
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) &protocol)broker)
&score)
) &find_neighbors_3dgrid)
#) &use_membrane_rg)####)use)this)flag)if)using)MP&specific)RG)score)
&membrane)
) &fixed_membrane)
) &no_interpolate_Mpair)
) &Menv_penalties)
&abinitio)
) &membrane)
) &explicit_pdb_debug)#)if)want)to)output)at)stages)0&4)
) &rg_reweight)${RG_WEIGHT})
) &stage2_patch)score_membrane_s2.wts_patch)
) &stage3a_patch)score_membrane_s3a.wts_patch)
) &stage3b_patch)score_membrane_s3b.wts_patch)
) &stage4_patch)score_membrane_s4.wts_patch)
&constraints)
) &cst_file)${CSTFILE})
) &cst_weight)${CST_WEIGHT})
) &epr_distance)
&fold_cst)
) &force_minimize)
) &seq_sep_stages)1.0)1.0)1.2)
&rigid)
) &rotation)0.1)
) &translation)0.5)
&evaluation)
) &gdtmm)
&rmsd)NATIVE)_tm_sse)${PDB}_tm_sse_052814.txt)
&out)
) &output)
) &file)
) ) &output_virtual)
) ) &silent_struct_type)binary)
&overwrite)
 
##loop#building#onto#BCL#and#RosettaTMH#models#
Vin#
# Vfile#
# # Vnative#${DIR}/${PDB}/${PDB}.pdb#
# # Vspanfile#${DIR}/${PDB}/${PDB}.span#
# # Vlipofile#${DIR}/${PDB}/${PDB}.lips4#
# # Vresidue_type_set#centroid#
Vchemical#
# Vpatch_selectors#CENTROID_HA#
Vscore#
# Vfind_neighbors_3dgrid#
Vevaluation#
# Vrmsd#NATIVE#_tm_sse#${DIR}/${PDB}/${PDB}_tm_sse_052814.txt#
Vmembrane#
# Vno_interpolate_Mpair#
# VMenv_penalties#
Vloops#
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# Vloop_file#${DIR}/${PDB}/${PDB}.loops#
# Vfrag_sizes#9#3#1#
# Vfrag_files#${DIR}/${PDB}/aa${PDB}09_05.200_v1_3#
${DIR}/${PDB}/aa${PDB}03_05.200_v1_3#none#
# Vremodel#quick_ccd#
# Vcen_weights#score_membrane#
# Vcen_patch#${DIR}/score_membrane_s4.wts_patch#
Vout#
# Voutput#
# Vno_nstruct_label#
# Vnstruct#1#
# Vfile#
# # Vsilent_struct_type#binary###only#if#outputting#silent#files,#not#
pdb#or#pdb_gz#files#
# # Vresidue_type_set#centroid#
Voverwrite#
 
Score patches 
#)score_membrane_s2.wts_patch)
pair)=)0.0)
Mpair)=)1.0)
env)=)0.0)
Menv)=)2.019)
cbeta)=)0.0)
Mcbeta)=)0.0)
Menv_non_helix)=)2.019)
Menv_termini)=)2.019)
Menv_tm_proj)=)2.019)
Mlipo)=)1.0)
)
#)score_membrane_s3a.wts_patch)
pair)=)0.0)
Mpair)=)1.0)
env)=)0.0)
Menv)=)2.019)
cbeta)=)0.0)
Mcbeta)=)0.5)
Menv_non_helix)=)2.019)
Menv_termini)=)2.019)
Menv_tm_proj)=)2.019)
Mlipo)=)1.0)
)
#)score_membrane_s3b.wts_patch)
pair)=)0.0)
Mpair)=)1.0)
env)=)0.0)
Menv)=)2.019)
cbeta)=)0.0)
Mcbeta)=)0.5)
Menv_non_helix)=)2.019)
Menv_termini)=)2.019)
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Menv_tm_proj)=)2.019)
Mlipo)=)1.0)
)
#)score_membrane_s4.wts_patch)
pair)=)0.0)
Mpair)=)1.0)
env)=)0.0)
Menv)=)2.019)
cbeta)=)0.0)
Mcbeta)=)2.5)
Menv_non_helix)=)2.019)
Menv_termini)=)2.019)
Menv_tm_proj)=)2.019)
Mlipo)=)1.0)
 
Command lines for folding 
MembraneAbinitio 
Rosetta/main/rosetta_source/bin/membrane_abinitio2.static.linuxgccrelease)&
database)/Rosetta/main/rosetta_database/)@${FLAGS})&out::nstruct)${NSTRUCT})&
out:file:silent)${OUTFILE})&out:sf)${OUTFILE}.sc)
 
Extended chain (and Extended chain + EPR if CST_WEIGHT ≠ 0.0) 
/Rosetta/main/rosetta_source/bin/minirosetta.mpi.linuxgccrelease)&database)
/Rosetta/main/rosetta_database/)@${FLAGS})&out::nstruct)${NSTRUCT})&
out:file:silent)${OUTFILE})&out:file:scorefile)${OUTFILE}.sc)
 
RosettaTMH (and RosettaTMH + EPR if CST_WEIGHT != 0.0) 
/Rosetta/main/rosetta_source/bin/minirosetta.mpi.linuxgccrelease)&database)
/Rosetta/main/rosetta_database/)@${FLAGS})&out::nstruct)${NSTRUCT})&
out:file:silent)${OUTFILE})&out:file:scorefile)${OUTFILE}.sc)
 
Weighting schemes tested 
RG score weights tested 
Both default and MP-specific RG scores were weighted by 0.0, 0.01, 0.25, 0.50, 
0.75, 1.00, 1.25, 1.50, 1.75, and 2.00 when testing effect of MP-specific RG score. 
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EPR restraint weights tested ! ! ! ! Quadratic!Penalty!
EPR!KBP!
! 0.0! 1.0! 10.0! 20.0! 30.0! 40.0! 50.0!0.0! ✓! ✓! ✓! ✓! ✓! ✓! ✓!1.0! ✓! ✓! ✓! ✓! ✓! ✓! ✓!10.0! ✓! ✓! ✓! ✓! ✓! ✓! ✓!20.0! ✓! ✓! ✓! ✓! ✓! ✓! ✓!30.0! ✓! ✓! ✓! ✓! ✓! ✓! ✓!40.0! ✓! ✓! ✓! ✓! ✓! ✓! ✓!50.0! ✓! ✓! ✓! ✓! ✓! ✓! ✓!
 
Analysis of results 
BCL models analysis 
#)score)BCL)pdbs)for)comparison)with)Rosetta)models)(after)loop)building))
bcl.exe)protein:Score)&pdblist)bcl_pdb.ls)&native)2K73A_bcl.pdb)&
score_table_write)2K73A_bcl_scores_071014.tbl.tmp)&weight_set))refinement.tbl)
&membrane)20)10)2.5)&tm_helices)2K73A_native.pool)&pool)2K73A_native.pool)&
sspred)JUFO9D)OCTOPUS)&sequence_data)./)2K73)>&)score.log)
)
##Computing#RMSD100SSE#in#the#BCL#
bcl.exe)protein:Compare)&reference_pdb)2K73A_bcl.pdb)&pdb_list)bcl_pdb.ls)&
quality)RMSD)&atoms)CA)&specify_residues)2K73A_bcl_res.ls)>&)
2K73A_bcl_rmsd100_062114.log)
)
#2K73A_bcl_res.ls)format)
'A')12)
'A')13)
'A')14)
'A')15)
'A')16)
'A')17)...)for)all)residues)for)which)to)compute)RMSD)
)
#)Refinement.tbl)(for)BCL)scoring))
bcl::storage::Table<double>)))))aaclash)aadist))aaneigh)aaneigh_ent)))))loop))))
loop_closure_gradient)))rgyr))))sseclash))))))))ssepack_fr))))))strand_fr)
co_score))))))))ss_OCTOPUS))))))ss_OCTOPUS_ent))ss_OCTOPUS_env))ss_JUFO9D)))))))
ss_JUFO9D_ent)))ss_JUFO9D_env)))ssealign))))))))mp_helix_topology)
weights)500)))))0.35))))50))))))50.0))))10.0))))50000)))5.0)))))500)))))8.0)))))
20))))))0.5)))))20.0))))))))))))20.0))))20))))))5.0)))))5.0)))))5.0)))))))8)))))))
500)
)
#)example)native)pool)file)–)based)on)DSSP)for)the)PDB)file)–)see)
*rms_tm_sse_052814.txt)examples)above.))These)are)the)same)residue)definitions)
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bcl::assemble::SSEPool)
HELIX))))1)))1)LEU)A))))2))VAL)A)))29))1))))))))))))))))))))))))))))))))))28)
HELIX))))2)))2)GLN)A)))36))SER)A)))58))1))))))))))))))))))))))))))))))))))23)
HELIX))))3)))3)PRO)A)))64))PHE)A)))73))1))))))))))))))))))))))))))))))))))10)
HELIX))))4)))4)LYS)A)))78))HIS)A))114))1))))))))))))))))))))))))))))))))))37)
HELIX))))5)))5)VAL)A))121))PHE)A))130))1))))))))))))))))))))))))))))))))))10)
HELIX))))6)))6)PHE)A))140))THR)A))162))1))))))))))))))))))))))))))))))))))23)
HELIX))))7)))7)LEU)A))173))LEU)A))192))1))))))))))))))))))))))))))))))))))20)
HELIX))))8)))8)PRO)A))199))ALA)A))212))1))))))))))))))))))))))))))))))))))14)
HELIX))))9)))9)TYR)A))227))HIS)A))253))1))))))))))))))))))))))))))))))))))27)
END)
 
Generation of RMSD100SSE histograms 
#)format)for)files)for)input)into)rmsd_to_rmsd100.py)
#)doesn’t)matter)how)many)fields)are)between)field)1)and)description,)but)
“SCORE:”)must)be)first,)and)“description”)last,)also)total)score)is)“score”)
SCORE:)score) rms_tm_sse) file) description)
SCORE:)103.718) 14.536)1FX8A_s01_b001_0000)S_0001)
SCORE:)51427.301) 17.6354) 1FX8A_s01_b001_0000)S_0002)
SCORE:)51299.817) 15.8242) 1FX8A_s01_b001_0000)S_0003)
SCORE:)52004.468) 18.2978) 1FX8A_s01_b001_0000)S_0004)
SCORE:)51368.199) 14.9345) 1FX8A_s01_b001_0000)S_0005)
SCORE:)297.978) 14.0197) 1FX8A_s01_b001_0000)S_0006)
SCORE:)51497.388) 15.4662) 1FX8A_s01_b001_0000)S_0007)
SCORE:)180.629) 13.0461) 1FX8A_s01_b001_0000)S_0008)
SCORE:)516.341) 16.3426) 1FX8A_s01_b001_0000)S_0009)
)
#)convert)Rosetta&computed)RMSD)values)to)RMSD100)
./rmsd_to_rmsd100.py)&&membrane)&&silent=${file})&n)${nres})&&
outfile=${file}.rmsdSSE100)&&rms_tag=tm_sse)
))))
#)Generate)histograms)and)summary)
perl)~/scripts/Smbins_RMSD_dist_from_score.pl)${file}.rmsdSSE100)5)|)awk)
'{print($2"\t"$4)}')|)head)&n21)>)${file}.rmsdSSE100.txt)
 
Calculating enrichment 
Usage:)compute_overall_performance.py)[options]))#)parses)file)as)field)0)=)
pdb)and)field)4)=)weight)&)1FX8A_tmh_s01_b001_0009_scores_rms_tm_sse_072214.sc)
Options:)
))&h,)&&help))))))))))))show)this)help)message)and)exit)
))&&filelist=FILELIST)))filelist)
))&&metric=METRIC)))))))header)of)column)wanting)to)average)
))&&score_fraction=SCORE_FRACTION)
))))))))))))))))))))))))what)fraction)of)models)do)you)consider)for)TP)etc)
))&&quality_fraction=QUALITY_FRACTION)
))))))))))))))))))))))))what)fraction)of)models)do)you)consider)for)TP)etc)
))&&p_ratio=RATIO)))))))(p+n)/p.)this)sets)your)max)enrichment)
))&&enrichment_output=ENRICHMENT_OUTPUT)
))))))))))))))))))))))))file)to)output)enrichment)values)for)each)pdb)and)
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))))))))))))))))))))))))weight)
))&&outfile=OUTFILE)))))outfile)
)
./compute_overall_performance.py)–&filelist)list)–&metric)rms_tm_sse)–&
score_fraction)0.1)–&quality_fraction)0.1)&–p_ratio)10)–&enrichment_output)
test.enrch)–&outfile)test.out)
)
Calculate loops fulfillment 
USAGE:))<pdb_filename>)<restraint_filename>)<#)restraints>)
#)restraint)min)is)0.00)restraint)max)=)3.8)*)(nres&1))
restraint)file)format:)<chain>)<atom>)<res>)<atom>)<res>)<min>)<max>)
 
Calculating contact order 
 Downloaded script from Baker laboratory website  
(http://depts.washington.edu/bakerpg/contact_order/) 
#)options:))&c)=)cutoff,)default)is)6;)&a)=)absolute)contact)order)
./contactOrder.pl)–c)8)–a)1U19A.pdb)! )
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APPENDIX F 
 
PROTOCOL CAPTURE FOR APPENDIX A: 
LIGAND-MIMICKING RECEPTOR VARIANT DISCLOSES BINDING AND 
ACTIVATION MODE OF PROLACTIN RELEASING PEPTIDE 
 
This appendix contains the protocol capture for the modeling work published in 
(Rathmann*, Lindner*, DeLuca*, Kaufmann, Meiler, and Beck-Sickinger, 2012), some 
of which is found in the manuscript’s Supplemental Information. *These authors 
contributed equally. Further details are also available in Appendix A, and more detailed 
information on comparative modeling in Rosetta can be found in reference (252). 
 
Computational details 
All models were generated by independent simulations using Vanderbilt 
University’s Center for Structural Biology computing cluster and the university’s 
Advanced Computing Center for Research and Education (ACCRE). Computations were 
performed on a combination of AMD Opteron and Intel Nehalem processor nodes. All 
Rosetta-related protocols were conducted using Rosetta version 3.4. 
 
Input files 
FASTA file for making fragments for loop building 
>)PrRPR)residues)58&347)
QLKGLIVLLYSVVVVVGLVGNCLLVLVIARVRRLHNVTNFLIGNLALSDVLMCTACVPLTLAYAFEPRGW)
VFGGGLCHLVFFLQPVTVYVSVFTLTTIAVDRYVVLVHPLRRRISLRLSAYAVLAIWALSAVLALPAAVH)
TYHVELKPHDVRLCEEFWGSQERQRQLYAWGLLLVTYLLPLLVILLSYVRVSVKLRNRVVPGCVTQSQAD)
WDRARRRRTFCLLVVVVVVFAVCWLPLHVFNLLRDLDPHAIDPYAFGLVQLLCHWLAMSSACYNPFIYAW)
LHDSFREELRKLLV)
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Spanfile required for RosettaMembrane 
TM)region)prediction)for)PrRPR_112210.octopus)predicted)using)OCTOPUS)
7)294)
antiparallel)
n2c)
)))4))))24)))))4))))24)
))40))))60))))40))))60)
))79))))99))))79))))99)
)119)))139)))119)))139)
)169)))189)))169)))189)
)220)))240)))220)))240)
)257)))277)))257)))277)
 
Disulfide file (defines disulfide bond that want to maintain) 
#)bridge)between)C134)(in)TM3)close)to)ECL))C211)(ECL2))
77)154)
 
XML file for docking 
The XML file gives the parser, or RosettaScripts, instructions for how to run the 
protocol. The protocol we used for this study is as follows:  
1. Import constraints D6.59-R19, E5.26-R19, W5.28-R19, Y5.38-R19 (last 
three have 50% confidence)  
2. Docking perturbation (4Å translation, 10 degree rotation) 
3. Fast relax with only 1 iteration  
4. Filter D6.59-R19 with 100% confidence  
5. Rebuild EL2  
6. Rebuild EL3  
7. Rebuild EL1  
8. Full fast relax  
9. Filter by disulfide linkage with 100% confidence (residues 134 and 211)  
10. Filter by D6.59-R19 
)
#)XML)file)
<dock_design> 
<SCOREFXNS>)#defines)non&standard)score)functions,)weight)
ROSETTAMEMBRANE)scores)by)10x))
<mem_cen_cst)weights=score_membrane>))
<Reweight)scoretype=atom_pair_constraint)weight=10/>))
</mem_cen_cst>)
<mem_fa_cst) weights=membrane_highres_Menv_smooth>)
<Reweight)scoretype=atom_pair_constraint)weight=10/>)
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</mem_fa_cst>)
</SCOREFXNS> 
<FILTERS>)
<DisulfideFilter)name=disulfide)targets=77,154)confidence=1.0/>)
<ResidueDistance)name=D659_R19)res1_res_num=245)res2_res_num=306)
distance=10.0)confidence=1.0/>))
</FILTERS> 
<TASKOPERATIONS>)
<InitializeFromCommandline)name=ifcl/>)
<RestrictToRepacking)name=rtrp/>)
</TASKOPERATIONS> 
<MOVERS>)
<Docking)name=dock)score_low=mem_cen_cst)score_high=mem_fa_cst)
fullatom=1)local_refine=1)optimize_fold_tree=1)conserve_foldtree=0)design=0)
task_operations=ifcl/>))
<LoopRemodel)name=loop3)loop_start_res_num=246)loop_end_res_num=258)
hurry=0)protocol=ccd)perturb_score=mem_cen_cst)refine_score=mem_fa_cst)
perturb=1)refine=1)design=0)/>)
<LoopRemodel)name=loop2)loop_start_res_num=139)loop_end_res_num=169)
hurry=0)protocol=ccd)perturb_score=mem_cen_cst)refine_score=mem_fa_cst)
perturb=1)refine=1)design=0)/> 
<LoopRemodel)name=loop1)loop_start_res_num=65)loop_end_res_num=74)
hurry=0)protocol=ccd)perturb_score=mem_cen_cst)refine_score=mem_fa_cst)
perturb=1)refine=1)design=0)/>)
<FastRelax)name=fastrlx_all)repeats=1)scorefxn=mem_fa_cst)/>)
<FastRelax)name=fastrlx_r1)repeats=1)scorefxn=mem_fa_cst)/>)
<PackRotamersMover)name=repack)scorefxn=mem_fa_cst)
task_operations=rtrp/>)
<ConstraintSetMover)name=fa_cst)cst_file=dock_fa.cst)/>))
<ConstraintSetMover)name=lowres_cst)cst_file=dock.cst)/>)
</MOVERS> 
<APPLY_TO_POSE>)
</APPLY_TO_POSE> 
<PROTOCOLS>)
<Add)mover_name=fa_cst/>)
<Add)mover_name=lowres_cst/>)
<Add)mover_name=dock/>)
<Add)mover_name=fastrlx_r1/>)
<Add)filter_name=D659_R19/>)
<Add)mover_name=loop2/>)
<Add)mover_name=loop3/>)
<Add)mover_name=loop1/>)
<Add)mover_name=fastrlx_all/>)
<Add)filter_name=disulfide/>)
<Add)filter_name=D659_R19/> 
</PROTOCOLS> 
</dock_design> 
 
Constraints file for docking 
AtomPair)CB)306)CB)245)BOUNDED)0.00)10.0)1.0)NOE)loose)
AtomPair)CB)306)CB)156)BOUNDED)0.00)10.0)1.0)NOE)loose)
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AtomPair)CB)306)CB)158)BOUNDED)0.00)10.0)1.0)NOE)loose)
AtomPair)CB)306)CB)168)BOUNDED)0.00)10.0)1.0)NOE)loose)
Constraints file for full-atom refinement 
AtomPair)CB)306)CB)245)BOUNDED)0.00)10.0)1.0)NOE)loose)
AtomPair)CB)306)CB)156)BOUNDED)0.00)10.0)1.0)NOE)loose)
AtomPair)CB)306)CB)158)BOUNDED)0.00)10.0)1.0)NOE)loose)
AtomPair)CB)306)CB)168)BOUNDED)0.00)10.0)1.0)NOE)loose)
 
Options file for relaxing threaded models 
&relax)
) &membrane)
#) &default_repeats)
#) &fastrelax_repeats)2)
&in)
) &path)
) ) &database)/blue/meilerlab/home/hirstsj/mini/minirosetta_database)
) &file)
) ) &l)
/blue/meilerlab/home/hirstsj/GPCRs/PrRPR/PrRPm_rlx_initial_1.ls)
) ) &spanfile)
/blue/meilerlab/home/hirstsj/GPCRs/PrRPR/PrRPR_112210.span)
) ) &fullatom)
&score)
) &weights)
/blue/meilerlab/home/hirstsj/mini/minirosetta_database/scoring/weights/membran
e_highres_Menv_smooth.wts)
&membrane)
) &normal_cycles)100))
) &normal_mag)15))
) &center_mag)2))
&out)
) &output)
) &nstruct)1000)
) &file)
) ) &silent)
/blue/meilerlab/home/hirstsj/GPCRs/PrRPR/mutate_templates/rlx_models/PrRPR_rlx
_112310_1.out)
) ) &silent_struct_type)binary)
) ) &scorefile)
/blue/meilerlab/home/hirstsj/GPCRs/PrRPR/mutate_templates/PrRPR_rlx_112310_1.f
asc)
) ) &fullatom)
&overwrite)
 
Options file for building loops into threaded model 
##Build)Initial)Loops)with)Fragments)
&loops)
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) &timer)#output)time)spent)in)seconds)for)each)loop)modeling)job)
) &fast)#reduce)the)number)of)cycles)used)during)loop)building.)remove)for)
production)runs.)
) &frag_sizes)9)3)1)#This)option)is)paired)with)the)option)&
loops:frag_files&)indicates)fragment)sizes)
) &frag_files)
/blue/meilerlab/home/hirstsj/GPCRs/PrRPR/aaPrRPm09_05.200_v1_3)
/blue/meilerlab/home/hirstsj/GPCRs/PrRPR/aaPrRPm03_05.200_v1_3)none))))
) &fa_input)#input)structures)are)in)full)atom)format)
#) &input_pdb)mutate_templates/PrRPR_3EML_renumber.pdb)
#) &loop_file)build_initial.loops)#loop)definition)file)
) &relax)fastrelax)
) &build_initial)#build)missing)density)
) &ccd_closure)
) &random_loop)
) &remodel)quick_ccd)
&packing)#rotamer)library)flags)
) &ex1aro)
) &ex1)
) &ex2)
) &repack_only)
&in)
) &path)
) ) &database)/blue/meilerlab/home/hirstsj/mini/minirosetta_database/)
) &fix_disulf)/blue/meilerlab/home/hirstsj/GPCRs/PrRPR/PrRPm_disulf.txt)
#read)disulfide)connectivity)information)
) &file)
) ) &fullatom)
) ) &psipred_ss2)
/blue/meilerlab/home/hirstsj/GPCRs/PrRPR/PrRPm.psipred_ss2)
) ) &spanfile)
/blue/meilerlab/home/hirstsj/GPCRs/PrRPR/PrRPR_112210.span)
&out)
#) &prefix)PrRPm_3EML_initial_112310_)
) &output)
) &pdb)
) &overwrite)
) &nstruct)100)#recommended)1000)
) &file)
) ) &fullatom)
#) ) &silent)PrRPm_initial_112310.out)
) ) &silent_struct_type)binary)
&max_inner_cycles)30)
&outer_cycles)1)
&membrane)
) &normal_cycles)100)
) &normal_mag)15)
) &center_mag)2)
&score)
) &weights)
/blue/meilerlab/home/hirstsj/mini/minirosetta_database/scoring/weights/membran
e_highres_Menv_smooth.wts)
&overwrite)
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Options file for peptide docking and loop building 
#)This)file)contains)2)chains)(A)and)B))with)chain)B)being)the)peptide.)The)
receptor)and)peptide)were)renumbered)starting)from)1))
&s)input.pdb))
&nstruct)500)#)number)of)models)to)build)
&out:output) #)output)files))
&out:file:fullatom) #)output)in)full)atom)detail))
&out:silentoutput_file.out)#)structure)is)stored)in)internal)coordinates)
instead)of)Cartesian)coordinates))
&out:silent_struct_type)binary) #)binary)silent)output)is)more)compressed)and)
extracted)more)robustly))
&out:scorefile)scores.fasc)#)output)a)scorefile,)which)doesn’t)store)
coordinates,)only)scores))
&jd2:ntrials)5) #)use)the)new)job)distributor))
&parser:protocol)parser_protocol.xml) #)The)protocol)we)use)is)actually)run)
by)RosettaScripts,)aka)the)parser))
&docking:dock_pert)4)10) #)during)docking)perturbation,)allow)for)4Å)
translation)and)10)degree)rotation))
&residues:patch_selectors)CTERM_AMIDATION) #)use)this)option)if)you)want)to)
amidate)the)C&terminus)of)the)peptide))
&max_inner_cycles)30))
&outer_cycles)1))
#)ROSETTAMEMBRANE)options))
&membrane:normal_cycles)100)#)number)of)cycles)to)search)for)membrane)normal))
&membrane:normal_mag)15) #)options)for)the)angle)allowance)of)normal)and)
center)search))
&membrane:center_mag)2))
&in:file:psipred_ss2)secondary_structure.psipred_ss2)#)secondary)structure)
prediction)input)in)psipred)format))
&in:file:spanfile)tmh.span)#)membrane)spanning)regions)of)receptor)predicted)by)
OCTOPUS)and)in)spanfile)format))
&in:file:fix_disulf)disulf.txt) #)file)containing)residue)pairs)between)which)
there)is)a)disulfide)bond)#)loop)building)options))
&loops:timer))
&loops:fast) #)reduce)number)of)loop)building)trials,)or)cycles))
&loops:frag_sizes)9)3)1) #)fragment)sizes)used)for)CCD)loop)building,)but)not)
using)1mers))
&loops:frag_files)aaTest_09_05.200_v1_3)aaTest_03_05.200_v1_3)none))
&loops:fa_input) #)fullatom)input))
&loops:relaxfastrelax) #)do)a)“fast”)relax,)which)consists)of)iterative)
rounds)of)side&chain)repacking)and)all)atom)minimization)
&loops:remodel)quick_ccd)
&packing:ex1)#)include)extra)rotamers)for)side&chain)repacking))
&packing:ex2))
&packing:repack_only))
&packing:linmem_ig)10)
&overwrite) #)overwrite)existing)output)files)having)the)same)name)
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Command lines 
Fragment generation for loop building 
make_fragments.pl)–id)<fasta_id>)input.fasta)
 
Threading for comparative modeling 
#)Example)of)template)is)2VT4.))Other)templates)used)were)2RH1,)3CAP,)1U19,)
3DQB,)and)3EML.)
awk)&v)loop_file_prefix=PrRPR_2VT4)&v)generate_loop_file="top")&v)templatepdb=)
2vt4A.pdb)&v)pdb_chain=A)&v)
blc_alignmentfile=NPY_RFamide_classA_profile_profile.blc)&v)tempseq=18)&v)
alignseq=11)&f)/sb/meiler/scripts/kaufmann_awk/awk_library.txt)&f)
/blue/meilerlab/apps/scripts/create_template_from_blc.awk)&f)
/sb/meiler/scripts/kaufmann_awk/aa_transform.txt)>)PrRPR_2VT4.pdb)
 
Peptide docking and loop building 
mpiexec)/bin/rosetta_scripts.mpistatic.linuxgccrelease)&database)
rosetta_database/)@dock_PrRP.options)&s)$START_PDB)&out:file:silent)$OUTFILE)&
out:file:scorefile)$SCOREFILE)
 
Analysis and selection of models 
Computing distance matrix for clustering using BCL 
bcl.exe)Quality)&quality)RMSD)&atom_list)CA)&pdb_list)pdb.ls)&aaclass)AACaCb)
Clustering with the BCL (436) 
#)Had)tried)clustering)at)3,)3.5,)4,)and)5A)cutoffs)and)decided)on)3.7A)
/bcl.exe)Cluster)&distance_input_file)filter_distRMSD.txt)&input_format)
TableLowerTriangle)&output_format)Rows)Centers)&output_file)cluster_cutoff3&
7.txt)&linkage)Average)&distance_definition)less)&output_pymol)1000)25)100)
10000)10)dendogram.py)&remove_nodes_below_size)100)&
remove_internally_similar_nodes)4)&pymol_label_output_string)&
pymol_scale_node_with_size+
Find the geometric centers of the leaf clusters 
awk)'{if($14==1)print}')Centers.txt)|)sort)&nrk10)>)leaves_centers.txt)
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Find if top scoring models in leaf clusters 
foreach)pdb)()`cat)top10_by_score.ls`)))
grep)$pdb)cluster_co3.7.Rows.txt)|)grep)"Leaf):)1")
end)
)! )
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